 
Official Title:  A Phase III, Randomized, Double -Blind, Placebo -Controlled Clinical 
Trial To  Evaluate the Efficacy and Safety Of Atezolizumab or Placebo 
in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide 
Followed By [CONTACT_123471] + Trastuzumab + Pertuzumab In Early Her2 -
Positive Breast Cancer  
Study ID: [REMOVED]  
Document  Date : Protocol  Version 6: 23-February -2023 
 
 
CONFIDENTIAL  
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland.   However, it may be implemented in individual countri es by [CONTACT_26702]'s 
local affiliates, including Genentech, Inc. in the [LOCATION_002].  The information 
contained in this document, especially any unpublished data, is the property of 
F. Hoffmann -La [COMPANY_002] Ltd (or under its control) and therefore is provided to yo u in 
confidence as an investigator, potential investigator, or consultant, for review by [CONTACT_10825], 
your staff, and an applicable Ethics Committee or Institutional Review Board.  It is 
understood that this information will not be disclosed to others without writ ten 
authorization from [COMPANY_002] except to the extent necessary to obtain informed consent 
from persons to whom the drug may be administered.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
Protocol BO40747, Version 6 PROTOCOL  
TITLE:  A PHASE III, RANDOMI ZED, DOUBLE -BLIND, 
PLACEB O-CONTROLLED CLINICAL TRIAL TO EVALUATE 
THE EFFICACY AND SAF ETY OF ATEZOLIZUMAB OR 
PLACEBO  IN COMBINATION WITH  NEOADJUVANT 
DOXORUBICIN   CYCLOPHOSPHAMIDE FOL LOWED BY 
[CONTACT_123472]   TRASTUZUMAB   PERTUZUMAB IN EARLY 
HER2 -POSITIVE BREAST CANC ER 
PROTOCOL NUMBER:  BO40747  
VERSION NUMBER:  [ADDRESS_138777] NUMBER:  [ADDRESS_138778] NUMBER:  [STUDY_ID_REMOVED]  
IND NUMBER:  [ADDRESS_138779]:  Atezolizumab (RO5541267),  
Pertuzumab (RO4368451),  
Trastuzumab (RO0452317) , 
Trastuzumab emtansine (RO5304020)  
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd  
APPROVAL : See electronic signature [CONTACT_123611] . 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
2/Protocol BO40747 , Version 6 PROTOCOL HISTORY  
 
Protocol  
Version  Date Final  
6 See electronic date stam p on the final page of this document  
5 12 February 2021  
4 14 February 2020  
3 4 June 2019  
2 22 March 2019  
1 9 July 2018  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
3/Protocol BO40747 , Version 6 PROTOCOL AMENDMENT, VERSION 6: 
RATIONALE  
Protocol BO40747 has been amended  to update safety information and align with the  
Trastuzumab Emtansine Investigator’ s Brochure, Version 16  and Atezolizumab 
Investigator’s Brochure, Version 19.  
Additional  changes to the protocol are summarized below:  
 The synopsis has been simplified to align with European Union Clinical Trial 
Regulation (Reg. No. 536/2014)  and other guidelines.  
 The responsibilities of the investigator and the role of the Medical Monitor in 
determining patient eligibility and during study conduct have been clarified 
(Sections  4.1.1 , 4.1.2, [IP_ADDRESS], 4.5.8, 4.5.9, 5.1.10, Appendix  11, and Appe ndix 12). 
 The medical term “Wegener granulomatosis” has been replaced by [CONTACT_123473] 
“granulomatosis with polyangiitis” to align with the updated preferred term in 
MedDRA (Section  4.1.2 and Appendix  9). 
 A new section of cautionary therapi[INVESTIGATOR_123392] -induced thrombocytopenia should be avoided 
in patients in this study (e.g. , thrombopoietin receptor agonists, recombinant 
thrombopoietins, recombinant interleukin) to align with the Trastuzumab Emt ansine 
Investigator’s Brochure, Version 16 (Section  [IP_ADDRESS]).  
 The email address for withdrawal from the Research Biosample Repository after site 
closure has been corrected (Section  [IP_ADDRESS]) . 
 In alignment with the Trastuzumab Emtansine Investigator’s Broch ure, Version 16, 
human recombinant thrombopoeitin has been identified as a risk factor for 
prolonged thrombocytopenia in patients who are being treated with trastuzumab 
emtansine (Section 5.1. 6.5). 
 Personal identifiable information (i.e., name [CONTACT_123612] e number) for the 
Medical  Monitors has been removed from the protocol (front matter and 
Section  5.4.1 ).  Medical Monitor contact [CONTACT_76943] a 
sentence indicating that this information will be provided separately to sites.  
 Language h as been added to permit the collection of infant health information if a 
female patient or a female partner of a male patient becomes pregnant to align with 
the Trastuzumab Emtansine Risk Management Plan (Sections  [IP_ADDRESS] and  [IP_ADDRESS]) . 
 It has been clarifie d that there is no requirement to report special situations within 
[ADDRESS_138780] be reported within 24  hours  
(Section  5.4.4) . 
 The Sponsor  record retention policy has been clarified (Section  7.1). 
 A description of the technical and organizational security measures taken to protect 
personal data has been added to align with [COMPANY_002] practices ( Section  8.4). 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
4/Protocol BO40747 , Version 6  Due to certain local requirements and an alignment of Sponsor process, it has been 
clarified that summaries of clinical study results may be available in health authority 
databases for public access in addition to redacted Clinical Study Reports 
(Section  9.6). 
 The medical term “primary biliary  cirrhosis” has been replaced by [CONTACT_123473] “primary 
biliary cholangitis” to align with the updated preferred term in MedDRA (Appendix  9). 
 To align with the Atezo lizumab Investigator’s Brochure, Version [ADDRESS_138781] been  made : 
– The list of identified risks for atezolizumab has been revised to include myelitis , 
facial paresis , and pericardial disorders  (Section 5. 1.1). 
– Hemophagocytic lymphohistiocytosis has been updated from a potential risk to 
an identified risk associated with atezolizumab and language has been revised 
accordingly (Section 5.1. 1) 
– The list of adverse events of special interest has been revised to include 
myelitis and facial paresis (Section 5.2.3).  
– Appendix  [ADDRESS_138782] previously experienced a 
pericardial disorder while receiving another immunostimulatory anti -cancer 
agent.  
– Appendix  9 has been revised to include autoimmune myelit is. 
– The adverse event management guidelines have been updated to align with the 
Addendum 1 and Addendum 2 to the Atezolizumab Investigator's Brochure, 
Version 19  (Appendix  9). 
 
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
5/Protocol BO40747 , Version [ADDRESS_138783]  Cancer  ................................ ................................ ..........  29 
1.4 Study Rationale and Benefit Risk Assessment  .......................  31 
2. OBJECTIVES AND ENDPO INTS  ................................ .................  35 
2.1 Efficacy Objectives  ................................ ................................ .. 35 
2.1.1  Co-Primary Efficacy Objective  ................................ .................  35 
2.1.2  Secondary Efficacy Objectives  ................................ ................  36 
2.1.3  Exploratory Efficacy Objectives  ................................ ...............  36 
2.2 Safety Objective  ................................ ................................ ....... 37 
2.3 Pharmacokinetic Objective  ................................ ......................  37 
2.4 Immunogenicity Objectives  ................................ ......................  37 
2.5 Biomarker Objectives  ................................ ...............................  38 
3. STUDY DESIGN  ................................ ................................ ...........  38 
3.1 Discontinuation of Experimental Treatment and Unblinding 
at Study Level  ................................ ................................ ..........  38 
3.1.1  Implications of Unblinding on Study Design and 
Assessments  ................................ ................................ ...........  39 
3.2 Descriptio n of the Study Prior to Stoppi[INVESTIGATOR_123393]  ................................ ................................ ................  39 
3.2.1  Overview of Study Design ................................ ........................  39 
3.2.2  Independent Data Monitoring Committee  ................................  47 
3.3 End of Study and Length of Study  ................................ ...........  47 
3.4 Rationale for Study Design  ................................ ......................  47 
3.4.1  Rationale for Atezolizumab Dose and Schedule  ......................  47 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
6/Protocol BO40747 , Version 6 3.4.2  Rationale for Chemotherapy Choice and Schedule  .................  48 
3.4.3  Rationale for Patient Population  ................................ ..............  49 
3.4.4  Rationale for Control Group and Combination with 
Atezolizumab  ................................ ................................ ...........  49 
3.4.5  Rationale for Trastuzumab Emtansine in Com bination with 
Atezolizumab as Adjuvant Treatment Option  ...........................  50 
3.4.6  Rationale for Pathologic Complete Response as Primary 
Endpoint  ................................ ................................ ..................  51 
3.4.7  Rationale for Biomarker Assessments  ................................ ..... 51 
3.4.8  Rationale for Patient -Reported Outcome Assessments  ...........  53 
4. MATERIALS AND METHOD S ................................ ......................  55 
4.1 Patients  ................................ ................................ ....................  55 
4.1.1  Inclusion Criteria  ................................ ................................ ...... 55 
4.1.2  Exclusion Criteria  ................................ ................................ ..... 58 
4.2 Method of Treatment Assignment and Blinding  .......................  61 
4.2.1  Treatment Assignment  ................................ .............................  61 
4.2.2  Blinding  ................................ ................................ ....................  62 
4.3 Study Treatment and Other Treatments Relevant to the 
Study Design  ................................ ................................ ...........  63 
4.3.1  Study Treatment Formulation, Packaging, and Handling  .........  63 
[IP_ADDRESS]  Atezolizumab and Placebo  ................................ ......................  63 
[IP_ADDRESS]  Pertuzumab (Perjeta) ................................ .............................  64 
[IP_ADDRESS]  Trastuzumab (Herceptin) ................................ .......................  64 
[IP_ADDRESS]  Trastuzumab Emtansine (Kadcyla) ................................ ........  64 
[IP_ADDRESS]  Chemotherapy  ................................ ................................ .........  64 
4.3.2  Study Treatment Dosage, Administration, and Compliance  .... 64 
[IP_ADDRESS]  Atezolizumab and Placebo  ................................ ......................  65 
[IP_ADDRESS]  Pertuzumab (Perjeta) ................................ .............................  66 
[IP_ADDRESS]  Trastuzumab (Herceptin) ................................ .......................  67 
[IP_ADDRESS]  Trastuzumab Emtansine (Kadcyla) ................................ ........  68 
[IP_ADDRESS]  Chemotherapy  ................................ ................................ .........  [ADDRESS_138784] Accountability  .....................  70 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
7/Protocol BO40747 , Version 6 4.3.5  Continued Access to Atezolizumab, Pertuzumab, 
Trastuzumab, and Trastuzumab Emtansine  ............................  71 
4.4 Concomitant Therapy  ................................ ..............................  71 
4.4.1  Permitted Therapy  ................................ ................................ ... 71 
4.4.2  Cautionary Therapy for Atezolizumab -Treated Patients  ..........  74 
[IP_ADDRESS]  Corticosteroids and TNF - Inhibitors  ................................ ....... 74 
[IP_ADDRESS]  Medications Given with Precaution due to Effects Related 
to Cytochrome P450 Enzymes  ................................ ................  74 
[IP_ADDRESS]  Herbal Therapi[INVESTIGATOR_014]  ................................ ................................ ..... 75 
[IP_ADDRESS]  Therapi[INVESTIGATOR_123394]  ................................ ................................ ..........  75 
4.4.3  Prohibited Therapy  ................................ ................................ .. 75 
4.5 Study Assessments  ................................ ................................ . 76 
4.5.1  Informed Consent Forms and Screening Log  ..........................  76 
4.5.2  Medical History, Concomitant Medication, and 
Demographic Data  ................................ ................................ ... 76 
4.5.3  Physical Examinations  ................................ .............................  76 
4.5.4  Vital Signs  ................................ ................................ ................  77 
4.5.5  Locoregional Tumor Status Assessments  ...............................  77 
4.5.6  Distant Sites Tumor Assessment  ................................ .............  78 
4.5.7  Disease Follow -Up and Confirmation of Disease 
Progression or Recurre nce ................................ ......................  79 
4.5.8  Surgical Specimen Pathology  ................................ ..................  82 
4.5.9  Laboratory, Biomarker, and Other Biological Samples  ............  82 
4.5.10  Electrocardiograms  ................................ ................................ .. 85 
4.5.11  Echocardiograms or Multiple -Gated Acquisition Scans  ...........  85 
4.5.12  Patient -Reported Outcomes  ................................ ....................  85 
[IP_ADDRESS]  EORTC QLQ -C30 ................................ ................................ .... 86 
[IP_ADDRESS]  FACT -G Single Item GP5  ................................ ........................  86 
[IP_ADDRESS]  EQ-5D-5L................................ ................................ .................  87 
4.5.13  Samples for  Whole Genome Sequencing  ................................  87 
4.5.14  Optional Samples for Research Biosample Repository  ...........  88 
[IP_ADDRESS]  Overview of the Research Biosample Repository  ....................  88 
[IP_ADDRESS]  Approval by [CONTACT_123474]  ................................ ................................ ...............  89 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
8/Protocol BO40747 , Version 6 [IP_ADDRESS]  Sample Collection  ................................ ................................ .... 89 
[IP_ADDRESS]  Confidentiality  ................................ ................................ ..........  89 
[IP_ADDRESS]  Consent to Participate in the Research Biosample 
Repository ................................ ................................ ................  90 
[IP_ADDRESS]  Withdrawal from the Research Biosample Repository  .............  90 
[IP_ADDRESS]  Monitoring and Over sight  ................................ .........................  91 
4.6 Treatment, Patient, Study, and Site Discontinuation  ................  91 
4.6.1  Study Treatment Discontinuation  ................................ .............  91 
4.6.2  Patient Discontinuation from Study  ................................ ..........  92 
4.6.3  Partial Withdrawal from Study  ................................ ..................  92 
4.6.4  Study Discontinuation  ................................ ..............................  93 
4.6.5  Site Discontinuation  ................................ ................................ . 93 
5. ASSESSMENT OF SAFETY  ................................ .........................  93 
5.1 Safety Plan  ................................ ................................ ..............  93 
5.1.1  Risks Associated with Atezolizumab  ................................ ........  94 
5.1.2  Risks Associated with Doxorubicin  ................................ ..........  94 
[IP_ADDRESS]  Cardiomyopathy  ................................ ................................ ....... 94 
5.1.3  Risks Associated with Cyclophosphamide  ...............................  95 
5.1.4  Risks Associated with Paclitaxel  ................................ ..............  95 
5.1.5  Risks Associated with Pertuzumab, Trastuzumab, and 
Trastuzumab Emtansine  ................................ ..........................  96 
[IP_ADDRESS]  Cardiotoxicity  ................................ ................................ ...........  97 
[IP_ADDRESS]  EGFR -Related Toxicities  ................................ .......................  100  
5.1.6  Risks Associated with Trastuzumab Emtansine  ....................  100  
[IP_ADDRESS]  Pulmonary Toxicity  ................................ ................................  100  
[IP_ADDRESS]  Hepatotoxicity  ................................ ................................ ........  101  
[IP_ADDRESS]  Left Ventricular Dysfunction  ................................ ...................  101  
[IP_ADDRESS]  Infusion -Related Reactions and Hypersensitivity Reactions  .. 102  
[IP_ADDRESS]  Hematologic Toxicity  ................................ ..............................  102  
[IP_ADDRESS]  Hemorrhage  ................................ ................................ ...........  103  
[IP_ADDRESS]  Neurotoxicity  ................................ ................................ ..........  103  
5.1.6. 8 Extravasation  ................................ ................................ .........  103  
5.1.7  Risks Associated with Combination Use of Pertuzumab 
with Trastuzumab and Paclitaxel  ................................ ...........  104  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
9/Protocol BO40747 , Version 6 5.1.8  Risks Associated with Combination Use of Atezolizumab 
and Doxorubicin, Cyclophosphamide, Paclitaxel, 
Trastuzumab, Pertuzumab, or Trastuzumab  Emtansine  ........  105  
5.1.9  General Plan to Manage Safety Concerns  ............................  107  
5.1.10  Dose Modifications  ................................ ................................  107  
[IP_ADDRESS]  Dose Modifications of Trastuz umab Emtansine and 
Atezolizumab/Placebo  ................................ ...........................  108  
5.2 Safety Parameters and Definitions  ................................ ........  109  
5.2.1  Adverse Events  ................................ ................................ ...... 110  
5.2.2  Serious Adverse Events (Immediately Reportable to the 
Sponsor)  ................................ ................................ ................  [ADDRESS_138785] (Immediately 
Reportable to the Sponsor)  ................................ ....................  111  
5.2.4  Selected Adverse Events  ................................ .......................  112  
[IP_ADDRESS]  Cardiac, General  ................................ ................................ .... 112  
[IP_ADDRESS]  Asymptomatic Left Ventricular Systolic Dysfunction  ..............  112  
5.3 Methods and Timing for Capturing and Assessing 
Safety  Parameters  ................................ ................................ . 113  
5.3.1  Adverse Event Reporting Period  ................................ ............  114  
5.3.2  Eliciting Adverse Event Information  ................................ ....... 114  
5.3.3  Assessment of Severity of Adverse Events  ...........................  114  
5.3.4  Assessment of Causality of  Adverse Events ..........................  115  
5.3.5  Procedures for Recording Adverse  Events  ............................  116  
[IP_ADDRESS]  Infusion -Related Reactions and Cytokine Release 
Syndrome  ................................ ................................ ..............  116  
[IP_ADDRESS]  Diagnosis versus Signs and Symptoms  ................................ . 117  
[IP_ADDRESS]  Adverse Events That Are Secondary to  Other Events  ...........  117  
[IP_ADDRESS]  Persistent or Recurrent Adverse Events  ................................  117  
[IP_ADDRESS]  Abnormal Laboratory Values  ................................ .................  118  
[IP_ADDRESS]  Abnormal Vital Sign Values  ................................ ...................  119  
[IP_ADDRESS]  Abnormal Liver Function Tests  ................................ ..............  119  
[IP_ADDRESS]  Deaths  ................................ ................................ ...................  120  
[IP_ADDRESS]  Preexisting Medical Conditions  ................................ ..............  120  
[IP_ADDRESS]  Lack of Efficacy or Worsening of HER2 -Positive Breast 
Cancer  ................................ ................................ ...................  120  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
10/Protocol BO40747 , Version 6 [IP_ADDRESS]  Hospi[INVESTIGATOR_123395]  ..........................  121  
[IP_ADDRESS]  Patient -Reported Outcome Data  ................................ ............  121  
[IP_ADDRESS]  Safety Biomarker Data  ................................ ...........................  [ADDRESS_138786]  ................................ ........  122  
[IP_ADDRESS]  Events That Occur prior to Study Treatment Initiation  ...........  122  
[IP_ADDRESS]  Events That Occur after Study Treatment Initiation  ...............  122  
5.4.3  Reporting Requirements for Pregnancies  ..............................  123  
[IP_ADDRESS]  Pregnancies in Female Patients  ................................ ............  123  
[IP_ADDRESS]  Pregnancies in Female Partners of Male Patients  .................  124  
[IP_ADDRESS]  Abortions ................................ ................................ ................  124  
[IP_ADDRESS]  Congenital Anomalies/Birth Defects  ................................ ...... [ADDRESS_138787] of Study  ................................ ............  128  
6.4 Summaries of Demographic and Baseline Characteristics  .... 129  
6.5 Efficacy Analyses  ................................ ................................ ... 129  
6.5.1  Co-Primary Efficacy Endpoint  ................................ ................  129  
6.5.2  Secondary Efficacy Endpoints  ................................ ...............  130  
[IP_ADDRESS]  pCR in the Subgroups  ................................ ...........................  130  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
11/Protocol BO40747 , Version 6 [IP_ADDRESS]  Event -Free Survival  ................................ ...............................  130  
[IP_ADDRESS]  Disease -Free Survival  ................................ ...........................  131  
[IP_ADDRESS]  Overall Survival  ................................ ................................ ...... 131  
[IP_ADDRESS]  Patient -Reported Outcomes of Role and Physical Function 
and GHS/HRQoL:  EORTC Data  ................................ ...........  132  
6.5.3  Exploratory Efficacy Endpoints  ................................ ..............  132  
[IP_ADDRESS]  Patient -Reported Outcomes of 
Disease/Treatment Related Symptoms, and Emotional 
and Social Function:  EORTC Data  ................................ ....... 132  
[IP_ADDRESS]  Patient -Reported Outcome of Treatment Bother:  FACT -G, 
GP5 Single -Item Data  ................................ ............................  132  
[IP_ADDRESS]  Health Economic EQ -5D-5L Data  ................................ ..........  [ADDRESS_138788] or Ethics  Committee  ....................  139  
8.4 Confidentiality  ................................ ................................ ........  140  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
12/Protocol BO40747 , Version [ADDRESS_138789] and Subsequent Infusions of 
Trastuzumab Emtansine  ................................ .............................  68 
Table  3 Hormonal Therapy  ................................ ................................ ...... 73 
Table  4 Definitions of and Procedures for Confirming Disease 
Recurrence, Death, and Other Noteworthy Events on 
Follow -Up ................................ ................................ ....................  80 
Table  5 Guidance for Managing Overlappi[INVESTIGATOR_70034]  .........................  105  
Table  6 Dose Modification Scheme for Trastuzumab Emtansine  ..........  109  
Table  7 Reporting Conventions for Le ft Ventricular Systolic 
Dysfunction/Congestive Heart Failure  ................................ ....... [ADDRESS_138790] 
Cancer  ................................ ................................ ........................  54 
Figure  3 Algorithm for Continuation and Discontinuation of Study 
Treatment on the Basis of LVEF Assessment .............................  99 
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
13/Protocol BO40747 , Version [ADDRESS_138791] OF APPENDICES  
Appendix  1 Schedule of Activities  ................................ ................................ ..... 152  
Appendix  2  Schedule of Pharmacokinetic and Immunogenicity Samples  ... 161  
Appendix  3  Schedule of Blood and Tissue Samples for Biomarker 
Analysis ................................ ................................ .....................  164  
Appendix  4  European Organisation for Research and Treatment of 
Cancer Quality -of-Life Questionnaire Core 30:  EORTC 
QLQ -C30................................ ................................ ...................  166  
Appendix  5  Functional Assessment of Cancer Therapy General (FACT -
G) Single -Item GP5  ................................ ................................ ... 168  
Appendix  6  EuroQol 5 -Dimension, 5 -Level Questionnaire: EQ -5D-5L ........  169  
Appendix  7  Ventana HER2 IHC Assay  ................................ .......................  172  
Appendix  8  Ventana HER2 ISH Assay  ................................ .......................  173  
Appendix  9  Preexisting Autoimmune Diseases and Immune Deficiencies  . 174  
Appendix  10  Anaphylaxis Precautions  ................................ ..........................  176  
Appendix  11  Overall Guidelines for Management o f Patients Who 
Experience Adverse  Events  ................................ ......................  177  
Appendix  12  Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with 
Atezolizumab  ................................ ................................ ............  187  
Appendix  13  Eastern Cooperative Oncology Group Scale of Performance 
Status  ................................ ................................ ........................  221  
Appendix  14  Guidelines for Management of Adverse Events Associated 
with Trastuzumab Emtansine  ................................ ....................  222  
Appendix  15  Guidelines for Management of Adverse Events that are 
Potential Overlappi[INVESTIGATOR_123396]  .... 227  
 
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
14/Protocol BO40747 , Version 6 PROTOCOL AMENDMENT A CCEPTANCE FORM  
TITLE:  A PHASE III, RANDOMI ZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED CLINICAL TRIAL TO EVALUATE 
THE EFFICACY AND SAF ETY OF ATEZOLIZUMAB OR 
PLACEBO IN COMBINATI ON WITH NEOADJUVANT 
DOXORUBICIN   CYCLOPHOSPHAMIDE FOL LOWED BY 
[CONTACT_123472]   TRASTUZUMAB   PERTUZUMAB IN EARLY 
HER2 -POSITIVE BREAST CANC ER 
PROTOCOL  NUMBER:  BO40747  
VERSION NUMBER:  [ADDRESS_138792] NUMBER:  [ADDRESS_138793] NUMBER:  [STUDY_ID_REMOVED]  
IND NUMBER:  [ADDRESS_138794]:  Atezolizumab (RO5541267),  
Pertuzumab (RO4368451),  
Trastuzumab (RO0452317) , 
Trastuzumab emtansine (RO5304020)  
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd  
 
I agree to conduct the study in accordance with the current protocol.  
   
Principal Investigator's Name  (print)    
   
Principal Investigator's Signature   [CONTACT_77065].  Please return a copy of 
the signed form as instructed by [CONTACT_27860] . 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
15/Protocol BO40747 , Version 6 PROTOCOL SYNOPSIS  
TITLE:  A PHASE III, RANDOMI ZED, DOUBLE -BLIND, P LACEBO -CONTROLLED 
CLINICAL TRIAL TO EV ALUATE THE EFFICACY AND SAFETY OF 
ATEZOLIZUMAB OR PLACEBO IN COMBINATI ON WITH NEOADJUVANT 
DOXORUBICIN   CYCLOPHOSPHAMIDE FOL LOWED BY 
[CONTACT_123472]   TRASTUZUMAB   PERTUZUMAB IN EARLY 
HER2 -POSITIVE BREAST  CANCER  
PROTOCOL NUMBER:  BO40747  
VERSION NUMBER:  [ADDRESS_138795] NUMBER:  [ADDRESS_138796] NUMBER:  [STUDY_ID_REMOVED]  
IND NUMBER:  [ADDRESS_138797]:  Atezolizumab (RO5541267),  
Pertuzumab (RO4368451),  
Trastuzumab (RO0452317) , 
Trastuzumab emtansine (RO5304020)  
PHASE:  Phase III  
INDICATION:  Early HER2 -positive breast cancer  
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd  
 
STUDY RATIONALE  
This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab 
compared with placebo when given in combination with neoadjuvant dose -dense anthracycline 
(doxorubicin)   cyclophosphamide followed by [CONTACT_114461]   trastuzumab   pertuzumab 
(ddAC -PacHP) in patients with early human epi[INVESTIGATOR_5169] 2 ( HER2 )-positive breast 
cancer at high risk of recurrence (T2 4, N13, M0).  
OBJECTIVES AND ENDPO INTS  
Specific objectives and corresponding endpoints fo r the study are outlined below.  
EFFICACY OBJECTIVES  
CO-PRIMARY EFFICACY OBJECTIVE  
The co -primary efficacy objective for this study is to evaluate the efficacy of 
atezolizumab   ddAC -PacHP compared with placebo   ddAC -PacHP in the early breast cancer 
(EBC) setting in the PD -L1positive (IC 1/2/3) and the intent -to-treat (ITT) population s on the 
basis of the following endpoint:  
 Pathological complete response (pCR), defined as the absence of residual invasive cancer 
on hematoxylin and eosin evaluation of the c omplete resected breast specimen and all 
sampled regional lymph nodes following completion of neoadjuvant systemic therapy 
(i.e., ypT0/is ypN0 in the current American Joint Committee on Cancer [AJCC] staging 
system, 8th edition) in the PD -L1positive and ITT populations  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
16/Protocol BO40747 , Version 6 SECONDARY EFFICACY O BJECTIVES  
The secondary efficacy objectives for this study are as follows:  
 To evaluate the efficacy of atezolizumab   ddAC -PacHP compared with 
placebo   ddAC -PacHP in the EBC setting on the basis of the following endpoin ts: 
­ pCR (ypT0/is ypN0) based upon hormone receptor status (estrogen receptor 
[ER]/progesterone receptor [PgR] positive or ER/PgR negative)  
­ pCR (ypT0/is ypN0) in the PD -L1negative (IC  0) population  
­ Event -free survival (EFS), defined as the time from random ization to the first 
documented disease recurrence, unequivocal tumor progression determined by [CONTACT_78017], or death from any cause, whichever occurs first, in all patients and 
based upon hormone receptor status (ER/PgR positive or ER/PgR ne gative) and PD -L1 
status (IC 0; IC 1/2/3)  
­ Disease -free survival (DFS), defined as the time from surgery to the first documented 
disease recurrence or death from any cause, whichever occurs first, in all patients who 
undergo surgery  and based upon hormone r eceptor status (ER/PgR positive or ER/PgR 
negative) and PD -L1 status (IC 0; IC 1/2/3)  
­ Overall survival (OS), defined as the time from randomization to death from any cause 
in all patients  and based upon hormone receptor status (ER/PgR positive or ER/PgR 
negative) and PD -L1 status (IC 0; IC 1/2/3)  
 To evaluate patient -reported outcomes ( PROs) of function (role, physical) and 
healt h-related quality of life (HRQoL) associated with atezolizumab   ddAC-PacHP 
compared with placebo   ddAC-PacHP , as measured by [CONTACT_123475] (EORTC) Quality of Life Questionnaire Core  30 
(QLQ -C30), on the basis of the following endpoint:  
­ Mean and mean changes from baseline score in function (role, physical) and global 
health status (GHS )/HRQoL by [CONTACT_74351], and between treatment arms as 
assessed by [CONTACT_123476]/HRQoL scales of the EORTC QLQ -C30 
 
SAFETY OBJECTIVE  
The safety objective for this study is to evaluate the safety of atezolizuma b  ddAC -PacHP 
compared with p lacebo   ddAC -PacHP in the neoadjuvant setting and the safety of 
atezolizumab combined with trastuzumab   pertuzumab (or combined with trastuzumab 
emtansine) compared with placebo combined with trastuzumab   pertuzumab (or combined with 
trastuzumab emtansi ne) in the adjuvant EBC setting on the basis of the following endpoints:  
 Incidence and severity of adverse events, with severity determined according to National 
Cancer Institute Common Terminology Criteria for Adverse Events, Version  5.0 
(NCI CTCAE v5.0)  
 Change from baseline in targeted vital signs  
 Change from baseline in targeted clinical laboratory test results  
 
PHARMACOKINETIC OBJE CTIVE  
The pharmacokinetic (PK) objective for this study is to characterize the PK profile of 
atezolizumab, pertuzumab, and trastuzumab when given in combination and of atezolizumab 
and trastuzumab emtansine when given in combination on the basis of the following endpoints:  
 Peak and trough (maximum serum concentration observed [C max] and minimum serum 
concentration under steady -state conditions within a dosing interval [C min]) of atezolizumab 
concentrations in serum at specified timepoints  
 Trough concentration for pertuzumab and trastuzumab in serum at specified timepoints  
 Peak and trough concentration for trastuzumab emtansine in serum at specified timepoints  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
17/Protocol BO40747 , Version 6 IMMUNOGENICITY OBJEC TIVES  
The immunogenicity objective for this study is to evaluate the immune response to 
atezolizumab, trastuzumab, pertuzumab, and trastuzumab emtansine  on the basis of the 
following endpoints:  
 Incidenc e of treatment -emergent anti -drug antibodies (ADAs) to atezolizumab and its 
impact on pharmacokinetics, efficacy, and safety  
 Incidence of treatment -emergent ADAs to trastuzumab, pertuzumab, and trastuzumab 
emtansine  
 
BIOMARKER OBJECTIVES  
The secondary biom arker objectives for this study are as follows:  
 To evaluate pCR (ypT0/is ypN0), EFS, DFS, and OS based upon PIK3CA mutation status  
 
OVERALL DESIGN  AND STUDY POPULATIO N 
DISCONTINUATION OF EXPERIMENTAL TREAT MENT AND UNBLINDING AT 
STUDY  LEVEL  
On 26 January 20 21, the independent Data Monitoring Committee ( iDMC ) met and conducted a 
review of unblinded safety and efficacy data.  Following their review of the data, the iDMC 
recommended to stop randomized treatment assignment with atezolizumab or placebo.  Study 
treatment without atezolizumab/placebo should be conti nued through the completion of the 
adjuvant treatment phase.  On 3 February 2021, the Sponsor issued an “Urgent Safety Measure 
Dear Investigator Letter” (USM DIL) communicating the request to stop treatment with 
atezolizumab or placebo and informed about t he unblinding of the study.  
The addition of atezolizumab did not result in an increase in the pCR rate compared with the 
control arm both in the ITT and the PD -L1positive population.  There were four Grade  5 
adverse events in the atezolizumab arm, which o ccurred in the neoadjuvant phase.  The iDMC 
commented that the difference in death between the two arms was not significant but in the 
margin of significance.  Considering that the majority of the patients had undergone surgery, 
their recommendation was to  stop the atezolizumab/placebo treatment administration from an 
ethical perspective.  
IMPLICATIONS OF UNBL INDING ON STUDY DESI GN AND ASSESSMENTS  
Following the discontinuation of atezolizumab or placebo, patients should continue all other 
study drugs without  atezolizumab or placebo and follow study assessments and follow -up 
assessments as described in the protocol.  Following the implementation of Protocol Version  5, 
the PK and ADA sample collection for atezolizumab, trastuzumab and pertuzumab (or 
trastuzumab  emtansine) is only required at the treatment discontinuation visit.  
The study was unblinded on 5 February 2021 and the unblinding date will be used as the 
clinical cutoff date for the primary analysis.  As per Statistical Analysis Plan, patients with 
missing pCR assessment will be counted as not achieving pCR in the analysis; this includes 
patients who have not yet undergone surgery and pCR assessment due to the early unblinding 
of the study.  Patients who are still in the neoadjuvant phase of the study at  the time of 
unblinding should continue their study treatment without atezolizumab or placebo and undergo 
surgery and pathological assessment as per study protocol followed by [CONTACT_123477].  
OVERVIEW OF STUDY DE SIGN  PRIOR TO STOPPI[INVESTIGATOR_123397] a global Phase III, randomized, double -blind, placebo -controlled study designed to 
evaluate the efficacy, safety, and pharmacokinetics of atezolizumab compared with placebo 
when given in  combination with neoadjuvant ddAC -PacHP in patients eligible for surgery with 
early HER2 -positive breast cancer at high risk of recurrence (T2 4, N13, M0). 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
18/Protocol BO40747 , Version 6 Several  key aspects of the study design and study population are summarized below.  
Phase:  Phase III Population Type:  Adult patients  
Control Method:  Placebo  Population Diagnosis 
or Condition:  Early HER2 -positive 
breast cancer  
Interventional 
Model:  Parallel group  Population Age:   [ADDRESS_138798] Compounds:  Atezolizumab 
(RO5541267),  
Pertuzumab 
(RO4368451),  
Trastuzumab 
(RO0452317),  
Trastuzumab 
emtansine 
(RO5304020)  Site Distribution:  Multi -site 
Active Comparator:  Not applicable  Study Intervention 
Assignment Method:  Randomization  and 
stratification  
Number of Arms:  Two  Number of 
Participants to Be 
Enrolled:  Approximately 453 
 
STUDY TREATMENT  
The investigational medicinal products for this study are atezolizumab, trastuzumab, 
pertuzumab, trastuzumab emtansine, doxorubicin, cyclophosphamide, and paclitaxel.  
ATEZOLIZUMAB AND PLACEBO  
During the neoadjuvant phase, atezolizumab/placebo will be administered by [CONTACT_22671] a 
fixed dose of 840 mg on Day 1 of each 14 -day cycle during Cycles 1 4, and 1200  mg on Day  1 
of each 21 -day cycle during Cycles 5 8.  During the adjuvant phase (postoperatively) , 
atezolizumab/placebo will be administered by [CONTACT_22671] a fixed dose of 1200 mg on Day  1 
of each 21 -day cycle (maximum of 22 cycles [neoadjuvant   adjuvant phases]).  
Atezolizumab/placebo should be administered as the first infusion.  
Treatment will c ontinue as scheduled or until disease progression, recurrence of disease, or 
unmanageable toxicity.  
Administration of atezolizumab will be performed in a monitored setting where there is 
immediate access to trained personnel and adequate equipment and medi cine to manage 
potentially serious reactions.  For anaphylaxis precautions, see the protocol.  Atezolizumab 
infusions will be administered per the instructions outlined in the protocol.  
Refer to the pharmacy manual for detailed instructions on drug prepara tion, storage, and 
administration.  
Guidelines for medical management of infusion -related reactions (IRRs) are provided in the 
protocol.  
No dose modification for atezolizumab is allowed.  
PERTUZUMAB  
Pertuzumab is given as a fixed non weight -based dose of 840 -mg IV loading dose, then 
420 mg IV Q3W.  Pertuzumab will be administered on Day 1 of a 21 -day cycle, to complete up 
to a total duration of 52 weeks (i.e., maximum of 18 cycles within 1 year) of HER2 -targeted 
therapy, inclusive of therapy given both in the  neoadjuvant and adjuvant setting.  
Atezolizumab/placebo should be administered prior to pertuzumab and trastuzumab.  The order 
of administration of pertuzumab and trastuzumab is according to investigator preference.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
19/Protocol BO40747 , Version 6 The initial dose of pertuzumab will be administered over 60 (  10) minutes, and patients will be 
observed for a further 60 minutes.  The infusion should be slowed or interrupted if the patient 
experiences infusion -related symptoms.  If the infusion is well tolerated, subsequent doses may 
be adm inistered over 30 (  10) minutes, and patients will be observed for a further [ADDRESS_138799] 
resolved before trastuzumab or chemotherapy is given or the patient is discharged.  Patients 
who experience infusion -related symptoms may be premedicated with analgesics and 
antihistamines for subsequent infusions.  
Guidelines for dosage modification and treatment interruption or discontinuation are provided in 
the protocol.  No dose reductions are allowed for pertuzumab.  If the patient misses a dose of 
pertuzumab for any cycle and the time between doses is  6 weeks, a reloading dose of 
pertuzumab (840 mg) should be given.  Subsequent maintenance pertuzumab (420  mg) will 
then be given Q3W, starting [ADDRESS_138800] dose of neoadjuvant 
pertuzumab is 6 weeks or more, a reloading dose of 840 mg of pertuzumab is required.  
TRASTUZUMAB  
Trastuzumab is given as a n 8-mg/kg IV loading dose and then 6 mg/kg IV Q3W.  Trastuzumab 
will be administered on Day 1 of a 21 -day cycle, to complete up to a total duration of 52  weeks 
(i.e.,  maximum of 18 cycles within 1 year) of HER2 -targeted therapy, inclusive of therapy given 
both in the neoadjuvant and adjuvant setting.  Atezolizumab/placebo should be administered 
prior to pertuzumab and trastuzumab.  The order of administration of pertuzumab and 
trastuzumab is according to investigator preference.  
Weight should be recorded du ring screening and on Day [ADDRESS_138801] be recalculated if the patient’s body weight has changed 
by  10% (inc reased or decreased) from the Cycle 1, Day 1 weight.  The amount of trastuzumab 
administered is calculated according to the patient’s actual body weight, with no upper limit.  
The initial dose of trastuzumab will be administered over 90 (  10) minutes, and patients will be 
observed for at least 30 minutes from the end of the infusion for infusion -related symptoms such 
as fever or chills.  Interruption or slowing of the infusion may help control such symptoms and 
may be resumed when symptoms abate.  If the in fusion is well tolerated, subsequent infusions 
may be administered over 30 (  10) minutes, and patients will be observed for a further 
[ADDRESS_138802] resolved before pertuzumab or 
chemotherapy is given or the patient i s discharged.  Patients who experience infusion -related 
symptoms may be premedicated with analgesics and antihistamines for subsequent infusions.  
Guidelines for dosage modification and treatment interruption or discontinuation are provided in 
the protocol.   No dose reductions are allowed for trastuzumab.  If the patient misses a dose of 
trastuzumab for any cycle and the time between doses is   6 weeks, a reloading dose of 
trastuzumab (8 mg/kg) should be given.  Subsequent maintenance trastuzumab (6  mg/kg) 
doses will then be given Q3W, starting [ADDRESS_138803] dose of neoadjuvant 
trastuzumab is 6 weeks or more, a reloading dose of 8 mg/kg of trastuzumab is required.  
TRASTUZUMAB  EMTANSI NE 
Trastuzumab emtansine will be given at a dose of 3.6  mg/kg by [CONTACT_16228] Q3W.  The dose of 
trastuzumab emtansine administered will be determined on the basis of the baseline weight of 
the patient.  Weight will be measured at each visit and the dose mus t be re -adjusted for weight 
changes  10% compared with the previous visit or baseline.  The investigator may choose to 
recalculate the dose at every cycle using actual weight at that time, in accordance to local 
practice.  Administration may be delayed to  assess or treat adverse events.  Dose reduction will 
be allowed, following the dose reduction levels provided in the protocol.  Once a dose has been 
reduced for an adverse event(s), it must not be re -escalated.  
Trastuzumab emtansine should be administered  in a monitored setting where there is 
immediate access to trained personnel and adequate equipment and medicine to manage 
potentially serious reactions.  Trastuzumab emtansine will be administered after the infusion of 
atezolizumab or placebo.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
20/Protocol BO40747 , Version 6 CHEMOTHERAP Y 
Chemotherapy will be administered in the neoadjuvant setting as follows:  
 Doxorubicin 60 mg/m2 IV on Day 1 of a 14 -day cycle for 4 cycles (Cycles 1 4); with  
 Cyclophosphamide 600 mg/m2 IV on Day 1 of a 14 -day cycle for 4 cycles  (Cycles  14); 
followed by  
 Paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks (Cycles 5 8) 
 
The dose of chemotherapy is calculated according to the patient’s BSA.  The BSA and the 
amount of drug administered must be recalculated if the patient’s body weight has changed by 
 10% ( increased or decreased) from baseline.  Recalculation of the amount of drug 
administered on the basis of smaller changes in body weight or BSA is at the investigators’ 
discretion.  
There is no mandatory delay between atezolizumab/placebo and ddAC chemothera py, 
assuming the infusion is well tolerated.  
See the protocol for details on the dosage and administration of doxorubicin, 
cyclophosphamide, and paclitaxel.  
DURATION OF PARTICIPATION  
The total length of the study, from screening of the first patient to the  end of the study, is 
expected to be approximately [ADDRESS_138804] patient in the 
study.  
COMMITTEES  
Independent Committees:  Independent  Data Monitoring Committee  
Other Committees:  Not applicable  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
21/Protocol BO40747 , Version [ADDRESS_138805] computed tomography (scan)  
CTCAE  Common Terminology Criteria for Adverse Events  
ctDNA  circulating -tumor DNA  
ddAC  dose -dense anthracycline 
(doxorubicin   cyclophosphamide)  
ddAC -PacHP  dose -dense anthracycline 
(doxorubicin   cyclophosphamide) followed by 
[CONTACT_114461]   trastuzumab   pertuzumab  
DFS disease -free survival  
DLT dose -limiting toxicity  
EBC early breast cancer  
EC Ethics Committee  
eCRF  electronic Case Report Form  
ECHO  echocardiogram  
EDC  electronic data capture  
EFS event -free survival  
EMA  European Medicines Agency  
EORTC  European Organisation for Research and Treatment of 
Cancer  
EQ-5D-5L EuroQol 5 -Dimension, 5 -Level (questionnaire)  
ER estrogen receptor  
ESMO  European Society for Medical Oncology  
FACT -G Functional Assessment of Cancer Therapy General  
FDA Food and Drug Administration  
FEC 5-fluorouracil, epi[INVESTIGATOR_14962], and cyclophosphamide  
FFPE  formalin -fixed, paraffin -embedded  
G-CSF granulocyte colony stimulating factor  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
22/Protocol BO40747 , Version [ADDRESS_138806]  
IND Investigational New Drug (Application)  
IRB Institutional Review Board  
IRR infusion -related reaction  
ISH in situ hybridization  
ITT intent -to-treat (population)  
IxRS  interactive voice or web -based response system  
LDH lactate dehydrogenase  
NE not evaluable  
LN lymph node  
LVEF  left ventricular ejection fraction  
LVSD  left ventricular systolic dysfunction  
MRI magnetic resonance imaging  
MUGA  multiple -gated acquisition (scan)  
NAST  neoadjuvant systemic therapy  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NCI CTCAE  National Cancer Institute Common Terminology Criteria 
for Adverse Events  
NGS  next-generation sequencing  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
23/Protocol BO40747 , Version 6 Abbreviation  Definition  
NRH  nodular regenerative hyperplasia  
NSCLC  nonsmall cell lung cancer  
NYHA  [LOCATION_001] Heart Association  
OS overall survival  
PacHP  paclitaxel   trastuzumab   pertuzumab  
pCR pathological complete response  
PET positron emission tomography  
PFS progression -free survival  
PgR progesterone receptor  
PK pharmacokinetic  
PRO  patient -reported outcome  
Q2W  every 2 weeks  
Q3W  every 3 weeks  
QLQ -C30 Quality -of-Life Questionnaire Core [ADDRESS_138807] cancer  
TNF- tumor necrosis factor - 
ULN upper limit of normal  
USM DIL  Urgent Safety Measure Dear Investigator Letter  
WES  whole exome sequencing  
WGS  whole genome sequencing  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
24/Protocol BO40747 , Version [ADDRESS_138808] cancer cases were diagnosed in 2012 (25% of all cancers in women) and there 
were 521,900  deaths (DeSantis et al. 2015; Ferlay et al. 2015).  The majority of breast 
cancers in the Western world is diagnosed when the cancer is still confined to the 
breast, with or without locoregional lymph node spread ( Sant et al. 2003; 
Jemal  et al. 2011; Ferlay et al. 2013 ; Howlader et al. 2016).  At these early stages ( IIII, 
early breast cancer [EBC]), the largely asymptom atic disease is usually operable and 
can be treated with curative intent.  
Approximately [ADDRESS_138809] human epi[INVESTIGATOR_47339] 2 (HER2) -positive disease (Wolff  et al. 2013).  Breast cancers over -expressing 
HER2 are the most  aggressive, and while current therapi[INVESTIGATOR_123398], u p to 1 in 4 women with HER2 -positive EBC will experience recurrence or 
death within 10 [ADDRESS_138810] chemotherapy ( Perez et al. 2014; Slamon et al. 2016; Cameron  et al. 2017 ).  
In those patients treated with neoadjuvant trastuzumab and pertuzumab with standard 
chemotherapy, 5 -year disease -free survival (DFS) rates sit at 84% (Gianni  et al. 2016).  
Patients who relapse with  metastatic or unresectable disease are generally incurable.  
Overall (i.e., all subtypes of breast cancer, including HER2 -negative disease), patients 
with metastatic disease have a median survival of approximately 24  months and a 
5-year life expectancy of 18% 26% in the [LOCATION_002] and Europe ( Sant et al. 2003 ; 
Howlader  et al. 2016 ).  With the advent of pertuzumab, life expectancy for patients with 
metastatic HER2 -positive breast cancer has greatly improved with an observed median 
overall survival (OS) of 56.5 months in the CLEOPATRA study.  Nevertheless, more 
than 50%  of patients receiving first -line treatment with trastuzumab, pertuzumab, and a 
taxane for metastatic disease die within 5 years ( Swain et al. 2015 ). 
New active agents  are still required for patients with HER2 -positive breast cancer, which 
is estimated to account for approximately 6,000 8,000 deaths per year in the United 
States, 19,000 26,000 deaths per year in Europe, and approximately 
78,000104,000  deaths per year g lobally ( DeSantis et al. 2015; Ferlay  et al. 2015; 
Howlader  et al. 2016 ).  Since metastatic disease is currently incurable, improving the 
results of initial therapy, when the disease is still localized to the breast and regional 
lymph nodes but without dis tant metastases offers the best chance of cure.  For patients 
who are not cured, improved initial therapy may also produce meaningful delays in 
disease recurrence and death.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
25/Protocol BO40747 , Version [ADDRESS_138811] been 
transformed by [CONTACT_123478]2 -targeted agents.  The humanized monoclonal 
antibody trastuzumab (Herceptin), which binds to the extracellular domain of HER2, is 
approved for use as a single agent or in  combination with chemotherapy or hormonal 
therapy in the metastatic setting, and as (neo)adjuvant tr eatment for patients with 
early -stage HER2 -positive breast cancer.  Globally, trastuzumab -based therapy is the 
recommended treatment for patients with HER2 -positive early -stage breast cancer who 
do not have contraindications for its use ( Herceptin P rescribing Information; 
European  Society for Medical Oncology [ESMO] guidelines [Senkus  et al. 2015]; 
National Comprehensive Cancer Network [NCCN] Guidelines, Ver sion 1.2017 
[Gradishar  et al. 2017]).  
An improvement to standard trastuzumab therapy for HER2 -positive EBC comes with 
the addition of another HER2 -targeted therapy, pertuzumab (Perjeta), approved in 
many countries for the treatment of HER2 -positive metast atic breast cancer and for 
neoadjuvant use in patients with high -risk, HER2 -positive EBC.  This combination has 
been adopted in global guidelines for use in these patients in the neoadjuvant setting 
(Perjeta  Prescribing Information; ESMO guidelines [Senkus  et al. 2015]; 
NCCN  Guidelines, Version 1.2017 [Gradishar et al. 2017]).  Pertuzumab has also been 
recently approved in the [LOCATION_002], Europe, and other countries throughout the world 
for post-surgery (adjuvant) treatment of HER2 -positive EBC at high r isk of recurrence  
(Perjeta  Prescribing  Information; NCCN 2019; Hammond et al. 2010).  
In HER2 -positive EBC, neoadjuvant pertuzumab   trastuzumab   docetaxel provides a 
statistically significant and clinically meaningful improvement in pathological complete 
response (pCR) rates over trastuzumab   docetaxel alone (45.8% vs. 29.0%; p   0.0141 ; 
Gianni  et al. 2012 ).  Patients in this study went on to receive additional chemotherapy 
following surgery regardless of pCR status.  In a descriptive analysis, 5 -year DFS  rates 
were reported to be higher in those patients who received neoadjuvant 
pertuzumab   trastuzumab   docetaxel than those patients who received 
trastuzumab   docetaxel alone (hazard ratio [HR]   0.60; 0.28 1.27).  In a study in which 
neoadjuvant pertuzu mab and trastuzumab were evaluated with either 
anthracycline -based chemotherapy or carboplatin -based chemotherapy, pCR rates 
(ypT0/is, ypN0 in the current American Joint Committee on Cancer [AJCC] staging 
system) for all regimens ranged from 57.3% 66.2%, w ith the highest pCR rate being 
achieved in the docetaxel   carboplatin   trastuzumab   pertuzumab regimen  
(Schneeweiss  et al. 2013 ).  Supporting these results, in the BERENICE study 
(Study  WO29217), pCR ( ypT0/is, ypN0 ) rates in two neoadjuvant regimens containing 
pertuzumab   trastuzumab   taxane and chemotherapy were high in both treatment arms 
(61.8% [Cohort A; dose -dense doxorubicin and cyclophosphamide (ddAC) -taxane]) and 
60.7% [Cohort B; 5-fluorouracil, epi[INVESTIGATOR_14962] , and cyclophosphamide  (FEC) -taxane] ; 
Swain  et al. 2018 ). 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
26/Protocol BO40747 , Version 6 Neratinib (Nerlynx) is a HER2 -targeted tyrosine kinase inhibitor that has recently been 
approved for use in the [LOCATION_002] as additional adjuvant therapy in patients with 
early -stage HER2 -positive breast cancer (Nerlynx Prescribing Information; 
Chan  et al. 2016 ]). 
Trastuzumab emtansine is an approved treatment for patients with HER2 -positive 
advanced breast cancer who have received therapy with trastuzumab and a taxane and 
who ha ve received prior therapy for metastatic disease or developed disease recurrence 
during or within 6  months of completing adjuvant therapy (Verma  et al 2012; 
NCCN  2019).  Study  BO27938 (Katherine) was designed to investigate the effect of 
trastuzumab emtans ine in patients with HER2 -positive early breast cancer.  The study 
was a randomized, multicente r, open -label Phase  III study to evaluate the efficacy and 
safety of trastuzumab emtansine compared with trastuzumab as adjuvant therapy for 
patients with HER2 -positive early breast cancer who have residual tumor present in the 
breast or axillary lymph nodes following neoadjuvant therapy containing a taxane and 
trastuzumab.  Results showed that invasive DFS was significantly improved  with 
trastuzumab emtansine compared  with trastuzumab (HR   0.50; 95%  CI: 0.39 to 0.64; 
p  0.001 ; von Minckwitz  et al 2019).  The estimated percentage of patients free of 
invasive disease at 3  years from randomization was 88.3% with trastuzumab emtansine 
and 77.0% with trastuzumab.  A higher proportion of patients receiving trastuzumab 
emtansine compared with patients receiving trastuzumab experienced Grade   3 
adverse events (25.7% vs. 15.4%), serious adverse events (12.7% vs. 8.1%), and 
adverse events leading to discontinuation of s tudy drug (18.0% vs. 2.1%).   The 
proportion of patients receiving adjuvant radiotherapy was 84.2% in the trastuzumab 
emtansine arm and  81.9% in the trastuzumab arm  (Primary  Clinical  Study  Report  [CSR ] 
Study  BO27938, Report  Number 1087528 , January  2019 ).  Higher rates of pulmonary 
toxicities, including pneumonitis and radiation pneumonitis, were reported in the 
trastuzumab emtansine arm  (21 patients; 2.8%)  compa red with the trastuzumab arm 
(6 patients; 0.8%).  In the trastuzumab emtansine arm, 1.5% of patie nts (n  11) 
experienced radiation pneumonitis, 1.1% of patients  (n  8) experienced pneumonitis, 
0.1% of patients  (n  1) experienced pulmonary fibrosis, and 0.1% of patients  (n  1) 
experienced pulmonary radiation injury.  In the trastuzumab arm, 0.7% of  patients  (n  5) 
experienced radiation pneumonitis, 0.1% of patients  (n  1) experienced pneumonitis; no 
patient experienced pulmonary fibrosis or pulmonary radiation injury.  In the trastuzumab 
emtansine arm, the majority of patients (18  of 21) experienced pulmonary toxicities of 
Grad e 1 or 2.  Of the 11  patients in the trastuzumab emtansine arm who experienced 
radiation pneumonitis, the event was Grade  1 or 2 in 9  patients ; 2 patients experienced 
Grade  3 events.  All events of radiation p neumoni tis resolved and were  reported in 
patients who received radiation concurrent with adjuvant trastuzumab emtansine.  Of the 
8 patients in the trastuzumab emtansine arm who experienced pneumonitis, the  event 
was Grade  1 or 2 in 7 patients ; 1 patient experienc ed a Grade  3 event of pneumonitis.  
Trastuzumab emtansine was withdrawn in all but one patient who experienced 
pneumonitis and all events resolved or resolved with sequelae 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
27/Protocol BO40747 , Version 6 (Primary  CSR  Study  BO27938, Report  Number  1087528 , January  2019 ).  Based on the 
results of the Katherine study, the U.S. Food and Drug Administration (FDA) and 
European Commission  have approved trastuzumab emtansine in the adjuvant  setting for 
patients with HER2 -positive early breast cancer who have residual invasive disea se after 
neoadjuvant taxane and trastuzumab -based treatment.  
1.3 BACKGROUND ON ATEZOL IZUMAB  
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD -L1 and inhibits 
the interaction between PD -L1 and its receptors, PD -1 and B7 -1 (also known as CD80) , 
both of which function as inhibitory receptors expressed on T  cells.  Therapeutic 
blockade of PD -L1 binding by [CONTACT_123479] -specific T -cell responses, resulting in improved anti -tumor activity 
(Fehrenbacher  et al. 2016; Rosenberg et al. 2016).  Atezolizumab  has minimal  binding  
to Fc receptors, thus eliminating detectable Fc -effector function and associated 
antibody -mediated clearance of activated effector T  cells.  
Atezolizumab shows anti -tumor a ctivity in both nonclinical models and cancer patients 
and is being investigated as a potential therapy in a wide variety of malignancies.  
Atezolizumab is being studied as a single agent in the advanced cancer and adjuvant 
therapy settings, as well as in combination with chemotherapy, targeted therapy, and 
cancer immunotherapy.  
Atezolizumab is approved for the treatment of urothelial carcinoma , nonsmall cell lung 
cancer (NSCLC) , small cell lung cancer, hepatocellular carcinoma,  melanoma,  and 
triple -negative breast cancer ( TNBC) .  Refer to the atezolizumab Investigator’s Brochure 
for further details.  
1.3.[ADDRESS_138812] Cancer  
Atezolizumab is currently being tested in multiple Phase I, II, and III studies, b oth as 
monotherapy and in combination with several anti -cancer therapi[INVESTIGATOR_123399].  See the Atezolizumab Investigator’s Brochure for full study descriptions and 
available data.  
The available safety and efficacy data in TNBC are primarily fro m three studies:  
 Study PCD4989g is a Phase Ia, multicenter, first -in-human, open -label, 
dose -escalation trial evaluating the safety, tolerability, immunogenicity, 
pharmacokinetics, exploratory pharmacodynamics, and preliminary evidence of 
biologic activity  of atezolizumab monotherapy in patients with locally advanced or 
metastatic solid malignancies or hematologic malignancies.  Data from the TNBC 
cohort have been reported and demonstrate promising safety and efficacy results 
regardless of line of therapy a nd PD -L1 expression (Schmid  et al. 2017).  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
28/Protocol BO40747 , Version 6  Study GP28328 is a Phase Ib multi -cohort trial of the safety and pharmacology of 
atezolizumab administered with bevacizumab and/or chemotherapy in patients with 
advanced solid tumors.  Arm F of the trial is evaluat ing atezolizumab administered in 
combination with weekly nab -paclitaxel in patients with TNBC.  Data from Arm  F 
have been submitted for publication and support the use of atezolizumab in 
combination with chemotherapy in patients with TNBC.  Confirmed respo nses were 
seen in 53.8% (95%  CI: 25.1%  to 80.8%) of patients with first -line metastatic TNBC 
and 39.4% (95%  CI: 22.9%  to 57.98%) of all patients regardless of line of therapy 
and PD -L1 expression.  No new safety signals were seen (Adams  et al. 2016).  
Results from Study GP28328 support the hypothesis that tumor -cell killing by 
[CONTACT_123480].  Boosting tumor -specific T -cell immunity in this setting by [CONTACT_123481]-L1 pathway may re sult in deeper and more durable responses than those 
observed with standard chemotherapy alone, and these responses may reasonably 
occur in tumors regardless of PD -L1 expression  (Merritt  et al. 2003; 
Apetoh  et al. 2007) . 
 Study WO29522 (IMpassion130) is a P hase III, global, multicenter, double -blind, 
two-arm, randomized, placebo -controlled study designed to evaluate the efficacy 
and safety of atezolizumab administered with nab -paclitaxel in patients with 
metastatic or unresectable locally advanced TNBC who h ave not received prior 
systemic therapy for metastatic breast cancer.  At the final analysis of 
progression -free survival (PFS) in the intent -to-treat (ITT) and the PD -L1positive 
patient population, a statistically significant benefit was observed with th e addition of 
atezolizumab to nab -paclitaxel with a median PFS of 5.5  months in the control arm 
and 7.2  months in the experimental arm (HR   0.80; 95% CI, 0.69 0.92; p   0.002) in 
the ITT population and a median PFS of 5.0  months in the control arm and 
7.5 months in the experimental arm (HR   0.62; 95% CI : 0.49 to 0.78; p   0.001) in 
the PD -L1positive population (Schmid et  al. 2018).  
An interim analysis of OS was performed.  The 16% reduction in the risk of death 
with atezolizumab   nab-paclitaxel compared  with placebo   nab-paclitaxel did not 
cross the interim boundary for statistical significance (HR: 0.759, available 
  0.0065), with a stratified HR of 0.84; 95% CI: 0.69  to 1.02; p   0.0840.  
The Kaplan -Meier estimated median OS was nearly 4 months longer in the 
atezo lizumab   nab-paclitaxel  arm (21.3 months vs. 17.6 months in the  
placebo   nab-paclitaxel arm).  No formal testin g of OS was performed in the 
PD-L1positive population because hierarch y of testing indicates formal testing can 
only occur if OS is statistically significant in the ITT population first.  However, OS 
resul ts were unprecedented in the PD -L1positive population.  A clinically 
meaningful reduction in the risk of death of 38% was observed with 
atezolizumab   nab-paclitaxel compared with placebo   nab-paclitaxel (stratified 
HR   0.62; 95% CI: 0.45  to 0.86).   This was accompanied by a 10 -month 
prolongation in the Kaplan -Meier estimated median OS in the 
atezolizumab   nab-paclitax el arm (25.0  months vs. 15.5  months 
placebo   nab-paclitaxel).  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
29/Protocol BO40747 , Version 6  Safety results from IMpassion130 are consistent with the known safety profile of 
atezolizumab monotherapy and atezolizumab in combination therapy, with no new 
safety concerns observed.  The overall safety profile of atezolizumab and 
nab-paclitaxel is concordant between the PD -L1positive and the overall 
safety -evaluable population.  
 
Ongoing studies exploring atezolizumab combinations in TNBC include the following:  
 Study WO39392 (IMpassion031) is a Phase III, randomized, placebo -controlled 
study evaluating the safety and efficacy of neoadjuvant nab -paclitaxel followed by 
[CONTACT_2715] -dense doxorubicin and cyclophosphamide administered in combination with 
either atezolizumab or placebo in early TNBC . 
 Study WO39391 (IMpassion030) is a Phase III, randomized study evaluating the 
safety and efficacy of adjuvant paclitaxel followed by [CONTACT_2715] -dense anthracycline and 
cyclophosphamide with or without atezolizumab in early TNBC.  
 Study NSABP B -59/GBG 9 6-GeparDouze is a randomized, double -blind Phase  III 
clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients 
with TNBC followed by [CONTACT_123482] (Geyer  et al. 2018).  
 
1.3.[ADDRESS_138813]  Cancer  
Ongoing studies exploring atezolizumab combinations in HER2 -positive patients include 
the following:  
 Study GO29831 is a Phase Ib open -label, multi -cohort study.  This study includes 
cohorts that evaluate the safety and pharmacoki netics of atezolizumab in 
combination with trastuzumab and pertuzumab or atezolizumab in combination with 
trastuzumab emtansine in patients with HER2 -positive breast cancer.   Enrollment in 
the study has been completed with a total of [ADDRESS_138814] 
cancer (early or metastatic).  
– Cohort 1A has enrolled [ADDRESS_138815] 1  cycle, no patients 
experienced a dose -limiting toxicity (DLT).  
– Cohort 1F has enroll ed a total of [ADDRESS_138816] 3  patients 
enrolled in Cohort 1F who experienced an event that met the protocol definition 
of a DLT.  However, stoppi[INVESTIGATOR_123400] C ohort 1F as defined in the 
protocol were not met and enrollment of the remaining 3 patients was 
completed . 
– Cohort 2D has enrolled [ADDRESS_138817] cancer 
who received atezolizumab in combination with trastuzumab and pertuzumab .  
This cohort was subsequently closed for resource alignment reasons unrelated 
to patient safety and efficacy.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
30/Protocol BO40747 , Version 6 – Cohort 2A has enroll ed a total of [ADDRESS_138818] -of-care (SOC) pre -operative docetaxel, carboplatin, trastuzumab, and 
pertuzumab and surgery .  Cohort 2B has enrolled 20 patients with 
HER2 -positive EBC who received 2  cycles of a tezolizumab in combination with 
trastuzumab emtansine with sequential tumor biopsies for biomarkers, followed 
by [CONTACT_123483] -operative docetaxel, carboplatin, trastuzumab, and pertuzumab 
and surgery . 
– Additional cohorts with patients with HER2 -positive metastat ic breast cancer 
are Cohorts  1B (n  6; safety run -in cohort; atezolizumab   trastuzumab 
emtansine) and 2C  (n  14; expansion cohort; atezolizumab   trastuzumab 
emtansine).  
With a data cut -off of [ADDRESS_138819] been no new safety signals 
overall emerging in the HER2 -positive cohorts of Study GO29831 , and adverse 
events are in line with the known safety profile of the individual components of the 
regimens being evaluated.  
 Study WO30085 (Kate2) is a Phase II randomized study of trastuzumab e mtansine 
with or without atezolizumab in HER2 -positive, locally advanced unresectable or 
metastatic breast cancer with prior exposure to a taxane and trastuzumab.  This 
study enrolled 202  patients.  
– On 22 November 2017, the independent Data Monitoring Commi ttee (iDMC) 
met and conducted a pre -planned benefit risk analysis.  Following this analysis, 
the iDMC recommended to the Sponsor that the study be unblinded with 
respect to treatment assignment to allow investigators and patients to have an 
open discussion  of the potential benefits and risks of continuing the 
experimental therapy.  Unblinding was based upon the improbability of meeting 
the progression -free survival endpoint, numerically higher rates of serious 
adverse events that included one fatal event (h emophagocytic syndrome), and 
numerically higher adverse events leading to discontinuation of study drugs in 
the atezolizumab arm.  The Sponsor issued a "Dear Investigator Letter" on 
11 December 2017 communicating the unblinding of the study.  
– The clinical c utoff date for the primary efficacy analysis was 
[ADDRESS_138820] ratio was 0.82  (95%  CI: 0.55  to 1.23; p   0.3332).  The median 
PFS for trastuzumab emtansine   placebo was 6.8  months (95%  CI: 4.0  to 11.1) 
and for trastuzumab emtansine   atezolizumab 8.2  months 
(95%  CI: 5.8 to 10.7).  The OS data were immature with a low event rate 
(11.6% in the trastuzumab emtansine   placebo arm vs. 9.8% in the 
trastuzumab  emtansine   atezolizumab arm).  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
31/Protocol BO40747 , Version 6 – The subgroup  results of the PFS analysis suggested potential benefit of the 
trastuzumab emtansine   atezolizumab arm in the PD -L1selected subgroup 
(tumor -infiltrating immune cell [ IC] 1/2/3), although the magnitude of the benefit 
is uncertain given the limited number  of patients and the observed imbalances 
in confounding factors.  The stratified hazard ratio of PFS assessment in the 
PD-L1selected subgroup was lower (HR: 0.60; 95%  CI: 0.32  to 1.11; 
p  0.0987) compared with the results of the PFS analysis in the ITT  population.  
The median PFS in PD -L1selected patients for trastuzumab 
emtansine   placebo was 4.1  months (2.7; 11.1) versus 8.5  months (5.7; not 
evaluable [NE]) with trastuzumab emtansine   atezolizumab.  
– The safety profile of the combination was consistent  with the known profiles of 
each study drug, and adverse events for the combination were manageable.  
Although the incidence of Grade   3 adverse events was similar between arms 
with 43.9% in the experimental arm and 41.2% in the control arm, 
thrombocytope nia, AST elevation, anemia, and pyrexia were numerically 
increased in the combination arm.  A  higher incidence of serious adverse 
events, of adverse events leading to atezolizumab  or placebo discontinuation, 
and of adverse events leading to dose reduction of trastuzumab emtansine was 
reported in the combination arm.  A  total of 13  patients (19.1%) in the 
trastuzumab emtansine   placebo arm experienced at least one serious adverse 
event compared with 43  patients (32.6%) in the trastuzumab 
emtansine   atezoli zumab arm.  The most common serious adverse event 
reported in the trastuzumab emtansine   atezolizumab arm was pyrexia 
(10 patients [7.6%]), which was mostly driven by [CONTACT_2360][INVESTIGATOR_123401]  1 or 2 
pyrexia (5.3%), 2  patients (1.5%) experienced Grade  3 pyrexia , and 1  patient 
(0.8%) experienced Grade  4 pyrexia; all [ADDRESS_138821] common serious adverse event s in the trastuzumab 
emtansine   placebo arm w ere seizure (2  patients [2.9%]) and abdominal pain 
(2 patients [2 .9%]).  One patient in the experimental arm experienced a fatal 
hemophagocytic syndrome.  For the trastuzumab emtansine selected adverse 
events, the incidence of thrombocytopenia, hepatotoxicity, peripheral 
neuropathy, and infusion -related reaction  or hypersensitivity Type  1 were 
numerically increased in the trastuzumab emtansine   atezolizumab arm.  For 
the atezolizumab adverse events of special interest, the incidence of 
immun e-mediated  hypothyroidism, immune -mediated  colitis, immune -mediated  
rash, an d immune -mediated  ocular inflammatory toxicity were numerically 
increased in the trastuzumab emtansine   atezolizumab arm compared with the 
trastuzumab emtansine   placebo arm.  
 
1.4 STUDY RATIONALE AND BENEFIT RISK ASSESSMENT  
Encouraging clinical data emerging  in the field of tumor immunotherapy have 
demonstrated that therapi[INVESTIGATOR_33385] T -cell responses against cancer can 
result in a significant survival benefit in patients with advanced malignancies 
(Hodi  et al. 2010; Kantoff et al. 2010; Chen et a l. 2012).  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
32/Protocol BO40747 , Version [ADDRESS_138822] serves as an immune checkpoint to temporarily dampen immune 
responses  in states of chronic antigen stimulation, such as chronic infection or cancer .  
PD-L1 is a transmembrane protein that downregulates immune responses through 
binding to its two receptors, PD -1 and B7 -1.  PD -1 is an inh ibitory receptor expressed on 
T cells following T -cell activation, and expression is sustained in states of chronic 
stimulation (Blank  et al. 2005; Keir et al. 2008 ).  B7-1 is a molecule expressed on 
antigen -presenting cells and activated T cells.  Binding of PD -L1 to PD -1 and B7 -1 
inhibits T -cell proliferation and activation, cytokine production, and cytolytic activity, 
leading to the functional inactivation or exhaus tion of T  cells (Butte  et al. 2007; 
Yang  et al. 2011).  Overexpression of PD -L1 on tumor cells has been reported to impede 
anti-tumor immunity, resulting in immune evasion (Blank  and Mackensen  2007).  
Therefore, interruption of the PD -L1 pathway represents  an attractive strategy for 
restoring tumor -specific T -cell immunity.  
Targeting the PD -L1 pathway with atezolizumab has demonstrated activity in patients 
with advanced malignancies who have failed SOC therapi[INVESTIGATOR_014].  Objective responses have 
been observed acro ss a broad range of malignancies, including NSCLC, urothelial 
carcinoma, renal cell carcinoma, melanoma, colorectal cancer, head and neck cancer, 
gastric cancer, breast cancer, and sarcoma.  In particular, available data from the TNBC 
cohorts in Studies PC D4989g and GP28328 have demonstrated activity and durable 
responses in patients receiving atezolizumab as monotherapy or in combination with 
nab-paclitaxel (see the Atezolizumab Investigator's Brochure for detailed efficacy 
results).   More recently, clinic ally meaningful improvement of OS with 
atezolizumab   nab-paclitaxel compared with placebo   nab-paclitaxel was observed in 
the Phase  III Study WO29522 (IMpassion130) in patients with PD -L1positive advanced 
TNBC (Schmid et al. 2018).  
While cancer immunoth erapy has demonstrated impressive results in patients with 
advanced malignancies, emerging data suggest that responses to cancer 
immunotherapy may be better when agents are administered in early -stage cancers, 
where higher levels of tumor -infiltrating lymp hocytes (TILs) may be present 
(Lee et al. 2017; Loi et al. 2017).  In particular, this may be more relevant in tumors 
where TILs are a prognostic factor, such as in early HER2 -positive breast cancer.  
Cancer immunotherapy is a relatively new focus for breast cancer studies.  It is 
hypothesized that an important mechanism of action of therapeutic antibodies such as 
trastuzumab and pertuzumab (both humanized monoclonal IgG antibodies) is to induce 
cellula r immunity via interactions with the Fc fragment of the molecule and/or destroy 
malignant cells, resulting in release of tumor antigens for uptake by [CONTACT_488] -presenting 
cells, which in turn upregulate immune effector cells.  With these mechanisms of action , 
the combination of trastuzumab and pertuzumab with an anti PD-L1 inhibitor such as 
atezolizumab might further enhance anti -tumor immune responses , thereby [CONTACT_123484] s. 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
33/Protocol BO40747 , Version 6 Nonclinical models provide support for this hypothesis.  It has been demonstrated that 
the addition of PD -1:PD -L1 blockade improves the therapeutic activity of a 
HER2 -positive monoclonal antibody in murine experimental model of 
HER2 -positive breast canc er (Stagg et al. 2011; data on file).  These findings suggest 
that antiPD-L1 immunostimulatory approaches may further capi[INVESTIGATOR_123402] -mediated effects of therapeutic antibodies.  With the potential for therapeutic 
synergy, combining atezolizumab (antiPD-L1 antibody) with trastuzumab and 
pertuzumab may further enhance the anti -tumor efficacy of these established anti -HER2 
treatments.  
The subtype of breast  cancers over -expressing HER2 is the most aggressive.  While 
current therapi[INVESTIGATOR_123403], u p to [ADDRESS_138823] chemotherapy 
(Perez  et al. 2014; Slamon et al. 2016; Cameron et al. 2017 ).  Patients who received 
neoadjuvant trastuzumab and pertuzumab with standard chemotherapy, a patient group 
with tumor size  [ADDRESS_138824] 
demonstrated pCR rates ran ging from 45% 68% ( Gianni  et al. 2012 ; 
Schneeweiss  et al. 2013 ; Untch  et al. 2016; van Ramshorst  et al. 2017 ; 
Swain  et al. 2018).  Even with such rates, 5 -year DFS rates in these patients are around 
84% and are expected to be lower in those who are node po sitive  (Gianni  et al. 2012 ).  
More recently, data from the APHINITY study have demonstrated high invasive DFS 
rates at 3  years (94.1%) and 4  years (92.3%) with adjuvant trastuzumab and 
pertuzumab plus chemotherapy  (von Minckwitz et al. 2017) .  However, in patients with 
node -positive disease, these values were numerically lower at both 3  years (92%) and 
4 years (89.9%).  As such, there is an opportunity to improve pCR rates and long -term 
outcomes for patients with high -risk, HER2 -positive breast cancer.  
Atezolizumab has been generally well tolerated.  Adverse events with potentially 
immune -mediated causes consistent with an immunotherapeutic agent, including rash, 
influenza -like illness, endocrinopathies, hepatitis or transaminitis, pneumonitis, colitis, 
and myasthenia gravis, have been observed (see the Atezolizumab Investigator's 
Brochure for detailed safety results).  To date, these events have been manageable with 
treatment or interruption of atezolizumab treatment.  
Atezolizumab in combination with taxanes  has been investigated or is currently being 
investigated as part of several studies including Studies GP28328, GO29436 
(IMpower150), GO29537 (IMpower130), GO30140, WO295 22 (IMpassion130), 
WO39392 (IMpassion031), and WO39391 (IMpassion030).  Atezolizumab i n 
combination with chemotherapeutic regimens including anthracyclines and 
cyclophosphamide is currently being investigated as part of Studies BO29563, 
GO29831 , WO39392 (IMpassion031), and WO39391 (IMpassion030).  Thus far, 
reported adverse events observed were similar to those experienced with the individual 
components of the study treatment and have generally been manageable.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
34/Protocol BO40747 , Version 6 See Section s 1.3.1  and 1.3.2  and the Atezolizumab Investigator’s Brochure for additional 
details.  Atezolizumab in combination with pertuzumab and trast uzumab is currently 
being investigated as part of Study  GO29831.  No new safety signals have been 
reported and the study is ongoing.  
The risk of overlappi[INVESTIGATOR_123404], 
cyclophosphamide, paclitaxel, trastuzumab, pertuzumab , and trastuzumab emtansine is 
thought to be manageable based on the mechanism of action of each product.  In order 
to evaluate any potential risks associated with this combination regimen, a safety review 
of the first 12  patients enrolled (appro ximately 6 patients per arm) will be performed by 
[CONTACT_123485] (without stoppi[INVESTIGATOR_123405]) after completion of 4  cycles of 
atezolizumab/placebo and doxorubicin   cyclophosphamide chemotherapy and 2  cycles 
of atezolizumab/placebo and paclitaxel   trastuzumab   pertuzumab chemotherapy.  
Furthermore, the first 26  patients of the study will be part of the safety cohort that will be 
closely monitored with additional cardiac monitoring ( see Appendix  1).  To reduce the 
risk of cardiac dysfunction with the c ombination used in this study, patients with 
cardiopulmonary dysfunction will be excluded from the study.  Cardiac function will be 
closely monitored for all patients, including regular measurements of left ventricular 
ejection fraction (LVEF) throughout t he study.  An iDMC will regularly review unblinded 
safety data (see  Section  3.2.2 ). 
This trial will enroll patients with early (T2 4, N13, M0) HER2 -positive breast cancer.  
HER2 status of the tumor will be centrally confirmed.  The study population will be such 
that the final population will contain no more than 50% of patients with 
hormone  receptorpositive disease.  Given the rate of rec urrence fo r these patients with 
very high -risk HER2 -positive breast cancer, this population is considered appropriate for 
trials of novel therapeutic candidates.  On the basis of recent results from 
Study  BO27938, trastuzumab emtansine has been added as a recommended treatment 
option in the adjuvant setting for patients who do not achieve pCR and will be given in 
combination with atezolizumab/placebo.   The anticipated benefit risk ratio for 
atezolizumab in combination with trastuzumab, pertuzumab, chemother apy, and 
trastuzumab emtansine is expected to be acceptable in this setting.  
In the setting of the COVID -[ADDRESS_138825] the incidence or severity of COVID -19. 
A possible consequence of inhibiting the PD -1/PD -L1 pat hway may be the modulation of 
the host  immune response to acute infection, which may result in immunopathology or 
dysregulated immune system defenses.  In nonclinical models, PD -1/PD -L1 blockade 
appears to be associated with serious exacerbation of infla mmation in the setting of 
acute (as opposed to chronic) viral infection with lymphocytic choriomeningitis virus 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
35/Protocol BO40747 , Version 6 (Clone  13; Frebel  et al. 2012).  However, there are insufficient and inconsistent clinical 
data to assess if outcome from COVID -19 is al tered by [CONTACT_123486].  
Severe COVID -19 appears to be associated with a cytokine  release syndrome (CRS) 
involving the inflammatory cytokines interleukin (IL) -6, IL-10, IL -2, and interferon - 
(Merad  and Martin  2020).  While it is not known , there m ay be a potential for an 
increased risk of an enhanced inflammatory response if a patient develops acute 
SARS -CoV-2 infection while receiving atezolizumab.  At this time, there is insufficient 
evidence for causal association between atezolizumab and an inc reased risk of severe 
outcomes from COVID -19. 
There may be potential synergy or overlap in clinical and radiologic features for 
immune -mediated pulmonary toxicity with atezolizumab and clinical and radiologic 
features for COVID -19related interstitial pneu monia.  Thus, investigators should use 
their clinical judgment when evaluating and managing patients with pulmonary 
symptoms.  
Neutropenia and lymphopenia associated with chemotherapy may increase the risk for 
developi[INVESTIGATOR_123406] a tezolizumab in combination with 
chemotherapy.  
2. OBJECTIVES AND ENDPO INTS  
This study (also known as IMpassion050) will evaluate the efficacy and safety of 
atezolizumab compared with placebo when given in combination with neoadjuvant 
dose -dense anthracycline (doxorubicin)   cyclophosphamide followed by 
[CONTACT_114461]   trastuzumab   pertuzumab (ddAC -PacHP) in patients with early 
HER2 -positive breast cancer at high risk of recurrence (T2 4, N13, M0).  Specific 
objectives and corresponding endpoints for the study a re outlined below.  
2.1 EFFICACY OBJECTIVES  
2.1.1  Co-Primary Efficacy Objective  
The co-primary efficacy objective for this study is to evaluate the efficacy of 
atezolizumab   ddAC -PacHP compared with placebo   ddAC -PacHP in the EBC setting  
in the PD -L1positive (IC 1/2/3) and the ITT population  on the basis of the following 
endpoint:  
 pCR, defined as the absence of residual invasive cancer on hematoxylin and eosin 
evaluation of the complete resected breast specimen and all sampled regional 
lymph nodes following comple tion of neoadjuvant systemic therapy (NAST ; 
i.e., ypT0/is ypN0 in the current AJCC staging system, 8th edition) in the 
PD-L1positive and ITT population s 
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
36/Protocol BO40747 , Version 6 2.1.2  Secondary Efficacy Objectives  
The secondary efficacy objectives for this study are as follows:  
 To evaluate the efficacy of atezolizumab   ddAC -PacHP compared with 
placebo   ddAC -PacHP in the EBC setting on the basis of the following endpoints:  
– pCR (ypT0/is ypN0) based upon hormone receptor status (estrogen receptor 
[ER]/progesterone receptor [PgR]  positive or ER/PgR negative)  
– pCR (ypT0/is ypN0)  in the PD -L1negative (IC 0) population  
– Event -free survival (EFS), defined as the time from randomization to the 
first documented disease recurrence, unequivocal tumor progression 
determined by [CONTACT_123487], or death from any cause, whichever 
occurs first, in all patients and based upon hormone receptor status (ER/PgR 
positive or ER/PgR negative) and PD -L1 status (IC 0; IC 1/2/3)  
– DFS, defined as the time from surgery to the first documented disease 
recurrence or death from any cause, whichever occurs first, in all patients who 
undergo surgery  and based upon hormone receptor status (ER/PgR positive or 
ER/PgR negative) and PD -L1 status (IC 0; IC 1/2/3)  
– OS, defined as the time from randomization to death from any cause in all 
patients  and based upon hormone receptor status (ER/PgR positive or ER/PgR 
negative) and PD -L1 status (IC 0; IC 1/2/3)  
 To evaluate patient -reported outcomes ( PROs) of function (role, physical) and 
health -related quality of life (HRQoL ) associated with atezolizumab   ddAC-PacHP 
compared with placebo   ddAC-PacHP , as measured by [CONTACT_123488] (EORTC) Quality of Life 
Questionnaire Core  30 (QLQ -C30), on the basis of the following endpoint:  
– Mean and mean changes from baseline score in function (role, physical) and 
global health status (GHS)/HRQoL by [CONTACT_74351], and between 
treatment arms as assessed by [CONTACT_123476]/HRQoL scales of the 
EORTC  QLQ -C30 
 
2.1.3  Exploratory Efficacy Obj ectives  
The exploratory efficacy objectives for this study are as follows:  
 To evaluate PROs of disease/treatment related symptoms and emotional, social 
function associated with atezolizumab   ddAC-PacHP by [CONTACT_20368] -C30 on 
the basis of the following endpoint:  
– Mean and mean changes from baseline score in disease/treatment related 
symptoms and emotional, social function by [CONTACT_123489]/scales and the emotional, 
social function scales of  the EORTC QLQ -C30 
 To evaluate any treatment burden patients may experience associated with the 
addition of atezolizumab  to ddAC -PacHP compared with placebo   ddAC -PacHP, as 
measured by a single item (GP5:  “I am bothered by [CONTACT_123490]”) fro m 
the physical well -being subscale of the Functional Assessment of Cancer 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
37/Protocol BO40747 , Version 6 TherapyGeneral ( FACT -G) quality -of-life instrument on the basis of the following 
endpoint:  
– Proportion of patients reporting each response option at each assessment 
timepoint by [CONTACT_123491]5 from the FACT -G 
 To evaluate patient’s health utility as measured by [CONTACT_43433] 5 Dimension, 
5-Level (EQ -5D-5L) questionnaire to generate utility scores for use in economic 
models for reimbursement on the basis of the following endpo int: 
– Utility scores of the EQ -5D-5L questionnaire  
 
2.2 SAFETY OBJECTIVE  
The safety objective for this study is to evaluate the safety of 
atezolizumab   ddAC -PacHP compared with placebo   ddAC -PacHP in the neoadjuvant 
setting and the safety of atezolizumab comb ined with trastuzumab   pertuzumab (or 
combined with trastuzumab emtansine ) compared with placebo combined with 
trastuzumab   pertuzumab (or combined with trastuzumab em tansine ) in the adjuvant 
EBC setting on the basis of the following endpoints:  
 Incidence  and severity of adverse events, with severity determined according to 
National Cancer Institute Common Terminology Criteria for Adverse Events, 
Version  5.0 (NCI CTCAE v5.0)  
 Change from baseline in targeted vital signs  
 Change from baseline in targeted clin ical laboratory test results  
 
2.3 PHARMACOKINETIC OBJE CTIVE  
The pharmacokinetic (PK) objective for this study is to characterize the PK profile of 
atezolizumab, pertuzumab, and trastuzumab when given in combination and of 
atezolizumab and trastuzumab emtansine  when given in combination on the basis of the 
following endpoints:  
 Peak and trough (maximum serum concentration observed [C max] and minimum 
serum concentration under steady -state conditions within a dosing interval [C min]) of 
atezolizumab concentrations i n serum at specified timepoints  
 Trough concentration for pertuzumab and trastuzumab in serum at specified 
timepoints  
 Peak and trough concentration for trastuzumab emtansine in serum at specified 
timepoints  
 
2.4 IMMUNOGENICITY OBJEC TIVES  
The immunogenicity obje ctive for this study is to evaluate the immune response to 
atezolizumab, trastuzumab, pertuzumab, and trastuzumab emtansine  on the basis of the 
following endpoints:  
 Incidence of treatment -emergent anti -drug antibodies (ADAs) to atezolizumab and 
its impact on pharmacokinetics, efficacy, and safety  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
38/Protocol BO40747 , Version 6  Incidence of treatment -emergent ADAs to trastuzumab, pertuzumab, and 
trastuzumab emtansine  
 
The exploratory immunogenicity objective for this study is to evaluate potential effects of 
ADAs on the basis of the follo wing endpoint:  
 Relationship between ADA status and efficacy, safety, or PK endpoints  
 
2.5 BIOMARKER OBJECTIVES  
The secondary biomarker objectives for this study are as follows:  
 To evaluate pCR (ypT0/is ypN0), EFS, DFS, and OS based upon PIK3CA mutation 
status  
 
The exploratory biomarker objectives for this study are as follows:  
 To evaluate pCR (ypT0/is ypN0) based upon stromal TIL infiltration level  
 To evaluate pCR (ypT0/is ypN0) based upon immune gene expression level  
 To identify biomarkers and/or changes in biomarkers that are predictive of response 
to atezolizumab   ddAC -PacHP  (i.e., predictive biomarkers), are early surrogates of 
efficacy, are associated with progression to a more severe disease state 
(i.e., prognostic biomarkers), are associated with acquired resistance to 
atezolizumab   ddAC -PacHP , are associated with suscep tibility to developi[INVESTIGATOR_123407] 
(i.e., safety biomarkers), can provide evidence of atezolizumab   ddAC -PacHP  
activity (i.e.,  pharmacodynamic biomarkers), or can increase the knowledge and 
understanding of disease biology and drug safety, on the basis of the following 
endpoint:  
­ Relationship between biomarkers (or changes in biomarkers) in blood and 
tumor tissue and efficacy, safety, PK, immunogenicity, or other biomarker 
endpoints  
 To eva luate biomarkers in association with EFS, DFS, and OS  
 To evaluate post -surgical circulating -tumor DNA (ctDNA) with outcome  
 To evaluate ctDNA on -treatment changes associated with 
atezolizumab   ddAC -PacHP compared with placebo   ddAC -PacHP and to evaluate 
its association with EFS, DFS, and OS 
 
3. STUDY DESIGN   
3.1 DISCONTINUATION OF E XPERIMENTAL TREATMEN T AND 
UNBLINDING AT STUDY LEVEL  
On 26 January 2021, the iDMC met and conducted a review of unblinded safety and 
efficacy data.  Following their review of the data, the iDMC recommended to stop 
randomized treatment assignment with atezolizumab or placebo.   Study treatment 
without atezolizumab/placebo should be continued through the completion of the 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
39/Protocol BO40747 , Version 6 adjuvant treatment phase.   On 3 February 2021 , the Sponsor issued a n “Urgent Safety 
Measure Dear Investigator Letter” (USM DIL) communicating the request to stop  
treatment with atezolizumab or  placebo and  inform ed about  the unblinding of the study.  
The addition of atezolizumab did not result in an increase in the pCR rate c ompared with 
the co ntrol arm both in the ITT and  the PD -L1positive  population.  There were 
four Grade  5 adverse events in the atezolizumab arm, which occurred in the 
neoadjuvant phase.  The iDMC commented that the difference in death between the 
two arms was not significant but in the margin of significance.  Considering that the 
majority of the patients had undergone surgery, their recommendation was to stop the 
atezolizumab/placebo treatment administration from an ethical perspective.  
3.1.1  Implicati ons of Unb linding on Study Desi gn and Assessments  
Following the discontinuation of atezolizumab or placebo, patients should continue  all 
other study drugs  without atezolizumab or placebo and follow study assessments and 
follow -up assessments as described in Appendix  1.  Following the implementation of 
Protocol , Version  5, the PK and ADA sample collection for atezolizumab, trastuzumab , 
and pertuzumab (or trastuzumab emtansine) is only required at the treatment 
discontinuation visit  (Appendix  2). 
The study was  unblinded on 5 February 2021 and the unblinding date will be used as the 
clinical cutoff date for the primary analysis.  As pe r Statistical Analysis Plan  (SAP) , 
patients with missing pCR assessment will be counted as not ac hieving  pCR in the 
analysis ; this includes patients who have not yet undergone surgery and pCR 
assessment due to the early unblinding of the study.  Patients w ho are still in the 
neoadjuvant phase of the study at the time of unblinding should continue their study 
treatment without atezolizumab or  placebo and undergo surgery and pathological 
assessment as per study protocol  followed by [CONTACT_123492].  
3.[ADDRESS_138826] cancer at high risk of recurrenc e (T24, 
N13, M0). 
Patients who have histologically confirmed invasive HER2 -positive breast cancer with a 
primary tumor size   2 cm by [CONTACT_123493] 
(node  positivity pathologically confirmed by [CONTACT_123494] -needle aspi[INVESTIGATOR_123408] -needle biopsy) 
are eligible.  Axillary surgery (including sentinel -node biopsy) prior to neoadjuvant 
treatment is prohibited.  HER2 positivity of the primary breast tumor will be confirmed by 

 
[CONTACT_120422] —F. Hoffmann -La [COMPANY_002] Ltd  
40/Protocol BO40747 , Version 6 a central laboratory (see Appendix  7 and Appendix  8).  Patients whose tumors are not 
centrally confirmed to be HER2 -positive will not be eligible.  Patients whose tumor tissue 
is not evaluable for PD -L1 by [CONTACT_123495].  Patients who do not 
initially meet eligibility criteria may  be re -screened once.  
Figure  1 presents an overview of the study design.  The schedules of activities are 
provided in  Appendix  1, Appendix  2, and Appendix  3.

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
41/Protocol BO40747 , Version 6 Figure  1 Study Schema  
 
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
42/Protocol BO40747 , Version 6 Figure  1 Study Schema  (cont.)  
 
Notes:   Following the receipt of the Urgent Safety Measure Dear Investigator Letter (USM DIL) dated 3 February 2021, patients will no longer 
receive atezolizumab or placebo.  
If trastuzumab emtansine is discontinued for toxicity not considered related to the trastuzumab component of the drug, treatm ent can be switched 
to trastuzumab and pertuzu mab with atezolizumab/placebo to complete a total of [ADDRESS_138827] to discontinue al l study 
treatment . 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
43/Protocol BO40747 , Version 6 Figure  1 Study Schema (cont.)   
ddAC -PacHP   dose -dense anthracycline (doxorubicin)   cyclophosphamide followed by [CONTACT_114461]   trastuzumab   pertuzumab; EBC   early breast 
cancer; ECHO   echocardiogram; ER   estrogen receptor; HER2   human epi[INVESTIGATOR_5169] 2 ; LN   lymph node; MUGA   multiple -gated 
acquisition (scan); pCR   pathologic complete response; PR   progesterone receptor; Rand   randomization.  
a LN determined through imaging and biopsy.   Ulcerating or inflammatory breast  (e.g.,  erythema and/or dermal involvement, and/or pathologic 
detection of tumor cells in dermal lymphatics)  cancer are excluded.  
b A real -time structured safety assessment of the first 12 patients enrolled (approximately 6 patients per arm) will be perfor med by [CONTACT_123496] (without stoppi[INVESTIGATOR_123405]) after the first [ADDRESS_138828] completed 4 cycles of atezolizumab/placebo   ddAC chemotherapy and 
2 cycles of atezolizumab/placebo   PacHP chemotherapy.  
c The first 26 patients enrolled (approximatel y 13 patients per arm) will undergo additional cardiac safety monitoring, including an additional ECHO 
or MUGA scan after the second dose of ddAC chemotherapy, as part of a cardiac safety cohort.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
44/Protocol BO40747 , Version [ADDRESS_138829] consented and ar e eligible will be randomized in a 1:[ADDRESS_138830] cancer.  
Randomization will be stratified by [CONTACT_123497]: 
 Stage at diagnosis (T2 ; T3 or 4) as determined by [CONTACT_123498], 
8th edition (specifically according to the Anatomic Stage Group rules)  
 Hormone receptor status (ER positive and/or PgR positive; ER negative and 
PgR negative)  
– Hormone receptor positive status will be capped at 50%.  
 PD-L1 status (IC 0; IC 1/2/3)  
 
Study treatment administration should begin within 7 days after randomization.  
During the neoadjuvant phase (i.e., prior to surgery; Cycles 1 8), all patients will receive:  
 Atezolizumab  or placebo 840 mg IV every 2 weeks (Q2W) for 4 cycles (Cycles  14) 
 ddAC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV) given with 
granulocyte  colonystimulating factor (G -CSF), granulocyte macrophage 
colonystimulating factor, or pegylated granulocyte colony stimulating factor 
support in accordance to local guidelines Q2W for 4  cycles (Cycles 1 4) 
 
Followed by:  
 Atezolizumab or placebo 1200 mg IV every 3 weeks (Q3W) for 4  cycles 
(Cycles  58) 
 Paclitaxel 80 mg/m2 IV every week (QW) for 4 cycles  (Cycles  58) 
 Trastuzumab 6  mg/kg IV (with an initial 8 -mg/kg IV loading dose) Q3W for 4  cycles 
(Cycles  58) 
 Pertuzumab 420  mg IV (with an initial 840 -mg IV loading dose) Q3W for 4  cycles 
(Cycles  58) 
 
A cycle will be considered missed during the neoadjuva nt phase if the subsequent cycle 
cannot be administered within [ADDRESS_138831] dose for Cycles  1[ADDRESS_138832] dose for Cycles 5 8.  In this situation, make -up treatment of missed cycles of 
chemotherapi[INVESTIGATOR_123409] -surgery (se e Appendix  11) prior to the adjuvant phase 
(described below).  
During the adjuvant phase (i.e., post -surgery; Cycles 9 22), the  following study 
treatments will be continued Q3W to complete up to a total duration of 52  weeks 
(i.e., maximum of 18 cycles within 1 year) of HER2 -targeted therapy, inclusive of therapy 
given both in the neoadjuvant and adjuvant setting:  
 Atezolizumab/plac ebo 1200 mg IV Q3W  
 Trastuzumab 6 mg/kg IV (with an initial 8 -mg/kg IV loading dose) Q3W  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
45/Protocol BO40747 , Version 6  Pertuzumab 420 mg IV (with an initial 840 -mg IV loading dose) Q3W  
 
Patients who do not achieve a pCR as defined in the protocol (i.e.,  ypT0/is ypN0 in the 
current AJCC staging system, 8th edition) have the option of receiving adjuvant 
treatment as outline d above or alternatively:  
 Atezolizumab or placebo as per initial treatment assignment 1200  mg IV Q3W 
combined with trastuzumab emtansine 3.6  mg/kg IV Q3W  
 
Treatment assignment will not be unblinded following pCR evaluation.   The treatment 
decision for patients who do not achieve a pCR after neoadjuvant therapy is per 
investigator discretion.  
Atezolizumab/placebo   trastuzumab   pertuzumab will be given to complete  52 weeks  of 
HER2 -directed therapy  (i.e., a maximum of 18 cycles of HER2 -directed therapy) .  
Adjuvant atezolizumab/placebo   trastuzumab emtansine will be given for 14  cycles.  
If trastuzumab emtansine is discontinued for toxicity not considered related to the  
trastuzumab component of the drug, treatment can be switched to trastuzumab and 
pertuzumab with atezolizumab/placebo to complete a total of [ADDRESS_138833] be discontinued from all study treatment  and will be managed as per local practice.  
Any patient who receives non -protocol therapy prior to surgery will be discontinued from 
study treatment and will be managed as per local practice; these patients will remain in 
the follow -up phase of the  study.  Fo r patients who do not achieve pCR, it is 
recommended to continue on study treatment with the option to receive 
atezolizumab/placebo   HP or atezolizumab/placebo   trastuzumab emtansine on the 
basis of a benefit risk assessment for the individual patient.  Alternatively, as per 
investigator discretion, local clinical guidelines for management of non -pCR patients may 
be followed; the patient  will remain in the follow -up phase of the study . 
Patients who discontinue one or more of the study treatment components  due to toxicity 
should not be automatically withdrawn from all study treatments.  Guidelines for dosage 
modification and treatment interruption or discontinuation for patients who experience 
adverse events are provided in Table  2, Table  3, Table  4, Appendix  11, 
and Appendix  12. 
Patients who discontinue early from all components of the pre - or post -operative study 
treatment should remain in the follow -up phase of the study .  Patients who discontinue 
prematurely from the study will not be replaced.  
The primary efficacy endpoint (pCR; ypT0/is ypN0) will be establ ished via local review 
following completion of neoadjuvant therapy and surgery.  In line with pCR guidance 
from the FDA (2014), pathologists who review study specimens will conduct review of 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
46/Protocol BO40747 , Version [ADDRESS_138834] infusion.  Platelet counts should be checked pr ior to surgery and 
should be  75,000 cells/ L.  Patients must undergo full axillary lymph node dissection at 
the time of definitive surgery.  Sentinel lymph node procedure alone is not permitted.  
If surgically feasible, i t is recommended that at least [ADDRESS_138835] local clinical practice (see  Section  4.4.1 ). 
An iDMC will eval uate safety data and study conduct on a regular basis during the study 
until the analysis of the primary endpoint of pCR, after which iDMC review of the study 
data will be discontinued.  An administrative interim analysis of efficacy will also take 
place o nce [ADDRESS_138836] 26 patients enrolled (approximately 
13 patient s in the control arm and approximately 13  patients in the atezolizumab arm) 
after all [ADDRESS_138837] 12 patients enrolled (approximately 6  patients 
in the control arm and approximately 6 patients in the atezolizumab arm) will be 
conducted without stoppi[INVESTIGATOR_123405].  This safety evaluation by [CONTACT_123499] [ADDRESS_138838] 
completed 6 cycles of neoadjuvant therapy (4 cycles of atezolizumab/placebo   ddAC 
and 2  cycles of atezolizumab/placebo   PacHP).  
Following completion of study treatment and surgery, all patients will continue to be 
followed for efficacy, safety, an d PRO objectives until the end of the study.  No interim 
efficacy analyses for early stoppi[INVESTIGATOR_123410], although an administrative interim 
analysis of efficacy is planned (see Section  3.2.2 ).  Safety assessments will include the 
occurrence and severity of adverse events and laboratory abnormalities graded per 
NCI CTCAE v5.0.  Laboratory safety assessments will include the regular monitori ng of 
hematology and blood chemistry.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
47/Protocol BO40747 , Version [ADDRESS_138839] 26 patients enrolled (approximately 13  patients in 
the control arm and approximately 13 patients in the atezolizumab arm) after all 
[ADDRESS_138840] discontinued the neoadjuvant portion of the study.  
Subsequent safety reviews will occur  periodically during the study, as defined in the  
iDMC Charter, until analysis of the primary endpoint (refer to the iDMC Charter).  
An administrative interim efficacy analysis is planne d once [ADDRESS_138841] been 
enrolled, completed neoadjuvant treatment and undergone surgery, with the results 
reviewed by [CONTACT_68200].  
All summaries and analyses for the iDMC review will be prepared by [CONTACT_123500] (iDCC).  
After r eviewing the data, the iDMC will provide a recommendation to the Sponsor as 
described in the iDMC Charter.  Final decisions will rest with the Sponsor.  
3.[ADDRESS_138842] patient  in the study .  The Sponsor may decide to terminate 
the study at any time.  
3.4 RATIONALE FOR STUDY DESIGN  
3.4.1  Rationale for Atezolizumab Dose and Schedule  
Atezolizumab will be administered at a fixed dose of 840 mg Q2W by [CONTACT_123501] 
(Cycles  14).  The atezolizumab dosing regimen will be s witched to 1200  mg Q3W for 
subsequent cycles.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
48/Protocol BO40747 , Version 6 The average atezolizumab exposure following the 840 mg Q2W dosage  (approved by 
[CONTACT_69391]  2019)  is expected to be similar to that of 1200  mg Q3W 
(Tecentriq U.S. Package Insert).  Anti -tumor activity has been observed across doses 
ranging from 1  mg/kg to 20 mg/kg Q3W.  In Study PCD4989g, the maximum tolerated 
dose of atezolizumab was not reached , and no dose -limiting toxicities were observed at 
any dose.  The fixed dose of 1200 mg Q3W (equivalent to an ave rage 
body  weightbased dose of 15  mg/kg Q3W) was selected on the basis of both 
nonclinical studies and available clinical PK, efficacy, and safety data ( Deng  et al.2016 ; 
refer to the to the Atezolizumab Investigator's Brochure for details).  
Based on the un derstanding of population -PK variability and atezolizumab 
concentration tumor dynamic relationship, [ADDRESS_138843] comparable efficacy and safety profiles.  
3.4.2  Rationale for Chemotherapy Choice and Schedule  
The backbone chemotherapy regimens (anthracycline followed by [CONTACT_123502]) used with 
HER2 -directed therapy in the neoadjuvant part of this study are based on published 
data,  routine clinical usage, as well as established clinical practice guidelines 
(e.g.,  Senkus  et al. 201 3; Gradishar et al 2017; Curigliano et al. 2017) for patients with 
high-risk, HER2 -positive EBC, in combination with pertuzumab and trastuzumab.  The 
doses of chemotherapy in this trial are all consistent with the prescribing information for 
each agent.  
NCCN-preferred neoadjuvant/adjuvant regimens for HER2 -positive EBC are AC or ddAC 
followed by [CONTACT_123503].  As per 
NCCN guidelines, pertuzumab can be added to trastuzumab -containing regimens 
including AC -paclitaxel (various schedules) for patients with HER2 -positive EBC and a 
tumor size  [ADDRESS_138844].  Gallen Guidelines also 
recommended dual anti -HER2 therapy with pertuzumab and trastuzumab and 
chemotherapy in the neoadjuvant setting for high -risk, HER2 -positive patients.  The 
recommended chemotherapy regimen is anthracycline followed by [CONTACT_123504]2 therapy (Curigliano  et al. 2017).  
Citron et al. (2003) compared standard Q3W and accelerated Q2W schedules of 
conc urrent doxorubicin and cyclophosphamide followed by [CONTACT_114461], or sequential 
doxorubicin, paclitaxel, and cyclophosphamide.  There was a significant improvement in 
OS with dose -dense therapy (risk ratio   0.69, p  0.013), with 3 -year OS of 92% in the 
dose-dense arms and 90% in the Q3W arms.  The SWOG S0221 study has shown that 
patients treated with weekly paclitaxel demonstrated equivalent efficacy to those treated 
with Q2W paclitaxel (Budd  et al. 2017).  
Combining dose -dense AC followed by [CONTACT_123505]2 -targeted therapy appears to 
be safe from a cardiac point of view, and toxicity does not seem to be increased in 
relation to previous non dose -dense HER2 clinical trials (Dang  et al. 2008; 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
49/Protocol BO40747 , Version 6 Dang  et al. 2010; Hudis et al. 2014).  The BERENICE study explo red the regimen that is 
used in the current study , namely ddAC followed by [CONTACT_123506]; pertuzumab and 
trastuzumab were given concurrently with the taxane.  The regimen was active, with high 
tpCR rate.   Cardiac and general safety of this regimen was as e xpected and was 
consistent with the known pertuzumab, trastuzumab, and chemotherapy safety profiles 
(Swain  et al. 2018).  
3.4.[ADDRESS_138845] cancer at high risk of 
recurrence (T2 4, N13).  Patients  are required to have histologically confirmed invasive 
HER2 -positive breast cancer with a primary tumor size  2 cm and node -positive disease 
(node  positivity pathologically confirmed by [CONTACT_123494] -needle aspi[INVESTIGATOR_123411] -needle 
biopsy).  H ER2 status will be centrally confirmed.   Based on observations in 
Study  WO30085 in patients with HER2 -positive advanced breast cancer, the expected 
proportion of PD -L1positive (IC 1/2/3) patients in Study  BO40747 is approximately 40% 
(using the Ventana an tiPD-L1 SP142 immunohistochemistry assay ; 
Emens  et al. 2018).  
Breast  cancers over -expressing HER2 are the most aggressive type of breast cancers.  
Although  current therapi[INVESTIGATOR_123412], there are still t hose who remain at high risk for recurrence and who have poor 
long-term outcomes.  These patients are largely identified using clinical parameters, 
including tumor size  [ADDRESS_138846] tumors  [ADDRESS_138847] chemotherapy was 
84% (Gianni  et al. 2016).  Data from the APHINITY study have demonstrated high 
invasive DFS rates at 3 years (94.1%) and 4  years (92.3%) with adjuvant trastuzumab 
and pertuzumab plus chemotherapy  (von Minckwitz et al. 2017) .  However, in patients 
with node -positive disease, these values were numerically lower at both 3  years (92%) 
and 4  years (89.9%).  Pa tients with node -positive disease fared worse compared with 
the ITT  population when treated with adjuvant chemotherapy   trastuzumab and 
pertuzumab in the APHINITY clinical trial (invasive DFS HR 0.77 vs. 0.81).  
The patient population for this study was se lected to target those patients who are at 
highest risk for recurrence and where the potential for cancer immunotherapy to improve 
long-term patient outcomes can have the greatest impact.  
3.4.4  Rationale for Control Group and Combination with 
Atezolizumab  
The co ntrol group for this study is current SOC for high -risk patients with HER2 -positive 
EBC.  The combination of chemotherapy with trastuzumab and pertuzumab is approved 
for use in the neoadjuvant setting and adjuvant continuation of this combination therapy 
is currently approved in the [LOCATION_002] and European Union.  The NCCN guidelines 
recommend the usage of AC -taxane -HP as pre -operative/adjuvant therapy in patients 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
50/Protocol BO40747 , Version 6 with  T2 or  N1 HER2 -positive, early -stage breast cancer (Curigliano  et al. 2017; 
Associa tion of Gynecologic Oncology [AGO] Guidelines 2018; Denduluri  et al. 2018; 
NCCN  Guidelines Version  4.2017 [Gradishar et al. 2018]).  Although  guidelines have yet 
to be updated with recent APHINITY data, the [ADDRESS_138848] Cancer Clinical 
Practice Guidelines also consider the usage of trastuzumab   pertuzumab combination 
with chemotherapy as an acceptable option as neoadjuvant therapy  
(Senkus  et al. 2013) . 
It is hypothesized that an important mechanism of action of therapeutic antibodies such 
as trastuzumab and pertuzumab is to induce cellular immunity via interactions with the 
Fc fragment of the molecule and/or destroy malignant cells resultin g in release of tumor 
antigens for uptake by [CONTACT_488] -presenting cells, which in turn upregulate immune 
effector cells.  The combination of these agents with an anti PD-L1 inhibitor might help 
to further enhance anti -tumor immune responses.  
Nonclinical mode ls provid e support for this hypothesis.  It has been demonstrated that 
the addition of PD -1:PD -L1 blockade improves the therapeutic activity of an anti -HER2 
monoclonal antibody in a murine model of HER2 -positive breast cancer 
(Stagg  et al. 2011).  This is supported by [CONTACT_123507], pertuzumab, and 
chemotherapy results in increased tumor immune infiltrate compared with any of the 
agents alone or in combinations that do  not includ e atezolizumab (data on file).  These 
findings suggest that anti PD-L1 immunostimulatory approaches may further capi[INVESTIGATOR_123413] e-mediated effects of therapeutic antibodies such as trastuzumab and 
pertuzumab.  
3.4.5  Rationale for Trastuzumab E mtansine in Combination with 
Atezolizumab as Adjuvant Treatment Option  
Results from Study BO27938 (Katherine) demonstrated a significant reduction in the risk 
of recurrence of invasive breast cancer or death in patients with HER2 -positive early 
breast canc er with residual invasive disease after completion of neoadjuvant therapy 
who were treated with adjuvant trastuzumab emtansine compared with those treated 
with adjuvant trastuzumab (HR   0.50; 95% CI, 0.39 0.64; p   0.001 ; 
von Minckwitz  et al. 2019).  These data resulted in a recent update of the NCCN 
guidelines that recommend trastuzumab emtansine for patients with residual disease for 
14 cycles.  The guidelines further recommend to switch treatment to 
trastuzumab   pertuzumab in patients who have to d iscontinue trastuzumab emtansine 
for toxicity to complete 1  year of HER2 -targeted therapy (NCCN 2019).  
At the discretion of the investigator, the adjuvant treatment options offered in the study 
(BO40747) for patients not achieving pCR are  trastuzumab emtan sine in combination 
with atezolizumab/placebo as assigned at randomization without unblinding of the 
treatment arm s, or atezolizumab/placebo   trastuzumab   pertuzumab.  This study 
(BO40747) will explore trastuzumab emtansine in combination with atezolizumab in 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
51/Protocol BO40747 , Version 6 patients with non -pCR with exposure in a limited number of patients .  Based on the 
assumption that 227 patients will be randomized to the experimental arm, an estimated 
drop-out rate of 10%, and an estimated pCR rate of 80% in the experimental arm, 
approximately 41 patients will be eligible to receive atezolizumab   trastuzumab 
emtansine based on their non -pCR status.  Similarly, 82 patients in the control arm are 
estimated to be eligible to receive placebo   trastuzumab emtansine based on their 
non-pCR status.  
3.4.6  Rationale for Pathologic Complete Response as Primary 
Endpoint  
The co-primary objective of this study is to evaluate the efficacy of 
atezolizumab   ddAC -PacHP compared with placebo   ddAC -PacHP  in patients with 
newly diagnosed HER2 -positive breast cancer  in the ITT and PD -L1positive patient 
populations .  Efficacy will be assessed using pCR.  
pCR was selected as the primary efficacy endpoint because  it is a validated, meaningful 
measure of respon se to therapy, and on the basis of data from several analyses and 
clinical trials and meta -analyses, there is an association between the pCR status of a 
patient and long -term outcomes (Liedtke et al. 2008; von  Minckwitz  et al. 2012; 
Cortazar  et al. 2014).  More recently, data from the I -SPY [ADDRESS_138849] shown that 
achieving pCR is a strong predictor of EFS and distant recurrence -free survival, 
EFS HR 0.21 [95% CI: 0.0 5 to 0.85]; DDFS HR 0.22 [95% CI: 0.08  to0.70] in patients 
with HER2 -positive breast cance r (Tripathy et al. 2017) . 
pCR will be defined as the absence of residual invasive cancer on hematoxylin and 
eosin evaluation of the complete resected breast specimen and all sampled regional 
lymph nodes following completion of NAST, in line with the FDA an d European 
Medicines Agency (EMA) guidance for industry on pCR endpoints (i.e.,  ypT0/Tis ypN0 in 
the current AJCC staging system).  
3.4.[ADDRESS_138850] that the expression of PD -L1 in tumors 
correlates with response to anti PD-1 and anti PD-L1 monotherapy 
(Topalian  et al. 2012; Herbst et al. 2014; Borghaei et al. 2015; Fehrenbacher  et al. 2016; 
Herbst  et al. 2016; Rosenberg et al. 2016; Schmid et  al. 2018).  Therefore, given the 
mode of action of  atezolizumab, PD -L1 is considered a potential candidate to predict 
response to treatment.  However, emerging data on the basis of studies targeting the 
PD-1/PD -L1 pathway showed that the results are complex and ambiguous .  Contributing 
factors are PD -L1 variability between different assays, status of the biopsy, and the 
dynamic expression of PD -L1.  Interestingly, in melanoma, the predictive nature of 
PD-L1 expression seems to depend on whether the disease is early stage or metastatic.  
In resected high -risk Stage  III melanoma, significantly longer recurrence -free survival 
was observed with adjuvant pembrolizumab compared with placebo in the ITT 
population.  Pembrolizumab was similarly effective in patients with PD -L1positive and 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
52/Protocol BO40747 , Version 6 PD-L1negative tumors sugg esting that the benefit of anti PD-1 treatment is not 
dependent on PD -L1 expression in an early disease setting  (Eggermont  et al. 2018) .  
In contrast, advanced melanoma patients treated with pembrolizumab in the metastatic 
setting experienced longer PFS an d OS when their tumors were PD -L1positive 
compared with patients whose tumors were PD -L1negative suggesting a predictive role 
of PD -L1 in this setting (Daud AI et  al. 2016).  On the basis of these findings, it is 
hypothesized that the predictive value of  PD-L1 expression for atezolizumab may differ 
between early versus metastatic disease.  Given the current uncertainty as to whether 
cancer immunotherapy can provide benefits in unselected versus PD -L1selected early 
breast cancer, this study (BO40747) will  enroll an all -comer population but will test 
efficacy in the ITT and PD -L1positive patient populations and stratify randomization on 
the basis of PD -L1 status.  
In the current study, baseline tumor specimens will be collected from patients and tested 
for PD-L1 expression by a central laboratory during the screening period.  
Randomization will be stratified by [CONTACT_4002] -L1 expression  (IC 0 vs. IC 1/2/3) as assessed by 
[CONTACT_9064] (IHC) . 
Other immune markers of interest are TILs.  In HER2 -positive breast c ancer, increased 
TIL concentrations have shown an association with increased frequency of response to 
neoadjuvant therapy and longer survival ( Loi et al. 2014; Salgado et al.  2015a,  2015b; 
Denkert  et al. 2018 ; Ignatiadis et al. 2018 ).  Not all data have shown consistent results 
(Bianchini  et al. 2015).  A standardized methodology for evaluating TILs has been 
established and will be applied to tissue samples in this study to understand the role of 
TILs in clinical benefit of the combination of atezolizumab  and ddAC -PacHP  
(Salgado  et al. 2015a, 2015b) .  In the PANACEA study in patients with HER2 -positive 
metastatic breast cancer treated with trastuzumab and pembrolizumab, the subgroup of 
patients with PD -L1positive tumor status and having 5% or more of TILs  present in the 
metastatic tumor achieved an objective response rate of 39%, while no objective 
responses were observed in the PD -L1negative cohort (Loi  et al. 2016).  
Other exploratory biomarkers, such as potential predictive and prognostic biomarkers 
related to the clinical benefit of the combination of atezolizumab and ddAC -PacHP, 
long-term benefit, tumor immunobiology (e.g.,  TILs, CD8 expression), mechanisms of 
resistance, or tumor type, may be analyzed.  In  addition, phosphatase and tensin 
homolog  may be performed.  
Differences in pCR rates and in long -term outcomes between patients with 
HER2 -positive breast cancer with hormone receptor positive disease and hormone 
receptornegative disease have been reported in several Phase  II/III studies, showing 
lower pCR rates for patients with hormone receptor positive compared with hormone 
receptornegative disease with pCR rates varying from 15%  to 30% (Gianni  et al. 2012; 
Untch  et al. 2016; Zhang and Hurvitz 2016; Swain et al. 2018).  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
53/Protocol BO40747 , Version [ADDRESS_138851] cancer (Schneeweis et al. 2013; Majewski  et al. 2015; 
Loibl  et al. 2016).  Therefore, PIK3CA mutations will also be assessed retrospectively in 
this study.  
In addition to baseline tumor collection, tumor tissue will also be collected by [CONTACT_123508], disease progression, clinical 
benefit of the combination of atezolizumab and ddAC -PacHP, and long -term efficacy.  
Blood samples will be collected at baseline and during the study to evaluate changes in 
biomarkers.  Changes in biomarkers such as cytokines  associated with T -cell activation 
and lymphocyte subpopulations, and ctDNA may provide evidence of biologic activity of 
the combination of atezolizumab and ddAC -PacHP and of their association with 
long-term efficacy outcomes .  Correlations between these biomarkers and safet y and 
efficacy endpoints will be explored to identify blood -based biomarkers that might predict 
which patients are more likely to benefit from the combination of atezolizumab  and 
ddAC -PacHP.  Exploratory biomarkers will also be tested for association with long-term 
efficacy.  
Exploratory research on safety biomarkers may be conducted to support future drug 
development.  Research may include further characterization of a safety biomarker or 
identification of safety biomarkers that are associated with suscepti bility to developi[INVESTIGATOR_123407] .  
Adverse event reports will not be derived from safety biomarker data by [CONTACT_1034], 
and safety biomarker data will not be included in the formal safety  analyses for this 
study.  In addition, safety biomarker data will not inform decisions on patient 
management.  
3.4.8  Rationale for Patient -Reported Outcome Assessments  
EBC is largely asymptomatic, with the majority of newly diagnosed patients exhibiting no 
disea se-specific, discernable symptoms (Barrett et al. 2009; Ryerson  et al. 2015).  
Therefore, toxicities, the corresponding treatment -related symptoms, and their impact 
define the patient experience (i.e., how patients feel and function).  These are important 
aspects to consider helpi[INVESTIGATOR_123414] a novel drug for this 
potentially curable indication.  Treatment -related symptoms associated with EBC 
regimens can have significant impact on patients’ lives, including their ability to con duct 
activities of daily living, on physical functioning, and on emotional and social aspects 
(Petersen  et al. 2016).  Therefore, it is critical to document the burden associated with 
EBC treatment and understand the experience of treatment -related symptom s and their 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
54/Protocol BO40747 , Version [ADDRESS_138852] directly from patients to further inform benefit risk assessment and treatment 
decision making (Montazeri 2008; Au et al. 2010; FDA 2013, 2015;  EMA 2016 ). 
A comprehensive assessment of treatment burden from the patient’s perspective in t his 
study will be conducted and will include a global assessment of the impact of treatment 
on patients’ functioning (role, physical) and HRQoL as secondary endpoints, as well as 
the experience of treatment -related symptoms and their associated level of bo ther and 
the impact on emotional and social functioning as exploratory endpoints.  The 
GHS/HRQoL, functional, and disease/treatment related symptom items and scales of 
the EORTC QLQ -C30 (see Appendix  4) and the treatment bother item GP5 from the 
FACT -G (see  Appendix  5) quality -of-life instrument will all be used to assess patients’ 
treatment burden (see Figure  2). 
Figure  [ADDRESS_138853] 
Cancer  
 
EORTC   European  Organisation for Research and Treatment of Cancer; FACT -G  Functional  
Assessment of Cancer Therapy General; HRQoL   health -related quality of life; 
QLQ -C30   Quality  of Life Questionnaire Core 30.  
 
Given the duration of treatment and the potential for long -term treatment impact, all PRO 
measures will be assessed at specified timepoints while patients are on treatment and 
after treatment disconti nuation as defined in the schedule of activities (see Appendix  1).  
All PRO  data collected will be analyzed per published scoring manuals to support and 
inform the benefit risk assessment of atezolizumab therapy  (Cella  1997; 
Fayers  et al. 2001) . 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
55/Protocol BO40747 , Version [ADDRESS_138854] 2 4, cN13, cM0 HER2 -positive breast cancer 
(tumor  2 cm and lymph node positive) will be enrolled in this study.  
4.1.[ADDRESS_138855] meet the following criteria for study entry:  
 Signed Informed Consent Form  
 Age  18 years at time of signing Informed Consent Form  
 Ability to comply with the study protocol, in the investigator's judgment  
 Confirmed diagnosis of HER2 -positive breast cancer, and hormonal and PD -L1 
status, as documented through  central testing of a representative tumor tissue 
specimen, is required.  
– A formalin -fixed paraffin -embedded (FFPE) tumor specimen in a paraffin block 
(preferred) or at least [ADDRESS_138856] be submitted prior to study enrollment.  Any deviation of the material 
requirements (see Appendix  3) are only allowed after Sponsor’s approval has 
been obtained.  
– HER2 -positive status will be determined on the basis of  pretreatment breast 
biopsy material and defined as an IHC score of 3   or positive by [CONTACT_93756] (ISH; see Appendix  3 and Appendix  7) prospectively assessed by 
a central laboratory prior to study enrollment.  ISH positivity is  defined as a ratio 
of  2 for the number of HER2 gene copi[INVESTIGATOR_123415] 17  copi[INVESTIGATOR_014].  A central laboratory will perform both IHC and ISH 
assays; however, only one positive result is required for eligibility.  
– PD-L1 status through  measurement of IHC will be used for stratification.  The 
maximum PD -L1 score assessed among samples submitted for eligibility will be 
used as the PD -L1 score for the patient.  
– ER/PgR status will be determined centrally based on pretreatment breast 
biopsy material according  to the American Society of Clinical Oncology (ASCO) 
and the College of American Pathologists guidelines (Hammond et al.  2010).  
 Primary breast tumor size of   2 cm by [CONTACT_123509]  
(see Section  4.5.5  for additional details)  
 Stage at presentation:  T2 T4, N1N3, M0 as determined by [CONTACT_123510], 
8th edition  (specifically in accordance with Anatomic Stage group rules ) 
 Pathologic confirmation of nodal involvement with malignancy must be determined 
by [CONTACT_123494] -needle aspi[INVESTIGATOR_123411] -needle biopsy.  Surgical excision of lymph nodes 
(e.g.,  sentinel lymph node biop sy and axillary lymph node biopsy) is not permitted.  
 Patients with multifocal tumors (more than one mass confined to the same quadrant 
as the primary tumor) are eligible provided  at least one focus is sampled and 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
56/Protocol BO40747 , Version 6 centrally confirmed as HER2 -positive (see Appendix  3 for tissue sample 
requirements).  
 Patients with multicentric tumors ( multiple tumors involving more than one quadran t) 
are eligible provided all discrete lesions are sampled and centrally confirmed as 
HER2  positive  (see Appendix  3 for tissue s ample requirements) . 
– In patients with multifocal or multicentric breast cancer, the largest lesion 
should be measured to determine T stage.  
 Patient agreement to undergo appropriate surgical management, including axillary 
lymph node surgery and partial or total mastectomy, after completion of neoadjuvant 
treatment  
 Eastern Cooperative Oncology Group Performance Status of 0 or 1  
 Baseline LVEF  55% measured by [CONTACT_6751] (ECHO) or multiple -gated 
acquisition (MUGA) scans  
 Adequate hematologic and end -organ function, defined by [CONTACT_123511], obtained within 14 days prior to initiation of study treatment:  
– ANC  1.5   109/L (1500 cells/ L) without G -CSF support  
– Lymphocyte count  0.5   109/L (500 cells/ L) 
– Platelet count  100   109/L (100,000 cells/ L) without transfusion  
– Hemoglobin  90 g/L (9 g/dL)  
Patients may be transfused to meet this criterion.  
– AST, ALT, and ALP  2.5   upper limit of normal (ULN)  
– Serum bilirubin  1.5   ULN with the following exception:  
Patients with known Gilbe rt disease:  serum bilirubin level  3  ULN 
– Creatinine clearance  30 mL/min (calculated using the Cockcroft -Gault 
formula)  
– Serum albumin  25 g/L (2.5 g/dL)  
– For patients not receiving therapeutic anticoagulation:  INR or aPTT  1.5   ULN 
within 14 days prior to initiation of study treatment  
– For patients receiving therapeutic anticoagulation:  
INR or aPTT within therapeutic limits for at least 1 week immediately prior 
to initiation of study treatment  
Stable anticoagulant regimen and stable INR during the 14 days 
immediately preceding initiation of study treatment  
 Negative HIV test at screening  
 Negative hepatitis B surface antigen (HBsAg) test at screening  
 Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total 
HBcAb test follo wed by a negative hepatitis B virus (HBV) DNA test at screening  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
57/Protocol BO40747 , Version 6 – The HBV DNA test will be performed only for patients who have a positive total 
HBcAb test.  
 Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV 
antibody test followed b y a negative HCV RNA test at screening  
– The HCV RNA test will be performed only for patients who have a positive 
HCV  antibody test.  
 For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contracept ive methods, and agreement to refrain 
from donating eggs, as defined below:  
– Women must remain abstinent or use contraceptive methods with a failure rate 
of  1% per year during the treatment period and for 5 months after the final 
dose of atezolizumab/plac ebo, [ADDRESS_138857] 
refrain from donating eggs during this same period.  
– A woman is considered to be of childbearing potential if she is postmenarcheal, 
has not reached a postmenopausal state (  12 continuous months of 
amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).  The 
definition of childbearing potential may be adapted for alignment with local 
guidelines or requirements.  
– Examples of contraceptive methods with a failure  rate of  1% per year include 
bilateral tubal ligation, male sterilization, copper intrauterine devices, hormonal 
contraceptives that inhibit ovulation, and hormone -releasing intrauterine 
devices in women with hormone receptor -negative tumors only; the us e of 
hormonal contraceptives and hormone releasing intrauterine devices are 
prohibited in women with hormone receptor positive tumors.  
– The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the prefer red and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.  
 For men:  agreement to remain abstinent (refrain from heterosexual  intercourse) or 
use contraceptive measures, and agreement to refrain from donating sperm, as 
defined below:  
– With a female partner of childbearing potential who is not pregnant, men who 
are not surgically sterile must remain abstinent or use a condom plus an 
additional contraceptive method that together result in a failure rate of  1% per 
year during the treatment period and for 6 months after the final dose of 
doxorubicin and/or cyclophosphamide, [ADDRESS_138858] refrain from donating 
sperm during this same period.  Male patients are encouraged to seek advice 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
58/Protocol BO40747 , Version 6 regarding cryoconservation of sperm prior to commen cing study treatment 
because of the possibility of infertility with chemotherapy.  
– With a pregnant female partner, men must remain abstinent or use a condom 
during the treatment period and for 6 months after the final dose of doxorubicin 
and/or cyclophospha mide, [ADDRESS_138859] to avoid exposing the embryo.  
– The reliability of sexual abstinence should be evaluated in relat ion to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.  
 
4.1.2  Exclusion  Criteria  
Patients who meet any of the following criteria will be excluded from study entry:  
 Prior hi story of invasive breast cancer  
 Stage IV (metastatic) breast cancer  
– Baseline tumor staging determination should be performed in alignment with 
AJCC staging  system, 8th edition (specifically in accordance with Anatomic 
Stage group rules).  
 Patients with synchronous bilateral invasive breast cancer  
 Patients with hormone receptor positive disease (estrogen receptor positive and/or 
progesterone receptor positive)  will be excluded once approximately 227  patients 
(50%  of the total target sample size) with hormone receptor positive disease have 
been enrolled . 
 Prior systemic therapy  for treatment of breast cancer  
 Previous therapy with anthracycline s or taxanes for any  malignancy  
 Ulcerating or inflammatory breast cancer (e.g.,  erythema and/or dermal 
involvement, and/or pathologic detection of tumor cells in dermal lymphatics)  
 Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph 
nodes  
 Sentinel lymph node procedure or axillary lymph node dissection prior to initiation of 
neoadjuvant therapy  
 History of other malignancy within [ADDRESS_138860] a negligible risk of metastasis or death (e. g., 5-year OS of 
 90%), such as adequately treated carcinoma in situ of the cervix, non -melanoma 
skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage  I 
uterine cancer  
 Cardiopulmonary dysfunction as defined by [CONTACT_123512]:  
– History of congestive heart failure of any classification  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
59/Protocol BO40747 , Version 6 – Angina pectoris requiring anti -anginal medication, serious cardiac arrhythmia 
not controlled by [CONTACT_123513], severe conduction abnormality, or 
clinically significant valvular disease  
– High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate 
 100/min at rest, significant ventricular arrhythmia [ventricular tachycardia], or 
higher -grade atrioventricular [AV] -block [second  degree AV -block Type  2 
[Mobitz 2] or third degree AV -block])  
– Significant symptoms (Grade   2) relating to left ventricular dysfunction, cardiac 
arrhythmia, or cardiac ischemia  
– Myocardial infarction within 12 months prior to randomization  
– Uncontrolled hypertension (systolic blood  pressure  180 mmHg and/or diastolic 
blood pressure   100 mmHg)  
– Evidence of transmural infarction on ECG  
– Requirement for oxygen therapy  
– Dyspnea at rest  
 Active or history of autoimmune disease or immune deficiency, including but not 
limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus 
erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid 
antibody syndrome, granulomatosis  with polyangiitis , Sjögren syndrome, 
Guillain -Barré syndrome, or multiple sclerosis ( see Appendix  [ADDRESS_138861] of autoimmune diseases and immune deficiencies), with the 
following exceptions:  
– Patients with a history of autoimmune -related hypothyroidism who are on a 
stable dose of thyroid -replacement hormone are eligible for the study.  
– Patients with controlled type 1 diabetes mellitus who are on a stable insulin 
regimen are eligible for the stud y. 
– Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with 
dermatologic manifestations only (e.g., patients with psoriatic arthritis are 
excluded) are eligible for the study provided all the following conditions are met:  
Rash must cover   10% of body surface area (BSA) . 
Disease is well controlled at baseline and requires only low -potency topi[INVESTIGATOR_030] . 
No occurrence of acute exacerbations of the underlying condition requiring 
psoralen plus ultraviolet A radiation, methotrexate,  retinoids, biologic 
agents, oral calcineurin inhibitors, or high -potency or oral corticosteroid s 
within the previous 12  months . 
 History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,  bronchiolitis 
obliterans), drug -induced pneumonitis, or i diopathic pneumonitis, or evidence of 
active pneumonitis on screening chest computed tomography (CT) scan  
– History of radiation pneumonitis in the radiation field (fibrosis) is permitted.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
60/Protocol BO40747 , Version 6  Active tuberculosis  
 Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation 
of study treatment or anticipation of need for a major surgical procedure during the 
study  
 Severe infection within 4 weeks prior to initiation of study treatment, including but 
not limited to hospi[INVESTIGATOR_1086] r complications of infection, bacteremia, or severe 
pneumonia  
 Treatment with therapeutic antibiotics within 2 weeks (IV antibiotics) or 5  days (oral 
antibiotics) prior to initiation of study treatment  
– Patients receiving prophylactic antibiotics (e.g., to p revent a urinary tract 
infection or chronic obstructive pulmonary disease [COPD] exacerbati on) are 
eligible for the study.  
 Prior allogeneic stem cell or solid organ transplantation  
 Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that contraindicates the use of an investigational drug and may 
affect the interpretation of the results, or may render the patient at high risk from 
treatment complications  
 Treatment with a live, attenuated vaccine within 4 wee ks prior to initiation of study 
treatment, or anticipation of need for such a vaccine during atezolizumab/placebo 
treatment or within 5 months after the final dose of atezolizumab/placebo  
 Treatment with investigational therapy within 28 days prior to initi ation of study 
treatment  
 Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], 
including anticytotoxic T lymphocyte -associated protein -4, antiPD-1, and 
antiPD-L1 therapeutic antibodies  
 Treatment with systemic immunostimulatory age nts (including but not limited to 
interferon and interleukin -2 [IL-2]) within 4 weeks or 5 half -lives of the drug 
(whichever is longer) prior to initiation of study treatment  
 Treatment with systemic immunosuppressive medication (including but not limited t o 
corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antitumor necrosis factor - [TNF -] agents) within 2 weeks prior to initiation of 
study treatment, or anticipation of need for systemic immunosuppressive medication 
during s tudy treatment, with the following exceptions:  
– Cyclophosphamide as part of the study treatment  
– Patients who received acute, low -dose systemic immunosuppressant 
medication or a one -time pulse dose of systemic immunosuppressant 
medication (e.g., [ADDRESS_138862] allergy) are eligible 
for the study after Medical Monitor approval has been obtained.  
– Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids 
for COPD or asthma, or low -dose corticosteroids for ortho static hypotension or 
adrenal insufficiency are eligible for the study.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
61/Protocol BO40747 , Version 6  History of severe allergic anaphylactic reactions to chimeric or humanized 
antibodies or fusion proteins  
 Known hypersensitivity to Chinese hamster ovary cell products or to any component 
of the atezolizumab formulation  
 Known allergy or hypersensitivity to the components of the paclitaxel, 
cyclophosphamide, or doxorubicin formulations  
 Known allergy or hypersensitivity to trastuzumab or pertuzumab formulations  
 Pregnancy or breastfeeding, or intention of becoming pregnant during study 
treatment or within 5 months after the final dose of atezolizumab/placebo, [ADDRESS_138863]  
– Women of childbearing potential must have a negative serum pregnancy test 
result within 7 days prior to initia tion of study treatment.  
 
Exclusions Related to Trastuzumab Emtansine in the Adjuvant Setting  
 Patients who achieved pCR defined as the absence of residual invasive cancer on 
hematoxylin and eosin evaluation of the complete resected breast specimen and all 
sampled regional lymph nodes following completion of neoadjuvant systemic 
therapy (i.e.,  ypT0/is ypN0 in the current AJCC staging system, 8th edition)  
 Evidence of clinically evident gross residual or recurrent disease following 
neoadjuvant therapy and surg ery 
 Unable to complete surgery with curative intent after conclusion of neoadjuvant 
systemic therapy  
 Patient discontinued treatment with trastuzumab because of toxicity during the 
neoadjuvant phase of the study . 
 Clinically significant history of liver dise ase, including cirrhosis, current alcohol 
abuse, autoimmune hepatic disorders, or sclerosis cholangitis  
 Patients with  current  Grade   2 peripheral neuropathy  
 Prior treatment with trastuzumab emtansine  
 Serum AST, ALT, and alkaline phosphatase  not within   1.5  ULN 
 Serum total bilirubin  not within  normal range  ( 1.0   ULN) 
– Except for patients with Gilbert’s syndrome, for whom direct bilirubin should be 
within the normal range . 
 Serum creatinine  not within   1.5   ULN 
 
4.[ADDRESS_138864] been completed, and eligibility has been established, the study site 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
62/Protocol BO40747 , Version 6 will enter demographic and baseline characteristics in the i nteractive voice or web -based 
response system (IxRS).  For those patients who are eligible for enrollment, the study 
site will obtain the patient’s identification number and treatment assignment from the 
IxRS.  
Randomization will occur in a 1:1 ratio using a permuted -block randomization method.  
Patients will be randomized to one of two treatment arms:  atezolizumab   neoadjuvant 
ddAC -PacHP or placebo   neoadjuvant ddAC -PacHP.  The randomization scheme is 
designed to ensure that an approximately equal number  of patients will be enrolled in 
each treatment arm within the categories defined for the following stra tification factors at 
baseline:  
 Stage at diagnosis (T2, T3 4) 
 Hormone receptor status (ER positive and/or PgR positive; ER negative and 
PgR negative)  
– Enrollment of patients with hormone receptor positive disease  will be capped 
at 50%.  
 PD-L1 status (IC 0; IC 1/2/3)  
 
Patients should receive their first dose of study treatment on the day of randomization if 
possible.  If treatment is not possible, the first dose should occur no later than 7  days 
after randomization.  
4.2.2  Blinding  
Study site personnel and patients will be blinded to treatment assignment during the 
study.  The Sponsor and its agents will also be blinded to treatment assignment, with the 
exception of  individuals who require access to patient treatment assignments to fulfill 
their job roles during a clinical trial (e.g., IxRS serv ice provider and iDMC members).  
In general, unblinding of participants during the conduct of the clinical trial is not allow ed.  
If unblinding is necessary for a medical emergency (e.g., in the case of a serious 
adverse event for which patient management might be affected by [CONTACT_123514]), the investigator will be able to break the treatment code by 
[CONTACT_123515].  The investigator is not required to contact [CONTACT_123516]; however,  investigator s are encouraged to consult with 
the Medical Monitor  prior to performing unblinding.  If knowledge of treatment 
assign ment is required to help investigators decide whether patients should switch to or 
start an approved therapy, the investigator will be able to break the treatment code by 
[CONTACT_123517].  Investigators are not allowed to break the treatment code to he lp 
decide if patients should switch to or start an unapproved therapy (including 
investigational treatments in other clinical trials)  without prior  approval by  [CONTACT_31807] . 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
63/Protocol BO40747 , Version [ADDRESS_138865] to stop treatment with atezolizumab or placebo and the unblinding of the 
study.  The Sp onsor unblind ed the study on 5 February 2021 and subsequently inform ed 
sites about treatment assignment of their patients.  
As per health authority reporting requirements, the Sponsor's drug safety representative 
will break the treatment code for all serious, unexpected suspected adverse reactions 
(see Section  5.7) that are considered by [CONTACT_123518].  The patient may continue to receive treatment, and the investigator , patient, 
and Sponsor personnel, with the exception of the drug safety representative and 
personnel who must have access to patient treatment assignments to fulfill their roles 
(as defined above), will remain blinded to treatment assignment.  
While PK and ADA samples must be collected from patients assigned to the comparator 
arm to maintain the blinding of treatment assignment, PK  and ADA assay results for 
these patients are general ly not needed for the safe conduct or proper interpretation of 
this study.  Laboratories responsible for performing study drug PK and ADA assays will 
be unblinded to patients' treatment assignments to identify appropriate samples to be 
analyzed.  PK sample s from patients assigned to the comparator arm will not be 
analyzed for study drug PK concentration except by [CONTACT_32236] (e.g.,  to evaluate a possible 
error in dosing).  Baseline ADA samples will be analyzed for all patients.  Postbaseline 
ADA samples from pa tients assigned to the comparator arm will not be analyzed for 
ADAs except by [CONTACT_32236].  
4.3 STUDY TREATMENT AND OTHER TREATMENTS REL EVANT 
TO THE STUDY DESIGN  
The investigational medicinal products (IMPs) for this study are atezolizumab, 
trastuzumab, pertuzumab,  trastuzumab emtansine, doxorubicin, cyclophosphamide, and 
paclitaxel.  The IMPs required for completion of this study will be provided by [CONTACT_25728].  
4.3.1  Study Treatment Formulation, Packaging, and Handlin g 
[IP_ADDRESS]  Atezolizumab and Placebo  
On [ADDRESS_138866] to stop 
treatment with atezolizumab or placebo.  Therefore, atezolizumab and placebo will no 
longer be supplied by [CONTACT_123519].   The f ollowing information reflects 
the situation prior to the USM DIL.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
64/Protocol BO40747 , Version [ADDRESS_138867] and placebo will be supplied by [CONTACT_14547] a sterile 
liquid in a single -use, 20 -mL glass vial.  The vial contains approximately 20  mL 
(1200  mg) of atezolizu mab solution; 14  mL of vial content contains approximately 
840 mg of atezolizumab.  
For information on the formulation and handling of atezolizumab , see the pharmacy 
manual and the Atezolizumab Investigator's  Brochure.  
[IP_ADDRESS]  Pertuzumab (Perjeta) 
Pertuzumab will be supplied by [CONTACT_14547]  a single -use formulation containing 
30 mg/mL pertuzumab formulated in 20 mM L -histidine (pH 6.0), 120 mM sucrose, and 
0.02%  polysorbate -20.  Each 20 -cc vial contains approximately 420  mg of pertuzumab 
(14.0 mL/vial).   For info rmation on the formulation and handling of pertuzumab, see the 
pharmacy manual and the Pertuzumab Investigator's Brochure, or the local prescribing 
information for pertuzumab.  
[IP_ADDRESS]  Trastuzumab (Herceptin) 
Trastuzumab will be supplied by [CONTACT_123520] a freeze -dried 
preparation for parenteral administration.  The vial is reconstituted with Sterile Water for 
Injection and the reconstituted solution contains 21 mg/mL.  
For information on the formulation and handling of trastuzumab, see the pharmac y 
manual and the Trastuzumab Investigator's Brochure, or the local prescribing 
information for trastuzumab.  
[IP_ADDRESS]  Trastuzumab Emtansine (Kadcyla) 
Trastuzumab emtansine will be supplied by [CONTACT_123521] -dried 
product.  The vial is recons tituted with Sterile Water for Injection and the reconstituted 
solution contains 20  mg/mL.  
For information on the formulation and handling of trastuzumab emtansine, see the 
pharmacy manual and the Trastuzumab Emtansine Investigator’s Brochure, or the local  
prescribing information for trastuzumab emtansine.  
[IP_ADDRESS]  Chemotherapy  
Doxorubicin, cyclophosphamide, and paclitaxel are administered in accordance with 
local prescribing information.  These drugs will be obtained locally by [CONTACT_123522].  
Refer to the respective local prescribing information or other appropriate local reference 
document for information on the formulation, preparation, administration, 
contraindications, and patient monitor ing. 
4.3.2  Study Treatment Dosage, Administration, and Compliance  
The treatment regimens are summarized in Section  3.2.1  and Figure  1. 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
65/Protocol BO40747 , Version 6 All study therapy will be completed following 52 weeks of HER2 -directed therapy 
(neoadjuvant and adjuvant ; i.e., a maximum of 18 cycle of HER2 -directed therapy ).  
Surgery should be performed at least [ADDRESS_138868] infusion.  Platelet counts should be checked prior 
to surgery and should be  75,000  cells/L. 
The first dose of postoperative treatment should not start until 2 weeks after surgery but 
should be administered within 45 days of surgery.  
Treatment will continue as scheduled or until progression, recurrence of disease, or 
unmanageable toxicity.  
Any dose mo dification should be noted on the Study  Drug Administration electronic 
Case Report Form (eCRF) .  Cases of accidental overdose or medication error, along 
with any associated adverse events, should be reported as described in Section  5.4.4 . 
Patients who discontinue one or more of the study treatment components due to toxicity 
should not be automatically withdrawn from all study treatments.  
Guidelines for dosage modification and treatment interruption or discontinuation for 
patients who experience adverse events and the timing of surgery are provided in 
Appendix  11 and Appendix  12. 
[IP_ADDRESS]  Atezolizumab and Placebo  
On [ADDRESS_138869] to stop 
treatment with atezolizumab or placebo.  
During the neoadjuvant phase, atezolizumab/placebo will be administered by [CONTACT_123523] a fixed dose of 840 mg on Day 1 of each 14 -day cycle during Cycles  14, and  
1200  mg on Day 1 of each 21 -day cycle during Cycles 5 8.  During the adjuvant phase 
(post -operatively), atezolizumab/placebo will be administered by [CONTACT_22671] a fixed 
dose of 1200 mg on Day 1 of each 21 -day cycle (maximum of 22  cycles 
[neoadjuvant   adjuvant phases]).  Atezolizumab/placebo should be administered as the 
first infusion.  
Treatment will continue as scheduled or until disease progression, recurrence of 
disease, or unmanageable toxicity.  
Administration of atezolizumab will be performed in a  monitored setting where there is 
immediate access to trained personnel and adequate equipment and medicine to 
manage potentially serious reactions.  For anaphylaxis precautions, see Appendix  10.  
Atezolizumab infusions will be administered per the instructions outlined in Table  1. 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
66/Protocol BO40747 , Version [ADDRESS_138870] Infusion  Subsequent Infusions  
 No premedication is permitted prior to the 
atezolizumab infusion.  
 Vital signs (pulse rate, respi[INVESTIGATOR_697], 
blood pressure, and temperature) should 
be measured within 60 minutes prior to the 
infusion.  
 Atezolizumab should be infused over 
60 ( 15) minutes.  
 If clinically indicated, vital signs should be 
measured every 15  ( 5) minute s during the 
infusion and at 30 ( 10) minutes after the 
infusion.  
 Patients should be informed about the 
possibility of delayed post -infusion 
symptoms and instructed to contact [CONTACT_123524].   If the patient experienced  an 
infusion -related reaction with any 
previous infusion, premedication with 
antihistamines, antipyretic  medications , 
and/or analgesics may be administered 
for subsequent doses at the discretion of 
the investigator.  
 Vital signs should be measured within 
60 minutes prior to the infusion.  
 Atezolizumab should be infused over 
30 ( 10) minutes if the previous infusion 
was tolerated without an infusion -related 
reaction, or 60 (  15) minutes if the 
patient experienced an infusion -related 
reaction with the previou s infusion.  
 If the patient experienced an 
infusion -related reaction with the previous 
infusion or if clinically indicated, vital 
signs should be measured during the 
infusion and at 30 ( 10) minutes after the 
infusion.  
 
Refer to the pharmacy manual for de tailed instructions on drug preparation, storage, and 
administration.  Guidelines for medical management of infusion -related reactions (IRRs) 
are provided in Appendix  12. 
No dose modification for atezolizumab is allowed.  
[IP_ADDRESS]  Pertuzumab (Perjeta) 
Pertuzumab is given as a fixed non weight -based dose of 840 -mg IV loading dose, then 
420 mg IV Q3W.  Pertuzumab will be administered on Day  1 of a 21 -day cycle, to 
complete up to a total duration of 52 weeks (i.e., maximum of 18 cycles within 1  year) of 
HER2 -targeted therapy, inclusive of therapy given both in the neoadjuvant and adjuvant 
setting (see Figure  1).  Atezolizumab/placebo should be administered prior to 
pertuzumab and trastuzumab.  The order of administration of pertuzumab and 
trastuzumab is according to  investigator preference.  
The initial dose of pertuzumab will be administered over 60  ( 10) minutes, and patients 
will be observed for a further 60 minutes.  The infusion should be slowed or interrupted if 
the patient experiences infusion -related symptoms .  If the infusion is well tolerated, 
subsequent doses may be administered over 30  ( 10) minutes, and patients will be 
observed for a further [ADDRESS_138871] resolved before trastuzumab or chemotherapy 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
67/Protocol BO40747 , Version 6 is given or the patient is discharged.  Patients who  experience infusion -related 
symptoms may be premedicated with analgesics and antihistamines for subsequent 
infusions.  
Guidelines for dosage modification and treatment interruption or discontinuation are 
provided in Section  5.1.10  and Appendix  11.  No dose reductio ns are allowed for 
pertuzumab.  If the patient misses a dose of pertuzumab for any cycle and the time 
between doses is  6 weeks, a reloading dose of pertuzumab (840 mg) should be given.  
Subsequent maintenance pertuzumab (420 mg) will then be given Q3W, starting 
[ADDRESS_138872] dose of 
neoadjuvant pertuzumab is 6 weeks  or more , a reloading dose of 840 mg of pertuzumab 
is required.  
[IP_ADDRESS]  Trastuzumab (Herceptin) 
Trastuzumab is given as an 8-mg/kg IV loading dose and then 6 mg/kg IV Q3W.  
Trastuzumab will be administered on Day 1 of a 21 -day cycle, to complete up to a total 
duration of 52  weeks (i.e., maximum of 18 cycles within 1 year) of HER2 -targeted 
therapy, inclusive of therapy given bo th in the neoadjuvant and adjuvant setting 
(see Figure  1).  Atezolizumab/placebo should be administered prior to pertuzumab and  
trastuzumab.  The order of administration of pertuzumab and trastuzumab is according 
to investigator preference.  
Weight should be recorded during screening and on Day [ADDRESS_138873] be recalculated if the patient’s body weight has 
changed by  10% (increased or decreased) from the Cycle 1, Day [ADDRESS_138874] ing to the patient’s actual body 
weight, with no upper limit.  
The initial dose of trastuzumab will be administered over 90 (  10) minutes, and patients 
will be observed for at least 30 minutes from the end of the infusion for infusion -related 
symptoms such  as fever or chills.  Interruption or slowing of the infusion may help control 
such symptoms and may be resumed when symptoms abate.  If the infusion is well 
tolerated, subsequent infusions may be administered over 30 (  10) minutes, and 
patients will be o bserved for a further [ADDRESS_138875] resolved before pertuzumab or chemotherapy is given or the patient is discharged. 
Patients who experience infusion -related symptoms may be premedicated with 
analgesics and antihista mines for subsequent infusions.  
Guidelines for dosage modification and treatment interruption or discontinuation are 
provided in Section  5.1.10  and Appendix  11.  No dose reductions are allowed for 
trastuzumab.  If the patient misses a dose of trastuzumab for any c ycle and the time 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
68/Protocol BO40747 , Version 6 between doses is   6 weeks, a reloading dose of trastuzumab (8  mg/kg) should be given.  
Subsequent maintenance trastuzumab (6 mg/kg) doses will then be given Q3W, starting 
[ADDRESS_138876] dose of 
neoadjuvant trastuzumab is 6 weeks  or more , a reloading dose of 8  mg/kg of 
trastuzumab is required.  
[IP_ADDRESS]  Trastuzumab Emtansine  (Kadcyla) 
Trastuzumab emtansine will be given at a dose of 3.6  mg/kg by [CONTACT_16228] Q3W.  The 
dose of trastuzumab emtansine administered will be determined on the basis of the 
baseline weight of the patient.  Weight will be measured at each visit and the dose must 
be re -adjusted for weight changes  10% compared with the previous visit or baseline.  
The investigator may choose to recalculate the dose at every cycle using actual weight 
at that time, in accordance with local practice.  Administration may be delayed to assess 
or treat adverse events.  Dose r eduction will be allowed, following the dose reduction 
levels provided in Table  6.  Once a dose has been reduced for an advers e event(s), it 
must not be re -escalated.  
See Table  [ADDRESS_138877] Infusion  Subsequent Infusions  
 No premedication is administered.  
 Vital signs (pulse rate, respi[INVESTIGATOR_697], 
blood pressure, and temperature) should 
be measured within 60  minutes prior to the 
infusion.  
 Administer the initial dose  as a 
90-minute  IV infusion.  
 Patients should be observed during the 
infusion and for at least 90  minutes 
following the initial dose for fever, chills, or 
other infusion -related reactions.  
 The infusion rate should be slowed or 
interrupted if the patient dev elops 
infusion -related symptoms.  
 The infusion site should be closely 
monitored for possible subcutaneous 
infiltration during drug administration.   Vital signs (pulse rate, respi[INVESTIGATOR_697], 
blood pressure, and temperature) should 
be measured within 60  minut es prior to the 
infusion.  
 If prior infusions were well tolerated, 
subsequent doses may be administered as 
30-minute  infusions.  
 Patients should be observed during the 
infusions and for at least 30  minutes after 
the infusion.  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
69/Protocol BO40747 , Version 6 Trastuzumab emtansine should be administered in a monitored setting where there is 
immediate access to trained personnel and adequate equipment and medicine to 
manage potentially serious reactions.  
Trastuzumab emtansine will be administered after the infusion of atezolizumab/placebo.  
[IP_ADDRESS]  Chemotherapy  
Chemotherapy will be administered in the neoadjuvant setting as follows:  
 Doxorubicin 60 mg/m2 IV on Day 1 of a 14 -day cycle for 4 cycles (Cycles 1 4); with  
 Cyclophosphamide 600 mg/m2 IV on Day 1 of a 14 -day cycle for 4  cycles  
(Cycles  14); followed by  
 Paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks (Cycles 5 8) 
The dose of chemotherapy is calculated according to the patient’s BSA.  The BSA and 
the amount of drug administered must be recalculated if the patient’s body weight has 
changed b y  10% (increased or decreased) from baseline.  Recalculation of the amount 
of drug administered on the basis of smaller changes in body weight or BSA is at the 
investigators’ discretion.  
There is no mandatory delay between atezolizumab/placebo and ddAC c hemotherapy, 
assuming the infusion is well tolerated.  
Doxorubicin  
Doxorubicin will be given as an IV bolus over 3 5 minutes or as an infusion over 
1530 minutes, in accordance with local SOC.  Dose delays and reduction for toxicity 
are permitted, and patients should receive G -CSF support according to local practice 
guidelines.  
Refer to the local prescribing information for details regarding the preparation and 
administration of doxorubicin.  
Cyclophosphamide  
Cyclophosphamide will be given as an IV bolus  over 35 minutes or as an IV  infusion, in 
accordance with local SOC.  Patients with BSA of  [ADDRESS_138878] their dose capped 
at 1200  mg. 
Dose delays and dose reductions for toxicity are permitted, and patients should receive 
G-CSF support according to local practice guidelines.  Oral cyclophosphamide is not 
permitted.  Refer to the local prescribing information for details regarding the preparation 
and administration of cyclophosphamide.  
Paclitaxel  
Paclitaxel will be administered as an IV infusion over 60 ( 10) minutes or according to 
local SOC, after atezolizumab/placebo, pertuzumab and trastuzumab administration, at 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
70/Protocol BO40747 , Version 6 a dose of 80  mg/m2.  See Appendix  [ADDRESS_138879] be closely observed from the start  of the infusion for hypersensitivity 
reactions, which may occur within minutes.  Severe hypotension, bronchospasm, or 
generalized rash/erythema requires immediate discontinuation of paclitaxel and 
appropriate treatment.  The infusion may be slowed for min or symptoms, such as 
flushing or local cutaneous reactions.  Patients experiencing severe hypersensitivity 
reactions should be discontinued from study treatment but maintained in the study 
unless consent is withdrawn.  Premedication consisting of a cortico steroid may be given 
according to institutional guidelines.  
Premedications/Supportive Care  
In general, chemotherapy supportive care  should be administered per ASCO, EORTC, 
or ESMO guidelines or local SOC.  For further details regarding permitted therapi[INVESTIGATOR_014],  
see Section  4.4.1 . 
Chemotherapy -induced nausea and vomiting prophylaxis and treatment should be 
administered as clinically indicated (see Section  4.4.2  for further guidance).  Because 
systemic corticosteroids may attenuate the potential beneficial immunologic effects of 
treatment with atezolizumab, alternative agents should be considered when clinically 
feasible, with the exception of guidance currently in the  protocol.  
Prophylactic G -CSF or GM -CSF may be used to mitigate the risk of hematologic 
toxicities according to local policies.  Treatment of neutropenia with G -CSF or GM -CSF 
is permitted according to local policies.  In all cases, G -CSF or GM -CSF will not  be 
considered as a study drug and will not be provided by [CONTACT_1034].  
4.3.3  Other Required Medication  
After surgery, patients with hormone receptor positive disease should receive adjuvant 
hormone therapy according to guidelines provided in Section  4.4.[ADDRESS_138880] Accountability  
All IMPs required for completion of this study (atezolizumab, pertuzumab, trastuzumab, 
trastuzumab emtansine, doxorubicin, cycl ophosphamide, and paclitaxel) will be provided 
by [CONTACT_76971].  The study site will 
acknowledge receipt of IMPs supplied by [CONTACT_1034], using the IxRS to confirm the 
shipment condition and content.  Any  damaged shipments will be replaced.  
IMPs will either be disposed of at the study site according to the study site's institutional 
standard operating procedure or be returned to the Sponsor (if supplied by [CONTACT_1034]) 
with the appropriate documentation.  The site's method of destroying Sponsor -supplied 
IMPs must be agreed to by [CONTACT_1034].  The site must obtain written authorization from 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
71/Protocol BO40747 , Version [ADDRESS_138881] any plans to provide [COMPANY_002] IMPs (atezolizumab, 
pertuzumab, trastuzumab, and trastuzumab emtansine) or any other study treatments or 
interventions to patients who have completed the study.  The Sponsor may evaluate 
whether to continue pr oviding pertuzumab, trastuzumab, and trastuzumab emtansine in 
accordance with the [COMPANY_002] Global Policy on Continued Access to Investigational 
Medicinal Product, available at the website  below.  Following the discontinuation of 
atezolizumab based on the iDMC ’s recommendation, continued access to atezolizumab 
will not be considered.  
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf  
 
4.4 CONCOMITANT THERAPY  
Concomitant therapy includes any medication (e.g., prescription drugs, over -the-counter 
drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol -mandated treatment from 30 days prior to initiation of study 
treatment (for the purposes of screening) until the treatment discontinu ation visit.  
Medication used by [CONTACT_25701] [ADDRESS_138882] all prior anti -canc er therapi[INVESTIGATOR_014], as 
applicable.  
4.4.1  Permitted Therapy  
Patients are permitted to use the following therapi[INVESTIGATOR_226]:  
 Acceptable methods of contraception must be used when the female patient or male 
partner is not surgically sterilized or does not meet the study definition of 
postmenopausal (  12 months of amenorrhea).  
 Prophylactic or therapeutic anticoagulation therapy (such  as warfarin at a stable 
dose or low -molecular -weight heparin)  
– Patients on anti -coagulant treatment should have their platelet coun t monitored 
closely during treatment with trastuzumab emtansine . 
 Inactivated influenza vaccinations  
 Megestrol acetate administered as an appetite stimulant  
 Mineralocorticoids (e.g.,  fludrocortisone)  
 Corticosteroids administered for COPD or asthma  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
72/Protocol BO40747 , Version 6  Low-dose corticosteroids administered for orthostatic hypotension or adrenocortical 
insufficiency  
 Medication to treat diarrhea (e.g., loperamide)  
 Colony -stimulating factors (e.g., G -CSF)  
 Estrogen -receptor antagonists (e.g., tamoxifen), aromatase inhibitors 
(e.g.,  anastrazole, exemestane), and gonadotropin -releasing hormone agonists 
(e.g.,  buserelin, triptorelin) after surgery, as per local practice and guidelines ;  
luteinizing hormone releasing hormone  agonist as part of an attempt at ovarian 
function preservation s tarting prior to chemotherapy  
 Radiotherapy after chemotherapy and surgery, during adjuvant therapy  
 
Premedication with antihistamines, antipyretics, and/or analgesics may be administered 
for the second and subsequent atezolizumab infusions only, at the dis cretion of the 
investigator.  
In general, investigators should manage a patient's care (including preexisting 
conditions) with supportive therapi[INVESTIGATOR_123416] (see Section  4.4.2  and Section  4.4.3 ) as clinically  indicated, per 
local standard practice.  Patients who experience infusion -associated symptoms may be 
treated symptomatically with acetaminophen, ibuprofen, diphenhydramin e, and/or 
H2-receptor antagonists (e.g.,  famotidine, cimetidine), or equivalent medications per local 
standard practice.  Serious infusion -associated events manifested by [CONTACT_27926], 
hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation,  or 
respi[INVESTIGATOR_40802] 
(e.g.,  supplemental oxygen and 2-adrenergic agonists; see Appendix  10). 
Radiotherapy  
Postoperative patient management may include radiotherapy as clinically indicated, and 
management of patients who do not achieve a pCR should follow current SOC 
guidelines.  Radiotherapy may be given con current with HER2 therapy and 
atezolizumab/placebo.  
Hormone Therapy  
Sites should prescribe hormonal therapy per standard local clinical practice.  Hormonal 
therapy is not considered study drug and will not be provided by [CONTACT_1034].   
Aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal 
patients who are hormone receptor positive, in countries where it has been registered 
for this indication.  Its use must be consistent with the registered label.  Hormone 
therapy is given after chemotherapy and surgery, during adjuvant therapy.  No other 
hormone therapy for primary breast cancer is allowed, unless approved for adjuvant  
therapy.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
73/Protocol BO40747 , Version [ADDRESS_138883] be classified according to one of the following menopausal status 
definitions:  
 Premenopausal:  
–  [ADDRESS_138884] menstrual period AND no prior bilateral ovariectomy  
AND  
Not receiving estrogen replacement  
 Postmenopausal:  
–  [ADDRESS_138885] menstrual period with no prior hysterectomy  
OR 
Prior bilateral ovariectomy  
OR 
Biochemical evidence of postmenopausal status, according to local policies  
 
Female patients should be treate d according to the recommendations in Table  3; 
however, investigators may follow local practice guidelines.  Male patients should be 
treated according to local policies.  
Table  3 Hormonal Therapy  
Patient Status a Hormone Therapy  
Hormone receptor negative  Not allowed  
Hormone receptor positive 
and premenopausal  Permitted:  
 Tamoxifen for 5 10 years with or  without ovarian 
suppression, as per local policy  
 Aromatase inhibitor for 5 years and ovarian suppression or 
ablation, followed by [CONTACT_123525] 10 years  
Hormone receptor positive 
and postmenopausal  The following regimens are permitted:  
 Aromatase inhibitor for 5 10 years  
 Aromatase inhibitor for 2 3 years, followed by [CONTACT_123526] a total of 5 years  
 Tamoxifen for 2 3 years, followed by [CONTACT_123527] a total of 5 years  
 Tamoxifen for 5 10 years, as per local policy  
 Tamoxi fen for 5 years, followed by [CONTACT_123528] 5 years  
a Hormone receptor positivity is defined as positive estrogen receptor or progesterone receptor 
or both.  The investigator may treat the patient with adjuvant hormone therapy according to 
local or central results of hormone receptor testing, but central results will be used in data 
analyses for the study.  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
74/Protocol BO40747 , Version 6 4.4.2  Cautionary Therapy for Atezolizumab -Treated Patients  
[IP_ADDRESS]  Corticosteroids and TNF - Inhibitors  
Systemic corticosteroids and TNF - inhibitors may attenuate potential beneficial 
immunologic effects of treatment with atezolizumab.  Therefore, with the exception of 
scenarios described elsewhere in the protocol (see Section  [IP_ADDRESS] ), in situations in 
which systemic corticosteroids or TNF - inhibitors would be routinely administered, 
alternatives, including antihistamines, should be considered.  If the alternatives are not 
feasible, systemic corticosteroids and TNF - inhibitors may be administered at the 
discretion of the investigator.  
Syste mic corticosteroids are recommended at the discretion of the investigator for the 
treatment of specific adverse events when associated with atezolizumab therapy 
(see Appendix  12 for details).  
[IP_ADDRESS]  Medications Given with Precaution due to Effects Related to 
Cytochrome P450 Enzymes  
The chemotherapeutic agents used in this study are associated with potential drug 
interactions.  The metab olism of paclitaxel is catalyzed by [CONTACT_097]450 isoenzymes CYP2C8 
and CYP3A4.  The PK of paclitaxel was shown to be altered in vivo as a result of 
interactions with compounds that are substrates, inducers, or inhibitors of CYP2C8 
and/or CYP3A4.  Doxorubicin is a major substrate of CYP3A4 and CYP2D6 and 
P-glycoprotein.  Cyclophosphamide is a pro -drug that is activated by [CONTACT_9058] P450s, 
including CYP2B6, 2C9, and 3A4.  
There is a moderate to high potential for drug drug interactions with any medication that 
is metabolized by [CONTACT_123529].  Therefore, such 
medications should be avoided when chemotherapy is being administered.  
Concomitant use of strong CYP3A4/5 inhibitors (such as ketoconazole and itraconazole) 
with trastuzumab emta nsine should be avoided.  An  alternate medication with no or 
minimal potential to inhibit CYP3A4/5 should be considered.  If  a strong CYP3A4/5 
inhibitor is co -administered with trastuzumab emtansine, patients should be closely 
monitored for adverse reactio ns.  Excessive alcohol intake should be avoided 
(occasional to moderate use is permitted).  
The investigator should consult the prescribing information for any concomitant 
medication as well as the Internet references provided below when determining whether  
a certain medication is metabolized by [CONTACT_123530].  In 
addition, the Medical Monitor  is available to advise  if questions arise regarding 
medications not listed above.  
 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/G
uidances/UCM292362.pdf  
 http://medicine.iupui.edu/clinpharm/ddis/table.aspx  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
75/Protocol BO40747 , Version 6 [IP_ADDRESS]  Herbal Therapi[INVESTIGATOR_123417], as their 
pharmacokinetics, safety profiles, and potential drug drug interactions are generally 
unknown.  However, their use for patients in the study is allowed at the discretion of the 
investigator  as long as they are not intended to treat cancer . 
[IP_ADDRESS]  Therapi[INVESTIGATOR_123418] (e.g., thrombopoietin receptor agonists, recombinant thrombopoietins, 
recombinant interleukin -11) should be avoided.  Adherence  to the relevant safety 
management guidelines to institute appropriate dose modifications of trastuzumab 
emtansine in case of thrombocytopenia is recommended  (Appendix  14).  If any of those 
agents needs to be co -administered with trastuzumab emtansine in line with local 
standard clinical practice, patients should be closely monitored for adverse reactions 
and overlappi[INVESTIGATOR_123419] s. 
4.4.3  Prohibited Therapy  
Use of the following concomitant therapi[INVESTIGATOR_123420]:  
 Concomitant therapy intended for the treatment of cancer (including but not limited 
to chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herba l 
therapy), whether health authority approved or experimental, is prohibited for 
various time periods prior to starting study treatment, depending on the agent 
(see Section  4.1.2 ), and during study treatment, until the patient has discontinued 
study treatment, with the exception of previously listed hormone therapy, 
radiotherapy, and surgery under certain circum stances (see Section  4.4.1  for 
details).  
 Investigational therapy is prohibited during study  treatment . 
 Live, attenuated vaccines (e.g.,  FluMist) are prohibited within 4 weeks prior to 
initiation of study treatment, during study treatment, and for 5  months after the final 
dose of atezolizumab/placebo.  
 Systemic immunostimulatory agents (including but not limited to interferons and 
IL-2) are p rohibited within 4 weeks or 5 drug-elimination half-lives (whichever is 
longer) prior to initiation of study treatment and during study treatment with 
atezolizumab/placebo because these agents could potentially increase the risk for 
autoimmune conditions w hen given in combination with atezolizumab.  
 Systemic immunosuppressive medications (including but not limited to azathioprine, 
methotrexate, and thalidomide) are prohibited during study treatment  with 
atezolizumab/placebo  because these agents could potentially alter the efficacy and 
safety of atezolizumab.  
 Estrogen replacement therapy (hormone replacement therapy)  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
76/Protocol BO40747 , Version 6 4.5 STUDY ASSESSMENTS  
The schedules of activities to be performed during the study are provided in  Appendix  1, 
Appendix  2, and Appendix  3.  All activities should be performed and documented for 
each patient.  
Patients will be closely monitored for safety and tolerability throughout the study.  
Patients should be assessed for toxicity prior to each dose; dosing wi ll occur only if the 
clinical assessment and local laboratory test values are acceptable.  
4.5.[ADDRESS_138886] be obtained before 
performing any  study -related procedures (incl uding screening evaluations).  Informed 
Consent Forms for enrolled patients and for patients who are not subsequently enrolled 
will be maintained at the study site.  
All screening evaluations must be completed and reviewed to confirm that patients meet 
all eligibility criteria before enrollment.  Leftover tumor tissue samples, local HER2 test 
information, baseline demographic, and disease -related characteristics data for all 
screened patients will be collected by [CONTACT_1034], in order to support a potential 
registration of a companion diagnostic.  The investigator will maintain a detailed record 
of all patients screened and document eligibility or record reasons for screening failure, 
as applicable.  
4.5.2  Medical History, Concomitant Medication, and Demographic 
Data 
Medical history, including clinically significant diseases, surgeries, cancer history 
(including prior cancer therapi[INVESTIGATOR_26649]), cardiovascular history, menopausal 
status, and smoking history, will be recorded at baseline.  In addition, all medic ations 
(e.g.,  prescription drugs, over -the-counter drugs, vaccines ) used by [CONTACT_25701] 
7 days prior to initiation of study treatment  will be recorded.  At the time of each 
follow -up physical examination, an interval medical history should be obtain ed and any 
changes in medications and allergies should be recorded.  
Demographic data will include age, sex, and self -reported race/ethnicity.  
4.5.[ADDRESS_138887] to cardiovascular signs and symptoms (e.g.,  elevated 
jugular venous pressure, sinus tachycardia, tachypnea, the presence of an S3 heart 
sound, crackles on ch est auscultation, etc.).  Bilateral breast examination, including 
evaluation of locoregional lymphatics, should be conducted ( see Section  4.5.5 ).  Any 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
77/Protocol BO40747 , Version [ADDRESS_138888]-baseline visits and as clinically indicat ed.  Changes from baseline abnormalities 
should be recorded in patient notes.  New or worsened clinically significant abnormalities 
should be recorded as adverse events on the Adverse Event eCRF.  
4.5.4  Vital Signs  
Vital signs will include measurements of respi[INVESTIGATOR_92196], pulse rate, systolic and 
diastolic blood pressure, and temperature.  
Vital signs should be measured within 60 minutes prior to each study treatment infusion 
and, if clinically indicated, during or after the infusions.  In addition, vital signs sh ould be 
measured at other specified timepoints as outlined in the schedule of activities 
(see Appendix  1).  The vital signs measured prior to the infusion of the first study drug at 
each cycle are required to be reported on the Vital Sign eCRF.  Other vita l signs are not 
required to be entered into the eCRF unless abnormal and clinically significant, in which 
case they are to be reported as adverse events.  
4.5.[ADDRESS_138889] be marked with a radiopaq ue marker via radiographic guidance 
(e.g.,  ultrasound) prior to initiation of neoadjuvant therapy.  
Clinical assessment of tumor measurement in the breast and/or lymph nodes should be 
conducted in a consistent manner at each evaluation.  Clinical measuremen ts of tumor 
in the breast should be performed, preferentially using calipers or a ruler/tape measure.  
If possible, these measurements should be conducted by [CONTACT_123531].  
Tumor measurements at baseline  and within 14 days prior to surgery are to be recorded 
in the eCRF.  The main purpose of performing a physical examination prior to each cycle 
is for patient safety and to provide information that may help to rule out progressive 
disease that would lead t o study treatment discontinuation.  
Mammo gram  
Bilateral mammogram should be obtained within 28 days prior to randomization.  
To minimize unnecessary radiation exposure and provided that the clinical status of the 
patient has not changed, the screening mammo gram can be performed up to 42  days 
prior to the start of study treatment.  Subsequent mammograms are optional during 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
78/Protocol BO40747 , Version 6 neoadjuvant treatment and prior to surgery and should be performed per investigator’s 
discretion.  Bilateral mammogram should occur at the study completion/early termination 
visit and every 12 months (  4 weeks) during the follow -up period.  Patients who have 
undergone mastectomy do not require mammograms on the side of mastectomy.  
Other Breast Imaging  
Eligibility with regards to the primary  breast tumor size (  2 cm) is to be confirmed 
through imaging (mammogram, positron emission tomography [PET] scan, CT  scan, 
magnetic resonance imaging [MRI], ultrasound, or X -ray).  The tumor should be 
accurately measured in at least one dimension and the  longest diameter recorded.  
Additional breast imaging throughout the study, such as MRI and ultrasound , are per 
investigator discretion.  MRI examination is not mandated by [CONTACT_123532].  If  MRI is conducted, suggested time lines for MRI are within [ADDRESS_138890], the s urgeon should reassess the patient and 
modify the surgical treatment plan as needed.  These treatments should be documented 
and reported in the eCRF.  
4.5.6  Distant Sites Tumor Assessment  
Baseline distant sites tumor staging procedures should be performed in alig nment with 
NCCN or national guidelines, within 28 days prior to randomization.  
As a reference, as per NCCN guidelines, staging procedures are based on clinical stage:  
 For Stage II and Stage IIIA:  Bone scan is to be performed in presence of bone pain 
and/o r elevated ALP; abdominal/pelvic CT scan in case of elevated ALP, abnormal 
liver function tests, abdominal symptoms or abnormal physical examination; and 
chest CT scan.  
 For Stage IIIB and Stage IIIC:  Bone scan and CT scan of chest, abdomen, and 
pelvis sho uld be conducted for all patients.  
 
In addition, liver function tests, brain imaging, bone scans, chest X -ray/diagnostic 
CT scan, liver imaging, and/or other radiographic modalities may be considered when 
clinically indicated to exclude metastatic disease.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
79/Protocol BO40747 , Version [ADDRESS_138891] cancer should be supported by [CONTACT_2085], laboratory, radiological, and/or histological 
findings.   Post-operatively, all patients must be followed to assess disease recurrence, 
second primary cancer, and survival.  The designation of disease recurrence, whether 
local, regional or distant, or a diagnosis of a second primary cancer can be made only 
when  clinical, laboratory, radiological , and/or histological findings support the diagnosis.  
During the post -operative portion of this study, disease status should be clinically 
evaluated and documented every [ADDRESS_138892] tumor during neoadjuvant therapy may include 
inflammatory response secondary to treatment -related tumor necrosis, infection/mastitis, 
or true tumor progression.  Additional diagnostic workup (e.g.,  biopsy for histologic 
confirmation of cancer versus immune -media ted inflammatory process), treatment, 
and/or multidisciplinary discussion should be considered to help elucidate whether 
disease progression is occurring and guide whether neoadjuvant treatme nt should be 
continued or not.  
Some patients may experience a sus pi[INVESTIGATOR_123421], without the possibility of confirming relapse of disease.  Efforts should be made 
to obtain a n autopsy report in such cases.  
The earliest date of diagnosis of disease progression, recurrent disease , or a diagnosis 
of a second primary cancer should be used and recorded.  This date should be based on 
objective clinical, radiological, histolo gical, or cytological evidence.  
Recurrent disease includes local, regional, or distant recurrence and contralate ral breast 
cancer.  While ipsilateral or contralateral in situ disease and second primary non -breast 
cancers (including in situ carcinomas and non -melanoma skin cancers) will not be 
counted as progressive disease or recurrent disease, these events should b e recorded.  
Patients who have a diagnosis of in situ breast disease or second (non -breast) 
malignancies should be maintained on a regular follow -up schedule whenever possible 
in order to fully capture any subsequent recurrent disease events.  
The definitio ns of and procedures for confirming disease recurrence, death, and other 
noteworthy events on follow -up are provided in Table  4. 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
80/Protocol BO40747 , Version 6 Table  4 Definitions of and Procedures for Confirming Disease 
Recurrence, Death, and Other Noteworthy Events on Follow -Up 
a) Local 
invasive 
recurrence  Ipsilateral 
breast after 
previous 
lumpectomy   Defined as evidence of invasive tumor (except DCIS 
and LCIS) in the ipsilateral breast after lumpectomy.  
Patients who develop clinical evidence of tumor 
recurrence in the remainder of the ipsilateral breast 
should have a biopsy of the suspi[INVESTIGATOR_123422].  
 Confirme d by [CONTACT_123533]   Defined as evidence of invasive tumor in any soft 
tissue or skin of the ipsilateral chest wall.  This 
includes the area bounded by [CONTACT_123534], extending superiorly to the clavicle and 
inferiorly to the costal margin.  Soft tissue 
recurrences in this area extending into the bony 
chest wall or across the midline will be considered as 
evidence of local recurrence.  
 Confirmed by [CONTACT_123535]  
b) Regional 
recurrence   Defined as the development of tumor in the ipsilateral internal 
mammary lymph nodes, ipsilateral axillary lymph nodes, or 
supraclavicular lymph nodes as well as extranodal soft tissue of the 
ipsilateral axilla.  Regional recurrence does  not include tumor in the 
opposite breast.  
 Confirmed by [CONTACT_123535], or radiologic evidence 
(especially in case of PET activity or visible internal mammary lymph 
nodes on CT scan or MRI if no biopsy was performed).  
CT   computed tomography (scan); DCIS   ductal carcinoma in situ; EFS   event -free survival; 
LCIS   lobular carcinoma in situ; MRI   magnetic resonance imaging; OS   overall survival; 
PET   positron emission tomography.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
81/Protocol BO40747 , Version 6 Table  4 Definitions of and Procedures for Confirming Disease 
Recurrence, Death, and Other Noteworthy Events on Follow -Up 
(cont.)   
c) Distant 
recurrence   Defined as evidence of tumor in all areas, with the exception of those 
described in a) and b) above.  
 Confirmed by [CONTACT_4868]:  
Skin, su bcutaneous tissue, and lymph nodes (other than local or 
regional)  
Positive cytology, aspi[INVESTIGATOR_337], or biopsy, OR  
Radiological (CT scan, MRI, PET scan, or ultrasound) evidence 
of metastatic disease  
Bone  
X-ray, CT scan, or MRI evidence of lytic or blastic lesions 
consistent with bone metastasis, OR  
Bone scan (requires additional radiological investigation, alone 
not acceptable in case of diagnostic doubt), OR  
Biopsy proof of bone metastases or cytology  
Bone marrow  
Positive cytology or histology or MRI  
Lung  
Radiologic (CT or PET scan) evidence of multiple pulmonary 
nodules consistent with pulmonary metastases  
Positive cytology or histology in case of diagnostic doubt 
(particularly for solitary lung lesions) if a biopsy is not performed.  
Serial scans should b e obtained if possible to document stability 
or progression.  
Proof of neoplastic pleural effusions should be established by 
[CONTACT_123536].  
Liver  
Radiologic evidence consistent with liver metastases, OR  
Liver biopsy or fine -needle aspi[INVESTIGATOR_123423]:  If radiological findings are not definitive (especially 
with solitary liver nodules), a liver biopsy is recommended; 
however, if a biopsy is not performed, serial scans should 
be obtained if possible to document stability or progression.  
Central nervo us system  
Positive MRI or CT scan, usually in a patient with neurologic 
symptoms, OR  
Biopsy or cytology in case of inconclusive imaging (e.g.,  for a 
diagnosis of meningeal involvement) and, depending from the 
general status of the patient, additional investigations (including 
cytology of the cerebrospi[INVESTIGATOR_872])  
CT   computed tomography (scan); DCIS   ductal carcinoma in situ; EFS   event -free survival; 
LCIS   lobular carcinoma in situ; MRI   magnetic resonance imaging; OS   overall survival; 
PET   positron emission tomography.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
82/Protocol BO40747 , Version 6 Table  4 Definitions of and Procedures for Confirming Disease 
Recurrence, Death, and Other Noteworthy Events on Follow -Up 
(cont.)   
d) Contralateral 
invasive 
breast cancer   Confirmed by [CONTACT_123537]  
e) Death from 
any cause   Any death occurring without prior breast cancer recurrence is 
considered an event for the following endpoints:  DFS, EFS, and OS.  
 Any death occurring during study (with or without prior breast cancer 
recurrence) is considered an event for th e following endpoint:  OS.  
CT   computed tomography (scan); DCIS   ductal carcinoma in situ; EFS   event -free survival ; 
LCIS   lobular  carcinoma in situ; MRI   magnetic  resonance imaging; OS   overall  survival; 
PET   positron  emission tomography.  
 
4.5.8  Surgical Specimen Pathology  
Primary endpoint of the study (pCR) will be as identified by [CONTACT_123538].  A complete pathologic response is defined 
as the absence of invasive disease in the breast a nd axilla (tpCR; i.e.,  ypT0 or ypTis, 
ypN0) based on microscopic examination of the surgical specimen following neoadjuvant 
therapy.  Guidelines regarding pathology specimen preparation and labeling are outlined 
in the pathology manual.  The Sponsor will p rospectively collect local pathology reports. 
If additional information on lymph nodes at surgery is present in other reports, these 
should also be submitted to the Sponsor.  
4.5.9  Laboratory, Biomarker, and Other Biological Samples  
Samples for the following labo ratory tests will be sent to the study site's local laboratory 
for analysis as outlined in the schedule of activities (see Appendix  1) and as clinically 
indicated : 
 Hematology:  WBC count, RBC count, hemoglobin, hematocrit, platelet count, and 
differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes, and 
other cells)  
 Chemistry panel (serum or plasma):  bicarbonate or total carbon dioxide 
(if considered SOC for the region), sodium, potassium, magnesium, chloride, 
glucose, BUN or urea, c reatinine, total  protein, albumin, phosphorus, calcium, 
total bilirubin, ALP, ALT, AST, and lactate dehydrogenase (LDH)  
 Coagulation:  INR and aPTT  
 Thyroid function testing:  thyroid -stimulating hormone,  free triiodothyronine (T3) 
(or total T3 for sites whe re free T3 is not performed), and free thyroxine (also known 
as T4)  
 HIV serology  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
83/Protocol BO40747 , Version 6  HBV serology:  HBsAg, total HBcAb, and (if HBsAg test is negative and total HBcAb 
test is positive) HBV DNA  
– If a patient has a negative HBsAg test and a positive total HBcAb t est at 
screening, an HBV DNA test must also be performed to determine if the patient 
has an HBV infection.  
 HCV serology:  HCV antibody and (if HCV antibody test is positive) HCV RNA  
– If a patient has a positive HCV antibody test at screening, an HCV RNA tes t 
must also be performed to determine if the patient has an HCV infection.  
 Pregnancy test  
– All women of childbearing potential will have a serum pregnancy test at 
screening, within [ADDRESS_138893] be done at the completion/early 
termination visit, and at [ADDRESS_138894].  
– A woman is considered to be of childbearing potential if she is postmenarcheal, 
has not reached a postmenopausal state (  12 continuous months of 
amenorrhea with no identified cause other t han menopause), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).  
 Urinalysis (pH, specific gravity, glucose, protein, ketones,  and blood); dipstick 
permitted.  
 
The following samples will be sent to one or several central labo ratories or to the 
Sponsor or a designee for analysis:  
 Serum sample for analysis of autoantibodies:  anti -nuclear antibody , 
antidouble -stranded DNA, circulating anti -neutrophil cytoplasmic antibody, and 
perinuclear anti -neutrophil cytoplasmic antibody  
 Serum samples for atezolizumab, trastuzumab, pertuzumab, and trastuzumab 
emtansine PK analysis through use of validated assays  
 Serum samples for assessment of ADAs to atezolizumab, trastuzumab, 
pertuzumab, and trastuzumab emtansine through use of validated assays  
 Blood and plasma samples for exploratory research on biomarkers at baseline and 
during treatment (see Appendix  3) 
 Tumor  tissue sample obtained at baseline for determination of HER2 status and 
PD-L1 expression, ER, and PgR status and for biomarker research (including but 
not limited to PIK3CA mutation status, TILs,  and CD8)  
– A representative FFPE tumor specimen in a paraffin  block (preferred) or at least 
[ADDRESS_138895] be submitted.  
In case of any deviation in submission of tissue material, the patient may still be 
eligible for the study, after Medical Monitor approval has b een obtained.   

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
84/Protocol BO40747 , Version 6 – Tumor tissue should be of good quality based on total and viable tumor content.   
Samples must contain a minimum of 50  viable tumor cells that preserve cellular 
context and tissue architecture regardless of needle gauge or retrieval method.  
Acceptable samples include those collected via core -needle biopsy (at least 
three  cores, embedded in a single paraffin block).  Fine-needle aspi[INVESTIGATOR_1516] 
(defined as samples that do not preserve tissue architecture and yield cell 
suspension and/or smears) is  not acceptable.  
 Tumor tissue sample obtained at time of surger y and at time of recurrence 
(if deemed clinically feasible) for exploratory biomarker research  
– A representative FFPE tumor specimen in a paraffin block (preferred) or at least 
[ADDRESS_138896] be submitted 
(see further details in  Appendix  3). 
 
Leftover tumor tissue samples from all screened patients may be used for future 
development of diagnostic tests relating to HER2 and PD -L1. 
Biomarker analyses may include but will not be limited to analysis of genes or gene 
signatures associated with HER2 pathway, tumor immune biology, PD -L1, lymphocyte 
subpopulations, T -cell receptor repertoire, cytokines associated with T -cell activation , 
and ctDNA.  Analyses may involve extraction of DNA, ctDNA, or RNA, analysis of 
mutations, and genomic profiling through use of next -generati on sequencing (NGS) of a 
comprehensive panel of genes.  Research will not be aimed at distinguishing germline 
mutations from somatic mutations.  NGS methods may include whole genome 
sequencing (WGS)/whole exome sequencing (WES) but only at participating si tes 
(see Section  4.5.13 ). 
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.  
Unless the p atient gives specific consent for his or her leftover samples to be stored for 
optional exploratory research (see Section  4.5.14 ), biologi cal samples will be destroyed 
when the final Clinical Study Report has been completed, with the following exceptions:  
 Serum samples collected for PK or immunogenicity analysis may be needed for 
additional immunogenicity characterization and for PK or immun ogenicity assay 
development and validation; therefore, these samples wi ll be destroyed no later than 
5 years after the final Clinical Study Report has been completed.  
 Tissue samples  collected for eligibility testing, at surgery, and at disease recurrence , 
and blood samples  collected for biomarker research will be destroyed no later than 
5 years after the final Clinical Study Report has been completed or earlier 
depending on local regulations.  
 For patients who are not enrolled, remaining tissue blocks will b e returned to the site 
no later than 6 weeks after eligibility determination.  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
85/Protocol BO40747 , Version [ADDRESS_138897] to the 
confidentiality standards described in Section  8.4. 
Given the complexity and exploratory nature of exploratory bio marker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy o n study data publication.  
4.5.10  Electrocardiograms  
A 12-lead ECG is required at screening and when clinically indicated (see  Appendix  1).  
ECGs for each patient should be obtained from the same machine wherever possible.  
Lead placement should be as consistent a s possible.  ECG recordings must be 
performed after the patient has been resting in a supi[INVESTIGATOR_21683] [ADDRESS_138898] review, sign, and date all ECG 
tracings.  Paper copi[INVESTIGATOR_123424]'s permanent 
study file at the site.  Any morphologic waveform changes or other ECG abnormalities 
must be documented on the eCRF.  
4.5.11  Echocardiograms or Multiple -Gated Acquisition Scans  
LVEF will be assessed by [CONTACT_18585] (preferably) or MUGA scan at specified timepoints, as 
outlined in the schedule of activities (see Appendix  1) and as clinically indicated.  
Patients should be reassessed with the same technique used for baseline cardiac 
evaluation throughout the study, unless clinicall y indicated.  
Investigators must be aware of local institutional regulations regarding the maximum 
allowable frequency of repeat MUGA scans.   The repeated administration of 
radioisotopes is limited in some nuclear medicine laboratories, and patients in thi s study 
require monitoring on more than four occasions within 1 year.  
4.5.12  Patient -Reported Outcomes  
To more fully characterize the clinical profile of atezolizumab, PRO data will be 
obtained  through use of the following instruments:  EORTC  QLQ -C30; item GP5 of  the 
FACT -G quality -of-life instrument; and the EQ -5D-5L. 
Official versions of the PRO instruments in booklet format, translated as required in the 
local language, will be distributed by [CONTACT_123539] e patient at the investigational site.  To ensure instrument validity and 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
86/Protocol BO40747 , Version [ADDRESS_138899] be 
completed by [CONTACT_123540]’s 
health sta te, laboratory results, or health record; before administration of study 
treatment; and/or prior to the performance of any other study assessments that could 
bias the patient’s responses.  In scenarios where laboratory assessments (e.g.,  blood 
draws) are d one in a different clinic than the one providing treatment  or when they  are 
done on a different day than study treatment administration , laboratory assessments can 
be completed before the completion of PROs as long as results have not been 
discussed with p atients.   If the patient is unable to complete the measure on her or his 
own, interviewer assessment is allowed but may only be conducted by a member of the 
clinic staff who reads the questionnaire items to the patient verbatim; no interpretation, 
rephrasi ng, or rewording of the questions is allowed during interview -assisted 
completion.  
Study personnel should review all questionnaires for completeness before the patient 
leaves the investigational site, and the hard copy originals of the questionnaires must be 
maintained as part of the patient’s medical record at the site for source data verification. 
These originals should have the respondent’s initials, study patient number and date, 
and time of completion recorded in compliance with good clinical practice.   Sites will 
enter patient responses to the PRO questionnaires into the electronic data capture 
(EDC) system.  
All patients will begin completion of the questionnaires with the EORTC QLQ -C30, 
followed by [CONTACT_92349] -G single item GP5, and then the EQ -5D-5L at timepoints 
corresponding with in -clinic visits; both while receiving study treatment and after 
treatment discontinuation.  See Appendix  1 for the frequency and timing of PRO 
assessments.  
[IP_ADDRESS]  EORTC QLQ -C30 
The EORTC QLQ -C30 is a validated, reliable self -report measure (Aaronson  et al. 1993; 
Fitzsimmons  et al. 1999 ; see Appendix  6).  It consists of 30  questions that assess 
5 aspects of patient functioning (physical, emotional, role, cognitive, and  social), 
3 symptom scales (fatigue, nausea and vomiting, pa in), global health/quality of life, and 
6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial 
difficulties) with a recall period of the previous week.  Scale scores can be obtained for 
the multi -item scales.  The  EORTC QLQ -C30 module takes approximately 10  minutes to 
complete.  
[IP_ADDRESS]  FACT -G Single Item GP5  
The FACT -G instrument Version 4 (see Appendix  5) is a validated and reliable 27 -item 
questionnaire comprised of 4 subscales that measure physical (7 items), social/family 
(7 items), emotional (6 items), and functional well -being (7 items), and is considered 
appropriate for use with patients with any for m of cancer ( Cella  et al. 1993 ; 
Webster  et al. 1999).  In this study, the single -item GP5 (“I am bothered by [CONTACT_123541] —F. Hoffmann -La [COMPANY_002] Ltd  
87/Protocol BO40747 , Version 6 of treatment”) from the physical well -being subscale of the FACT -G has been selected 
for individual item analysis to document the level of bother of symptoms on patients ’ 
lives.  Patients will assess how true the statement “I am bothered by [CONTACT_76726]” has been for them in the previous 7 days on a 5 -point scale (0   not at all; 
1  a little bit; 2   somewhat; 3   quite  a bit; 4   very much).  The single -item GP5 from the 
FACT -G takes less than 1 minute to complete.  
[IP_ADDRESS]  EQ-5D-5L 
The EQ -5D-5L is a validated self -report health status questionnaire that is used to 
calculate a health status utility score for use in health econom ic analyses 
(EuroQol  Group 1990; Brooks 1996; Herdman et al. 2011; Janssen  et al. 2013; 
see Appendix  6).  There are two compone nts to the EQ -5D-5L:  a five -item health state 
profile that assesses mobility, self -care, usual activities, pain/discomfort, and 
anxiety/depression, as well as a visual analog scale that measures health state.  
Published weighting systems allow for creatio n of a single composite score of the 
patient’s health utility.  Utility scores will be used in this study for informing 
pharmacoeconomic evaluations.  As such, the utility results will not be included in the 
Clinical Study Report.  The EQ -5D-5L takes appro ximately 3 minutes to complete.  
4.5.13  Samples for Whole Genome Sequencing  
At participating sites, blood samples  will be collected for DNA extraction to enable WGS 
to identify mutations that are predictive of response to study drug, are associated with 
progression to a more severe disease state, are associated with acquired resistance to 
study drug, are associated with susceptibility to developi[INVESTIGATOR_68146], can lead to 
improved adve rse event monitoring or investigation, or can increase the knowledge and 
understanding of disease biology and drug safety.  Research will aim to distinguish 
germline mutations from somatic mutations.  The samples may be sent to one or more 
laboratories for  analysis . 
Collection and submission of WGS samples is contingent upon the review and approval 
of the exploratory research by [CONTACT_25733]'s Institutional Review Board or Ethics 
Committee (IRB/EC) and, if applicable, an appropriate regulatory body.  If a site  has not 
been granted approval for WGS  sampling, this section of the protocol ( Section  4.5.13 ) 
will not be applicable at that site.  
Genomics is increasingly informing researchers’ understanding of disease pathobiology.  
WGS provides a comprehensive characterization of the genome and, along with clinical 
data collected in this study, may increase the opportunity for developi[INVESTIGATOR_123425] a drug or develop adverse events.  Data  will be 
analyzed in the context of this study but will also be explored in aggregate with  data from 
other studies.  The availability of a larger dataset will assist in identification and 
characterization of important biomarkers and pathways to support future drug 
development.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
88/Protocol BO40747 , Version 6 For sampling procedures, storage conditions, and shipment instructio ns, see the 
laboratory manual.  
Blood samples collected for WGS are to be stored until they are no longer needed or 
until they are exhausted.  However, the storage period will be in accordance with the 
IRB/ECapproved Informed Consent Form and applicable la ws (e.g.,  health authority 
requirements).  
When a patient withdraws from the study, samples collected prior to the date of 
withdrawal may still be analyzed, unless the patient specifically requests that the 
samples be destroyed or local laws require destruc tion of the samples.  However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data.  
Patient medical information associated with WGS samples is confidential and may be 
disclosed to third  parties only as permitted by [CONTACT_25734] (or  separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_4677], unless permitted or required by [CONTACT_2371].  
Given the complexity and exploratory nature of the WGS ana lyses, data derived from 
these analyses will generally not be provided to study investigators or patients unless 
required by [CONTACT_2371].  The aggregate results of any conducted research will be available in 
accordance with the effective Sponsor policy on study da ta publication.  
4.5.14  Optional Samples for Research Biosample Repository  
[IP_ADDRESS]  Overview of the Research Biosample Repository  
The Research Biosample Repository (RBR) is a centrally administered group of facilities 
used for the long -term storage of human biological spec imens, including body fluids, 
solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  The 
collection, storage, and analysis of RBR samples will facilitate the rational design of new 
pharmaceutical agents and the development of diagnos tic tests, which may allow for 
individualized drug therapy for patients in the future.  
Samples for the RBR will be collected from patients who give specific consent to 
participate in this optional research.  RBR samples will be used to achieve the following 
objectives:  
 To study the association of biomarkers with efficacy or disease recurrence  
 To identify safety biomarkers that are associated with susceptibility to developi[INVESTIGATOR_123426]  
 To increase knowledge and understanding of disease biology and drug safety  
 To study drug response, including drug effects and the processes of drug absorption 
and disposition  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
89/Protocol BO40747 , Version 6  To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays  
 
[IP_ADDRESS]  Approval by [CONTACT_123542], storage, and analysis of RBR samples is contingent upon the review and 
approval of the exploratory research and the RBR portion of the Informed Consent  Form 
by [CONTACT_25733]'s IRB/EC and, if applicable, an appropriate regulatory body.  If a site has not 
been granted approval for RBR sampling, this section of the protocol ( Section  4.5.14 ) 
will not be applicable at that site.  
[IP_ADDRESS]  Sample Collection  
The following samples will be stored in the RBR and used for research purposes, 
including but not limited to research on biomarkers related to atezolizum ab, 
ddAC -PacHP, and diseases or drug safety:  
 Biomarker blood samples collected at timepoints defined in the schedule of activities  
 Leftover blood, serum, plasma, and tumor tissue samples and any derivatives 
thereof (e.g., DNA, RNA, proteins, peptides)  
 
The above samples may be sent to one or more laboratories for analysis  of germline or 
somatic mutations via WGS, WES, or other genomic analysis methods .  Genomics is 
increasingly informing researchers’ understanding of disease pathobiology.  WGS and 
WES provi de a comprehensive characterization of the genome and exome, respectively, 
and, along with clinical data collected in this study, may increase the opportunity for 
developi[INVESTIGATOR_123427] a drug or develop 
adverse events.  
Data  generated from RBR samples will be analyzed in the context of this study but will 
also be explored in aggregate with data from other studies.  The availability of a larger 
dataset will assist in identification and characterization of important biomarkers and 
pathways to support future drug development.  
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.  
RBR samples are to be stored until they are no longer needed or until they are 
exhausted.  However, the RBR storage period will be in accordance with the 
IRB/ECapproved Informed Consent Form and applicable laws (e.g.,  health authority 
requirements).  
[IP_ADDRESS]  Confidentiality  
RBR s amples and associated data will be labeled with a unique patient identification 
number.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
90/Protocol BO40747 , Version [ADDRESS_138900] parties only as permitted by [CONTACT_25734] (or  separat e 
authorization for use and disclosure of personal health information) signed by [CONTACT_4677], unless permitted or required by [CONTACT_2371].  
Given the complexity and exploratory nature of the analyses of RBR samples, data 
derived from these analyses will generally n ot be provided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.  
Data generated from RBR samples must be available for inspection upon request by 
[CONTACT_25735], and Sponsor monitors, 
representatives, and collaborators, as appropriate.  
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RBR data will become and remain the exclusive and unburdened property 
of the Sponsor, except where agreed otherwise.  
[IP_ADDRESS]  Consent to Participate in the Research Biosample Repository  
The Informed Consent Form will contain a separate section t hat addresses participation 
in the RBR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RBR.  Patients will be 
told that they are free to refuse to participate and  may withdraw their consent at any time 
and for any reason during the storage period.  A separate, specific signature [CONTACT_20030] a patient's agreement to provide optional RBR samples.  Patients 
who decline to participate will not provide a separate signature.  
The investigator should document whether or not the patient has given consent to 
participate and (if applicable) the date(s) of consent, by [CONTACT_76990].  
In the event of an RBR participant's  death or loss of competence, the participant's 
samples and data will continue to be used as part of the RBR research.  
 
[IP_ADDRESS]  Withdrawal from the Research Biosample Repository  
Patients who give consent to provide RBR samples have the right to withdraw their 
cons ent at any time for any reason.  However, if RBR samples have been tested prior to 
withdrawal of consent, results from those tests will remain as part of the overall research 
data.  If a patient wishes to withdraw consent to the testing of his or her RBR s amples 
during the study, the investigator must inform the Medical Monitor in writing of the 
patient's wishes through use of the appropriate RBR Subject Withdrawal Form and must 
enter the date of withdrawal on the RBR Research Sample Withdrawal of Informed 
Consent eCRF.  If a patient wishes to withdraw consent to the testing of his or her RBR 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
91/Protocol BO40747 , Version [ADDRESS_138901] inform the Sponsor by [CONTACT_123543]:  
global .[EMAIL_2452]  
 
A patient's withdrawal from this study does not, by [CONTACT_5071], constitute withdrawal of consent 
for testing of RBR samples.  Likewise, a patient's withdrawal of consent for testing of 
RBR samples does not constitute withdrawal from this s tudy.  
[IP_ADDRESS]  Monitoring and Oversight  
RBR samples will be tracked in a manner consistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system, to ensure compliance with data confident iality as well as 
adherence to authorized use of samples as specified in this protocol and in the Informed 
Consent Form.  Sponsor monitors and auditors will have direct access to appropriate 
parts of records relating to patient participation in the RBR for  the purposes of verifying 
the data provided to the Sponsor.  The site will permit monitoring, audits, IRB/EC review, 
and health authority inspections by [CONTACT_123544].  
4.[ADDRESS_138902] permanently discontinue study treatment if they experience any of the 
following:  
 Intolerable toxicity related to study treatment, including development of an 
immune -mediated adverse event determined by [CONTACT_70150]'s potential response to therapy and  severity of the event  
 Any medical condition that may jeopardize the patient's safety if he or she continues 
study treatment  
 Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the patient  
 Use of another non -protocol anti -cancer therapy  
 Pregnancy  
 Confirmation of disease progression or disease recurrence  
 Withdrawal by [CONTACT_4676]  
 Following rec eipt of the USM DIL dated [ADDRESS_138903]  discontinue treatment with atezolizumab or placebo . 
 
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study treatment prematurely will not be 
replaced.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
92/Protocol BO40747 , Version [ADDRESS_138904]  cancer surgery and pathological assessment will be performed and reported 
according to protocol requirements for  patients who discontinue study treatment during 
the neoadju vant phase  (for any reason other than disease progression)  and who 
proceed to surgery without receiving any other non -study anti -cancer therapy prior to 
surgery.   Patients who discontinue neoadjuvant study treatment due to disease 
progression contribute a no n-pCR result and their disease progression must be reported.  
Patients who discontinue study treatment early  for any reason,  enter t he follow -up phase 
of the study ( Appendix  1). 
4.6.[ADDRESS_138905] the right to voluntarily withdraw  from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include but are not limited to the following:  
 Patient withdrawal of consen t 
– From study treatment and/or procedures only (i.e.,  survival follow -up permitted)  
OR 
– From survival follow -up (patient does not want to be contact[INVESTIGATOR_530])  
 Study termination or site closure  
 Investigator or Sponsor determines it is in the best interest of the pat ient. 
 Patient non -compliance, defined as failure to comply with protocol requirements as 
determined by [CONTACT_123545].  If a patient requests to be withdrawn from the study, this request 
must be documented in the source documents and signed by [CONTACT_093].  Patients 
who withdraw from the study will not be replaced.  
If a patient withdraws from the study, the study staff may use a public information source 
(e.g.,  county records) to obtain information about survival status where permitted by 
[CONTACT_1769].  
4.6.[ADDRESS_138906].  It should be 
documented in both the medical records and the eCRF that the patient agreed to be 
contact[CONTACT_123546][INVESTIGATOR_123428]’s withdrawal of informed consent.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
93/Protocol BO40747 , Version 6 4.6.4  Study Discontinuation  
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include but are not limited to the following:  
 The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients  
 Patient enrollment is unsatisfactory  
 
The Sponsor will notify the investigator if the Sponsor dec ides to discontinue the study.  
4.6.5  Site Discontinuation  
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include but  are not limited to the following:  
 Excessively slow recruitment  
 Poor protocol adherence  
 Inaccurate or incomplete data recording  
 Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice  
 No study activity (i. e., all patients have completed the study and all obligations have 
been fulfilled)  
 
5. ASSESSMENT OF SAFETY  
5.1 SAFETY PLAN  
The safety plan for patients in this study is based on clinical experience with 
atezolizumab, ddAC -PacHP, and trastuzumab emtansine in comp leted and ongoing 
studies.  The anticipated important safety risks are outlined below 
(see Section  5.1.15.1.8 ). 
Measures will be taken to ensure the safety of patients participating in this study, 
including the use of stringent inclusion and exclusion criteria and close moni toring of 
patients during the study.  Administration of atezolizumab/placebo, ddAC -PacHP, and 
trastuzumab emtansine will be performed in a monitored setting in which there is 
immediate access to trained personnel and adequate equipment and medicine to 
mana ge potentially serious reactions.  Guidelines for managing patients who experience 
anticipated adverse events, including criteria for dosage modification and treatment 
interruption or discontinuation, are provided in Appendix  11, Appendix  12, Appendix  14, 
and Appendix  15.  See Section  5.1.105.6 for details on safety reporting (e.g.,  adverse 
events, pregnancies) for this study.  
In the setting of a pandemic or epi[INVESTIGATOR_901], screening for active infections (including 
SARS -CoV-2) during study participation should be c onsidered according to local or 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
94/Protocol BO40747 , Version 6 institutional guidelines or guidelines of applicable professional societies (e.g.,  American 
Society of Clinical Oncology  or European Society for Medical Oncology ). 
Severe COVID -19 appears to be associated with a CRS involving the inflammatory 
cytokines IL -6, IL-10, IL -2, and IFN - (Merad and Martin 2020 ).  If a patient develops 
suspected CRS during the study, a differential diagnosis should include COVID -19, 
which should be confirmed or refuted through assessment of e xposure history, 
appropriate laboratory testing, and clinical or radiologic evaluations per investigator 
judgment.  If a diagnosis of COVID -19 is confirmed, the disease should be managed as 
per local or institutional guidelines.  
5.1.1  Risks Associated with Atezo lizumab  
Atezolizumab has been associated with risks such as the following:  IRRs and 
immune -mediated hepatitis, pneumonitis, colitis, pancreatitis, diabetes mellitus, 
hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, Guillain -Barré  
syndrome, myasthenic syndrome or myasthenia gravis, facial paresis, myelitis, 
meningoencephalitis, myocarditis, pericardial disorders, nephritis , and myositis , and 
severe cutaneous adverse reactions .  In addition, immune -mediated reactions may 
involve any  organ system and lead to hemophagocytic lymphohistiocytosis  (HLH) .  
Refer to Appendix  12 of the protocol and Section 6 of the Atezolizumab Investigator's 
Brochure for a detailed description of anticipated safety risks for atezolizumab.  
5.1.2  Risks Associated with Doxorubic in 
Doxorubicin is known to cause serious cardiomyopathy; arrhythmias, including 
life-threatening arrhythmias; increased incidence of secondary acute myelogenous 
leukemia  and myelodysplastic syndrome; extravasation and tissue necrosis; severe 
myelosuppressi on resulting in serious infection, septic shock, need for transfusions, 
hospi[INVESTIGATOR_059], and death; tumor lysis syndrome; radiation sensitization and radiation 
recall; embryofetal toxicity; infertility ; alopecia; hyperuricemia ; vomiting ; nausea ; and 
other gastrointestinal effects.   Hypersensitivity reactions, such as fever, urticaria and 
anaphylaxis have been occasionally reported.  
Refer to the local prescribing information for doxorubicin for more  details regarding the 
full safety profile of doxorubicin , including boxed warnings and contraindications.  
Dose reduction and dose delays will be allowed as indicated in the relevant local 
prescribing information and Appendix  11 and will be managed as per local practice.  
[IP_ADDRESS]  Cardiomyopathy  
Patients treated with doxorubicin are at risk of developi[INVESTIGATOR_123429] -related 
myocardial damage.  Significant cardiac events, including acute heart failure and LVEF 
of  40%, have been observed in clinical trials of doxorubicin.  Cardiomyopathy may 
develop during treatment or up to several years after completion of treatment.  There is 
an additive or potentially synergistic increase in the risk of car diomyopathy in patients 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
95/Protocol BO40747 , Version [ADDRESS_138907] meet specified LVEF requirements to be included in this study 
(see Section  4.1.1 ). 
Left ventricular function will be monitored by [CONTACT_123547]  4.5.11  and the schedule of 
activities (se e Appendix  1).  For the algorithm for continuation and discontinuation of 
study treatment  based on LVEF measurements see Figure  3. 
5.1.3  Risks Associated with Cyclophosphamide  
Cyclophosphamide has been associated with myel osuppression sometimes leading to 
severe immunosuppression and infections that can be serious and sometimes fatal; 
hemorrhagic cystitis, pyelitis, ureteritis, and hematuria  (with some fatal cases of 
urotoxicity) ; myocarditis, myopericarditis (which may be accompanied by [CONTACT_123548], leading to severe cardiac heart failure) , arrhythmias, 
and congestive heart failure; pulmonary toxicity including pneumonitis, pulmonary 
fibrosis, and pulmonary veno -occlusive disease  leading to respi[INVESTIGATOR_1399];  secondary 
malignancies; veno -occlusive liver disease; embryo -fetal toxicity; infertility; impairment of 
wound -healing; hyponatremia; alopecia; nausea ; vomiting ; stomatitis  and diarrhea ; 
anaphyla ctic reactions including thos e with fatal outcomes ; and cecitis . 
Refer to the local prescribing information for cyclophosphamide for more  details 
regarding the full safety profile of cyclophosphamide , including boxed warnings and 
contraindications.  
Dose reduction and dose delays will be allowed as indicated in the relevant local 
prescribing information and Appendix  11, and managed as per local practice.  
5.1.[ADDRESS_138908] of a corticosteroid 
(dexamethasone 8 10 mg by [CONTACT_123549] 12 and 6 hours before 
paclitaxel), diphenhydramine (or its equivalent) [ADDRESS_138909] (cimetidine 300 mg or ranitidine 50 mg IV 30  to 
60 minutes before paclitaxel).  Patients who experience severe hypersensitivi ty reactions 
to paclitaxel despi[INVESTIGATOR_123430] -challenged with the drug.  
Warnings related to paclitaxel use include myelo suppression (primarily neutropenia), 
which is dose -dependent and is the DLT during paclitaxel treatment ; and increased  risk 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
96/Protocol BO40747 , Version [ADDRESS_138910] be interrupted or discontinued 
because of initial or recurrent hypertension.  Other significant cardiovascular events 
possibly related to single -agent paclitaxel occurred in approximately 1% of all patients, 
and included syncope, rhythm abnormalities, and venous thrombosis.  
Paclitaxel treatment is frequently associated with peripheral neuropathy , and other 
serious neurologic events following paclitaxel administration have included grand mal 
seizures, syncope, ataxia, and neuroencephalopathy.  
Injection site reactions, including reactions secondary to extravasation, were usually mild 
and consisted of erythema, tenderness, skin discoloration, or swelling at the injection 
site; more severe events s uch as phlebitis, cellulitis, induration, skin exfoliation, necrosis, 
and fibrosis have also been reported, with onset during or up to 10  days after paclitaxel 
infusions.  
Caution should be exercised when paclitaxel is concomitantly administered with known 
substrates, inhibitors, and inducers of CYP3A4 or CYP2C8; see Section  [IP_ADDRESS] . 
Paclitaxel  is contraindicated in patients with severe hepatic impairment . 
For more details regarding the safety profile of paclitaxel, refer to the local paclitaxel 
prescribing information.  
Dose reduction and dose delays will be a llowed as indicated in the relevant local 
prescribing information and Appendix  11 and will be managed as per local practice.  
5.1.5  Risks Associated with Pertuzumab, Trastuzumab, and 
Trastuzumab Emtansine  
The known risks associated with trastuzumab treatment include cardiac toxicity (as 
described below), infusion -related reactions, hypersensitivity and anaphylaxis, febrile 
neutropenia, diarrhea, pulmonary toxicity, as well as risk of oligohydramnios.  Refer  to 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
97/Protocol BO40747 , Version 6 the Trastuzumab Investigator’s Brochure for a full description of the trastuzumab safety 
profile, warnings, precautions, and guidance for investigators . 
For pertuzumab, infusion -related reactions, anaphylaxis and hypersensitivity , diarrhea, 
interstitia l lung disease, left ventricular systolic dysfunction and symptomatic left 
ventricular systolic dysfunction/congestive heart failure, skin reactions/rash, leu kopenia, 
and mucositis are adverse events of particular clinical relevance.  Refer to the 
Pertuzum ab Investigator’s Brochure for a full description of the pertuzumab safety 
profile, warnings, precautions, and guidance for investigators.  
Identified risks with trastuzumab emtansine are interstitial lung disease and acute 
respi[INVESTIGATOR_1505], he patotoxicity, nodular regenerative hyperplasia of the 
liver, left ventricular dysfunction, infusion -related reactions, hypersensitivity reactions, 
hemorrhage, thrombocytopenia, and peripheral neuropathy.  Refer to the Trastuzumab 
Emtansine Investigator’s B rochure for a full description of the trastuzumab emtansine 
safety profile, warnings, precautions, and guidance for investigators.  
The administration of pertuzumab, trastuzumab, and trastuzumab emtansine should be 
performed in a setting with emergency equi pment and staff who are trained to monitor 
medical situations and respond to medical emergencies.  Patients will be monitored 
during each infusion for adverse effects (see Section  [IP_ADDRESS]  and [IP_ADDRESS]  for details).  
The management of infusion -associated sy mptoms is outlined in Appendix  11 
and Appendix  14. 
[IP_ADDRESS]  Cardiotoxicity  
LVEF declines have been reported with drugs that block HER2 activity, including 
pertuzumab, trastuzumab, and trastuzumab emtansine.  
To enter this study, all patients must have a LVEF (by [CONTACT_123550]) of  55% 
and regular monitoring of LVEF is required throughout the study according to the 
schedule of activities (se e Appendix  1).  For the algorithm for continuation and 
discontinua tion of study treatment based on LVEF measurements , see Figure  3. 
If severe symptomatic heart failure develops ([LOCATION_001] Heart Association [NYHA] 
Class  III or IV) , the patient must discontinue anti -HER2 therapy.  If there is a significant 
LVEF decrease (LVEF decline  10 percentage points from baseline to an LVEF value 
 50%),  anti-HER2 therapy should be withheld and a repeat LVEF  assessment 
performed within approximately [ADDRESS_138911] discontinue 
anti-HER2 therapy.  Patients who develop asymptomatic cardiac dysfunctio n may 
benefit from more frequent monitoring (e.g.,  every 68 weeks).  Heart failure or left 
ventricular dysfunction should be treated and monitored according to standard medical 
practice.  These patients should be evaluated by a certified cardiologist, and  the results 
of this evaluation should be reported on the eCRF.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
98/Protocol BO40747 , Version 6 Patients who discontinue pertuzumab, trastuzumab, or trastuzumab emtansine for heart 
failure or LVEF decline should continue to undergo LVEF assessments according to the 
sche dule of activities (see Appendix  1)irrespective of the initiation of alternative 
systemic anti -cancer therapy until resolution, improvement to baseline status, no 
further improvement can be expected, or death.  Additional LVEF assessments may be 
required for these patients (beyond those specified in the schedule of activities), 
according to the investigator’s clinical judgment.  The results of these assessments 
should be reported.

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
99/Protocol BO40747 , Version 6 Figure  3 Algorithm for Continuation and Discontinua tion of Study Treatment on the Basis of LVEF Assessment  
 
HER2   human epi[INVESTIGATOR_5169] 2 ; LVEF   left ventricular ejection fraction.   
a Three intermittent holds of study treatment will lead to discontinuation.  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
100/Protocol BO40747 , Version 6 [IP_ADDRESS]  EGFR -Related Toxicities  
Although pertuzumab targets the HER2 receptor, it inhibits heterodimerization with other 
members of the HER family (e.g., epi[INVESTIGATOR_3506] [EGFR; HER1]).  
Accordingly, it may cause toxicities associated with the use of EGFR inhibitors such as 
diarrhea, rash, and other dermatologic toxicities (e.g.,  dry skin, pruritus, nail disorders, or 
mucositis).  
To prevent dehydration, early treatment of diarrhea with anti -diarrheal medication should 
be considered, and patients sho uld be treated with fluids and electrolyte replacement, as 
clinically indicated.  
Treatment recommendations for EGFR -associated rash include topi[INVESTIGATOR_123431] (for severe reactions).  
These agents may be us ed in patients experiencing pertuzumab -related rash, as 
clinically indicated, although they have not been studied in this context.  
Mucositis is generally not considered preventable; although for some cytotoxic agents, 
mucositis may be reduced by [CONTACT_123551] e mouth using ice chips before and during the 
infusion.  
5.1.6  Risks Associated with Trastuzumab Emtansine  
[IP_ADDRESS]  Pulmonary Toxicity  
Cases of interstitial lung disease (ILD), including pneumonitis, some leading to acute 
respi[INVESTIGATOR_123432] e been reported in clinical trials with 
trastuzumab emtansine.  Signs and symptoms include dyspnea, cough, fatigue, and 
pulmonary infiltrates.  These events may or may not occur as sequelae of infusion 
reactions.  
Permanently discontinue treatment with tras tuzumab emtansine in patients diagnosed 
with ILD or pneumonitis, except for radiation pneumonitis in the adjuvant setting, where 
trastuzumab emtansine should be permanently discontinued for Grade   3, or for 
Grade  [ADDRESS_138912] due to complications of advanced malignancy, 
co-morbidities, and receiving concurrent pulmonary radiation therapy may be at 
increased risk of pulmonary toxicity.  
Guidelines for management of trastuzumab emtansine in patients who develop ILD or 
pneumonitis are provided in Appendix  14. 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
101/Protocol BO40747 , Version 6 [IP_ADDRESS]  Hepatotoxicity  
The following events have been reported  with administration of trastuzumab emtansine : 
 Serious hepatobiliary disorders  
– Serious hepatobiliary disorders, including nodular regenerat ive hyperplasia 
(NRH) of the liver and hepatobiliary disorders with a fatal outcome due to 
drug-induced liver injury, have been observed in patients treated with 
trastuzumab emtansine.  Some of the observed cases may have been 
confounded by [CONTACT_123552].  
 Increased serum transaminases  
– Asymptomatic increases in serum transaminase concentration (transaminitis) 
have been observed.  Grade  [ADDRESS_138913] been observed frequently; 
Grade  [ADDRESS_138914]  of 
trastuzumab emtansine, that is, an increase in the proportion of patients with 
Grade  1 or 2 elevations in transaminases with successive cycles has been 
observed; however, there was no increase in the proportion of patients with 
Grade  3 abnormalities ov er time.  
 NRH  
– Cases of NRH have been identified from liver biopsies in patients treated with 
trastuzumab emtansine who presented with signs and symptoms of portal 
hypertension.  NRH is a rare liver condition characterized by [CONTACT_123553].  NRH 
may lead to non -cirrhotic portal hypertension.  Diagnosis of NRH can only be 
confirmed by [CONTACT_26745].  Biopsy -confirmed NRH leading to fatal hepatic 
failure has been reported.  
– NRH should be c onsidered in all patients with clinical symptoms of portal 
hypertension, even with normal transaminases, and no other manifestations of 
cirrhosis; in patients with a cirrhosis -like pattern seen on a CT scan of the liver; 
and/or in patients with liver failu re following long -term treatment with 
trastuzumab emtansine.  
 
Guidelines for management of trastuzumab emtansine in patients who develop  
increased serum transaminases, increased serum bilirubin, or NRH are provided in 
Appendix  14. 
[IP_ADDRESS]  Left Ventricular Dysfunction  
Patients treated with trastuzumab emtansine are at risk of developi[INVESTIGATOR_123433].  To date, significant cardiac events, including LVEF of  40%, have been 
observed (infrequently) in clinical trials of trastuzumab emtansine; therefore, 
symptomatic CHF is a potential risk.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
102/Protocol BO40747 , Version 6 Guidelines for patient monitoring and management of trastuzumab emtansine in patients 
who develop  left ventricular dysfunction are provided in Section  [IP_ADDRESS]  and 
Appendix  14. 
[IP_ADDRESS]  Infusion -Related Reactions and Hypersen sitivity Reactions  
IRRs and hypersensitivity reactions have been reported with administration of 
trastuzumab emtansine.  Despi[INVESTIGATOR_123434] (reactions 
involving cytokine release) and hypersensitivity (allergic) reactions, the cli nical 
manifestations are the same.  In general, IRRs are expected to be more frequent and 
severe with the first infusion and to decrease in number and severity over time.  The 
severity of true hypersensitivity reactions would be expected to increase with 
subsequent infusions.  
IRRs, characterized by [CONTACT_91842] flushing, chills, pyrexia, 
dyspnea, hypotension, wheezing, bronchospasm, and tachycardia have been reported 
in clinical trials of trastuzumab emtansine.  In  general, these sy mptoms were not severe.  
In most patients, these reactions resolved over the course of several hours to a day after 
the infusion was terminated.  
Hypersensitivity reactions, including serious anaphylactic -like reactions, have been 
observed in clinical trials of trastuzumab emtansine.  Patients with a history of 
intolerance to trastuzumab are excluded from this study  (see Section  4.1.2 ). 
Administration of trastuzumab emtansine will be performed in a setting with access to 
emergency facilities and staff who are trained to monitor and respond to medical 
emergencies.  Patients should be closely m onitored for IRRs during and after each 
infusion of trastuzumab emtansine.  
Guidelines for management of patients who experience IRRs or hypersensitivity 
reactions are provided in  Appendix  14. 
[IP_ADDRESS]  Hematologic Toxicity  
Thrombocytopenia has been reported in patients in clinical trials of trastuzumab 
emtansine.  The majority of these patients had Grade  1 or 2 events (platelet count 
 50,000/L), with the nadir occurring by [CONTACT_2006]  8 and generally improving to Grade  0 or 1 
(platelet count  75,000/L) by [CONTACT_123554] (i.e.,  within 3  weeks).  
Evaluation of this safety parameter across vari ous clinical studies has shown a higher  
incidence and severity of thrombocytopenia in Asian patients.  
Patients with thrombocytopenia (  100,000/mm3) and patients on anticoagulant 
treatment should be monitored closely during treatment with trastuzumab emtansine.  
It is required that platelet counts are monitored prior to each trastuzumab emtansine 
dose.  Rare cases of severe prolonged thrombocytopenia  defined as persisting (  Grade  3 
thrombocytopenia events lasting for more than 90 days) have been reported with 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
103/Protocol BO40747 , Version [ADDRESS_138915] of these cases, 
patients received concomitant recombinant human thrombop oietin.   Trastuzumab 
emtansine has not been studied in patients with platelet counts  100,000/mm3 prior to 
initiation of treatment.  In  the event of decreased platelet count to Grade   3 
( 50,000/mm3), do not administer trastuzumab emtansine until platelet counts recover to 
Grade  1 ( 75,000/mm3). 
Declines in other hematopoietic lineages (e.g.,  leukopenia, neutropenia, and anemia) 
were less frequent than that observed for platelets.  
Guidelines for management of trastuzumab emtansine in patients who develop 
hematologic toxicity are provided in Appendix  14. 
[IP_ADDRESS]  Hemorrhage  
Cases of hemorrhagic events, including central nervous sys tem, respi[INVESTIGATOR_696], and 
gastrointestinal hemorrhage, have been reported with trastuzumab emtansine.  Some of 
these bleeding events resulted in fatal outcomes.  In  some of the observed cases, the 
patients were also receiving anticoagulation therapy, anti -platelet therapy, or had 
thrombocytopenia; in others, there were no known additional risk factors.  Caution 
should be used with these agents, and additional monitoring should be considered when 
concomitant use during treatment with trastuzumab emtansine is med ically necessary.  
[IP_ADDRESS]  Neurotoxicity  
Peripheral neuropathy, mainly Grade  1 and predominantly sensory, has been reported in 
clinical trials of trastuzumab emtansine.  
Patients with Grade  3 peripheral neuropathy should not be considered for treatment 
with trastuzumab emtansine.  
Guidelines for management of trastuzumab emtansine in patients who develop  
peripheral neuropathy are provided i n Appendix  14. 
[IP_ADDRESS]  Extravasation  
In trastuzumab emtansine clinical studies, reactions secondary to extravasation have 
been observed.  These reactions were usually mild and consisted of erythema, 
tenderness, skin irritation, pain, or swelling at the inf usion site.  These reactions have 
been observed more frequently within 24  hours of the infusion.  
Closely monitor the infusion site for possible subcutaneous infiltration during drug 
administration.  Specific treatment for trastuzumab emtansine extravasatio n is unknown 
at this time.  Patients should be managed symptomatically per local institutional 
guidelines.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
104/Protocol BO40747 , Version 6 5.1.7  Risks Associated with Combination Use of Pertuzumab with 
Trastuzumab and Paclitaxel  
Pertuzumab was well tolerated in combination with trastuzumab (St udy WO20697), with 
an increase in the incidence but not severity of the common adverse events seen with 
single -agent pertuzumab (notably, diarrhea, rash, and fatigue).  
Study  WO29217 (BERENICE) is an open -label, nonrandomized, multicenter, 
multinational Phase II study to evaluate pertuzumab in combination with trastuzumab 
and standard neoadjuvant anthracycline -based chemotherapy in patients with 
HER2 -positive, locally advanced, inflammatory, or EBC.  Eligible patients were allocated, 
by [CONTACT_093], to receive one of the two treatment regimens:  ddAC given Q2W for 
4 cycles, followed by [CONTACT_123555] 12 weeks, with pertuzumab and trastuzumab 
given Q3W from the start of paclitaxel; or FEC given Q3W for 4 cycles, followed by 
[CONTACT_123556] Q3W f or 4 cycles, with pertuzumab and trastuzumab given Q3W from 
the start of docetaxel (FEC→docetaxel   pertuzumab and trastuzumab).  
 There were no unexpected safety signals in Study WO29217.  
 During the overall treatment period, the most frequently reported adv erse events 
( 10% of patients) considered to be related to pertuzumab or trastuzumab included 
diarrhea, IRR, fatigue, ejection fraction decreased, epi[INVESTIGATOR_3940], arthralgia, myalgia, 
asthenia, anemia, and mucosal inflammation.  Grade  [ADDRESS_138916] 
commonly reported terms were febrile neutropenia, neutropenia, diarrhea, and 
stomatitis.  The serious adverse events during the overall treatment period reported 
by  2% o f patients in either cohort included febrile neutropenia, diarrhea, 
neutropenic sepsis, device -related infection, ejection fraction decreased, and 
pyrexia.  The adverse event profile observed in Study WO29217 is consistent with 
the established safety profi le of pertuzumab and trastuzumab in combination with 
chemotherapy.  
 The most common laboratory post -baseline abnormalities for the overall study 
period were hematological.  The highest incidence of Grade 3 or 4 abnormalities 
was reported for lymphocytopenia , absolute neutrophil count, and low white blood 
cell count.  
 For those patients who received ddAC  followed by [CONTACT_123557] :  The cardiac safety observed during the overall study period in 
patients with normal cardiac function at baseline remained in line with that observed 
in previous clinical studies with dual HER2 -containing treatment regimens and the 
known clinical profile of pertuzumab and trastuzumab.  The incidence of NYHA 
Class  III or IV heart failure occurring during th e overall study period was low.  Based 
on the known cardiac safety profile of pertuzumab and trastuzumab from studies 
with dual HER2 -containing treatment regimens, there were no unexpected findings.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
105/Protocol BO40747 , Version 6 5.1.8  Risks Associated with Combination Use of Atezolizumab an d 
Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, 
Pertuzumab, or Trastuzumab Emtansine  
The following adverse events are important potential overlappi[INVESTIGATOR_123435], cyclophosphamide, pa clitaxel, 
trastuzumab, or pertuzumab:  cardiotoxic and gastrointestinal (diarrhea, colitis) events.  
Additional potential overlappi[INVESTIGATOR_123436], skin rash, 
hypersensitivity and IRRs.  Myelosuppression (neutropenia, anemia, or  
thrombocytopenia) is an important potential overlappi[INVESTIGATOR_123437] 
(doxorubicin, cyclophosphamide, paclitaxel) and HER2 targeted therapy (trastuzumab, 
pertuzumab).  The risk of overlappi[INVESTIGATOR_123438].  
When there is a possibility of overlappi[INVESTIGATOR_50685], the attribution of an adverse event to 
particular drug(s) will be based on the investigator’s clinical judgment.  See  Table  5 
below for sources in the protocol that provide guidance for managing overlappi[INVESTIGATOR_123439].  
Table  5 Guidance for Managing Overlappi[INVESTIGATOR_123440]   Section [IP_ADDRESS]  and Appendix  11 (Doxorubicin and 
Cyclophosphamide, Cardiotoxicity)  
Cyclophosphamide   Appendix  11 (Doxorubicin and Cyclophosphamide, Cardiotoxicity)  
Pertuzumab   Section [IP_ADDRESS]  and Appendix  11 (Pertuzumab and Trastuzumab, 
Cardiotoxicity)  
Trastuzumab   Section [IP_ADDRESS]  and Appendix  11 (Pertuzumab and Trastuzumab, 
Cardiotoxicity)  
Atezolizumab   Appendix  12 (Immune -Mediated Myocarditis, including Table 6)  
Paclitaxel   Section 5.1.4  and local prescribing information for paclitaxel  
Diarrhea or colitis  
Pertuzumab   Section [IP_ADDRESS]  and Appendix  11 (Pertuzumab and Trastuzumab, 
EGFR -Related Toxicities)  
Paclitaxel   Appendix  11 and local prescribing information for paclitaxel  
Atezolizumab   Appendix  12 (Gastrointestinal Events, including Table 3)  
 
  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
106/Protocol BO40747 , Version 6 Table  5 Guidance for Managing Overlappi[INVESTIGATOR_70034] (cont.)   
Event  Source in Protocol for Guidance  
Respi[INVESTIGATOR_123441]   Appendix  12 (Pulmonary Events, including Table 1), Appendix  15, 
and the Atezolizumab Investigator’s Brochure  
Pertuzumab   Pertuzumab Investigator’s Brochure  
Trastuzumab   Trastuzumab Investigator’s Brochure  
Cyclophosphamide   Local prescribing information for cyclophosphamide  
Paclitaxel   Appendix  11 (Pulmonary Events/Pneumonitis) and local prescribing 
information for paclitaxel  
Trastuzumab 
emtansine   Appendix  15 and the Trastuzumab Emtansine Investigator’s 
Brochure  
Skin rash  
Pertuzumab   Section [IP_ADDRESS]  and Appendix  11 (Pertuzumab and Trastuzumab, 
EGFR -Related Toxicities)  
Atezolizumab   Appendix  12 (Dermatologic Events, including Table 9)  
Paclitaxel   Local prescribing information for paclitaxel  
Hypersensitivity and infusion -related reactions  
Atezolizumab   Section [IP_ADDRESS]  and Appendix  12 (Infusion -Related Reactions, 
including Table 7)  
Pertuzumab   Section [IP_ADDRESS]  and Appendix  11 (Pertuzumab and Trastuzumab, 
Infusion -Associated Symptoms)  
Trastuzumab   Section [IP_ADDRESS]  and Appendix  11 (Pertuzumab and Trastuzumab, 
Infusion -Associated Symptoms)  
Paclitaxel   Sections [IP_ADDRESS]  (Paclitaxel) and 5.1.4 , and the local prescribing 
informat ion for paclitaxel  
Myelosuppression  
Paclitaxel   Section 5.1.4 , Appendix  11, and the local prescribing information for 
paclitaxel  
Doxorubicin   Local prescribing information for doxorubicin  
Cyclophosphamide   Local prescribing information for cyclophosphamide  
Pertuzumab   Pertuzumab Investigator’s Brochure  
Trastuzumab   Trastuzumab Investigator’s Brochure  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
107/Protocol BO40747 , Version 6 Table  5 Guidance for Managing Overlappi[INVESTIGATOR_70034] (cont.)   
Event  Source in Protocol for Guidance  
Hepatotoxicity  
Atezolizumab   Appendix  15 and the Atezolizumab Investigator’s Brochure  
Trastuzumab 
emtansine   Appendix  15 and the Trastuzumab Emtansine Investigator’s 
Brochure  
 
For additional information, dose reductions and management, see Section  5.1.1 5.1.6  
in conjunction with Appendix  11, Appendix  12, Appendix  14, and Appendix  15 as well as 
the local prescribing information for doxorubicin, cyclophosphamide, and paclitaxel, and 
the Tr astuzumab, Pertuzumab, Atezolizumab, and Trastuzumab Emtansine 
Investigator’s Brochures.  
5.1.9  General Plan to Manage Safety Concerns  
Safety will be evaluated in this study through the monitoring of all serious and 
non-serious adverse events defined and graded according to NCI CTCAE v5.0.  Patients 
will be assessed for safety (including laboratory test values) according to the schedule of 
activities in Appendix  [ADDRESS_138917] be reviewed prior 
to each infusion.  
General safety assessments will include serial interval histories, physical examinations, 
and specific laboratory studies, including serum chemistry and blood counts 
(see Section  4.[ADDRESS_138918] and timing of study 
assessments).  
Cardiac monitoring (ECHO or MUGA scan) will be performed on all patients enrolled in 
the study and will be obtained at baseline and at regular intervals throughout the study. 
See Appendix  [ADDRESS_138919] 
(see  Section  5.2.2  and 5.2.3 ) will be reported in an expedited fashion 
(see Section  5.4.2 ). 
5.1.10  Dose Modifications  
Reasons for dose modifications or delays, the supportive measures taken, and the 
outcomes will be documented in the patient's chart and recorded on the eCRF.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
108/Protocol BO40747 , Version 6 The severity of adverse events will be graded according to the NCI CTCAE v5.0.  
 For any concomitant conditions reported at baseline, the dose modifications will 
apply according to the corresponding shift in toxicity grade, if the i nvestigator 
determines that it is appropriate.  For example, if a patient has Grade 1 asthenia at 
baseline that increases to Grade 2 during treatment, this will be considered a shift of 
one grade and treated as Grade 1 toxicity for dose -modification purpos es. 
 When several toxicities with different grades of severity occur at the same time, the 
dose modifications should be according to the highest grade observed.  
 If, in the opi[INVESTIGATOR_871], a toxicity is considered to be attributable solely 
to on e component of the study treatment and the dose of that component is delayed 
or modified in accordance with the guidelines below, the other component may be 
administered if there is no contraindication.  
 
See Appendix  11 and Appendix  12 for dose modific ation guidelines.  
[IP_ADDRESS]  Dose Modifications of Trastuzumab Emtansine and 
Atezolizumab/Placebo  
Treatment management guidelines reflect the guidance prior to the issuance of the 
USM  DIL dated 3 February 2021 .  Following the mandated discontinuation of blinded 
study  treatment with atezolizumab or placebo, these guidelines still apply; however, 
these guidelines apply without treatment with atezolizumab/placebo.  
If trastuzumab emtansine is held for toxicity, then atezolizumab/placebo must also be 
held.  If  trastuzumab emtansine is discontinued for toxicity, atezolizumab/placebo must 
not be continued as single agent and must either be discontinued also or may be 
continued in combination with trastuzumab and pertuzumab to complete a total of 1  year 
of HER2 -targeted therap y if the investigator considers the toxicity to be related to 
trastuzumab emtansine without compromising the continued use of trastuzumab.  
If treatment with atezolizumab/placebo had been discontinued prior to the 
discontinuation of trastuzumab emtansine o r if both treatments are discontinued 
concurrently, it is at the investigator’s discretion to switch treatment to trastuzumab and 
pertuzumab if the toxicity is not considered related to the trastuzumab component of 
trastuzumab emtansine.  
If study treatment  is temporarily interrupted because of toxicity caused by [CONTACT_123558]/placebo, the treatment cycles will be restarted such that the 
atezolizumab/placebo and trastuzumab emtansine infusions remain synchronized.  
If significant tras tuzumab emtansine related toxicities have not recovered to Grade  [ADDRESS_138920] dose 
was received.  “Significant” and “related” will be based on the judgment of the 
investigator (in co nsultation with the Sponsor’s Medical Monitor or designee when 
appropriate).  For  example, alopecia even if considered related to trastuzumab 
emtansine would most likely not be considered to be significant.  In  general, when the 
significant related toxicit y (or any other toxicity that the investigator chooses to delay 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
109/Protocol BO40747 , Version 6 dosing for) resolves to Grade  1 or baseline, the patient may resume trastuzumab 
emtansine if the delay is not  [ADDRESS_138921] dose received.  Patients should be 
re-evaluated weekly dur ing the delay, whenever possible.  If  dosing resumes, the patient 
may receive trastuzumab emtansine either at the same dose level as before or at one 
lower dose level (see Table  6), at the discretion of the investigator.  Subsequent cycles 
should remain Q3W.  If  a patient requires a dose reduction, dosing will be reduced by 
[CONTACT_123559]  6.  A maximum of two dose reductions is allowed for 
trastuzumab emtansine.  No dose re -escalation is permitted.  A  patient treated with 
2.4 mg/kg of trastuzumab emtansine who develops an adverse event requiring a dose 
reduction must discontinue trastuzumab emtansine.  For patients who experience 
Grade  [ADDRESS_138922] weekly for recovery.  If  values do 
not recover to baseline or Grade  [ADDRESS_138923] dose , and the investigator wishes to re -start treatment with trastuzumab emtansine 
based on a positive benefit risk assessment for the individual patient, the Medical 
Monitor is available fo r consultation . 
Table  6 Dose Modification Scheme for Trastuzumab Emtansine  
Dose Reduction Schedule  Dose Level (mg/kg, Q3W)  
Starting dose  3.[ADDRESS_138924] dose reduction  3.0 
Second dose reduction  2.4 
Requirement for further dose reduction  Discontinue treatment  
Q3W   every 3 weeks.  
Note:  The dose of trastuzumab emtansine, once reduced, may not be re -escalated.  
A maximum of two dose reductions is allowed; patients with any further requirement for 
dose reduction will discontinue treatment with trastuzumab emtansine and 
atezolizumab/placebo.  
 
5.[ADDRESS_138925], performing 
protocol -specified safety laboratory assessments, measuring protocol -specified vital 
signs, and conducting other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.  
Certain types of events require immediate r eporting to the Sponsor, as outlined 
in Section  5.4. 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
110/Protocol BO40747 , Version [ADDRESS_138926], regardless of causal attribution.  An adverse event can 
therefore be any of the following:  
 Any unfavorable and unintended sign (including a n abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product  
 Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition ; see Section  [IP_ADDRESS]  
and Section  [IP_ADDRESS]  for more information)  
 Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline  
 Any deterioration in a laboratory value or other clinical test (e.g.,  ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study treatment  
 Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignme nt of study treatment (e.g.,  screening invasive 
procedures such as biopsies)  
 
5.2.2  Serious Adverse Events (Immediately Reportable to the 
Sponsor)  
A serious adverse event is any adverse event that meets any of the following criteria:  
 Is fatal (i.e., the adverse event actually causes or leads to death)  
 Is life threatening (i.e.,  the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)  
– This does not include any adverse event that, had it occurred in a more severe 
form or wa s allowed to continue, might have caused death.  
 Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section  [IP_ADDRESS] ) 
 Results in persisten t or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient's ability to conduct normal life 
functions)  
 Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study treatmen t 
 Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)  
 
The terms "severe" and "serious" are not synonymous.  Severity refe rs to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to NCI  CTCAE; 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
111/Protocol BO40747 , Version 6 see Section  5.3.3 ); the eve nt itself may be of relatively minor medical significance (such 
as severe headache without any further findings).  
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.  
Serious adverse events are required to be reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the event; see Section  5.4.2  for 
reporting instructions).  
5.2.[ADDRESS_138927] (Immediately Reportable to 
the Sponsor)  
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learning of the event; 
see Section  5.4.2  for reporting instructions).  Adverse events of special inter est for this 
study are as follows:  
 Cases of potential drug -induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
[CONTACT_25742]'s Law (see Section  [IP_ADDRESS] ) 
 Suspected transmission of an infectious agent by [CONTACT_104841], as defined 
below:  
– Any organism, virus, or infectious particle (e.g., prion protein transmitt ing 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exp osed to a medicinal product.  This term applies only 
when a contamination of study treatment is suspected.  
 Pneumonitis  
 Colitis  
 Endocrinopathies:  diabetes mellitus, pancreatitis, adrenal insufficiency, 
hyperthyroidism, and hypophysitis  
 Hepatitis, including  AST or ALT  10   ULN 
 Systemic lupus erythematosus  
 Neurological disorders:  Guillain -Barré syndrome, myasthenic syndrome or 
myasthenia gravis, and meningoencephalitis  
 Events suggestive of hypersensitivity, IRRs, cytokine  release syndrome, 
influenza -like illness, HLH, and MAS  
 Nephritis  
 Ocular toxicities (e.g., uveitis, retinitis, optic neuritis)  
 Myositis  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
112/Protocol BO40747 , Version 6  Myopathies, including rhabdomyolysis  
 Grade  2 cardiac disorders  
 Asymptomatic decline in LVEF requiring treatment or leading to discontinuation of 
trastuzumab, pertuzumab, or trastuzumab emtansine  
 Vasculitis  
 Autoimmune hemolytic anemia  
 Severe cutaneous reactions (e.g., Stevens -Johnson syndrome, dermatitis bullous, 
toxic epi[INVESTIGATOR_194])  
 Myelitis  
 Facial paresis  
 
5.2.4  Selected Adverse Events  
Additional data will be collected for the following selected adverse events . 
[IP_ADDRESS]  Cardiac, General  
Symptomatic left ventricular systolic dysfunction (referred to as heart failure) should be 
reported as a serious adverse event.  If the diagnosis is heart failure, it should  be 
reported as such and not in terms of the individual signs and symptoms (i.e.,  report heart 
failure rather than dyspnea on exertion, bilateral ankle edema, and tachycardia; 
see Section  [IP_ADDRESS] ).  A cardiac consultation is recommended for patients who develop 
symptomatic left ventricular systolic dysfunction (heart failure).  Heart failure should be 
graded according to the NCI CTCAE v5.0 for “heart failure” (Grade 2, 3, 4, or 5) and in 
addition according to the NYHA classification.  
Heart failure occurring at any point during the study (including the follow -up period), 
even beyond the 90 days after the final dose of study treatment (see Section 5.6) must 
be reported, irrespective of causal relationship, and followed until one of the following 
occurs:   resolution or improvemen t to baseline status, no further improvement can be 
expected, or death.  
[IP_ADDRESS]  Asymptomatic Left Ventricular Systolic Dysfunction  
Asymptomatic declines in LVEF should generally not be reported as adverse events 
because LVEF data are collected separately in the eC RF.  Exceptions to this rule are as 
follows:  
 An asymptomatic decline in LVEF  10 percentage points from baseline to an 
LVEF   50% must be reported as an adverse event with the term "ejection fraction 
decreased " as per NCI CTCAE v 5.0, and, in addition, a comment in the adverse 
events comments field  should confirm that this event was asymptomatic.  
 An asymptomatic decline in LVEF requiring treatment or leading to discontinuation 
of trastuzumab, pertuzumab, or trastuzumab emtansine must be reported as an 
adve rse event of special interest (see Section  5.2.3 ); a comment in the adverse 
event comments field should confirm that this event was asympt omatic.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
113/Protocol BO40747 , Version 6  
Table  7 summarizes the reporting conventions for left ventricular systolic dysfunction 
and heart failure.  
Table  7 Reporting Conventions for Left Ventricular Systolic 
Dysfunction/Congestive Heart Failure  
Observation  How to Report  Term to be 
Reported  Grading  
Asymptomatic decline in 
LVEF of  10 percentage 
points from baseline or to an 
LVEF of  50% No additional reporting 
required; LVEF results to 
be reported on eCRF.  NA NA 
Asymptomatic decline in 
LVEF of  10 percentage 
points from baseline to an 
LVEF of  50% AE a (eCRF AE eForm)  Ejection fraction 
decreased a NCI CTCAE for 
"ejection fraction  
decreased"  
Asymptomatic decline in 
LVEF requiring treatment or 
leading to discontinuation of 
trastuzumab, pertuzumab, 
or trastuzumab emtansine  AE (eCRF AE eForm)  
and reported as a 
non-serious AESI on an 
SAE form  Ejection fraction 
decreased a NCI CTCAE for 
"ejection fraction 
decreased"  
Heart failure/CHF 
(symptomatic LVSD) b AE (eCRF AE eForm) and 
SAE (SAE form)  "Heart failure"  NCI CTCAE for 
"heart failure" and 
NYHA class  
AE   adverse event; AESI   adverse event of special interest; CHF   congestive hea rt failure; 
eCRF   electronic case report form; e -Form   electronic form; LVEF   left ventricular ejection 
fraction; LVSD   left ventricular systolic dysfunction; NA   not applicable; NCI CTCAE   National 
Cancer Institute Common Terminology Criteria for Ad verse Events; NYHA   [LOCATION_001] Heart 
Association; SAE   serious adverse event.  
a Report the status as asymptomatic and provide the LVEF value in the comments field as 
appropriate.  
b Any symptomatic LVSD event must be reported as "heart failure."  
 
5.3 METHODS AND TIMING FOR CAPTU RING AND ASSESSING 
SAFETY  PARAMETERS  
The investigator is responsible for ensuring that all adverse events (see Section  5.2.1  for 
definition) are recorded on the Adverse Event eCRF and reported to  the Sponsor in 
accordance with instructions provided in this section and in Section s 5.45.6. 
For each adverse event recorded on the A dverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section  5.2.2  for seriousness criteria), severity 
(see Section  5.3.3 ), and causality (see Section  5.3.4 ).   

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
114/Protocol BO40747 , Version [ADDRESS_138928].  All 
adverse events, whether reported by [CONTACT_25743],  will be 
recorded in the patient's medical record and on the Adverse Event eCRF.  
After informed consent has been obtained but prior to initiation of study treatment , only 
serious adverse events caused by a protocol -mandated intervention (e.g.,  invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section  5.4.2  for instructions for reporting serious adverse events).  
After initiation of study treatment , all adverse events will be reported until [ADDRESS_138929].  
For reporting of heart failure, see Section  [IP_ADDRESS]  and 5.6. 
Study drug related serious adverse events will be reported indefinitely (even if the study 
has been closed).  Instructions for reporting adverse events that occur after the adverse 
event reporting period are provided in Section  5.6. 
5.3.2  Eliciting Adverse Event Information  
A consistent methodology of non -directive questionin g should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:  
 "How have you felt since your last clinic visit?"  
 "Have you had any new or changed health problems  since you were last here?"  
 
5.3.3  Assessment of Severity of Adverse Events  
The adverse event severity grading scale for the NCI CTCAE (v5.0) will be used for 
assessing adverse event severity.  Table  8 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
115/Protocol BO40747 , Version 6 Table  8 Adverse Event Severity Grading Scale for  Events Not Specifically 
Listed in NCI CTCAE  
Grade  Severity  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
or intervention not indicated  
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a 
3 Severe or medically significant, but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; or 
limiting  self-care activities of daily living b, c 
4 Life-threatening consequences or urgent intervention indicated d 
5 Death related to adverse event d 
NCI CTCAE   National Cancer Institute Common Terminology Criteria for Adverse Events . 
Note:  Based on the most recent version of NCI CTCAE (v5.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
a Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.  
b Examples o f self -care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by [CONTACT_25744].  
c If an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 5.4.2  for reporting instructions), per the definition of serious 
adverse event in Section  5.2.[ADDRESS_138930] be reported as seri ous adverse events (see Section 5.4.2  for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 . 
 
5.3.4  Assessment of Causality of Adverse Events  
Investigators should us e their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to study treatment, indicating "yes" or "no" 
accordingly.  Th e following guidance should be taken into consideration (see 
also Table  9): 
 Temporal relationship of event onset to the initiation of study treatment  
 Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study treatment, or reintroduction of study treatment (as 
applicable)  
 Known association of the event with study treatment or with similar treatments  
 Known association of the event with the disease under study  
 Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event  
 Presence of non -treatment -related factors that are k nown to be associated with the 
occurrence of the event  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
116/Protocol BO40747 , Version 6  
Table  9 Causal Attribution Guidance  
Is the adverse event suspected to be caused by [CONTACT_123560], 
evidence, science -based rationales, and clinical judgment?  
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of study treatment, and the adverse event cannot be readily explained by 
[CONTACT_102]'s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the 
adverse event follows a known pattern of response to study treatment; and/or the 
adverse event abates or resolves upon discontinuation of study treatment or dose 
reduction and, if  applicable, reappears upon re -challenge.  
NO An advers e event will be considered related, unless it fulfills the criteria specified below .   
Evidence exists that the adverse event has an etiology other than study treatment 
(e.g.,  preexisting medical condition, underlying disease, intercurrent illness, 
or conc omitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of study treatment (e.g., cancer diagnosed [ADDRESS_138931] dose of study treatment).  
 
For patients receiving combination therapy, causality will be assessed individually for 
each protocol -mandated therapy.  
5.3.[ADDRESS_138932] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations . 
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.  
[IP_ADDRESS]  Infusion -Related Reactions  and Cytokine  Release Syndrome  
There may be significant overlap in signs and symptoms of IRRs and cytokine  release 
syndrome.  While IRRs occur during or within 24 hours after treatment administration, 
time to onset of CRS may vary.  Differential diagnosis should be applied, particularly for 
late-onset CRS (occurring more than 24 hours after treatment administration), to rule out 
other etiologies such as delayed hypersensitivity reactions, sepsis or infections, HLH, 
tumor lysis syndrome, early disease progression, or other manifestations of systemic 
inflammation.  
Adverse events that occur during or within 24 hours after study treatment a dministration 
and are judged to be related to study treatment infusion should be captured as a 
diagnosis (e.g., "infusion -related reaction"  or "cytokine  release syndrome" ) on the 
Adverse Event eCRF.  If possible, avoid ambiguous terms such as "systemic rea ction."  
Cases of late -onset CRS should be reported as "cytokine  release syndrome" on the 
Adverse Event eCRF.  Associated signs and symptoms should be recorded on the 
dedicated I nfusion -Related Reaction eCRF.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
117/Protocol BO40747 , Version 6 If a patient experiences both a local and syste mic reaction to the same dose of study 
treatment, each reaction should be recorded separately on the Adverse Event eCRF, 
with signs and symptoms also recorded separately on the dedicated Infusion -Related 
Reaction eCRF.  
In recognition of the challenges in c linically distinguishing between IRRs and CRS, 
consolidated guidelines for medical management of IRRs and CRS are provided 
in Appendix  12. 
[IP_ADDRESS]  Diagnosis versus Signs and Symptoms  
A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than 
jaundice, asterixis, and elevated trans aminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or syndrome 
at the time of reporting, each individual event should be recorded on the Adverse Event 
eCRF.  If a diagnosis is subsequent ly established, all previously reported adverse events 
based on signs and symptoms should be nullified and replaced by [CONTACT_40877], with a starting date that corresponds to the starting 
date of the first symptom o f the eventual diagnosis.  
[IP_ADDRESS]  Adverse Events That Are Secondary to Other Events  
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:  
 If vomiting results in mild dehydration wi th no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.  
 If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.  
 If a severe gastrointestinal hemorrhage leads to renal failure, b oth events should be 
reported separately on the eCRF.  
 If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.  
 If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately  on the eCRF.  
 
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.  
[IP_ADDRESS]  Persistent or Recurrent Adverse Events  
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
118/Protocol BO40747 , Version 6 Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adver se event becomes 
more severe, the most extreme severity should also be recorded on the Adverse Event 
eCRF.  If the event becomes serious, it should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning that the event became ser ious; 
see Section  5.4.2  for reporting instructions).  The Adverse Event eCRF should be 
updated by  [CONTACT_25748] "non -serious" to "serious," providing the date that 
the event became serious, and compl eting all data fields related to serious adverse 
events.  
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Advers e Event eCRF.  
[IP_ADDRESS]  Abnormal Laboratory Values  
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:  
 Is accompanied by [CONTACT_4659]  
 Results i n a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)  
 Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy  
 Is clinically significant  in the investigator's judgment  
– Note:  For oncology trials, certain abnormal values may not qualify as adverse 
events.  
 
It is the investigator's responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deci ding whether an isolated laboratory 
abnormality should be classified as an adverse event.  
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g.,  ALP and bilirubin 5   ULN associated with cholestasis), only the diagnosi s 
(i.e., cholestasis) should be recorded on the Adverse Event eCRF.  
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indi cating whether the test result is above or below the normal range 
(e.g., "elevated potassium," as opposed to "abnormal potassium").  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term s hould be recorded as the adverse event.  For example, an  elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
119/Protocol BO40747 , Version 6 Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded on ce on the Adverse Event eCRF (see Section  [IP_ADDRESS]  for 
details on recording persistent adverse events).  
[IP_ADDRESS]  Abnormal Vital Sign Values  
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria:  
 Is accompanied by [CONTACT_4659]  
 Results in a change in study treatment (e.g., dosage modifi cation, treatment 
interruption, or treatment discontinuation)  
 Results in a medical intervention or a change in concomitant therapy  
 Is clinically significant in the investigator's judgment  
 
It is the investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.  
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g.,  high blood pressure), only the diagnosis (i.e.,  hypertension) should be recorded on 
the Adverse Event eCRF.  
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section  [IP_ADDRESS]  for 
details on recording persistent adverse events).  
[IP_ADDRESS]  Abnormal Liver Function Tests  
The finding of an elevated ALT or AST ( 3  ULN) in combination with either an elevated 
total bilirubin (  2  ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury 
(as defined by [CONTACT_25742]'s Law).  There fore, investigators must report as an adverse event the 
occurrence of either of the following:  
 Treatment -emergent ALT or AST  3  ULN in combination with total bilirubin 
 2  ULN 
 Treatment -emergent ALT or AST  3  ULN in combination with clinical jaundice  
 
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see  Section  [IP_ADDRESS] ) 
and reported to the Sponsor immediately (i.e., no more than 24  hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest 
(see Section  5.4.2 ). 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
120/Protocol BO40747 , Version 6 [IP_ADDRESS]  Deaths  
For this protocol, mortality is an efficacy endpoint.  Deaths that occur during the 
protocol -specified adverse event reporting period (see Section  5.3.1 ) that are attributed 
by [CONTACT_123561]2 -positive breast cancer  should be 
recorded on the Death Attributed to Progressive Disease eCRF.  All other deaths t hat 
occur during the adverse event reporting period, regardless of relationship to study 
treatment, must be recorded on the Adverse Event eCRF and immediately reported to 
the Sponsor (see Section  5.4.2 ).  An independent monitoring committee will monitor the 
frequency of deaths from all causes.  
Death should be considered an outcome and not a distinct event.  The event or condition 
that cause d or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "une xplained death"  should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by [CONTACT_25749].  The term "sudden death"  should not be 
used unless  combined with the presumed cause of death (e.g.,  "sudden cardiac death").  
Deaths that occur after the adverse event reporting period should be reported as 
described in Section  5.6. 
[IP_ADDRESS]  Preexisting Medical Conditions  
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditi ons eCRF.  
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of  the condition worsens during the study.  When 
recording such events on the  Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by [CONTACT_9672]  
(e.g.,  "more frequent headaches").  
[IP_ADDRESS]  Lack of Efficacy or Worsening of HER2 -Positive Breast Cancer  
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should not be recorded as adverse events.  These data wil l be 
captured as efficacy assessment data only.  Instances of disease recurrence will be 
verified by [CONTACT_123562].  In rare 
cases, the determination of clinical progression will be based on symptomatic 
deter ioration.  However, every effort should be made to document progression through 
use of objective criteria.  If there is any uncertainty as to whether an event is due to 
disease progression, it should be reported as an adverse event.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
121/Protocol BO40747 , Version 6 [IP_ADDRESS]  Hospi[INVESTIGATOR_123442] (i.e., inpatient admission to a hospi[INVESTIGATOR_307]) 
or prolonged hospi[INVESTIGATOR_25676] a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2 ), except as outlined 
below.  
An event that leads to hospi[INVESTIGATOR_26664] a serious adverse event:  
 Hospi[INVESTIGATOR_25678]  
 Planned hospi[INVESTIGATOR_33402] (e.g., for study treatment 
administration or performance of an efficacy measurement for the study)  
 Hospi[INVESTIGATOR_272] a preexist ing condition, provided that all of the following criteria 
are met:  
– The hospi[INVESTIGATOR_33403] . 
– The patient has not experienced an adverse event . 
 Hospi[INVESTIGATOR_123443] a serious adverse event, but should be report ed as an adverse event 
instead:  
 Hospi[INVESTIGATOR_25682]  
 
[IP_ADDRESS]  Patient -Reported Outcome Data  
Adverse event reports will not be derived from PRO data  by [CONTACT_1034], and safety 
analyses will not be performed using PRO data.  Sites are not expected to review the 
PRO data for adverse events.  
[IP_ADDRESS]  Safety Biomarker Data  
Adverse event reports will not be derived from safety biomarker data by [CONTACT_1034], 
and saf ety biomarker data will not be included in the formal safety analyses for this 
study.  In addition, safety biomarker data will not inform decisions on patient 
management.  
5.[ADDRESS_138933] report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_138934] 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
122/Protocol BO40747 , Version [ADDRESS_138935] report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study treatment:  
 Serious adverse events (define d in Section  5.2.2 ; see Section  5.4.2  for details on 
reporting requirements)  
 Adverse events of special interest (defined in Section  5.2.3 ; see Section  5.4.2  for 
details on reporting requirements)  
 Pregnancies (see Section  5.4.3  for details on reporting requirements)  
 Accidental overdoses or medication errors (see Section  5.4.4  for details on reporting 
requirements)  
 
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:  
 New signs or symptoms or a change in the diagnosis  
 Significant new diagnostic test results  
 Change in causality based on new information  
 Change in the event's outcome, including recovery  
 Additional narrative information on the clinical course of the event  
 
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.  
5.4.[ADDRESS_138936]  
[IP_ADDRESS]  Events That Occ ur prior to Study Treatment Initiation  
After informed consent has been obtained but prior to initiation of study treatment, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The paper Clinical Trial Adverse Event/S pecial Situations Form provided to investigators 
should be completed and submitted to the Sponsor or its designee immediately (i.e., no 
more than 24 hours after learning of the event), either by [CONTACT_123563].  
[IP_ADDRESS]  Events That Occur after Study Treatment Initiation  
After initiation of study treatment, serious  adverse events and adverse events of special 
interest will be reported until [ADDRESS_138937] all case details that can be gathered immediately (i.e., within 24  hours 
after learning of the event) on the Adverse  Event eCRF and s ubmit the report via the 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
123/Protocol BO40747 , Version 6 EDC system.  A  report will be generated and sent to [COMPANY_002] Safety Risk Management by 
[CONTACT_27950].  
In the event that the EDC system is unavailable, the paper Clinical Trial Adverse Event/  
Special  Situations Form provided to investigators should be completed and submitted to 
the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
event), either by [CONTACT_123564].  Once the EDC system is available, all 
information will need to be entered and  submitted via the EDC system.  
Instructions for reporting serious adverse events that occur after the reporting period are 
provided in Section  5.6. 
5.4.3  Reporting Requirements for Pregnancies  
[IP_ADDRESS]  Pregnancies in Female Patients  
Female patients of childbearing potential will be instructed to immediately inform t he 
investigator if they become pregnant during the study or within 5 months after the final 
dose of atezolizumab/placebo, 6 months after the final dose of doxorubicin, 12  months 
after the final dose of cyclophosphamide, 6 months after the final dose of pac litaxel, and 
7 months after the final dose of trastuzumab, pertuzumab, or trastuzumab emtansine 
(whichever is longer).  A paper Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no m ore than 
24 hours after learning of the pregnancy), either by [CONTACT_123565].  Pregnancy 
should not be recorded on the Adverse Event eCRF.  The investigator should  
discontinue study treatment and counsel the patient, discussing the risks of the 
pregnancy and the possible effects on the fetus.  Monitoring of the patient should 
continue until conclusion of the pregnancy.  Any serious adverse events associated with 
the pregnancy (e.g., an event in the fetus, an event in the mother during or after the 
pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the 
Adverse Event eCRF.  In addition, the investigator will submit a Clinical Trial Preg nancy 
Reporting Form when updated information on the course and outcome of th e pregnancy 
becomes available.  
Attempts should be made to collect and report infant health information.  When 
permitted by [CONTACT_779], an Authorization for the Use and Disclosure of  Infant Health 
Information would need to be signed by [CONTACT_123566] (as per local regulations) to 
allow for follow -up on the infant.   If the authorization has been signed, the infant's 
health status at birth should be recorded on the Clinical Trial P regnancy Reporting 
Form.  In addition, the Sponsor may collect follow -up information on the infant's 
health status at 3, 6, and 12  months after birth.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
124/Protocol BO40747 , Version 6 [IP_ADDRESS]  Pregnancies in Female Partners of Male Patients  
Male patients will be instructed through the Informed Con sent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
6 months after the final dose of doxorubicin and/or cyclophosphamide, 6 months after 
the final dose of paclitaxel, and 7 months after the final do se of trastuzumab, 
pertuzumab, or trastuzumab emtansine (whichever is longer).  A paper Clinical Trial 
Pregnancy Reporting Form should be completed and submitted to the Sponsor or its 
designee immediately (i.e., no more than 24 hours after learning of the pregnancy), 
either by [CONTACT_123567].  Attempts should be made to collect and report details 
of the course and outcome of any pregnancy in the partner of a male pa tient exposed to 
study treatment.  When permitted by [CONTACT_779], the pregnant partner would need to sign an 
Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow -
up on her pregnancy.  If the authorization has been signed, t he investigator should 
submit a Clinical Trial Pregnancy Reporting Form when updated information on the 
course and outcome of the pregnancy becomes available.  An investigator who is 
contact[CONTACT_123568], to support an informed 
decision in cooperation with the treating physician and/or obstetrician.  
Attempts should be made to collect and report infant health information.  When 
permitted by [CONTACT_779], an Authorization for the Use and Disclosure of Infant Health 
Information would need to be signed by [CONTACT_123566] (as per local regulations) to 
allow for follow -up on the infant.   If the authorization has been signed, the infan t's 
health status at birth should be recorded on the Clinical Trial Pregnancy Reporting 
Form.  In addition, the Sponsor may collect follow -up information on the infant's 
health status at 3, 6, and 12  months after birth.  
[IP_ADDRESS]  Abortions  
Any abortion should be cla ssified as a serious adverse event (as  the Sponsor considers 
abortions to be medically significant), recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section  5.4.2 ). 
[IP_ADDRESS]  Congenital Anomalies/Birth Defects  
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
treatment or th e female partner of a male patient exposed to study treatment should be 
classified as a serious adverse event, recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section  5.4.2 ). 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
125/Protocol BO40747 , Version 6 5.4.4  Reporting Requirements for Cases of Accidental Overdose or 
Medication Error  
Accidental overdose and medication error (hereafter collectively referred to as "special 
situations"), are defined as follows:  
 Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose  
 Medication error:  accidental deviation in the administration of a drug   
– In some cases, a medication error may be intercepted prior to administration of 
the drug.  
 
Special situations are not in themselves adverse events but may result in adverse 
events.  Each adverse event associated with a special situation should be recorde d 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately 
(i.e., no more than 24  hours after learning of the event; see Section  5.4.2 ).  For 
atezolizumab/placebo, trastuzumab, pertuzumab, and trastuzumab emtansine, adverse 
events associated with special situations should be recorded as desc ribed below for 
each situation:  
 Accidental overdose:  Enter the adverse event term.  Check the "Accidental 
overdose" and "Medication error" boxes.  
 Medication error that does not qualify as an overdose:  Enter the adverse event 
term.  Check the "Medication error" box.  
 Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and "Medication error" boxes.  
 
In addition, all special situations associated with atezolizumab/placebo, trastuzumab, 
pertuzumab, an d trastuzumab emtansine, regardless of whether they result in an 
adverse event, should be recorded on the Adverse Event eCRF .  In the instance where 
this results in a serious adverse event, the event must be  reported to the Sponsor 
immediately (i.e.,  no more than 24  hours after learning of the event).  Special situations 
should be recorded as described below:  
 Accidental overdose:  Enter the drug name [INVESTIGATOR_1238] "accidental overdose" as the event 
term.  Check the "Accidental overdose" and "Medication error" boxes.  
 Medication error that does not qualify as an overdose:  Enter the name [CONTACT_26865] a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expi[INVESTIGATOR_26669]) as the event term.  Check the "Medication error" box.  
 Medication error that qualifies as an overdose:  Enter the drug name [INVESTIGATOR_1238] "accidental 
overdose" as the event term.  Check the "Accidental overdose" and "Medication 
error" boxes.  Enter a description of t he error in the additional case details.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
126/Protocol BO40747 , Version 6  Intercepted medication error:  Enter the drug name [INVESTIGATOR_1238] "intercepted medication 
error" as the event term.  Check the "Medication error" box.  Enter a description of 
the error in the additional case details.  
As an exa mple, an accidental overdose that resulted in a headache would require the 
completion of two Adverse Event eCRF pages, one to report the accidental overdose 
and one to report the headache.  The "Accidental overdose" and "Medication error" 
boxes would need to be checked on both eCRF pages.  
5.[ADDRESS_138938] to 
follow -up, or the patient withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study treatment or trial -related 
procedures until a final outcome can be reported.  
During  the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient's medical record to facilitate source data 
verification.  
All pregnancies reported during the study should be followed until pregn ancy outcome.  
5.5.[ADDRESS_138939], and pregnancies, the 
Sponsor or a designee may follow  up by [CONTACT_756], fax, email, and/or a monitoring visit 
to obtain additional case details and outcome infor mation (e.g.,  from hospi[INVESTIGATOR_123444], consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.  
5.[ADDRESS_138940] (defined as [ADDRESS_138941]), deaths eit her 
attributed by [CONTACT_123561]2 -positive breast cancer or due 
to an adverse event considered by [CONTACT_123569], should be reported through use of the Long -Term Survival Follo w-Up eCRF . 
Heart failure occurring at any point during the study, even beyond the [ADDRESS_138942] be reported, irrespective of causal relationship, and 
followed until one of the following occurs:  resolution or improve ment to baseline status, 
no further improvement can be expected, or death.  Heart failure, irrespective of causal 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
127/Protocol BO40747 , Version 6 relationship, that that occurs after study closure should be reported to [COMPANY_002] as a 
spontaneous report to be included in the [COMPANY_002] Global Safe ty Database.  
In addition, if the investigator becomes aware of a serious adverse event that is believed 
to be related to prior exposure to study treatment, the event should be reported through 
use of the Adverse Event eCRF.  However, if the EDC system is n ot available 
(e.g.,  completion of the study), the investigator should report these events directly to the 
Sponsor or its designee, either by [CONTACT_123570]/Special Situations Form using the fax num ber or email address 
provided to investigators.  
5.[ADDRESS_138943] experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.  
To determine reporting requirements for single ad verse event cases, the Sponsor will 
assess the expectedness of these events using the following reference documents:  
 Atezolizumab Investigator's Brochure  
 Pertuzumab Investigator's Brochure  
 Trastuzumab Investigator's Brochure  
 Trastuzumab Emtansine Investigator’s Brochure  
 European Summary of Product Characteristics (EU -SmPC) for doxorubicin, 
cyclophosphamide, and paclitaxel  
 
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity  and frequency reported in the 
applicable reference document.  
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].  
6. STATISTICAL CONSIDER ATIONS AND ANA LYSIS PLAN  
6.1 ANALYSIS POPULATIONS  
The analysis populations are defined as follows:  
 The ITT population is defined as all randomized patients, whether or not the 
assigned study treatment was received.  
 The PD -L1positive  population is defined as patients in the  ITT population whose 
PD-L1 status is IC  1/2/3 at the time of randomization.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
128/Protocol BO40747 , Version 6  The PRO -evaluable population is defined as patients in the ITT population with a 
baseline and  1 postbaseline PRO assessment . 
 The safety -evaluable population is defined as patien ts who received any amount of 
any study drug.  
 
For all efficacy analyses, patients will be assigned to the treatment group to which they 
were randomized.  
For safety analyses, patients will be assigned to treatment groups as treated, and all 
patients who received any dose of atezolizumab will be included in the atezolizumab 
treatment arm.  
6.2 DETERMINATION OF SAM PLE SIZE  
The global study will randomize approxima tely 453 patients in total.   Assuming a 
prevalence of 40% of PD -L1positive patients (defined as tumors with a PD -L1 
expression level of IC 1/2/3), the PD -L1positive population is estimated to comprise 
approximately 181 patients.  
6.2.1  Type I Error Control  
The Type I error ( ) for this study is 0.05 (two -sided).  The Type I error will be controlled 
for the following efficacy endpoints:  
 Co-primary efficacy endpoi nt of pCR, as defined in  Section  2.1.1, in the 
PD-L1positive population wit h an allocated  of 0.048  
 Co-primary efficacy endpoint of pCR, as defined in Section  2.1.1, in the 
ITT population with an allocated  of 0.002  
 
In the PD -L1positive population, t his sample size will allow for 80% power to detect an 
improvement in pCR proportion from 70% in the placebo   ddAC -PacHP  to 90% ( 20%) 
in the atezolizumab   ddAC -PacHP  group at the 4.8%  level of significance (two -sided) 
assuming a dropout of 7% of the pat ients (i.e., p atients without pCR assessment will be 
regarded as not achieving pCR resulting in an improvement in pCR proportion from  
65% to 83% ;  18%).  
In the ITT population , this sample size will allow for 82.8% power to detect an 
improvement in pCR pro portion from 60% in the placebo   ddAC -PacHP  to 80%  ( 20%) 
in the atezolizumab   ddAC -PacHP  group at the 0.2% level  of significance (two -sided) , 
assuming a dropout of 10% of the patients (i.e., p atients without pCR assessment will be 
regarded as not achieving pCR resulting in an improvement in pCR proportion from  
54% to 72%;  18%).  
6.[ADDRESS_138944]  OF STUDY  
For all randomized patients (i.e., ITT population), a participant flowchart for depi[INVESTIGATOR_123445], 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
129/Protocol BO40747 , Version [ADDRESS_138945] of the study, 
patient management, or patient assessment will be also tabulated by  [CONTACT_2939].  
6.4 SUMMARIES OF DEMOGRA PHIC AND BASELINE 
CHARACTERISTICS  
Demographic variables such as age, sex, race/ethnicity, a nd baseline characteristics 
(in particular, stratification variables) will be summarized by [CONTACT_120387].   Only descriptive analyses are planned; no formal statistical tests will be 
applied.  Continuous variables will be reported and summarized by [CONTACT_123571] (mean, standard deviation, median, and 
range includin g minimum and maximum), and categorical (i.e., discrete) data will be 
reported and summarized by [CONTACT_22977].  The baseline value of any 
variable will be defined as the last available value prior to the first administration of study 
treatme nt. 
6.[ADDRESS_138946] cancer at 
high risk of recurrence (T2 4, N13) as measured by [CONTACT_123572]-L1positive populations .  pCR is estab lished following completion of neoadjuvant 
therapy and surgery.  
pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin 
evaluation of the complete resected breast specimen and all sampled regional lymph 
nodes following completion  of NAST (i.e.,  ypT0/is ypN0 in the current AJCC staging 
system) . 
Patients with missing pCR assessment will be counted as not achieving a pCR.  
Treatment comparison of pCR will be made using Cochran -Mantel -Haenszel test 
stratified by [CONTACT_123573] (T2 vs. T3 or 4), hormone receptor status (positive vs. 
negative) and PD -L1 status (IC 0 vs. IC  1/2/3) , if applicable.  The 2-sided  significance  
level in the PD -L1positive population is 4.8% and in the ITT population 0.2% .  The 
stratification factors will be based on data collected by [CONTACT_123574].  Confidence intervals for the difference in pCR rate between the 
two arms will be determined using the normal approximation to the binomial  distribution.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
130/Protocol BO40747 , Version 6 A summary table that presents the  number and proportion of pCR in each treatment 
arm, together with the 2 -sided 95%  CI with use of the Clopper -Pearson method  will be 
produced  (Clopper and Pearson 1934) . 
6.5.2  Secondary Efficacy Endpoints  
The secondary efficacy endpoints are the following:  
 pCR (ypT0/is ypN0) based upon hormone receptor status (ER/PgR positive or 
ER/PgR negative)  in all patients (ITT population)  and based upon PD -L1 status 
(IC 0; IC 1/2/3)  
 pCR (ypT0/is ypN0) in the PD -L1negative (IC 0) population  
 EFS, defined as the time from randomization until documented disease recurrence, 
unequivocal tumor progression determined by [CONTACT_12707], or death 
from any cause in all patients (ITT population)  and based upon hormone receptor 
status (ER/PgR  positive or ER/PgR negative) and PD -L1 status (IC 0; IC 1/2/3)  
 DFS, defined as the time from surgery until documented disease recurrence or 
death from any cause in all patients (ITT population) who undergo surgery  and 
based upon hormone receptor status (E R/PgR positive or ER/PgR negative) and 
PD-L1 status (IC 0; IC 1/2/3)  
 OS, defined as the time from randomization to the date of death from any cause in 
all patients (ITT population)  and based upon hormone receptor status (ER/PgR 
positive or ER/PgR negative)  and PD -L1 status (IC 0; IC 1/2/3)  
 PROs of function (role, physical) and HRQoL in PRO -evaluable population  
 
[IP_ADDRESS]  pCR in the Subgroups  
pCR is defined in analogous manner to the primary endpoint and will be analyzed with 
the same methodology in the subgroups.  Th e stratification factors in the subgroup 
analysis will be as defined below:  
 pCR by [CONTACT_9573]:  The stratification factors will be disease stage 
and PD -L1 status.  
 pCR by [CONTACT_4002] -L1 status:  The stratification factors will be disease stage and hormo ne 
receptor status.  
 
[IP_ADDRESS]  Event -Free Survival  
EFS is defined as the time from randomization to the first documented disease 
recurrence, unequivocal tumor progression determined by [CONTACT_12707] , or 
death from any cause, whichever occurs first.  
Patie nts without an event at the time of the analysis will be censored on the date on 
which they are last known to be alive and event free, on or before the clinical data cutoff 
date of the respective analysis.  Patients with no postbaseline information will be  
censored at the date of randomization.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
131/Protocol BO40747 , Version [ADDRESS_138947] stratified 
by [CONTACT_123575].  The HR for EFS will be 
estimated using a Cox proportional hazards model.  The 95% CI for the HR will be 
provided.  Kaplan -Meier methodology will be used to estimate the median EFS 
(if reached) for each treatment arm, and Kaplan -Meier curves will be  produced.  
Brookmeyer -Crowley methodology will be used to construct the 95% CI for the median 
EFS for each treatment arm (Brookmeyer and Crowley 1982).  The Kaplan -Meier 
approach will be also used to estimate landmark EFS rates, including 3 -year EFS rates , 
and corresponding 95% CIs for each treatment arm.  Results from an unstratified 
analysis will also be provided.  
The EFS analysis will be performed approximately [ADDRESS_138948] will be 
performed, including adjuvant treatment regimen.  Full details will be prov ided in 
the SAP.  
[IP_ADDRESS]  Disease -Free Survival  
DFS is defined as the time from surgery (i.e., the first dat e of no disease) to the first 
documented disease recurrence or death from any cause, whichever occurs first.  
Patients who do not undergo surgery at the end of neoadjuvant treatment will be 
excluded from the analysis of DFS.  
Patients without a DFS event at  the time of analysis will be censored at the date when 
they were last known to be alive and event free.   Patients who do not have information 
after surgery will be censored at the date of surgery.  
DFS will be analyzed with the use of the same methodology as specified for EFS.  The 
DFS analysis will be performed approximately [ADDRESS_138949] will be 
performed, i ncluding adjuvant treatment regimen.  Full details will be provided in 
the SAP.  
[IP_ADDRESS]  Overall Survival  
OS is defined as the time from randomization to death from any cause.  Patients who 
are not reported as having died at the time of analyses will be censored at the date when 
they were last known to be alive.  Patients who do not have information after base line 
will be censored at the date of randomization.  OS will be analyzed with the use of the 
same methodology as specified for EFS.  The OS analysis will be performed 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
132/Protocol BO40747 , Version [ADDRESS_138950] will be 
performed, including adjuvant treatment regimen.  Full details will be provided in the  
SAP.  
[IP_ADDRESS]  Patient -Reported Outcomes of Role and Physical Function and 
GHS/HRQo L:  EORTC Data  
The primary PRO endpoints are mean and mean changes from baseline score in 
function (role, physical) and GHS/HRQoL.  Summary statistics (mean, standard 
deviation, median, and range) of linearly transformed  absolute scores  and mean 
changes fr om baseline  (with 95% CI)  will be calculated for the functional (role [Question 
{Q} 6, Q7], physical [Q1 Q5]), and the GHS/HRQoL (Q29, Q30) scales of the 
EORTC  QLQ -C30 at each assessment timepoint for  each arm.  The mean (and 95%  CI) 
and median of the absolute  scores and the changes from baseline will be reported for 
interval and continuous  variables.  Previously published minimally important differences 
will be used to identify  meaningful change from baseline within each treatment group on 
the function al and GHS/HRQoL scales (Osoba et al. 1998; Cocks et al. 2011).  
The EORTC QLQ -C30 (Version 3) data will be scored according to the EORTC  scoring 
manual (Fayers et al. 2001) .  PRO completion, compliance rates, and reasons for 
missing data will be summarized  at each timepoint by [CONTACT_2939].  Details of the 
analysis, including methods for handling missing data, will be specified in the SAP.  
6.5.3  Exploratory Efficacy Endpoints  
[IP_ADDRESS]  Patient -Reported Outcomes of Disease/Treatment Related 
Symptoms, and Emotional and Soci al Function:  EORTC Data  
Summary statistics (mean, standard deviation, median, and range) of linearly 
transformed absolute scores  and mean changes from baseline  (with 95%  CI) will be 
calculated for all disease/treatment related symptom items and scales, an d the 
emotional and social function scales of the  EORTC QLQ -C30 (see Appendix  4) at each 
assessment timepoint for  each arm.  
[IP_ADDRESS]  Patient -Reported Outcome of Treatment Bother:  FACT -G, GP5 
Single -Item Data  
A descriptive analysis of absolute scores and the proportion of patients selecting each 
response option at each assessment timepoint by [CONTACT_123576]5 (“I am bothered by [CONTACT_123490]”) from the FACT -G physical 
well-being subscale (see Appendix  5).  Item GP5 from V ersion [ADDRESS_138951] -G 
Questionnaire will be scored according to the Functional Assessment of Chronic Illness 
Therapy scoring manual (Cella 1997).  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
133/Protocol BO40747 , Version 6 [IP_ADDRESS]  Health Economic EQ -5D-5L Data  
Health utility data from the EQ -5D-5L (see Appendix  6) will be evaluated in 
pharmacoeconomic models.  The results from the health economic data analyses will be 
reported separately from the clinical study r eport.  
6.[ADDRESS_138952] A term, appropriate MedDRA 
levels, and NCI CTCAE v5.0 grade, regardless of relationship to study drug as assessed 
by [CONTACT_093].  For each patient, if multiple incidences of the same adverse events 
occur, the maximum severity reported will be used in  the summaries.  
The following treatment -emergent adverse events will be summarized separately:  
 Adverse events leading to withdrawal of study drug  
 Adverse events leading to dose reduction or interruption  
 Grade   3 adverse events, Grade  5 adverse events, serious adverse events  
 Adverse events of special interest  
 Selected adverse events on the basis of  the safety profile of the study drug  
 
All deaths and causes of death will be summarized.  
6.6.3  Laboratory Data  
Laboratory data with values outside of the normal ran ges will be identified.  Relevant 
laboratory values will be summarized by [CONTACT_123577], with NCI CTCAE  v5.0 
Grade  3 and Grade 4 values identified, where appropriate.  Changes from baseline in 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
134/Protocol BO40747 , Version 6 NCI CTCAE  v5.0 grade (i.e., shift tables) will be als o provided by [CONTACT_2939].  
Of note, abnormal laboratory data that are clinically significant will be reported as 
adverse events and summarized in the adverse event tables.  
A Hy’s  Law analysis will be provided:  the finding of an elevated ALT or AST 
(3  baseline value) in combination with either an elevated total bilirubin ( 2  ULN) or 
clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is 
considered to be an indicator of severe liver injury (as defined by [CONTACT_25742]'s Law).  
6.6.4  Vital Signs  
Changes in selected vital signs will be summarized by [CONTACT_123578] . 
6.7 PHARMACOKINETIC ANAL YSES  
Atezolizumab serum concentration data (C min and C max) will be tabulated and 
summarized.  Descriptive statistics will include me ans, medians, ranges, standard 
deviations, coefficient of variation (%CV), and others as appropriate.  
The pertuzumab, trastuzumab, and trastuzumab emtansine concentrations in serum will 
also be tabulated and summarized.  Additional PK and PD analyses may b e conducted 
as appropriate.  
6.[ADDRESS_138953] one ADA  result , with 
patients grouped according to treatment received.  
The numbers and proportions of ADA -positive patients and ADA -nega tive patients at 
baseline (baseline prevalence) and after baseline (post -baseline incidence) will be 
summarized by [CONTACT_1570].  When determining post-baseline  incidence, patients 
are considered to be ADA -positive if they are ADA -negative or have missi ng data at 
baseline but develop an ADA response following study drug exposure 
(treatment -induced ADA response), or if they are ADA -positive at baseline and the titer 
of one or more post -baseline samples is at least 0.60 titer unit greater than the titer of  
the baseline sample (treatment -enhanced ADA response).  Patients are considered to 
be ADA -negative if they are ADA -negative or are missing data at baseline and all 
post-baseline samples are negative, or if they are ADA -positive at baseline but do not 
have  any post -baseline samples with a titer that is at least 0.60 titer uni t greater than the 
titer of the baseline sample (treatment unaffected).  
The relationship between ADA status and safety, efficacy, and pharmacokinetics  may be 
investigated.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
135/Protocol BO40747 , Version 6 6.9 BIOMARKER ANALYSES  
Biomarker analyses will be performed as follows:  
 Analysis of pCR by [CONTACT_123579], 
hormone receptor status, and PD -L1 status.  Cutoffs for stromal TIL infiltration levels 
will be specified in t he SAP.  
 Analysis of pCR by [CONTACT_123580], hormone receptor status and PD -L1 status.  Cutoffs for immune gene 
expression levels will be specified in the SAP.  
 Analysis of pCR, EFS, DFS, and OS  by [CONTACT_23587]3CA mut ation status will be stratified by 
[CONTACT_123573], hormone receptor  status, and PD -L1 status.  
 
Descriptive statistics will be utilized for the analysis and reporting of other exploratory 
biomarker objectives outlined in  Section  2.5.  This may include appropriate multivariate 
analyses.  Further details will be specified in the SAP.  
6.[ADDRESS_138954] information from data accumulated thus far for reasons external to the 
study (administrative objective , to inform the initiation of a possible subsequent trial ), an 
administrative interim efficacy analysis of pCR is planned to take place once 
[ADDRESS_138955] interim efficacy analyses after the primary analysis 
for pCR and before the final analysis for EFS and OS, if needed (e.g.,  for regulatory or 
publication purposes).  The decision to conduct an optional interim analysis, alo ng with 
the rationale, timing, and statistical details for the analysis will be documented in the 
Sponsor’s trial master file prior to the conduct of the interim analysis.  The interim 
analysis will be performed and interpreted by [CONTACT_123581].  Access to treatment assignment information will 
follow the Sponsor’s standard procedures.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
136/Protocol BO40747 , Version [ADDRESS_138956] data clarificati on from the sites, which the sites 
will resolve electronically in the EDC system.  
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data and any other 
externall y generated electronic study data will be sent directly to the Sponsor, using the 
Sponsor's standard procedures to handle and process the electronic transfer of these 
data.  
eCRFs and correction documentation will be maintained in the EDC system's audit tra il.  
System backups for data stored by [CONTACT_123582]'s standard procedures.  
PRO data will be collected on paper questionnaires at the site.  The data from the 
questionnaires will be  entered into the EDC system by [CONTACT_6624].  
The Sponsor will retain study data for [ADDRESS_138957] be kept with the study records.  Acknowledgement of receipt 
of the data is required.  
7.3 SOURCE DATA DOCUMENT ATION  
Study monitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by [CONTACT_77038], complete, and verifiable from source  documents.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
137/Protocol BO40747 , Version 6 Source documents (paper or electronic) are those in which patient data are r ecorded 
and documented for the first time.  They include but are not limited to hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PRO questionnaires, evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, 
copi[INVESTIGATOR_123446], microfiche, photographic negatives, microfilm or magnetic media, X -rays, 
patient files, and records kept at pharmacies, laboratories, and medico -technical 
departments involved in a clinical trial.  
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i .e., no prior written or electronic record of the data) and 
considered source data.  
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section  7.5. 
To facilitate source data verification and review, the investigators and institu tions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by [CONTACT_25756].  
7.4 USE OF COMPUTERIZED SYSTEM S 
When clinical observations are entered directly into a study site's computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance wit h health 
authority requirements pertaining to computerized systems used in clinical research.  
An acceptable computerized data collection system allows preservation of the original 
entry of data.  If original data are modified, the system should maintain a  viewable audit 
trail that shows the original data as well as the reason for the change, name [CONTACT_40916], and date of the change.  
7.[ADDRESS_138958] to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  Written  
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
138/Protocol BO40747 , Version 6 [COMPANY_002] will retain study data for 25 years after the final Clinical Study Report has been 
completed or for the length of time required by [CONTACT_109851], whichever is longer.  
8. ETHICAL CONSIDERATIO NS 
8.1 COMPLIANCE WITH LAWS  AND REGULATIONS  
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice  and the p rinciples of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clin ical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the [LOCATION_002] or under a U.S. 
Investigational New Drug (IND) Application will comply with U.S. FDA regulations and 
applicable local, state, and fede ral laws.  Studies conducted in the European Union or 
European Economic Area will comply with the E.U. Clinical Trial s Directive (2001/20/EC)  
or Clinical Trials Regulation (536/2014)  and applicable local, regional, and national 
laws. 
8.2 INFORMED CONSENT  
The S ponsor's sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Child's Informed Assent Form or Mobile Nursing Informed Consent 
Form, if  applicable) will be provided to each site.  If applicable, it will be provided in a 
certif ied translation of the local language.  The Sponsor or its designee must review and 
approve any proposed deviations from the Sponsor's sample Informed Consent Forms 
or any alternate consent forms proposed by [CONTACT_779] (collectively, the "Consent Forms") 
before IRB/EC submission.  The final IRB/EC approved Consent Forms must be 
provided to the Sponsor for health authority submission purposes according to local 
requirements.  
If applicable, the Informed Consent Form will contain separate sections for any option al 
procedures.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optional procedure.  
Patients will be told that they are free to refuse to participate and may withdraw t heir 
consent at any time for any reason.  A separate, specific signature [CONTACT_33509] a patient's agreement to participate in optional procedures.  Patients who 
decline to participate will not provide a separate signature.  
The Consent Forms  must be signed and dated by [CONTACT_12718]'s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed consent process and that 
written in formed consent was obtained prior to participation in the study.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
139/Protocol BO40747 , Version [ADDRESS_138959] the willingness of the patient 
to participate.  Th e final revised IRB/EC approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.  
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in  accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written infor med consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.  
A copy of each signed Consent Form must be provided to the patient or the patient's 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient's study file or in the site file and must be available for verification by [CONTACT_33483].  
For sites in the [LOCATION_002], each Consent Form may also include patient authorization 
to allow use and disclosure of  personal health information in compliance with the U.S. 
Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health informatio n under the HIPAA regulations, the review, approval, and  other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.  
8.[ADDRESS_138960] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study is initiated.  
In addition, any patient recruitm ent materials must be approved by [CONTACT_1201]/EC.   
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the 
requirements, policies, and procedures est ablished by [CONTACT_1201]/EC.  Investigators are 
also responsible for promptly informing the IRB/EC of any protocol amendments 
(see Section  9.7). 
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety rep orts 
or other safety -related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577] /EC, and 
archived in the site's study file.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
140/Protocol BO40747 , Version [ADDRESS_138961] parties only as permitted by [CONTACT_25734] (or  separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_4677], unless permitted or required by [CONTACT_2371].  
Medical information may be given to a patient's p ersonal physician or other appropriate 
medical personnel responsible for the patient's welfare, for treatment purposes.  
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be pr ovided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication 
(see Section  9.6). 
Data generated by [CONTACT_25757], Sponsor monitors, 
representativ es, and collaborators, and  the IRB/EC for each study site, as appropriate.  
Study data, which may include data on mutations, may be submitted to government or 
other health research databases or shared with researchers, government agencies, 
companies, or oth er groups that are not participating in this study.  These data may be 
combined with or linked to other data and used for research purposes, to advance 
science and public health, or for analysis, development, and commercialization of 
products to treat and diagnose disease.  In addition, redacted clinical study reports and 
other summary reports will be provided upon request.  
8.5 FINANCIAL DISCLOSURE  
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health auth orities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (see definition of end of 
study in Section  3.3). 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
141/Protocol BO40747 , Version [ADDRESS_138962] of 
the study to be fully  documented, including but not limited to the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.  
9.[ADDRESS_138963] on patient safety a nd 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and re quire 
reporting to health authorities.  As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.  
9.3 MANAGEMENT OF STUDY QUALITY  
The Spons or will implement a system to manage the quality of the study, focusing on 
processes and data that are essential to ensuring patient safety and data integrity.  The 
Sponsor will identify potential risks associated with critical trial processes and data and  
will implement plans for evaluating and controlling these risks.  Risk evaluation and 
control will include the selection of risk -based parameters (e.g.,  adverse event rate, 
protocol deviation rate) and the establishment of quality tolerance limits for the se 
parameters.  Detection of deviations from quality tolerance limits will trigger an 
evaluation to determine if action is needed.  Details on the establishment and monitoring 
of quality tolerance limits will be provided in a Quality Tolerance Limit Manage ment Plan.  
9.4 SITE INSPECTIONS  
Site visits will be conducted by [CONTACT_26833], patients' medical records, and eCRFs.  The investigator will 
permit national and local health authorities; Sponsor monito rs, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.  
9.5 ADMINISTRATIVE STRUC TURE  
This trial will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  The Sponsor 
will provide clinical operations management, data management, and medical monitoring.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
142/Protocol BO40747 , Version 6 Up to 120 sites globally will participate to randomize approximately 453 patients.  
Screening and enrollment will occur through an IxRS.  
Central facilities will be used for certain study assessments thro ughout the study 
(e.g.,  specified laboratory tests, biomarker analyses, and PK analyses), as specified in 
Section  4.5.9 .  Accredited loca l laboratories will be used for routine monitoring; local 
laboratory ranges will be collected.  
An iDMC will be employed to monitor and evaluate patient safety throughout the study.  
9.6 DISSEMINATION OF DAT A AND PROTECTION OF TRADE 
SECRETS  
Regardless of the out come of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries of the U.S. National Institutes of Health and the 
EMA,  and in peer -reviewed journals.  The Sponsor will comply with all requirements for 
publication of study results.  Study data may be shared with others who are not 
participating in this study , and redacted clinical study reports and /or other summaries of 
clinical study results may be available in health authority databases for public access, 
as required by [CONTACT_1295], and  will be provided upon request (see Section  8.4 for 
more details).  For more information, refer to the [COMPANY_002] Global Policy on Sharing of 
Clinical Study Information  at the following website:  
https://www.roche.com/innovation/process/clinical -trials/data -sharing/  
 
The results of this study may be published or presented at scientific congresse s.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within [ADDRESS_138964] editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
143/Protocol BO40747 , Version 6 Authorship will be determined by [CONTACT_14346].  Any formal publication 
of the study in  which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_26834].  
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.  
9.7 PROTOCOL AMENDMENTS  
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.  
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for chan ges necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g.,  change in Medical Monitor or contact [CONTACT_3031]).  
10. REFERENCES  
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organi zation for Research 
and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 1993;85:365 76. 
Adams S, Diamond J, Hamilton E, et al. Safety and clinical activity of atezolizumab 
(anti-PDL1) in combination with nab -paclitaxel in patients with metastatic 
triple -negative breast cancer.  Cancer Res 2016;76(Suppl): Abstract P2 -11-06. 
[AGO] Association of Gynecologic Oncology. Guidelines of the AGO Breast Committee  
[resource on the Intern et]. March 2018 [cited 18 June 2018]. Available from: 
http://www.ago -online.de/en/guidelines -mamma/march -2018/.  
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4 -dependent contribution of 
the immune system to anticancer chemotherapy and rad iotherapy. Nat Med 
2007;13:1050 9. 
Au HJ, Ringash J, Brundage M, et al. Added value of health -related quality of life 
measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev 
Pharmacoecon Outcomes Res 2010;10:119 28. 
Barrett T, Bow den DJ, Greenberg DC, et al. Radiological staging in breast cancer: which 
asymptomatic patients to image and how. Br J Cancer 2009;101:1522 8. 
Bianchini G, Pusztai L, Pi[INVESTIGATOR_118487] T, et al. Immune modulation of pathologic complete  
response after neoadjuvant HER2 -directed therapi[INVESTIGATOR_123447]. Ann 
Oncol 2015;26:2429 36. 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
144/Protocol BO40747 , Version 6 Blank C, Gajewski TF, Mackensen A. Interaction of PD -L1 on tumor cells with PD -1 on 
tumor -specific T cells as a mechanism of immune evasion: implications for tumor 
immunotherapy. Ca ncer Immunol Immunother 2005;54:307 14. 
Blank C, Mackensen A. Contribution of the PD -L1/PD -[ADDRESS_138965] to T -cell exhaustion: 
an update on implications for chronic infections and tumor evasion. Cancer 
Immunol Immunother 2007;56:739 45. 
Borghaei H, Paz -Ares L,  Horn L, et al. Nivolumab versus docetaxel in advanced 
nonsquamous non small -cell lung cancer. N Engl J Med 2015;373;1627 39. 
Brookmeyer R, Crowley J. A k -sample median test for censored data. J Am Stat Assoc 
1982;77:433 40. 
Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53 72. 
Budd GT, Barlow WE, Moore HCF, et al. SWOG S0221 updated: Randomized 
comparison of chemotherapy schedules in breast cancer adjuvant therapy. J  Clin 
Oncol 2017;35: Abstract 521.  
Butte MJ, Keir ME, Phamduy TB. Prog rammed death -1 ligand 1 interacts specifically 
with the B7 -1 costimulatory molecule to inhibit T cell responses. Immunity 
2007;27:111 22. 
Cameron D, Pi[INVESTIGATOR_94899] -Gebhart MJ, Gelber RD, et al. Herceptin Adjuvant (HERA) Trial 
Study Team. 11 years' follow -up of tr astuzumab after adjuvant chemotherapy in 
HER2 -positive early breast cancer: final analysis of the HERceptin Adjuvant 
(HERA) trial. Lancet 2017;389:1195 205. 
Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) 
measurement system version 4. Evanston, IL: Center on Outcomes, Research and 
Education (CORE) at Evanston Northwestern Healthcare and Northwestern 
University, 1997.  
Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy 
(FACT) scale: development and validation of the general measure. J Clin Oncol 
1993;11:570 9.  
Chan A, Delaloge S, Holmes FA, et al. ExteNET Study Group. Neratinib after 
trastuzumab -based adjuvant therapy in patients with HER2 -positive breast cancer 
(ExteNET): a multicentre, randomised,  double -blind, placebo -controlled, phase  3 
trial. Lancet Oncol 2016;17:367 77. 
Chen DS, Irving BA, Hodi FS. Molecular pathways: next -generation 
immunotherapy inhibiting programmed death -ligand 1 and programmed death -1. 
Clin Cancer Res 2012;18:6580 7. 
Citro n ML, Berry DA, Cirrincione C, et al. Randomized trial of dose -dense versus 
conventionally scheduled and sequential versus concurrent combination 
chemotherapy as postoperative adjuvant treatment of node -positive primary breast 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
145/Protocol BO40747 , Version 6 cancer: first report of Inter group Trial C9741/Cancer and Leukemia Group B 
Trial 974.  J Clin Oncol. 2003;21:1431 9. Epub 2003 Feb 13.  
Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of 
the binomial, Biometrika 1934;26:404 16. 
Cocks K, King MT,  Velikova G, et al. Evidence -based guidelines for determination of 
sample size and interpretation of the European Organisation for the Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 
2011;29: 8996. 
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long -term 
clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 
2014;384:164 72. 
Curigliano G, Burstein HJ, Winer EP, et al. De -escalating and escalating treatments fo r 
early -stage breast cancer: the St. Gallen International Expert Consensus 
Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 
2017;28:1700 12. 
Dang C, Fornier M, Sugarman S, et al. The safety of dose -dense doxorubicin and 
cyclophospha mide followed by [CONTACT_123583] -2/neu 
overexpressed/amplified breast cancer. J Clin Oncol 2008;26:1216 22. 
Dang C, Lin N, Moy B, et al. Dose -dense doxorubicin and cyclophosphamide followed by 
[CONTACT_123584]2/neu -
overexpressed/amplified breast cancer is not feasible because of excessive 
diarrhea. J Clin Oncol 2010;28:2982 8. 
Daud AI, Wolchok JD, Robert C, et al. Programmed death -ligand 1 expression and 
response to the anti -programmed death 1 antibo dy pembrolizumab in melanoma. 
J Clin Oncol 2016;34:4102 9. 
Denduluri N, Chavez -MacGregor M, Telli ML, et al. Selection of optimal adjuvant 
chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice 
guideline focused update. J Clin On col 2018. doi: 10.1200/JCO.2018.78.8604. 
[Epub ahead of print] . 
Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, 
pharmacodynamics, tissue distribution, and tumor penetration of anti PD-L1 
monoclonal antibody, an immune checkpoint inhibitor. MAbs 2016;8:593 603. 
Denkert C, von Minckwitz G, Darb -Esfahani S, et al. Tumour -infiltrating lymphocytes and 
prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients 
treated with neoadjuvant therapy. Lancet Oncol 2018;19:40 50. 
DeSantis CE, Bray F, Ferlay J, et al. International variation in female breast cancer 
incidence and mortality rates. Cancer Epi[INVESTIGATOR_1948] 
2015;24:1495 506. 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
146/Protocol BO40747 , Version 6 Eggermont AMM, Blank CU, Mand ala M, et al. Adjuvant pembrolizumab versus placebo 
in resected stage III melanoma. N Engl J Med 2018;378:1789 1801.  
[EMA] European Medicines Agency. Appendix 2 to the guideline on the evaluation of 
anticancer medicinal products in man: the use of patient -reported outcome (PRO) 
measures in oncology studies [resource on the Internet]. April 2016 [cited 
8 December 2017]. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/04/WC5002
[ZIP_CODE].pdf.  
Emens LA, Esteva F, Beresford M,  et al. Results from KATE2, a randomized phase  2 
study of atezolizumab (atezo)+trastuzumab emtansine (T -DM1) vs placebo 
(pbo)+T -DM1 in previously treated HER2+ advanced breast cancer (BC) [abstract]. 
Proceedings of the 41st San  Antonio Breast Cancer Sympos ium: 48 December 
2018; San Antonio, TX. Abstract  PD3-01. 
EuroQol Group. EuroQol: a new facility for the measurement of health -related quality of 
life. Health Policy 1990;16:199 208. 
Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ -C30 scoring manua l, 
3rd ed. Brussels: European Organisation for Research and Treatment of Cancer, 
2001.  
[FDA] U.S. Food and Drug Administration. The voice of the patient report: breast cancer 
[resource on the Internet]. 2 April 2015 [cited 8 December 2017]. Available from:  
https://www.fda.gov/downloads/Drugs/NewsEvents/UCM464932.pdf.  
[FDA] U. S. Food and Drug Administration. Structured approach to benefit -risk 
assessment in drug regulatory decision -making. PDUFA implementation plan: 
fiscal years 2013 2017 [resource on the I nternet]. February 2013 [cited 
8 December 2017]. Available from: 
http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UC
M329758.pdf.  
[FDA] U. S. Food and Drug Administration. Guidance for industry:  pathological complete 
response in ne oadjuvant treatment of high -risk early -stage breast cancer: use as 
an endpoint to support accelerated approval. October 2014 [cited 31 May 2018]. 
Availabel from: https://www.fda.gov/downloads/drugs/guidances/ucm305501.pdf.  
Fehrenbacher L, Spi[INVESTIGATOR_20116] A, Ballinge r M, et al. Atezolizumab versus docetaxel for patients 
with previously treated non -small -cell lung cancer (POPLAR): a multicentre, 
open -label, phase 2 randomised controlled trial. Lancet 2016;387:1837 46. 
Ferlay  J, Soerjomataram I,  Dikshit R, et al. Cancer  incidence and mortality worldwide: 
sources, methods and major patterns in GLOBOCAN 2012. Int  Cancer 
2015;136:E359 86. 
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and 
mortality worldwide: IARC CancerBase No. 11 [resource  on the Internet]. Lyon, 
[LOCATION_009]: International Agency for Research on Cancer; 2013 [cited 26 June 2018]. 
Available from: http://globocan.iarc.fr.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
147/Protocol BO40747 , Version 6 Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality 
of life (QoL) questionna ire module to supplement the EORTC core cancer QoL 
questionnaire, the QLQ -C30 in patients with pancreatic cancer. EORTC Study 
Group on Quality of Life. Eur J Cancer 1999;35:939 41. 
Frebel H, Nindl V, Schuepbach RA, et al. Programmed death 1 protects from f atal 
circulatory failure during systemic virus infection of mice. J Exp Med 
2012;209:2485 99. 
Geyer CE, Loibl S, Rastogi P, et al. NSABP B -59/GBG 96 -GeparDouze: A randomized 
double -blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with 
atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) 
followed by [CONTACT_123482]. J Clin Oncol 2018;36(15_suppl). 
Abstract TPS603.  
Gianni L, Pi[INVESTIGATOR_118487] T, Im YH, et al. Efficacy and safety of neoadjuvant pert uzumab and 
trastuzumab in women with locally advanced, inflammatory, or early HER2 -positive 
breast cancer (NeoSphere): a randomised multicentre, open -label, phase 2 trial. 
Lancet Oncol 2012;13:25 32. 
Gianni L, Pi[INVESTIGATOR_118487] T, Im YH, et al. [ADDRESS_138966] cancer (NeoSphere): a multicentre, open -label, Phase  2 
randomised trial. Lancet Oncol 2016;17:791 800. 
Gradishar WJ, Anderson BO, B alassanian R, et al. National Comprehensive Cancer 
Network. Breast Cancer (Version 1.2017). Available from: 
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.  
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, Version 4.2017, 
NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 
2018;16:310 20. 
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical 
Oncology/College of American Pathologists guideline recommendations for 
immunohistochemical testing o f estrogen and progesterone receptors in breast 
cancer. J Clin Oncol 2010;28:2784 95. 
Herbst RS, Baas P, Kim D -W, et al. Pembrolizumab versus docetaxel for previously 
treated PD -L1-positive, advanced non -small -cell lung cancer (KEYNOTE -010): a 
randomised c ontrolled trial. Lancet 2016;387;1540 50. 
Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the 
anti-PD-L1 antibody MPDL3280A  in cancer patients. Nature 2014;515:563 7. 
Herceptin (trastuzumab) Prescribing Information, Genentech.  
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level version of EQ -5D (EQ -5D-5L). Qual Life Res 2011;20:1727 36. 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
148/Protocol BO40747 , Version 6 Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipi[INVESTIGATOR_123448]. N Engl J Med 2010;363:711 23. 
Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 19752013 
[resource on the Internet]. National Cancer Institute. 2016 [based on November 
2015 SEER data submission, updated September 2016; cited  26 June 2018]. 
Available from: http://seer.cancer.gov/csr/1975_2013/.  
Ignatiadis M, Van den Eynden G, Salgado ER, et al. Tumor -infiltrating lymphocytes in 
patients receiving trastuzumab/pertuzumab -based chemotherapy: a TRYPHAENA 
substudy. Eur J Cancer 201 8;92:S15.  
Janssen MF, Pi[INVESTIGATOR_19370], Golicki D, et al.  Measurement properties of the EQ -5D-5L 
compared to the EQ -5D-3L across eight patient groups: a multi -country study. 
Qual Life Res 2013;22:1717 27. 
Jemal A, Bray F, Center MM, et al. Global cancer statisti cs. CA Cancer 
J Clin 2011;61:69 90. 
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel -T immunotherapy for 
castration -resistant prostate cancer. N Engl J Med 2010;363:411 22. 
Keir ME, Butte MJ, Freeman GJ, et al. PD -1 and its ligands in tolerance and  immun ity. 
Annual Rev Immunol 2008;26:677 704. 
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine 
release syndrome and neurologic toxicity associated with immune effector cells. 
Biol Blood Marrow Transplant 2019;25:625 38. 
Lee HJ, Kim Y A, Sim CK, et al. Expansion of tumor -infiltrating lymphocytes and their 
potential for application as adoptive cell transfer therapy in human breast cancer. 
Oncotarget 2017;8:113345 59. 
Loi S, Andre F, Maibach R, et al. PANACEA (IBCSG 45 -13/BIG 4 -13): a pha se Ib/II trial 
evaluating the efficacy of pembrolizumab and trastuzumab in patients with 
trastuzumab -resistant, HER2 -positive, metastatic breast cancer. Cancer Res 
2016;76([ADDRESS_138967]): Abstract OT3 -01-05. 
Loi S, Giobbe -Hurder A, Gombos A, et al. Phase Ib/II s tudy evaluating safety and 
efficacy of pembrolizumab and trastuzumab in patients with trastuzumab -resistant 
HER2 -positive metastatic breast cancer: res ults from the PANACEA (IBCSG 
45-13/KEYNOTE -014) study. Cancer Res 2018;78([ADDRESS_138968]):GS2 -06. 
Loi S, Michiel s S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple 
negative breast cancer and predictive for trastuzumab benefit in early breast 
cancer: results from the FinHER trial. Ann Oncol 2014;25:1544 50. 
Loibl S, Majewski I, Guarneri V, et al. PIK3CA mutations are associated with reduced 
pathological complete response rates in primary HER2 -positive breast cancer: 
pooled analysis of 967 patients from five prospective trials investigating lapatinib 
and trastuzumab. Ann Oncol 2016  ;27:151925. 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
149/Protocol BO40747 , Version [ADDRESS_138969] cancer. Clin Oncol 2008;26:1275 81. 
Majewski IJ, Nuciforo P, Mittempergher L, et al. PIK3CA mutations are associated with  
decreased benefit to neoadjuvant human epi[INVESTIGATOR_13392]  2-targeted therapi[INVESTIGATOR_123449]. J Clin Oncol 2015;33:1334 9. 
Merad M, Martin JC. Pathological inflammation in patients with COVID -19: a key role for 
monocytes and macrophages. Nat Rev Immunol 2020;20:355 62. 
Merritt RE, Mahtabifard A, Yamada RE, et al. Cisplatin augments cytotoxic 
T-lymphocyte -mediated antitumor immunity in poorly immunogenic murine lung 
cancer. J Thorac Cardiovasc Surg 2003;126:1609 17. 
Montazeri A. Health -related quality of life in breast cancer patients: a bibliographic 
review of the literature from 1974 to 2007. J Exp Clin Canc Res 2008;27:1 31. 
[NCCN] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines 
on Oncology (NCCN Guidelines ), bre ast cancer, V4.2018 [resource on the 
internet] 8  February 2019 [cited 20 February 2019]. Available from: 
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.  
Nerlynx (neratinib) Prescribing Information, Puma Biotechnology, Inc.  
Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in 
health -related quality of life score. J Clin Oncol 1998;16:139 44. 
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for 
human epi[INVESTIGATOR_33372] 2 –positive breast cancer: planned joint 
analysis of overall survival from NSABP B -31 and NCCTG N9831. J Clin Oncol 
2014;32:3744 52. 
Perjeta (pertuzumab) Prescribing Information, Genentech.  
Petersen JA, Gauthier MA, Pi[INVESTIGATOR_123450] E, et al. Importance of the patient voice in drug 
development: early -stage breast cancer and measurement gaps concerning the 
treatment experience. Cancer Res 2016;76([ADDRESS_138970]):P1 -10-20. 
Rosenberg JE, Hoffman -Censits J, Powle s T, et al. Atezolizumab in patients with locally 
advanced and metastatic urothelial carcinoma who have progressed following 
treatment with platinum -based chemotherapy: a single -arm, multicentre, phase  2 
trial. Lancet 2016;387:1909 20. 
Ryerson AB, Miller J , Eheman CR. Reported breast symptoms in the national breast 
cancer and cervical cancer early detection program. Cancer Causes Control 
2015;26:733 40. 
Salgado R, Denkert C, Campbell C, et al. Tumor -infiltrating lymphocytes and 
associations with pathologica l complete response and event -free survival in 
HER2 -positive early -stage breast cancer treated with lapatinib and trastuzumab: a 
secondary analysis of the NeoALTTO trial. JAMA Oncol 2015a;1:448 54. 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
150/Protocol BO40747 , Version 6 Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor -infiltrating lymphocytes 
(TILs) in breast cancer: recommendations by [CONTACT_123585] 
2014. Ann Oncol 2015b;26:259 71. 
Sant M, Allemani C, Capocaccia R, et al., on behalf of the EUROCARE Working Group. 
Stage at diagnosis is a key e xplanation of differences in breast cancer survival 
across Europe. Int J Cancer 2003;106:416 22. 
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab -paclitaxel in advanced 
triple -negative breast cancer. N  Engl J Med 2018;379:2108 21. 
Schmid P, Cruz C, Braiteh FS, et al. Atezolizumab in metastatic triple -negative breast 
cancer (mTNBC): long -term clinical outcomes and biomarker analyses. Cancer 
Res 2017;77([ADDRESS_138971]):2986.  
Schneeweiss A, Chia S, Hickish T, et al.  Pertuzumab plus trastuzumab in combination  
with standard neoadjuvant anthracycline -containing and anthracycline -free 
chemotherapy regimens in patients with HER2 -positive early breast cancer: 
a randomized phase II cardiac safety study (TRYPHAENA).  Ann Oncol 
2013;24:2278 84. 
Senkus E, Kyriakides S,  Ohno S, et al. Primary breast cancer: ESMO clinical practice 
guidelines for diagnosis, treatment and follow -up. Ann Oncol 
2015;26(Suppl  5):v830. 
Senkus E, Kyriakides S, Penault -Llorca F, et al. Primary breast cancer: ESMO clinical 
practice guidelines for  diagnosis, treatment and follow -up. Ann Oncol 
2013;24(Suppl 6):7 23. 
Slamon DJ, Eiermann W, Robert NJ, et al., on behalf of the BCIRG -006 Investigators. 
Ten year follow -up of BCIRG -006 comparing doxorubicin plus cyclophosphamide 
followed by [CONTACT_114501] (AC T) with doxorubicin plus cyclophosphamide followed 
by [CONTACT_114502] (AC TH) with docetaxel, carboplatin and 
trastuzumab (TCH) in HER2  early breast cancer patients. Cancer Res 
2016;76([ADDRESS_138972]):S5 04. 
Stagg J, Loi S, Divisekera U, et al. Anti –ErbB-2 mAb therapy requires type I and II 
interferons and synergizes with anti –PD-1 or anti -CD137 mAb therapy. Proc Natl 
Acad Sci [LOCATION_003] 2011;108:7142 7. 
Swain SM, Baselga J, Kim S -B, et al. Pertuzumab, trastuzumab, and docetaxel in 
HER2 -positive metastatic bre ast cancer. N Engl J Med 2015;372:724 34. 
Swain SM, Ewer MS, Viale G, et al. BERENICE Study Group. Pertuzumab, trastuzumab, 
and standard anthracycline - and taxane -based chemotherapy for the neoadjuvant 
treatment of patients with HER2 -positive localized bre ast cancer (BERENICE): a 
phase II, open -label, multicenter, multinational cardiac safety study. Ann Oncol 
2018;29:646 53. 
Tecentriq (atezolizumab) U.S. Package Insert, Genentech.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
151/Protocol BO40747 , Version 6 Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of 
antiPD-1 antibody in cancer. N Engl J Med 2012;366:2443 54. 
Tripathy D, Chien AJ, Hylton N, et al. Adaptively randomized trial of neoadjuvant 
chemotherapy with or without the Akt inhibitor MK -2206: graduation results from 
the I-SPY 2 trial. J Clin Oncol 2015;33(15_suppl). Abstract 524.  
Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent -based 
paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto -GBG 
69): a randomised, phase 3 trial. Lancet Oncol 2016; 17:34556. 
van Ramshorst MS, van Werkhoven E, Mandjes IAM, et al. Trastuzumab in combination 
with weekly paclitaxel and carboplatin as neo -adjuvant treatment for HER2 -positive 
breast cancer: the TRAIN -study. Eur J Cancer 2017;74:47 54. 
Verma S, Miles D, Gi anni L, et  al. Trastuzumab emtansine for HER2 -positive advanced 
breast cancer. N  Engl J Med 2012;367:1783 91. 
von Minckwitz G, Huang C -S, Mano MS, et  al. Trastuzumab emtansine for residual 
invasive HER2 -positive advanced breast cancer. N  Engl J Med 2019;38 0:61728. 
von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and 
trastuzumab in early HER2 -positive breast cancer. N Engl J Med 
2017;377:122 31. 
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic 
complete re sponse on prognosis after neoadjuvant chemotherapy in various 
intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796 804. 
Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness 
Therapy (FACIT) measurement system: validation  of version 4 of the 
corequestionnaire. Qual Life Res 1999;8:604.  
Wolff AC, Hammond ME, Hicks DG, et al., on behalf of the American Society of Clinical 
Oncology and College of American Pathologists. Recommendations for human 
epi[INVESTIGATOR_19074] r [ADDRESS_138973] cancer: American Society of 
Clinical Oncology/College of American Pathologists clinical practice guideline 
update. J Clin Oncol 2013;31:3997 4013.  
Yang J, Riella LV, Chock S, et al. The novel costimulatory programmed death ligand 
1/B7.[ADDRESS_138974] is functional in inhibiting alloimmune responses in vivo. J Immunol 
2011;187:1113 9. 
Zhang B, Hurvitz S. Long -term outcomes of neoadjuvant treatment of HER2 -positive 
breast cancer. Clin Adv Hematol Oncol 2016;14:520 30. 
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
152/Protocol BO40747 , Version 6 Appendix  1 
Schedule of Activities  
 Screening/  
Baseline a Treatment Cycles  
Treatment 
Discontinuation/Early 
Termination Visit d 
Follow - 
Up e Neoadjuvant Phase  
Cycles14: 14 -Day Cycles  
Cycles 58: 21 -Day Cycles  Pre-
Surgery 
Visit/  
Surgery b Adjuvant Phase c  
(Cycles  922)  
21-Day Cycles  
Days –28 
to –1  Days –14 
to –1 Day 1 of Each Cycle ( 3 days)  Day 1 of Each 
Cycle ( 3 days)   30 Days after  
Final Dose  1 2 3 4 5 6 7 8 
Informed consent f x               
Baseline tumor tissue sample g x              
Demographic data  x              
Medical history and baseline 
conditions  x              
Disease status assessment h x  x x x x x x x x  x x x 
Tumor staging i x              
Bilateral mammogram j x            x x 
Surgical treatment plan k x          x    
Pathologic response 
assessment l           x    
Vital signs m x  x x x x x x x x  x x  
Weight  x  x x x x x x x x  x   
Height  x              
Complete physical 
examination  n  x         x   x  
Limited physical examination o   x x x x x x x   x   
Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
153/Protocol BO40747 , Version 6  Screening/  
Baseline a Treatment Cycles  
Treatment 
Discontinuation/Early 
Termination Visit d 
Follow - 
Up e Neoadjuvant Phase  
Cycles14: 14 -Day Cycles  
Cycles 58: 21 -Day Cycles  Pre-
Surgery 
Visit/  
Surgery b Adjuvant Phase c  
(Cycles  922)  
21-Day Cycles  
Days –28 
to –1  Days –14 
to –1 Day 1 of Each Cycle ( 3 days)  Day 1 of Each 
Cycle ( 3 days)   30 Days after  
Final Dose  1 2 3 4 5 6 7 8 
ECOG Performance Status p x  x    x   x  x x  
ECHO/MUGA scan q x  See footnote "q" x x 
ECG (12 -lead) r x  As clinically indicated  
Hematology s  x t x  x x x x x x x  x x  
Chemistry u  x t x  x x x x x x x  x x  
Pregnancy test v  x x x x x x x x x  x x x 
Coagulation (INR, aPTT)   x t        x   x  
TSH, free T3 (or total T3), 
free T4 w x t  x     x      x  x  
HIV, HBV, and HCV serologies  x               
Urinalysis x x   As clinically indicated  
EORTC QLQ -C30, EQ -5D-5Ly   x x x x x x x x  x x x  
FACT -G, single -item GP5 y, z    x x x x x x x  x x x  
Serum autoantibody sample aa x              
PK samples and ADA samples  See Appendix  2 for detailed schedule.  
Blood and plasma sample for 
biomarkers  See Appendix  3 for detailed schedule.  

Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
154/Protocol BO40747 , Version 6  Screening/  
Baseline a Treatment Cycles  
Treatment 
Discontinuation/Early 
Termination Visit d 
Follow - 
Up e Neoadjuvant Phase  
Cycles14: 14 -Day Cycles  
Cycles 58: 21 -Day Cycles  Pre-
Surgery 
Visit/  
Surgery b Adjuvant Phase c  
(Cycles  922)  
21-Day Cycles  
Days –28 
to –1  Days –14 
to –1 Day 1 of Each Cycle ( 3 days)  Day 1 of Each 
Cycle ( 3 days)   30 Days after  
Final Dose  1 2 3 4 5 6 7 8 
Blood sample for WGS or WES    x            
Whole blood sample types for 
RBR (optional)    x            
Tumor tissue (fresh sample 
preferred) at screening, 
on-study,  and at time of 
disease progression or 
recurrence  See Appendix  3 for detailed schedule.  
Concomitant medications bb  x  x x x x x x x x x x x x 
Adverse events cc  x x x x x x x x x x x x x 
Atezolizumab/placebo 
administration dd 
Stopped with protocol version 5    x x x x x x x x  x   
Dose -dense doxorubicin 
administration ee   x x x x         
Dose -dense cyclophosphamide 
administration ff   x x x x         
Pertuzumab administration gg       x x x x  x   
Trastuzumab administration hh       x x x x  x   

Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
155/Protocol BO40747 , Version 6  Screening/  
Baseline a Treatment Cycles  
Treatment 
Discontinuation/Early 
Termination Visit d 
Follow - 
Up e Neoadjuvant Phase  
Cycles14: 14 -Day Cycles  
Cycles 58: 21 -Day Cycles  Pre-
Surgery 
Visit/  
Surgery b Adjuvant Phase c  
(Cycles  922)  
21-Day Cycles  
Days –28 
to –1  Days –14 
to –1 Day 1 of Each Cycle ( 3 days)  Day 1 of Each 
Cycle ( 3 days)   30 Days after  
Final Dose  1 2 3 4 5 6 7 8 
Paclitaxel administration ii       x x x x     
Trastuzumab emtansine 
administration kk            x   
Survival follow -up and 
anti-cancer treatment jj              x  
ADA   anti-drug antibody; AJCC   American Joint Committee on Cancer; CT   computed tomography (scan); ddAC   dose -dense anthracycline 
(doxorubicin)   cyclophosphamide; ECHO   echocardiogram; eCRF   electronic Case Report Form; EORTC   European Organisation for Research 
and Treatment of Cancer; EQ -5D-5L   EuroQol 5 -Dimension, 5 -Level (questionnaire); FACT -G  Functional Assessment of Cancer 
TherapyGeneral; FFPE   formalin -fixed, paraffin -embedded; HBV   hepatitis B virus; HCV   hepatitis C virus; MUGA   multiple -gated acquisition 
(scan); NAST   neoadjuvant systemic therapy; pCRpathological complete response; PK   pharmacokinetic; PRO   patient -reported outcome; 
Q3W   every 3 weeks; QLQ -C30   Quality of Life Question naireCore 30; RBR   Research Biosample Repository; SOC   standard of care; 
T3   triiodothyronine; T4   thyroxine; TSH   thyroid -stimulating hormone; WES   whole exome sequencing; WGS   whole genome sequencing.  
Notes:  On treatment days, all assessments should be performed prior to dosing, unless otherwise specified.  
a Results of SOC tests or examinations performed prior to obtaining informed consent and within 28 days prior to Cycle 1 , Day 1 may be used; 
such tests do not need to be repeated for screenin g.  
b Pre-surgical visit and associated assessments should occur within [ADDRESS_138975] dose of neoadjuvant therapy.  Platelet counts should be checked prior to surgery and should be 
 75,000  cells/L. 
c All study therapy will be completed when the patient has received up to a total duration of 52 wee ks of HER2 -targeted study therapy 
(neoadjuvant   adjuvant  [i.e., a maximum of 18 cycles of HER2 -targeted treatment ]). 
d Patients who discontinue study treatment will return to the clinic for a treatment discontinuation visit no more than 30 days  after thei r final dose of 
study treatment  or no more than 30 days from the date the decision was made to permanently discontinue study treatment.  
Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
156/Protocol BO40747 , Version 6 e The survival follow -up period begins from the date of treatment completion/early termination  visit with a duration of [ADDRESS_138976] a window of  [ADDRESS_138977] be documented before any study -specific screening procedure is performed, and may be obtained more than 28  days 
before initiation of study treatment.  
g After signing of the Informed Consent Form, retrieval and submission of tumor tissue sample can occur outside the 28 -day screening period.  
Tumor tissue should be of good quality based on total and viable tumor content (sit es will be informed if the quality of the submitted specimen is 
inadequate to determine tumor PD -L1 status).  An FFPE block (preferred) or at least [ADDRESS_138978] ration at each 
cycle of study treatment during neoadjuvant therapy and within 14  days prior to surgery.  During the postoperative portion of this study, disease 
status should be clinically evaluated and documented every 3 months for 2 years, and then every 6 months thereafter until the  end of the study.  
In addition, liver function tests, brain imaging, bone scans, ches t X-ray/diagnostic CT scan, liver imaging, and/or other radiographic modalities 
may be considered when clinically indicated to exclude metastatic disease; these assessments should be performed within a tim eline as per 
current local SOC practice.  Whenever possible, disease recurrence should be confirmed pathologically.  If disease  progression or disease  
recurrence is diagnosed at any time during the study, patients will discontinue  study treatment and enter the follow -up phase of the study.  
Disease status assessments and imaging (mammogram) can be done as per local standard of care for patients with confirmed disease 
progression or recurrence.  All other follow -up assessments apply to patients with disease progression or recurrence as per Schedule of 
Assess ments.  
i Baseline tumor staging procedures should be performed in alignment with AJCC, 8th edition (specifically in accordance with Anatomic Stage 
group rules) at diagnosis, within 28 days of randomization.  Tumor size is to be determined via radiologic me asurement and node positivity 
pathologically confirmed by [CONTACT_14239][INVESTIGATOR_123451].  See Section  4.5.6  for requirement s related to baseline distant sites 
tumor staging procedures.  
j Bilateral mammogram should be obtained within 28 days prior to randomization.  Alternatively, provided that the clinical stat us of the patients has 
not changed, the screening mammogram can be  performed up to 42  days prior to the start of study treatment.  Subsequent mammograms are 
optional during neoadjuvant treatment and prior to surgery and should be performed per investigator’s discretion.  Bilateral mammogram should 
occur at the treatment  completion/early termination visit and every 12 months (  4 weeks) during the follow -up period.  Patients who have 
undergone mastectomy do not require mammograms on side of mastectomy.  Patients with confirmed disease progression or recurrence can 
undergo imaging procedures as per local standard of care.  
k The patient should be evaluated by a surgeon prior to initiation of neoadjuvant therapy as well as after completion of neoadj uvant th erapy/prior to 
surgery.  At baseline, the surgeon should evaluate the patient and create a surgical treatment plan.  Then , after completion of NAST, the 
surgeon should reassess the patient and modify the surgical treatment plan as needed.  

Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
157/Protocol BO40747 , Version [ADDRESS_138979] cancer surgery and pathological assessment will be performed and reported accordi ng to protocol requ irements 
for patients who discontinue study treatment during the neoadju vant phase  (for any reason other than disease progression) and who proceed to 
surgery without receiving any other non -study anti -cancer therapy prior to surgery .  Patients who disconti nue neoadjuvant study treatment due to 
disease progression contribute a non -pCR result and their disease progression must be reported.  
m Includes respi[INVESTIGATOR_697], pulse rate, systolic and diastolic blood pressure, and temperature.  Record abnormalities ob served at baseline on the 
General Medical History and Baseline Conditions eCRF.  At subsequent visits, record new or worsened clinically significant ab normalities on the 
Adverse Event eCRF.  For the first infusion, vital signs should be measured within 60  minutes prior to each infusion and, if clinically indicated, 
every 15  ( 5) minutes during the infusion and at 30  ( 10) minutes after the infusion.  For subsequent infusions, vital signs should be measured 
within 60  minutes prior to each infusion and, if clinically indicated or if symptoms occurred during the previous infusion, during the infusion and at 
30 ( 10) minutes after the infusion.  The vital signs measured prior to the infusion of the first study drug at each cycle are require d to be reported 
on the Vital Sign eCRF.  Other vital signs are not required to be entered into the eCRF unless abnormal and cl inically significant, in which case 
they are to be reported as adverse events.  
n Includes evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_123452], 
gastrointestinal, genitourinary, and neurolo gic systems.  See Section  4.5.[ADDRESS_138980] new  or worsened clinically 
significant abnormalities on the Adverse Event eCRF.  
p See Appendix  13. 
q Cardiac monitoring (ECHO or M UGA scan) will be performed on all patients enrolled in the study.  ECHO/MUGA results need to be reviewed 
and acted upon as soon as they are available, but study interventions may continue while ECHO/MUGA results are being read ass uming that the 
subject is  asymptomatic from a cardiac standpoint.  ECHO is the preferred method.  The same method used for a given patient at screening 
should be used throughout the study, unless clinically indicated.  ECHO or MUGA scan should be obtained at baseline, after th e second dose of 
ddAC for the cardiac safety cohort (first 26 patients enrolled), after the fourth dose of ddAC  (and prior to Cycle  5, Day 1), and then every 
3 months ( 2 week s) during study treatment.  ECHO or MUGA scan should be obtained at the early termination visit if not performed within the 
previous [ADDRESS_138981] 2  years and then 
annually until the en d of study.  Patients who discontinue study drug(s) for heart failure or LVEF decline should continue to undergo LVEF 
assessments according to this schedule of activities irrespective of the initiation of alternative systemic anti -cancer therapy until reso lution, 
improvement to baseline status, and no further improvement can be expected, or death.  Additional ECHO or MUGA scans should be obtained if 
clinically indicated.  

Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
158/Protocol BO40747 , Version [ADDRESS_138982] 10  minutes prior to ECG recording.  
s Hematology includes WBC count, RBC count, hemoglobin, hematoc rit, platelet count, and differential count (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes, and other cells).  Local laboratory assessment can be performed up to 3 days  prior to study treatment administration 
with the option of repeating on t he day of study treatment, including the weekly administration of paclitaxel during  Cycles  58.  Local assessment 
must be reviewed prior to every study treatment administration.  
t If screening laboratory assessments were performed within [ADDRESS_138983] to be repeated. 
u Chemistry panel (serum or plasma) includes bicarbonate or total carbon dioxide (if considered SOC for the region), sodium, po tassium, 
magnesium, chloride, glucose, BUN or urea, creatinine, total protein,  albumin, phosphorus, calcium, total bilirubin, ALP, ALT, AST, and LDH.  
Local laboratory assessments can be performed up to 3 days  prior to study treatment administration with the option of repeating on the day of 
study treatment, including the weekly adm inistration of paclitaxel during Cycles  58.  Local assessments must be reviewed prior to every study 
treatment administration.  
v All women of childbearing potential (as defined in Section  4.1.1 ) will have a serum pregnancy test at screening, within [ADDRESS_138984] be done at the  treatment  completion/early termination visit, and at [ADDRESS_138985].  
w TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed on Day 1 of Cycle 1 and eve ry fourth cycle 
thereafter.  
x Includes pH, specific gravity, glucose, protein, ketones, and blood; dipstick permitted.  
y The PRO assessments (EORTC QLQ -C30, followed by [CONTACT_92349] -G single item GP5, and then the EQ -5D-5L questionnaire) will be completed 
by [CONTACT_123540]’s health state, laboratory results, or hea lth record; before 
administration of study treatment; and/or prior to the performance of any other study assessments that could bias the patient ’s responses.   In 
scenarios where laboratory assessments (e.g., blood draws) are done in a different clinic than  the one providing treatment or when they are 
done on a different day than study treatment administration, laboratory assessments can be completed before the completion of  PROs as long 
as results have not been discussed with patients.  Study personnel shou ld review all questionnaires for completeness before the patient leaves 
the investigational site.  EORTC QLQ -C30 and EQ -5D-5L questionnaires will be completed by [CONTACT_123586] (Cycle 1, Day 1); on Day 1 of 
every cycle thereafter until Cycle  8; on Cycle 9, Day 1; on Day 1 of every other cycle thereafter until Cycle 22; and at the treatment 
discontinuation /early termination visit.  If cycles are missed or delayed as permitted by [CONTACT_760], the PRO questionnaires should be 
completed on the day that  the patient receives treatment for that cycle, before administration of study treatment.  Patients who discontinue study 
treatment for any reason will continue to complete the EORTC QLQ -C30, FACT -G single item GP5, and EQ -5D-5L questionnaires in  clinic 

Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
159/Protocol BO40747 , Version 6 during the follow -up period at the following timepoints:  every 3 months (  28 days) for the first year and then every 6  months ( 28 days)  
thereafter until the end of the study.  
z While on study treatment, all patients will complete the FACT -G, single item GP5 beginning on Cycle 2, Day 1; on Day 1 of every cycle thereafter 
until Cycle 8; on Cycle 9, Day 1; on Day 1 of every other cycle thereafter until Cycle 22; and at the treatment discontinuati on/early termination 
visit. 
aa Auto-antibody testing includes anti-nuclear antibody, anti double -stranded DNA, and circulating anti -neutrophil cytoplasmic antibody, and 
perinuclear anti -neutrophil cytoplasmic antibody.  The baseline sample will be obtained pre -treatment Cycle 1, Day 1, before the first dose of 
study drug and stored.  For patients who show evidence of immune mediated toxicity, additional samples may be collected and assesse d 
(including the baseline sample) at that time point.  All samples will be analyzed centrally.  
bb Includes any medication (e.g., pr escription drugs, over -the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) 
used by a patient in addition to protocol -mandated study treatment from 30 days prior to initiation of study treatment (for the purposes of 
screeni ng) until the treatment discontinuation visit.  Medication used by [CONTACT_25701] [ADDRESS_138986].  After this period, the Sponsor should be notified if the investigator becomes aware of any serious adverse event 
that is believed to be related to prior exposure to study trea tment (see Section  5.6).  For reporting instructions for deaths, please 
see Section  [IP_ADDRESS] . 
dd During the neoadjuvant phase, atezolizumab/placebo will be administered by [CONTACT_22671] a fixed dose of 840 mg on Day 1 of each 
14-day cycle during Cycles 1 4, and 1200  mg on Da y 1 of each 21 -day cycle during Cycles 5 8.  During the adjuvant phase (post -operatively), 
atezolizumab/placebo will be administered by [CONTACT_22671] a fixed dose of 1200 mg on Day 1 of each 21 -day cycle (maximum of 22  cycles 
[neoadjuvant   adjuvant phase s]).  Atezolizumab/placebo should be administered as the first infusion.  The initial dose of atezolizumab/placebo 
will be delivered over 60 (  15) minutes.  Subsequent infusions will be delivered over 30 (  10) minutes if the previous infusion was tolerated 
without infusion -associated adverse events, or 60 (  15) minutes if the patient experienced an infusion -associated adverse event with the 
previous infusion.   See Section  [IP_ADDRESS]  for additional details.   Following the distribution of the USM DIL dated 3 February 2021, blinded 
atezolizumab /placebo  will no longer be administered to patients.  
ee Doxorubicin 60 mg/m2 IV on Day 1 of a 1 4-day cycle for 4 cycles (Cycles 1 4) according to local practice guidelines.  See Section  [IP_ADDRESS]  for 
additional details.  

Appendix 1: Schedule of Activities  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
160/Protocol BO40747 , Version 6 ff Cyclophosphamide 600 mg/m2 IV on Day 1 of a 14 -day cycle for 4 cycles (Cycles 1 4) according to local practice guidelines.  
See Section  [IP_ADDRESS]  for additional details.  
gg Pertuzumab is given as a fixed non weight -based dose of 840 -mg IV loading dose, then 420 mg IV Q3W.  Pertuzumab will be administered on 
Day 1 of a 21 -day cycle, to complete up to a total duration of 52 weeks (i.e., maximum  of 18 cycles within 1 year) of HER2 -targeted therapy, 
inclusive of therapy given both in the neoadjuvant and adjuvant setting .  Day 1 dose administrations are to be performed within a 
 3-day window, unless treatment is delayed or on hold to manage toxicity.  If the scheduled dose administration coincides with a holiday that 
precludes administration, administration should be performed within 7  days following the scheduled date.   See Section  [IP_ADDRESS]  for additional 
details.  
hh Trastuzumab is given as an 8 -mg/kg IV loading dose and then 6 mg/kg IV Q3W.  Trastuzumab will be administered on Day 1 of a 21 -day cycle, 
to complete up to a tota l duration of 52 weeks (i.e., maximum of 18 cycles within 1 year) of HER2 -targeted therapy, inclusive of therapy given 
both in the neoadjuvant and adjuvant setting.   Day 1 dose administrations are to be performed within a  3-day window, unless treatment i s 
delayed or on hold to manage toxicity.  If the scheduled dose administration coincides with a holiday that precludes administ ration, administration 
should be performed within 7  days following the scheduled date.   See Section  [IP_ADDRESS]  for additional details.  
ii Paclitaxel is given 80 mg/m2 IV weekly for 12 continuous weeks (Cycles 5 8) according to local practice guidelines.   Chemotherapy should be 
given after pertuzumab and trastuzumab.  See Section  [IP_ADDRESS]  for additional details.  
jj After treatment discontinu ation, information on survival follow -up and new anti -cancer therapy (including targeted therapy and immunotherapy) 
will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months for 1 year,  then every 6  months 
until the end of the study (unless the patient withdraws consent or the Sponsor terminates the study).  If a patient requests  to be withdrawn from 
follow -up, this request must be documented in the source documents and signed by [CONTACT_093].  If the patient withdraws from study, the 
study staff shall use a public information source (e.g., county records) to obtain information about survival status only, wh ere allowable by [CONTACT_21482].  
kk Trastuzumab emtansine will be an option for patients wh o did not achieve pCR after completion of neoadjuvant treatment.  Trastuzumab 
emtansine will be given as 3.6  mg/kg IV infusion on Day  1 of a 21 -day cycle for a maximum of 14  cycles in the adjuvant setting.   Day 1 dose 
administrations are to be performed wi thin a  3-day window, unless treatment is delayed or on hold to manage toxicity.  If the scheduled dose 
administration coincides with a holiday that precludes administration, administration should be performed within 7  days following the scheduled 
date.   See Section  [IP_ADDRESS]  for additional details.  

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
161/Protocol BO40747 , Version [ADDRESS_138987] 
infusion of 
atezolizumab/ 
placebo, 
pertuzumab, and 
trasuzumab   Atezolizumab PK (serum)  
 Atezolizumab ADA (serum)  
 Pertuzumab PK (serum)  
 Pertuzumab ADA (serum)  
 Trastuzumab PK (serum)  
 Trastuzumab ADA (serum)   Atezolizumab PK 
(serum)  
 Atezolizumab ADA 
(serum)  
 Pertuzumab PK (serum)  
 Pertuzumab ADA 
(serum)  
 Trastuzumab PK 
(serum)  
 Trastuzumab ADA 
(serum)  
30 ( 10) min after 
end of the 
atezolizumab/  
placebo infusion   Atezolizumab PK (serum)   Atezolizumab PK 
(serum)  
Day 1 of 
Cycles 2, 
3, 4, 8, 12, 
and 16  Prior (within 
3 days) to the 
atezolizumab/  
placebo, 
pertuzumab, and 
trasuzumab 
infusions   Atezolizumab PK (serum)  b 
 Atezolizumab ADA (serum)  b 
 Pertuzumab PK (serum) 
(Cycles 8 and 12 only)  a,b 
 Pertuzumab ADA (serum) 
(Cycles 8 and 12 only)  a,b 
 Trastuzumab PK (serum) 
(Cycles 8 and 12 only)  a,b 
 Trastuzumab ADA (serum) 
(Cycles 8 and 12 only)  a,b  Atezolizumab PK 
(serum)  b 
 Atezolizumab ADA 
(serum)  b 
 Pertuzumab PK (serum) 
(Cycles 8 and 12 only) 
a,b 
 Pertuzumab ADA 
(serum) (Cycles 8 and 
12 only)  a,b 
 Trastuzumab PK 
(serum) (Cycles 8 and 
12 only)  a,b 
 Trastuzumab ADA 
(serum) (Cycles 8 and 
12 only)  a,b 
Appendix 2: Schedule of Pharmacokinetic and Immunogenicity Samples  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
162/Protocol BO40747 , Version 6 Visit  Timepoint  Treatment Arms  
Atezolizumab with ddAC -PacHP  Placebo with ddAC -PacHP  
Day 1 of 
Cycle 9  Prior (within 
3 days) to the first 
infusion of 
trastuzumab 
emtansine   Trastuzumab emtansine and 
total trastuzumab PK (serum) b 
 DM1 PK (plasma)  b 
 Trastuzumab emtansine ADA 
(serum)b  Trastuzumab emtansine 
and total trastuzumab 
PK (serum)b 
 DM1 PK (plasma)  b 
 Trastuzumab emtansine 
ADA (serum)b 
30 ( 10) min after 
the end of the 
trastuzumab 
emtansine 
infusion   Trastuzumab emtansine and 
total trastuzumab PK (serum)  b 
 DM1 PK (plasma)  b  Trastuzumab emtansine 
and total trastuzumab 
PK (serum)  b 
 DM1 PK (plasma)  b 
Day 1 of 
Cycle 12  Prior (within 
3 days) to the 
trastuzumab 
emtansine 
infusion   Trastuzumab emtansine and 
total trastuzumab PK (serum)  b 
 Trastuzumab emtansine ADA 
(serum)  b  Trastuzumab emtansine 
and total trastuzumab 
PK (serum)  b 
 Trastuzumab emtansine 
ADA (serum)  b 
30 ( 10) min after 
the end of the 
trastuzumab 
emtansine 
infusion   Trastuzumab emtansine and 
total trastuzumab PK (serum)  b 
 DM1 PK (plasma)  b  Trastuzumab emtansine 
and total trastuzumab 
PK (serum)  b 
 DM1 PK (plasma)  b 
Treatment 
discont. 
visit 
( 30 days 
after final 
dose)  At visit   Atezolizumab PK (serum)  
 Atezolizumab ADA (serum)  
 Pertuzumab PK (serum)  
 Pertuzumab ADA (serum)  
 Trastuzumab PK (serum)  
 Trastuzumab ADA (serum)  
 Trastuzumab emtansine and 
total trastuzumab PK (serum)  
 DM1 PK (plasma)  
 Trastuzumab emtansine ADA 
(serum)   Pertuzumab PK (serum)  
 Pertuzumab ADA 
(serum)  
 Trastuzumab PK 
(serum)  
 Trastuzumab ADA 
(serum)  
 Trastuzumab emtansine 
and total trastuzumab 
PK (serum)  
 DM1 PK (plasma)  
 Trastuzumab emtansine 
ADA (serum)  
  
Appendix 2: Schedule of Pharmacokinetic and Immunogenicity Samples  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
163/Protocol BO40747 , Version 6 ADA   anti-drug antibody; ddAC -PacHP   dose -dense anthracycline 
(doxorubicin)   cyclophosphamide followed by [CONTACT_114461]   trastuzumab   pertuzumab ; 
discont.   discontinuation; DM1   derivative of maytansine; pCR   pathological complete response; 
PK   pharmacokinetic.  
Notes:  PK and ADA samples for atezolizumab, pertuzumab, and trastuzumab will be collected for 
all patients.  PK and ADA samples for trastuzumab emtansine will be collected for only those 
patients recei ving trastuzumab emtansine.  In an event where a dose is withheld, predose PK and 
ADA samples should be collected regardless if possible on the day of the planned dose.  If more 
than one dose is withheld, the PK and ADA samples will be handled on a case -by-case basis.  
a Patients who do not achieve pCR and switch treatment to atezolizumab/placebo with 
trastuzumab emtansine in the adjuvant phase of the study are not required to provide PK and 
ADA samples for trastuzumab and pertuzumab at Cycle 12.  
b Following the discontinuation of atezolizumab or placebo, this sample collection is no longer 
required.  The PK and ADA sample collection for atezolizumab, trastuzumab and pertuzumab 
(or trastuzumab emtansine) is only required at the treatment discontinuat ion visit following the 
implementation of Protocol Version 5.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
164/Protocol BO40747 , Version 6 Appendix  3  
Schedule of Blood and Tissue Samples for Biomarker Analysis  
Blood Samples  
Visit Timepoint  Sample Type  
Cycle 1, Day 1  Pretreatment  Plasma sample for biomarkers  
Blood sample for WGS/WES a, b 
Whole blood sample for RBR b, c 
Cycle 2, Day 1  Pretreatment  Plasma sample for biomarkers  
Surgery  Pre-surgery  Plasma sample for biomarkers  
Cycle 9, Day 1  Pretreatment  Plasma sample for biomarkers  
Cycle 13, Day 1  Pretreatment  Plasma sample for biomarkers  
Cycle 17, Day 1  Pretreatment  Plasma sample for biomarkers  
Treatment discontinuation 
( 30 days after final dose) d At any time during visit  Plasma sample for biomarkers  
Disease recurrence  At any time during visit  Plasma sample for biomarkers  
RBR   Research Biosamle Repository; WES   whole exome sequencing; WGS   whole 
genome sequencing.  
a Not applicable for a site that has not been granted approval for WGS/WES.  
b If missed on Day 1, this blood sample can be collected at any point in the study.  
c Not applicable for a site that has not been granted approval for RBR sampling and 
performed only for patients at participa ting sites who have provided written optional RBR 
consent to participate. 
d If treatment is discontinued due to disease recurrence, the treatment discontinuation 
sample does not apply and only the disease recurrence sample needs to be collected.  
 
  
Appendix 3: Blood and Tissue Samples for Biomarker Analysis  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
165/Protocol BO40747 , Version 6 Tissue  Samples  
Visit Timepoint  Requirement  Sample Type  
Screening a Pre-treatment  Mandatory  A representative FFPE tumor specimen in a paraffin 
block (preferred) or at least [ADDRESS_138988] contain a minimum of 50  viable 
tumor cells.  
Samples are to be collected via core -needle biopsy 
(at least three cores, embedded in a single paraffin 
block).  Fine -needle aspi[INVESTIGATOR_123453].  
For patients with multifocal tumors, at least  one focus 
must be sampled and centrally confirmed as 
HER2 -positive .  A representative FFPE tumor 
specimen in a paraffin block is preferred or at least 
[ADDRESS_138989] 11  slides are required from each 
lesion.  In  addition to this requirement, a total of 
9 slides is required f or the remaining biomarker tests.  
Preferably, these additional 9  slides are derived from 
one lesion.  
Surgery   Mandatory  A representative FFPE tumor specimen in a paraffin 
block (preferred) or at least [ADDRESS_138990] be 
submitted.  
Disease 
recurrence b  Mandatory, 
if clinically 
feasible  A representative FFPE tumor specimen in a paraffin 
block (preferred) or at least [ADDRESS_138991] be 
submitted. 
FFPE   formalin -fixed, paraffin -embedded;  HER2   human epi[INVESTIGATOR_5169] 2.  
a A pretreatment tumor biopsy is required for central eligibility testing.  A new pretreatment tumor 
biopsy may be performed if tissue test results do not meet eligibility criteria.   Submission of a 
tumor sample can occur outside the 28 -day screening period.  Patients with multicentric 
tumors are eligible provided all discrete lesions are sampled and centrally confirmed as 
HER2 -positive.  
b If deemed clinically feasible by [CONTACT_123587] 40 days after recurrence or prior to 
the next anti -cancer therapy, whichever is sooner.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
166/Protocol BO40747 , Version 6 Appendix  4  
European Organisation for  Research and Treatment of Cancer 
Quality -of-Life Questionnaire Core 30:  EORTC QLQ -C30 
 

Appendix 4: European Organisation for Research and Treatment of Cancer Quality -of-Life 
Questionnaire Core 30 :  EORTC QLQ -C30 
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
167/Protocol BO40747 , Version 6  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
168/Protocol BO40747 , Version 6 Appendix  5  
Functional Assessment of Cancer Therapy General (FACT -G) 
Single -Item GP5  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
169/Protocol BO40747 , Version 6 Appendix  6  
EuroQol 5 -Dimension, 5 -Level Questionnaire: EQ -5D-5L 
 

Appendix 6:  EuroQol 5-Dimension , 5-Level  Questionnaire: EQ -5D-5L 
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
170/Protocol BO40747 , Version 6  

Appendix 6:  EuroQol 5-Dimension , 5-Level  Questionnaire: EQ -5D-5L 
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
171/Protocol BO40747 , Version 6  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
172/Protocol BO40747 , Version [ADDRESS_138992] anti -HER -2/neu (4B5) Rabbit Monoclonal Primary Antibody 
(PATHWAYHER2 [4B5]) is a rabbit monoclonal antibody intended for laboratory use for 
the semi -quantitative detection of human epi[INVESTIGATOR_5169] 2  (HER2 ) antigen in 
sections of formali n-fixed, paraffin -embedded breast cancer tissue to determine tumor 
HER2 immunohistochemistry (IHC) status and to select HER2 -positive patients for 
enrollment in Study  BO40747.  
The PATHWAY HER2 (4B5) IHC assay is an automated immunohistochemical staining 
assay system comprising a pre -dilute, ready -to-use, rabbit monoclonal primary antibody  
(clone  4B5) directed against the internal domain of HER2, the BenchMark ULTRA 
automated slide staining platform, and ultraView universal DAB detection kit.   The 
reagents a nd the IHC procedure are optimized for use on the BenchMark ULTRA 
automated slide stainer, utilizing VSS software (Ventana System Software).  Details of 
the staining protocol and scoring criteria can be found in instruction for use and 
interpretation guide  published by [CONTACT_123588].  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
173/Protocol BO40747 , Version 6 Appendix  8  
Ventana HER2 ISH Assay  
Probe Cocktail is intended to determine the ratio of the human epi[INVESTIGATOR_5169] 2  
(HER2 ) gene to chromosome  17 using two -color chromogenic in situ hybridization (ISH) 
in formalin -fixed, paraffin -embedded (FFPE) human breast cancer tissue to determine 
tumor H ER2 gene status and select HER2 -positive patients for enrollment in 
Study  BO40747.  
The Ventana INFORM HER2 Dual ISH assay consists of a d initrophenyl (DNP) -labeled 
double stranded probe that targets the HER2 gene region of chromosome  17 and a 
digoxigenin (DIG) -labeled double stranded probe that hybridizes to repetitive sequences 
in the centromeric region of chromosome 17 (INFORM Chromosome 17 probe).  The 
probes are packaged as a mixture and require the use of Ventana’s ultraView™ 
SISHDNP Detection Kit, ultraView Red DIG Detection Kit, and other accessory reagents 
to stain routinely processed, FFPE tissue sections on Ventana automated slide stainer 
instruments.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
174/Protocol BO40747 , Version 6 Appendix  9  
Preexisting Autoimmune Diseases and Immune Deficiencies  
Patients should be carefully questioned regarding their history of acquired or congenital 
immune deficiencies or auto immune disease.  Patients with any history of immune 
deficiencies or autoimmune disease listed in the table below are excluded from 
participating in the study.  Possible exceptions to this exclusion could be patients with a 
medical history of such entities  as atopic disease or childhood arthralgias where the 
clinical suspi[INVESTIGATOR_33415].  Patients with a history of 
autoimmune -related hypothyroidism on a stable dose of thyroid replacement hormone 
may be eligible for this study.  In additio n, transient autoimmune manifestations of an 
acute infectious disease that resolved upon treatment of the infectious agent are not 
excluded (e.g.,  acute Lyme arthritis).  Caution should be used when considering 
atezolizumab for patients who have previously  experienced a severe or life -threatening 
skin adverse reaction or pericardial disorder while receiving another immunostimulatory 
anti-cancer agent.   The Medical Monitor is available to advise on  any uncertainty over 
autoimmune exclusions.  
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
175/Protocol BO40747 , Version 6 Autoimmune Diseases and Immune Deficiencies  
 Acute disseminated 
encephalomyelitis  
 Addison disease  
 Ankylosing spondylitis  
 Antiphospholipid antibody 
syndrome  
 Aplastic anemia  
 Autoimmune hemolytic 
anemia  
 Autoimmune hepatitis  
 Autoimmune 
hypoparathyroidism  
 Autoim mune hypophysitis  
 Autoimmune myelitis  
 Autoimmune myocarditis  
 Autoimmune oophoritis  
 Autoimmune orchitis  
 Autoimmune 
thrombocytopenic purpura  
 Behçet disease  
 Bullous pemphigoid  
 Chronic fatigue syndrome  
 Chronic inflammatory 
demyelinating 
polyneuropathy  
 Churg -Strauss syndrome   Crohn disease  
 Dermatomyositis  
 Diabetes mellitus type 1  
 Dysautonomia  
 Epi[INVESTIGATOR_123454]  
 Gestational pemphigoid  
 Giant cell arteritis  
 Goodpasture syndrome  
 Granulomatosis  with 
polyangiitis  
 Graves disease  
 Guillain -Barré syndrome  
 Hashimoto disease  
 IgA nephropathy  
 Inflammatory bowel disease  
 Interstitial cystitis  
 Kawasaki disease  
 Lambert -Eaton myasthenia 
syndrome  
 Lupus erythematosus  
 Lyme disease, chronic  
 Meniere syndrome  
 Mooren ulcer  
 Morphea   Multiple sclerosis  
 Myasthenia gravis  
 Neuromyotonia  
 Opsoclonus myoclonus 
syndrome  
 Optic neuritis  
 Ord thyroiditis  
 Pemphigus  
 Pernicious anemia  
 Polyarteritis nodosa  
 Polyarthritis  
 Polyglandular autoimmune 
syndrome  
 Primary biliary  cholangitis  
 Psoriasis  
 Reiter syndrome  
 Rheumatoid arthritis  
 Sarcoidosis  
 Scleroderma  
 Sjögren syndrome  
 Stiff-Person syndrome  
 Takayasu arteritis  
 Ulcerative colitis  
 Vitiligo  
 Vogt-Koyanagi -Harada 
disease  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
176/Protocol BO40747 , Version [ADDRESS_138993] operating procedures.  
REQUIRED EQUIPMENT A ND MEDICATION  
The following equipment and medication are needed in the event of a suspected 
anaphylactic reaction during study trea tment infusion.  
 Monitoring devices:  ECG monitor, blood pressure monitor, oxygen saturation 
monitor, and thermometer  
 Oxygen  
 Epi[INVESTIGATOR_33414], intravenous, and/or endotracheal administration in 
accordance with institutional guidelines  
 Antihistamines  
 Corticosteroids  
 Intravenous infusion solutions, tubing, catheters, and tape  
 
PROCEDURES  
In the event of a suspected anaphylactic reaction during study treatment infusion, 
the following procedures should be performed:  
1. Stop the study treatment  infusion.  
2. Call for additional medical assistance.  
3. Maintain an adequate airway.  
4. Ensure that appropriate monitoring is in place, with continuous ECG and pulse 
oximetry monitoring if possible.  
5. Administer antihistamines, epi[INVESTIGATOR_238], or other medications and IV fluids as 
required by [CONTACT_123589].  
6. Continue to observe the patient and document observations.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
177/Protocol BO40747 , Version 6 Appendix  11  
Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
DOSE MODIFICATIONS, TREATMENT INTERRUPTI ON, AND 
MANAGEMENT  GUIDELINES  
When there is a possibility of overlappi[INVESTIGATOR_50685], the attribution of an adverse e vent to 
particular drug(s) will be based on the investigator’s clinical judgment.  See Section  5.1.[ADDRESS_138994] be tapered over  1 month to  10 mg/day oral prednisone or 
equivalent before atezolizumab can be resumed.  If atezolizumab is wi thheld for 
 12 weeks after event onset, the patient will be discontinued from atezolizumab.  
However, atezolizumab may be withheld for  12 weeks to allow for patients to taper off 
corticosteroids prior to resuming treatment.  Atezolizumab can be resumed after being 
withheld for  12 weeks if the patient is likely to derive clinical benefit.  The decision to 
re-challenge patients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  Atezolizumab treatment may be suspended for reasons 
other than toxicity (e.g.,  surgical procedures ).  The acceptable length of treatment 
interruptio n must be based on the investigator's  benefitrisk assessment and in 
alignment with the protocol requirements for the duration of treatment and documented 
by [CONTACT_093].   The Medical Monitor is available to advise as needed . 
DOXORUBICIN AND CYCLOPHOSPHAMIDE  
Dose reduction and dose delays will be allowed as indicated in the relevant local 
prescribing information for doxorubicin and cyclophosphamide, and should be managed 
as per local practice.  
Cardiotoxicity  
If severe symptomatic heart failure  develops ([LOCATION_001] Heart Association [NYHA] 
Class  III or IV) or there is a significant left ventricular ejection fraction (LVEF) decrease 
(LVEF decline  10 percentage points from baseline to an LVEF value  50%), the 

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
178/Protocol BO40747 , Version [ADDRESS_138995] discontinue atezolizumab   doxorubicin   cyclophosphamide and not 
proceed with  anti-HER2 therapy .  Heart failure or left ventricular dysfunction should be 
treated and monitored according to standard medical practice.  These patients should be 
evaluated by a certified cardiologist  and the results of this evaluation should be reported 
on the eCRF.  
Patients who discontinue atezolizumab   doxorubicin   cyclophosphamide for heart 
failure or LVEF decline should continue to undergo LVEF assessments according to the 
schedule of activities  (see Appendix  1)irrespective of the initiation of alternative 
systemic anti -cancer therapy until resolution, improvement to baseline status, no 
further improvement can be expected, or death.  Additional LVEF assessments may be 
required for these patients  (beyond those specified in the schedule of activities), 
according to the investigator’s clinical judgment.  The results of these assessments 
should be reported.  
Liver Function  
The major route of elimination of doxorubicin is the hepatobiliary system.  Serum total 
bilirubin should be evaluated before and during treatment with doxorubicin.  Patients with 
elevated bilirubin may experience slower clearance of the drug with an increase in 
overall toxicity.  Lower doses are recommended in these patients.  Patients with severe 
hepatic impairment should not receive doxorubicin.  
PACLITAXEL  
Dose reduction and dose delays will be allowed as indicated in the relevant local 
prescribing information for paclitaxel, and managed as per local practice.  
Pulmonary Events /Pneumonitis  
Paclitaxel should be permanently discontinued upon ruling out infectious etiology (using 
routine microbiological and/or immunologic methods) and making a diagnosis of 
pneumonitis.  After infectious etiology is ruled out, IV high -dose corticost eroid therapy 
should be instituted without delay, with appropriate premedication and secondary 
pathogen coverage.  The patient will discontinue paclitaxel treatment but may continue 
receiving other study drugs as per Table [ADDRESS_138996] 
administered dose to allow resolution of adverse events.  If dosing with trastuzumab and 

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
179/Protocol BO40747 , Version [ADDRESS_138997] dose and the 
inves tigator wishes to restart trea tment with trastuzumab and pertuzumab  based on a 
positive benefit risk assessm ent for the individual patient,  the Medical Monitor is 
available for consultation .  For guidance on drug administration requirements related to 
delayed or missed doses, please see Table 1  below.   No dose reduction is permitted for 
either pertuzumab or trastuzumab.  Note tha t if trastuzumab is permanently 
discontinued, the patient will not receive adjuvant treatment on study but will enter the 
study follow -up period.  
Table 1  Pertuzumab and Trastuzumab Administration Guidance 
Regarding Delayed or Missed Doses  
Time Between Two 
Sequential Doses  Pertuzumab  Trastuzumab  
 6 weeks  The 420 -mg dose of pertuzumab  IV 
should be administered as soon as 
possible.  Do not wait until the next 
planned dose.  The 6  mg/kg dose of trastuzumab 
IV should be administered as soon 
as possible.  Do not  wait until the 
next planned dose.  
 6 weeks  The loading dose of 840  mg 
pertuzumab IV should be 
re-administered  as a 60 -minute 
infusion, followed by a maintenance 
dose of 420 mg IV administered over 
a period of 30 to 60 minutes every 
3 weeks thereafter.  The loading dose of 8  mg/kg of 
trastuzumab IV should be 
re-administered  over approximately 
90 minutes, followed by a 
maintenance dose of 6  mg/kg 
IV administered  over a period of 
30 or 90 minutes every 3  weeks 
thereafter.  
 
Infusion -Associated Symptoms  
If infusion -associated symptoms occur, patients should be monitored until complete 
resolution of signs and symptoms.  Patients who experience infusion -associated 
symptoms may be managed by [CONTACT_123590] (e.g., -agonists, antihistamines, 
antipyretics, or corticosteroids), as determined by [CONTACT_123591].  Patients who experience infusion -associated symptoms may subsequently 
be premedicated with an algesia and antihistamines.  If the infusion is well tolerated, 
patients will be observed for 30 minutes following subsequent infusions.  The infusion of 
pertuzumab or trastuzumab should be stopped in patients who develop dyspnea or 
clinically significant hypotension (defined as per investigator discretion).  Patients who 
experience an NCI CTCAE Grade 3 or 4 allergic reaction or acute respi[INVESTIGATOR_123455].  

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
180/Protocol BO40747 , Version 6 Cardiotoxicity  
If severe symptomatic heart failure deve lops (NYHA Class III or IV) , the patient must 
discontinue anti -HER2 therapy.  If there is a significant LVEF decrease (LVEF decline 
 10 percentage points from baseline to an LVEF value  50%) anti -HER2 therapy 
should be withheld and a repeat LVEF assessment performed within approximately 
[ADDRESS_138998] discontinue anti -HER2 therapy.  Patients who 
develop asymptomatic cardiac dysfunctio n may benefit from more frequent monitoring 
(e.g.,  every 68 weeks).  Heart failure or left ventricular dysfunction should be treated 
and monitored according to standard medical practice.  These patients should be 
evaluated by a certified cardiologist and the results of this evaluation should be reported 
on the eCRF.  
Patients who discontinue anti -HER2 therapy for heart failure or LVEF decline should 
continue to undergo LVEF assessments according to the schedule of activities 
(Appendix  1)irrespective  of the  initiation of alternative systemic anti -cancer 
therapyuntil resolution, improvement to baseline status, no further improvement can 
be expected, or death.  Additional LVEF assessments may be required for these patients 
(beyond those specified in the sched ule of activities), according to the investigator’s 
clinical judgment.  The results of these assessments should be reported.  
Pulmonary Toxicity  
Severe pulmonary events have been reported with the use of the trastuzumab  IV 
formulation in the postmarketing s etting.  These events have occasionally been fatal.  
They may occur as part of an IRR or with delayed onset.  In addition, cases of interstitial 
lung disease, including lung infiltrates, acute respi[INVESTIGATOR_1505] (ARDS), 
pneumonia, pneumonitis, p leural effusion, respi[INVESTIGATOR_1506], acute pulmonary edema, 
and respi[INVESTIGATOR_123456].  These events 
have been most common with the first infusion, and their severity has decreased with 
subsequent infusions.  Se rious reactions have been treated successfully with supportive 
therapy, such as oxygen, -agonists, and corticosteroids.  ARDS has been reported with 
a fatal outcome.  
Refer to the Trastuzumab Investigator’s Brochure and Pertuzumab Investigator’s 
Brochure f or the most recent data related to the associated risks.  
Epi[INVESTIGATOR_14907] (EGFR) Related Toxicities  
To prevent dehydration, early treatment of diarrhea with anti -diarrheal medication should 
be considered, and patients should be treated with  fluids and electrolyte replacement, as 
clinically indicated.  

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
181/Protocol BO40747 , Version 6 Treatment recommendations for EGFR -associated rash include topi[INVESTIGATOR_123457], and topi[INVESTIGATOR_123458] (for severe reactions).  
These agents may be used in patients exp eriencing pertuzumab -related rash, as 
clinically indicated, although they have not been studied in this context.  
Mucositis is generally not considered preventable; although for some cytotoxic agents, 
mucositis may be reduced by [CONTACT_123592].  
MODIFICATIONS OF STU DY TREATMENT REGIMEN  IF AGENT(S) CANNOT 
BE ADMINISTERED (IN THE EVENT OF TOXICIT Y) 
Investigators may consult with the Medical Monitor before discontinuing all components 
of study treatment.  See Table 2 , Table 3 , and Table 4  for modifications of study 
treatment regimen in the event that agent(s) cannot be administered  (e.g., due to 
toxicity).  
  

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
182/Protocol BO40747 , Version 6 Table 2  Neoadjuvant Cycles 1 4:  Atezolizumab/Placebo and Dose -Dense 
(dd) Doxorubicin (A)   Cyclophosphamide (C)  
Regimen  Unable to Administer  within 
14 Days of Scheduled Dosing 
(i.e., Cycle X , D1   14 Days)  Action  
Atezolizumab/  
Placebo   ddAC  Either A or C  Do not continue with only one  component of 
the chemotherapy backbone.  
Move to 4 cycles of 
atezolizumab/placebo   PacHP . 
Per investigator discretion:   Option to make up 
missed chemotherapy cycles post -surgery 
and prior to adjuvant therapy with 
atezolizumab/placebo   HP. 
Note:  Due to increased risk of cardiotoxicity, 
ddAC is NOT to be given within 21  days of 
prior H and/or P. b  ddAC is NOT to be given 
concurrently with H and/or  P. 
ddAC  Move to 4 cycles 
atezolizumab/placebo   PacHP . 
Per investigator discretion:  Option to make up 
missed chemotherapy cycles post -surgery 
and prior to adjuvant therapy with 
atezolizumab/placebo    HP. 
Note:  Due to increased risk of cardiotoxicity, 
ddAC is NOT to be given wit hin 21  days of 
prior H and/or P.b  ddAC is NOT to be given 
concurrently with H and/or  P. 
Atezolizumab/placebo  Continue ddAC then switch to PacHP followed 
by [CONTACT_123593]  HP adjuvant therapy.  
Atezolizumab/placebo may be reintroduced 
with subsequent cycles of therapy a if criteria 
for restarting are met.  (See above in 
Appendix  11 and also Appendix  12, Risks 
Associated with Atezolizumab and Guidelines 
for Management of Adverse Events 
Associated with Atezolizumab.)  
A  doxorubicin; C   cyclophosphamide; D1   Day 1; dd   dose -dense; ddAC   dose -dense anthracycline 
(doxorubicin)   cyclophosphamide; H   trastuzumab ; P   pertuzumab ; 
PacHP   paclitaxel   trastuzumab   pertuzumab . 
a When atezolizumab is restarted, the infusions should remain synchronized and aligned with the 
chemotherapy schedule.  
b The only exception is the period between Cycle 4 and Cycle 5 during which the Cycle  4 ddAC 
administration will be given 14 days prior to the Cycle 5 administration of HP.  
 

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
183/Protocol BO40747 , Version 6 Table 3  Neoadjuvant Cycles 58:  Atezolizumab/Placebo and 
Paclitaxel   Trastuzumab   Pertuzumab (PacHP)  
Regimen  Unable to Administer  Action  Impact on Adjuvant 
(Post -Operative) 
Treatment  
If 1 agent in the regimen cannot be administered (i.e., due to toxicity) within 21  days of 
scheduled dosing (i.e. , Cycle X , D1    21 days)  
Atezolizumab/  
Placebo    
PacHP  Atezolizumab/placebo   Continue PacHP.  
Atezolizumab/placebo 
may be reintroduced with 
subsequent cycles of 
therapy a if criteria for 
restarting are met.  
(See  above in 
Appendix  11 and also 
Section  5, Assessment of 
Safety, and Appendix  12, 
Risks Associated with 
Atezolizumab and 
Guidelines for 
Management of Adverse 
Events Associated with 
Atezolizumab.)  HP adjuvant treatment.  
Atezolizumab/placebo 
may be reintroduced  
with subsequent cycles 
of therapy a if criteria for 
restarting are met.  
(See above in 
Appendix  11 and also 
Section  5, Assessment 
of Safety, and 
Appendix  12, Risks 
Associated with 
Atezolizumab and 
Guidelines for 
Management of Adverse 
Events Associated with 
Atezolizumab.)  
Pertuzumab (P)  Continue atezolizumab/  
placebo   PacH.  
Pertuz umab may be 
reintroduced with 
subsequent cycles of 
therapy a if criteria for 
restarting are met.  
(See above in 
Appendix  11 and also 
Section  5, Assessment of 
Safety.)  Pertuzumab may be  
reintroduced with 
subsequent cycles of 
therapy a if criteria for 
restarting are met.  
(See above in 
Appendix  11 and also 
Secti on 5, Assessment 
of Safety.)  
Trastuzumab (H)  Continue Atezolizumab/  
Placebo   PacP.  
Trastuzumab may be 
reintroduced with 
subsequent cycles of 
therapy a if criteria for 
restarting are met.  
(See  above in 
Appendix  11 and also 
Section  5, Assessment of 
Safety.)  If H is permanently 
discontinued, no further 
adjuvant treatment (no 
H, P or atezolizumab/  
placebo).  Patient en ters 
study follow -up. 

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
184/Protocol BO40747 , Version 6 Table 3  Neoadjuvant Cycles 5 8:  Atezolizumab/Placebo and 
Paclitaxel   Trastuzumab   Pertuzumab (PacHP) (cont.)  
Regimen  Unable to Administer  Action  Impact on Adjuvant 
(Post -Operative) 
Treatment   
Paclitaxel (Pac)  b   Per investigator  
discretion, either:  
(1) Proceed to surgery.  
(2) Continue 
atezolizumab/  
placebo   HP. 
Paclitaxel (Pac) may be 
reintroduced with 
subsequent cycles of 
therapy a if criteria for 
restarting are met. (See 
above in Appendix  11 and 
also Section  5, 
Assessment of Safety.)  Per investigator 
discretion:  
Option to make up 
missing chemotherapy 
cycle(s) post -surgery 
followed by 
[CONTACT_70152]/  
placebo   HP adjuvant 
treatment.  
(Per investigator 
discretion:  HP and 
atezolizumab/placebo 
may be added to 
post-surgery 
chemotherapy.)  
If 2 agents in the regimen cannot be administered (i.e., due to toxicity) within 21  days of 
scheduled dosing (i.e., Cycle X , D1    21 days)  
Atezolizumab/  
Placebo   
PacHP  Pac   H  Proceed to surgery.  
Postoperatively, per investigator discretion option to 
make up missing Pac   H  P  atezolizumab/placebo, 
followed by [CONTACT_123594] H   P  atezolizumab/placebo if 
criteria for restarting agent(s) are met.  (See above in 
Appendix  11 and also Section  5, Assessment of 
Safety, and Appendix  12, Risks Associated with 
Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab.)  
If two or more of Pac, H, or P have been permanently 
discontinued then the patient stops all study therapi[INVESTIGATOR_123459].  Pac    P  
H   P  
D1   Day 1; H   trastuzumab; P   pertuzumab; Pac   paclitaxel; 
PacHP   paclitaxel   trastuzumab   pertuzumab.  
a When agent is restarted, the infusions should remain synchronized and aligned with the 
treatment schedule.  
b Patients may continue atezolizumab/placebo   HP during periods of chemotherapy -induced 
myelosuppression (e.g., chemotherapy may be delayed but H/P/atezolizumab/placebo are 
given while blood counts are waiting to recover) but should be carefully monitored for 
complications of neutropenia.  
 

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
185/Protocol BO40747 , Version 6 Table 4  Adjuvant Cycles 9 22:  Atezolizumab/Placebo and 
Trastuzumab   Pertuzumab (HP) or Atezolizumab/Placebo and 
Trastuzumab Emtansine  
Regimen  Unable to Administer within 
21 Days of Scheduled Dosing 
(i.e., Cycle X D1   21 Days)  Action  
Atezolizumab/  
Placebo    HP Atezolizumab/placebo   Continue HP.  
Atezolizumab/placebo may be 
reintroduced with subsequent cycles of 
therapy if criteria for restarting are met. 
(See above in Appendix  11 and also 
Section  5, Assessment of Safety, and 
Appendix  12, Risks Associate d with 
Atezolizumab and Guidelines for 
Management of Adverse Events 
Associated with Atezolizumab.)  
Pertuzumab (P)  Continue atezolizumab/placebo   H. 
Pertuzumab may be reintroduced with 
subsequent cycles of therapy if criteria 
for restarting are met.   (See above in 
Appendix  11 and also Section  5, 
Assessment of Safety.)  
Trastuzumab (H)  Per investigator discretion, may either:  
(1) Hold all agents.  
(2) Continue atezolizumab   P. 
Trastuzumab may be reintroduced with 
subsequent cycles of therapy if criteria 
for restarting are met.   (See above in 
Appendix  11 and also Section  5, 
Assessment of Safety.)  
If/when trastuzumab is permanently 
discontinued, then discontinue all 
components of the regimen and move to 
follow up.  
 

Appendix 11: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
186/Protocol BO40747 , Version 6 Table 4  Adjuvant Cycles 9 22:  Atezolizumab/Placebo and 
Trastuzumab   Pertuzumab (HP) or Atezolizumab/Placebo and 
Trastuzumab Emtansine (cont.)  
Regimen  Unable to Administer within 
21 Days of Scheduled Dosing 
(i.e., Cycle X , D1    21 Days)  Action  
Atezolizumab/ 
Placebo + 
Trastuzumab 
Emtansine  Atezolizumab/placebo  Continue trastuzumab emtansine . 
Atezolizumab/placebo may be 
reintroduced with subsequent cycles of 
therapy if criteria for restarting are met.  
 Trastuzumab emtansine  Hold all agents.  
Trastuzumab emtansine (with 
atezolizumab/placebo) may be 
reintroduced with subsequent cycles of 
therapy if criteria for re -starting are met.   
(See Section  5.1.6 , Section  [IP_ADDRESS] , 
Appendix  14, and Appendix  15) 
If trastuzumab emtansine is 
permanently discontinued for toxicity not 
considered related to the  trastuzumab 
component of the drug, treatment can 
be switched to trastuzumab and 
pertuzumab with atezolizumab/placebo 
to complete a total of 1  year of 
HER2 -targeted therapy.  
D1   Day 1; H   trastuzumab; P   pertuzumab.  
Notes:  All study therapy will be completed following 52 weeks of HER2 -targeted therapy 
(neoadjuvant   adjuvant), regardless of the number of cycles administered.  
Following the distribution of the USM DIL dated 3 February 2021, patients will no longer receive 
atezolizumab or placebo.  
 

 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
187/Protocol BO40747 , Version 6 Appendix  12  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizumab  
When there is a possibility of overlappi[INVESTIGATOR_50685], the attribution of an adverse event to 
particular drug(s) will be based on the investigator’s clinical judgment.  See Section  5.1.[ADDRESS_138999], and in severe cases, immune -mediated 
toxicities may require acute management with top ical corticosteroids, systemic 
corticosteroids, or other immunosuppressive agents.  
The following are general recommendations for management of any other adverse events 
that may occur and are not specifically listed in the following subsections.  
 Patients and family caregivers should receive timely and up -to-date information 
about immunotherapi[INVESTIGATOR_014], their mechanism of action, and the clinical profile of 
possible immune -related adverse events prior to initiating therapy and throughout 
treatment and survival fo llow -up.  There should be a high level of suspi[INVESTIGATOR_123460].  
 In general, atezolizumab therapy should be continued with close monitoring for 
Grade  1 toxicities, with the exception of some neurologic toxicities.  
 Consider holdi ng atezolizumab for most Grade 2 toxicities and resume when 
symptoms and/or laboratory values resolve to Grade 1 or better.  Corticosteroids 
(initial dose of 0.5 1 mg/kg/day of prednisone or equivalent) may be administered.  
 For Grade [ADDRESS_139000] ent (lasting for more than 5 days) events, treat as a 
Grade 3 event.   
 Hold atezolizumab for Grade 3 toxicities and initiate treatment with high -dose 
corticosteroids (1 2 mg/kg/day prednisone or equivalent).  Corticosteroids should 
be tapered over 1 month to 10 mg/day oral prednisone or equivalent, before 
atezolizumab can be resumed.  If symptoms do not improve within 48 to 72 hours 
of high -dose corticosteroid use, other immunosuppressants may be offered for some 
toxicities.  
 In general, Grade 4 toxicities w arrant permanent discontinuation of atezolizumab 
treatment, with the exception of endocrinopathies that are controlled by 
[CONTACT_123595] -replacement therapy.  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
188/Protocol BO40747 , Version 6  The investigator should consider the benefit risk balance a given patient may be 
experiencing prior to  further a dministration of atezolizumab.  Resumption of 
atezolizumab may be considered in patient s who are deriving benefit and ha ve fully 
recovered from the immune -mediated event.  The decision to re -challenge patients 
with atezolizumab should be based on the investigator ’s assessment of the benefits 
and risks and documented by [CONTACT_093].  The Medical Monitor  is available to 
advise as needed . 
PULMONARY EVENTS  
Pulmonary events may present as new or worsening cough, chest pain, fever, dyspnea, 
fatigue, hypoxia, pneumonitis, and pulmonary.  Patients will be assessed for pulmonary 
signs and symptoms throughout the study and will also have computed tomography (CT) 
scans of the chest performed as clinically indicated.  
All pulmonary events should be thoroughl y evaluated for other commonly reported 
etiologies , such as pneumonia or other infection, lymphangitic carcinomatosis, 
pulmonary embolism, heart failure, chronic obstructive pulmonary disease, or pulmonary 
hypertension.  COVID -19 evaluation should be perfo rmed per institutional guidelines 
where relevant.  Management guidelines for pulmonary events are provided in  Table  1. 
Table  1 Management Guidelines for Pulmonary Events, Including 
Pneumonitis  
Event  Management  
Pulmonary 
event, Grade 1   Continue atezolizumab and monitor closely.  
 Re-evaluate on serial imaging.  
 Consider patient referral to pulmonary specialist.  
 For Grade 1 pneumonitis, consider withholding atezolizumab.  
BAL   bronchoscopic alveolar lavage.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be based on the investigator's  benefitrisk assessment  and in alignment with the 
protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 
mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients wit h atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
d In case of pneumonitis, atezolizumab should not be resumed after permanent 
discontinuation.  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
189/Protocol BO40747 , Version 6 Table  1 Management Guidelines for Pulmonary Events, Including 
Pneumonitis  (cont.)  
Event  Management  
Pulmonary 
event, Grade 2   Withhold atezolizumab for up to 12 weeks after event onset. a 
 Refer patient to pulmonary and infectious disease specialists and 
consider bronchoscopy or BAL  with or without transbronchial 
biopsy . 
 Initiate treatment with 1 2 mg/kg/day oral prednisone or equivalent.  
 If event resolves to Grade 1 or better , resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139001] 
the Medical Monitor. c, d 
 For recurrent events, or events with no improvement after 
4872 hours of corticosteroids, treat as a Grade 3 or 4 event.  
Pulmonary 
event, Grade 3 
or 4  Permanently discontinue atezolizumab and contact [CONTACT_76962]. c, d 
 Oral or IV broad -spectrum antibiotics should be administered in 
parallel to the immunosupp ressive treatment.  
 Bronchoscopy or BAL with or without transbronchial biopsy  is 
recommended.  
 Initiate treatment with 1 2 mg/kg/day IV methylprednisolone . 
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
BAL   bronchoscopic alveolar lavage.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be based on the investigator's  benefitrisk assessment  and in ali gnment with the 
protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 
mg/day oral  prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizu mab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
d In case of pneumonitis, atezolizumab should not be resumed after permanent 
discontinuation.   
 
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
190/Protocol BO40747 , Version [ADDRESS_139002] adequate liver function, as manifested by [CONTACT_33496], and liver function will be monitored throughout 
study treatment.  Management guidelines for hepatic events are p rovided in  Table  2. 
Patients with right upper  quadrant abdominal pain and/or unexplained nausea or 
vomiting should have liver function tests (LFTs) performed immediately and reviewed 
before adminis tration of the next dose of study drug.  
For patients with elevated LFTs, concurrent medication, viral hepatitis, and toxic or 
neoplastic etiologies should be considered and addressed, as  appropriate.  
Table  2 Management Guidelines for Hepatic Events  
Event  Management  
Hepatic event, 
Grade 1   Continue atezolizumab.  
 Monitor LFTs until values resolve to within normal limits.  
Hepatic event, 
Grade 2  All events:  
 Monitor LFTs more frequently until return to baseline values.  
Events of   5 days’ duration : 
 Withhold atezolizumab for up to 12 weeks after event onset. a 
 Initiate treatment with 1 2 mg/kg/day oral prednisone or 
equivalent.  
 If event resolves to Grade 1 or  better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139003] the Medical Monitor. c 
LFT   liver function test.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must  be based on the investigator’s  benefitrisk assessment  and in alignment with 
the protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to 
 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizumab  should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical 
Monitor is available to advise as needed . 

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
191/Protocol BO40747 , Version 6 Table  2 Management Guidelines for Hepatic Events  (cont.)   
Event  Management  
Hepatic event, 
Grade 3 or 4   Permanently discontinue atezolizumab and contact [CONTACT_76962].  c 
 Consider patient referral to gastrointestinal specialist for 
evaluation and liver biopsy to establish etiology of hepatic 
injury.  
 Initiate treatment with 1 2 mg/kg/day oral prednisone or 
equivalent.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event reso lves to Grade 1 or better, taper corticosteroids over 
 1 month.  
LFT   liver function test.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must be based o n the investigator's benefitrisk assessment and in alignment with 
the protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to 
 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_74169].  The Medical 
Monitor is available to advise as needed .  
 
GASTROINTESTINAL EVE NTS 
Management guidelines for diarrhea or colitis are provided in  Table  3. 
All events of diarrhea or colitis should be thoroughly evaluated for other more common 
etiologies.  For events of significant duration or magnitude or associated with signs of 
systemic inflammation or acute -phase reactants (e.g.,  increased C -reactive protein, 
platelet count, or bandemia):  Perform sigmoidoscopy (or colonoscopy, if appropriate) 
with colonic biopsy, with three to five specimens for standard paraffin block to check for 
inflammation and lymphocytic infiltrates to confirm colitis diagnosis.  
  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
192/Protocol BO40747 , Version 6 Table  3 Management Guidelines for Gastrointestinal Events (Diarrhea or 
Colitis)  
Event  Management  
Diarrhea or 
colitis, Grade 1   Continue atezolizumab.  
 Initiate symptomatic treatment.  
 Endoscopy is recommended if symptoms persist for  7 days.  
 Monitor closely.  
Diarrhea or 
colitis, Grade 2   Withhold atezolizumab for up to 12 weeks after event onset. a 
 Initiate symptomatic treatment.  
 If strong clinical suspi[INVESTIGATOR_79296] -mediated colitis, start 
empi[INVESTIGATOR_123461].  
 Patient referral to GI specialist is recommended.  
 For recurrent events or events that persist  5 days, initiate treatment 
with 12 mg/kg/day oral prednisone or equivalent.  If the event does 
not improve within 48 hours after initiating corticosteroids, consider 
adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139004] the 
Medical  Monitor. c 
GI   gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
based on the investigator’s benefitrisk assessment  and in alignment with the protocol 
requirements for the duration of treatment and documented by [CONTACT_093].  The 
Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients wit h atezolizumab should be based on the investigator’s benefit risk assessment 
and documented by [CONTACT_093].  The Medical Monitor is available to advise as 
needed . 
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
193/Protocol BO40747 , Version 6 Table  3 Management Guidelines for Gastrointestinal Events (Diarrhea or 
Colitis)  (cont.)  
Event  Management  
Diarrhea or 
colitis, Grade 3   Withhold atezolizumab  for up to 12 weeks after event onset. a 
 Refer patient to GI specialist for evaluation and confirmatory biopsy.  
 Initiate treatment with 12 mg/kg/day IV methylprednisolone or 
equivalent and convert to 12 mg/kg/day oral prednisone or 
equivalent  upon improvement.   If event does not improve within 
48 hours after initiating corticosteroids, consider adding an 
immunosuppressive agent.  
 If event r esolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139005] the 
Medical  Monitor. c 
Diarrhea or 
colitis, Grade 4   Permanently discontinu e atezolizumab and contact [CONTACT_76962]. c 
 Refer patient to GI specialist for evaluation and confirmat ory biopsy.  
 Initiate treatment with 12 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 2 mg/kg/day oral prednisone or 
equivalent  upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better , taper corticosteroids over 
 1 month.  
GI   gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
based on the investigator’s  benefitrisk assessment  and in alignment with the protocol 
requirements for the duration of treatment and documented by [CONTACT_093].  The 
Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, th ey must be tapered over  1 month to  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator’s benefit risk assessment 
and documented by [CONTACT_093].  The Medical Monitor is available to advise as 
needed .  
 
ENDOCRINE EVENTS  
Management guidelines for endocrine events are provided in  Table  4. 

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
194/Protocol BO40747 , Version [ADDRESS_139006] if an endocrinopathy is suspected.  Thyroid -stimulating hormone (TSH) 
and free triiodothyronine and thyroxine levels should be measured to determine whether 
thyroid abnormalities are present.  Pi[INVESTIGATOR_33418] 
(e.g.,  TSH, growth hormone, luteinizing hormone, follicle -stimulating hormone, 
testosterone, prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH 
stimulation test) and magnet ic resonance imaging (MRI) of the brain (with detailed 
pi[INVESTIGATOR_33419]) may help to differentiate primary pi[INVESTIGATOR_123462].  
Table  4 Management Guidelines for Endocrine Events  
Event  Management  
Grade  1 
hypothyroidism   Continue atezolizumab.  
 Initiate treatment with thyroid replacement hormone.  
 Monitor TSH closely . 
Grade  2 
hypothyroidism   Consider withholding atezolizumab.  
 Initiate treatment with thyroid replacement hormone.  
 Monitor TSH closely.  
 Consider patient referral to endocrinologist.  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
MRI   magnetic resonance imaging; TSH   thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be based on the investigator’s  benefitrisk assessment and in alignment with the 
protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 
mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -related event.  The decision to 
re-challenege p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
195/Protocol BO40747 , Version 6 Table  4 Management Guidelines for Endocrine Events  (cont.)  
Event  Management  
Grade  3 and 4 
hypothyroidism   Withhold atezolizumab.  
 Initiate treatment with thyroid replacement hormone.  
 Monitor TSH closely . 
 Refer to an endocrinologist.  
 Admit patient to the hospi[INVESTIGATOR_123463] 
(bradycardia, hypothermia, and altered mental status).  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
 Permanently discontinue atezolizumab and contact [CONTACT_123596] -threatening immune -mediated 
hypothyroidism. c 
Grade  1 
hyperthyroidism  TSH  0.1 mU/L and  0.5 mU/L:  
 Continue atezolizumab.  
 Monitor TSH every 4 weeks.  
 Consider patient referral to endocrinologist.  
TSH  0.1 mU/L:  
 Follow guidelines for Grade  2 hyperthyroidism.  
 Consider patient referral to endocrinologist.  
MRI   magnetic resonance imaging; TSH   thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral prednisone or 
equivalent.  The acceptable length of the extended period of time must  be based on the 
investigator’s  benefitrisk assessment and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune -related event.  The decision to re -challenege p atients with 
atezolizumab should be based on the investigator’s benefit risk assessmen t and documented 
by [CONTACT_093].  The Medical Monitor is available to advise as needed . 
  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
196/Protocol BO40747 , Version 6 Table  4 Management Guidelines for Endocrine Events  (cont.)  
Event  Management  
Grade  2 
hyperthyroidism   Consider withholding atezolizumab.  
 Initiate treatment with anti-thyroid drug such as 
methimazole or carbimazole as needed.  
 Consider patient referral to endocrinologist.  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
Grade  3 and  4 
hyperthyroidism   Withhold atezolizumab.  
 Initiate  treatment with anti -thyroid drug s such as methimazole 
or carbimazole as needed.  
 Refer to an endocrinologist.  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
 Permanently discontinue atezolizumab and contact [CONTACT_123596] -threatening immune -mediated 
hyperthyroidism. c 
MRI   magnetic resonance imaging; TSH   thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroi ds (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be based on the investigator’s  benefitrisk assessment and in alignment with the 
protocol requirements for the duration  of treatment and documented by [CONTACT_1275].  The Medical Mo nitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 
mg/day oral prednisone or equivalent before atezolizumab can be r esumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -related event.  The decision to 
re-challenege p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed .  
  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
197/Protocol BO40747 , Version 6 Table  4 Management Guidelines for Endocrine Events  (cont.)  
Event  Management  
Symptomatic adrenal 
insufficiency, 
Grade  24   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to endocrinologist.  
 Perform appropriate imaging.  
 Initiate treatment with 12 mg/kg/day IV methylprednisolone 
or equivalent and convert to 12 mg/kg/day oral prednisone 
or equivalent  upon improvement . 
 If event resolves to Grade 1 or better and patient is stable on 
replacement therapy, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139007] the Medical Monitor. c 
Hyperglycemia, 
Grade  1 or 2   Continue atezolizumab.  
 Investigate for diabetes.  If patient has Type [ADDRESS_139008] Type  1 
diabetes, treat as per institutional guidelines.  
 Monitor for glucose control.  
Hyperglycemia, 
Grade  3 or 4   Withhold atezolizumab.  
 Initiate treatment with insulin.  
 Evaluate for diabetic ketoacidosis and manage as per 
institutional guidelines.  
 Monitor for glucose control.  
 Resume atezolizumab when symptoms resolve and glucose 
levels are stable.  
MRI   magnetic resonance imaging; TSH   thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be the investigator’s benefitrisk assessment and in alignment wi th the protocol 
requirements for the duration of treatment and documented by [CONTACT_093].  The 
Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 
mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed .  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
198/Protocol BO40747 , Version 6 Table  4 Management Guidelines for Endocrine Events  (cont.)  
Event  Management  
Hypophysitis 
(pan-hypopi[INVESTIGATOR_297]), 
Grade 2 or 3   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to endocrinologist.  
 Perform brain MRI (pi[INVESTIGATOR_33421]).  
 Initiate treatment with 12 mg/kg/day IV methylprednisolone or 
equivalent and convert to 12 mg/kg/day oral prednisone or 
equivalent  upon improvement.  
 Initiate hormone replacement if clinically indicated.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139009] the Medical  Monitor. c 
 For recurrent hypophysitis, treat as a Grade 4 event.  
Hypophysitis 
(pan-hypopi[INVESTIGATOR_297]), 
Grade 4   Permanently discont inue atezolizumab and contact [CONTACT_76962]. c 
 Refer patient to endocrinologist.  
 Perform brain MRI (pi[INVESTIGATOR_33421]).  
 Initiate treatment with 12 mg/kg/day IV methylprednisolone or 
equivalent and convert to 12 mg/kg/day oral prednisone or 
equivalent  upon improvement.  
 Initiate hormone replacement if clinically indicated.  
MRI   magnetic resonance imaging; TSH   thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be based on the investigator’s benefitrisk assessment and in alignment with the 
protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 
mg/day o ral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezol izumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed .  
 
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
199/Protocol BO40747 , Version [ADDRESS_139010] should evaluate visual complaints (e.g., uveitis, retinal events).  
Management guidelines for ocular events are provided in  Table  5. 
Table  5 Management Guidelines for Ocular Events  
Event  Management  
Ocular event, 
Grade 1   Continue atezolizumab.  
 Patient referral to ophthalmologist is strongly recommended.  
 Initiate treatment with topi[INVESTIGATOR_33422].  
 If symptoms persist, treat as a Grade 2 event.  
Ocular event, 
Grade 2   Withhold atezolizumab for up to 12 weeks after event onset . a 
 Patient referral to ophthalmologist is strongly recommended.  
 Initiate treatment with topi[INVESTIGATOR_33422].  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139011] 
the Medical  Monitor. c 
Ocular event, 
Grade 3 or 4   Permanently discontinue atezolizumab and contact 
[CONTACT_123597]. c 
 Refer patient to ophthalmologist.  
 Initiate treatment with 1 2 mg/kg/day oral prednisone or equivalent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
based on the investigator’s  benefitrisk assessment  and in alignment with the protocol 
requirements for the duration of treatment and documented by [CONTACT_941] i nvestigator.  The 
Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to 
 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator’s benefit risk 
assessment and documented by [CONTACT_093].  The Medical Monitor is available to 
advise as needed .  
 

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
200/Protocol BO40747 , Version [ADDRESS_139012] IAC EVENTS  
Management guidelines for cardiac events are provided in  Table  6. 
IMMUNE -MEDIATED  MYOCARDITIS  
Immune -mediated myocarditis should be suspected in any patient presenting with signs 
or symptoms suggestive of myocarditis, including but not limited to laboratory (e.g., B -
type natriuretic peptide) or cardiac  imaging abnormalities , dyspnea, chest pain, 
palpi[INVESTIGATOR_814], fati gue, decreased exercise tolerance, or syncope.  Myocarditis may also 
be a clinical manifestation of myositis or associated with pericarditis (see section on 
pericardial disorders below) and should be managed accordingly.  Immune -mediated 
myocarditis needs to be distinguished from myocarditis resulting from infection 
(commonly viral [e.g., in a patient who reports a recent history of gastrointestinal 
illness ]), ischemic events, underlying arrhythmias, exacerbation of preexisting cardiac 
conditions, or progre ssion of malignancy.  
All patients with possible myocarditis should be urgently evaluated by [CONTACT_33500], an ECG, a chest X -ray, an echocardiogram, and a cardiac MRI as 
appropriate per institutional guidelines.  A cardiologist shoul d be consulted.  An 
endomyocardial biopsy may be considered to enable a definitive diagnosis and 
appropriate treatment, if clinically indicated.  
Patients with signs and symptoms of myocarditis, in the absence of an identified 
alternate etiology, should be treated according to the guidelines in  Table  6. 
IMMUNE -MEDIATED PERI CARDIAL DISORDERS  
Immune -mediated pericarditis should be suspected in any patient presenting with chest 
pain and may be associated with immune -mediated myoca rditis (see section on 
myocarditis above).  
Immune -mediated pericardial effusion and cardiac tamponade should be suspected in 
any patient presenting with chest pain associated with dyspnea or hemodynamic 
instability.  
Patients should be evaluated for other c auses of pericardial disorders such as infection 
(commonly viral), cancer -related (metastatic disease or chest radiotherapy), 
cardiac  injuryrelated (post myocardial infarction or iatrogenic), and autoimmune 
disorders, and should be managed accordingly.  
All patients with suspected pericardial disorders should be urgently evaluated by 
[CONTACT_123598], chest X -ray, transthoracic echocardiogram, and cardiac MRI as 
appropriate per institutional guidelines.  A cardiologist should be consulted.  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
201/Protocol BO40747 , Version [ADDRESS_139013] a detailed cardiac evaluation to determine the etiology 
and manage accordingly.  
Table  6 Management Guidelines for Immune -Mediated  Cardiac Events  
Event  Management  
Immune -mediated 
myocarditis, 
Grade s 24 
 
Immune -mediated 
pericardial disorders, 
Grades  24  Permanently discontinue atezolizumab and contact [CONTACT_76962].  
 Refer patient to cardiologist.  
 Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, VAD , or 
pericardiocentesis  as appropriate.  
 Initiate treatment with 1 2 mg/kg/day IV methylp rednisolone or 
equivalent and convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or b etter, taper corticosteroids over  
 1 month.  
ECMO   extracorporeal membrane oxygenation; VAD   ventricular assist device . 
 
INFUSION -RELATED REA CTIONS  AND CYTOKINE  RELEASE SYNDROME  
No premedication is indicated for the administration of Cycle 1 of atezolizumab.  
However, patients who experience an infusion -related reaction (IRR) or cytokine  release 
syndrome (CRS) with atezolizumab may receive premedication with antihistamines , 
antipy retic  medications , and/or analgesics (e.g., acetaminophen) for subsequent 
infusions.  Metamizole (dipyrone) is prohibited in treating atezolizumab -associated IRRs 
because of its potential for causing agranulocytosis.  
IRRs are known to occur with the admini stration of monoclonal antibodies and have 
been reported with atezolizumab.  These reactions, which are thought to be due to 
release of cytokines and/or other chemical mediators, occur within 24  hours of 
atezolizumab administration and are generally mild t o moderate in severity.  
CRS is defined as a supraphysiologic response following administration of any immune 
therapy that results in activation or engagement of endogenous or infused T cells and/or 

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
202/Protocol BO40747 , Version 6 other immune effector cells.  Symptoms can be progressive,  always include fever at the 
onset, and may include hypotension, capi[INVESTIGATOR_7946] (hypoxia), and end -organ dysfunction 
(Riegler  et al. 2019).  CRS has been well documented with chimeric antigen receptor 
T-cell therapi[INVESTIGATOR_70074] T -cell engager antibody  therapi[INVESTIGATOR_123464] -1 or PD -L1, including atezolizumab  
(Rotz  et al. 2017; Adashek  and Feldman 2019) . 
There may be significant overlap in signs and symptoms of IRRs and CRS, and in 
recognition of the cha llenges in clinically distinguishing between the two, consolidated 
guidelines for medical management of IRRs and CRS during Cycle 1 are provided 
in Table  7. 
Severe COVID -19 appears to be associated with a CRS involving the inflammatory 
cytokines interleukin (IL) -6, IL-10, IL -2, and IFN - (Merad and Martin 2020 ).  If a patient 
develops suspected CRS during the study, a differentia l diagnosis should include 
COVID -19, which should be confirmed or refuted through assessment of exposure 
history, appropriate laboratory testing, and clinical or radiologic evaluations per 
investigator ’s judgment.  If a diagnosis of COVID -19 is confirmed, the disease should be 
managed as per local or institutional guidelines.  
Table  7 Management Guidelines for Infusion -Related Reactions  and 
Cytokine  Release Syndrome  
Event  Management  
Grade 1 a 
Fever b with or 
without 
constitutional 
symptoms    Immediately interrupt infusion.  
 Upon symptom resolution, wait for 30 minutes and then restart 
infusion at half the rate being given at the time of event onset.  
 If the infusion is tolerated at the reduced rate for 30 minutes , the 
infusion rate may be increased to the original rate.  
 If symptoms recur, discontinue infusion of this dose.  
 Administer symptomatic treatment, c including maintenance of 
IV fluids for hydration.  
 In case of rapid decline or prolonged CRS (  2 days) or in patients 
with significant symptoms and/or comorbidities, consider 
managing as per Grade 2.  
 For subsequent infusions, consider administration of oral 
premedication with antihistamines, antipyretic  medications , and/or 
analgesics, and monitor clos ely for IRRs and/or CRS.  
  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
203/Protocol BO40747 , Version 6 Table  7 Management Guidelines for Infusion -Related Reactions and 
Cytokine Release Syndrome  (cont.)  
Event  Management  
Grade 2 a Fever b 
with hypotension 
not requiring 
vasopressors  
and/or  
Hypoxia requiring 
low-flow oxygen d 
by [CONTACT_123599] -by  Immediately i nterrupt infusion.  
 Upon symptom resolution, wait for 30  minutes and then restart 
infusion at half the rate being given at the time of event onset.  
 If symptoms recur, discontinue infusion of this dose.  
 Administer symptomatic treatment. c 
 For hypotension, administer IV fluid bolus as needed.  
 Upon symptom resolution, wait for 30  minutes and then restart 
infusion at half the rate being given at the time of event onset.  
 If symptoms recur, discontinue infusion of this d ose. 
 Administer symptomatic treatment. c 
 For hypotension, administer IV fluid bolus as needed.  
 Monitor cardiopulmonary and other organ function closely (in the 
ICU, if appropriate).  Administer IV fluids as clinically indicated, 
and manage constitutional symptoms and organ toxicities as per 
institutional practice.  
 Consider anti -cytokine therapy.  
 Consider hospi[INVESTIGATOR_70076].  
If no improvement within 24 hours, manage as per Grade 3, that 
is, hospi[INVESTIGATOR_28068] (monitoring  in the ICU is recommended), 
permanently discontinue atezolizumab, and contact [CONTACT_76962] . 
 If symptoms resolve to  Grade 1 or better for 3 consecutive days, 
the next dose of atezolizumab may be administered.  
 For subsequent infusions, consider admin istration of oral 
premedication with antihistamines, antipyretic  medications , and/or 
analgesics and monitor closely for IRRs and/or CRS.  
 If symptoms do not resolve to Grade [ADDRESS_139014] the Medical Monitor.  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
204/Protocol BO40747 , Version 6 Table  7 Management Guidelines for Infusion -Related Reactions and 
Cytokine  Release Syndrome  (cont.)  
Event  Management  
Grade 3a 
Fever b with 
hypotension 
requiring a 
vasopressor (with 
or without 
vasopressin)  
and/or  
Hypoxia requiring 
high-flow oxygen d 
by [CONTACT_21294], 
face mask, 
non-rebreather 
mask, or Venturi 
mask   Permanently discontinue atezolizumab and contact [CONTACT_76962] . e 
 Administer symptomatic treatment . c 
 For hypotension, administer IV fluid bolus and vasopressor as 
needed.  
 Monitor cardiopulmonary and other organ function closely; 
monitoring in the ICU is recommended.  Administer IV fluids as 
clinically indicated, and manage constitutional symptoms and 
organ toxicities as per institutional practice.  
 Rule out other inflammatory condit ions that can mimic CRS 
(e.g.,  sepsis).  If no improvement within 24 hours, initiate workup 
and assess for signs and symptoms of HLH or MAS as described 
in this appendix.  
 Administer IV corticosteroids (e.g.,  methylprednisolone 
2 mg/kg/day or dexamethasone 10 mg every 6 hours).  
 Consider anti -cytok ine therapy.  
 Hospi[INVESTIGATOR_70078].  If no 
improvement within 24 hours, manage as per Grade  4, 
that is, admit patient to ICU and initiate hemodynamic monitoring, 
mechanical ventil ation, and/or IV fluids and vasopressors as 
needed; for patients who are refractory to anti -cytokine therapy, 
experimental treatments may be considered at the discretion of the 
investigator and in consultation with the Medical Monitor . 
Grade 4a  
Fever b with 
hypotension 
requiring multiple 
vasopressors 
(excluding 
vasopressin)  
and/or  
Hypoxia requiring 
oxygen by 
[CONTACT_123600] 
(e.g.,  CPAP, 
BiPAP, intubation 
and mechanical 
ventilation)   Permanently discontinue atezolizumab and contact [CONTACT_76962] . e 
 Administer symptomatic treatment . c 
 Admit patient to ICU and initiate hemodynamic monitoring, 
mechanical ventilation, and/or IV fluids and vasopressors as 
needed.  Monitor other organ function closely.  Manage 
constitutional symptoms and organ toxicities  as per institutional 
practice.  
 Rule out other inflammatory conditions that can mimic CRS 
(e.g.,  sepsis).  If no improvement within 24 hours, initiate workup 
and assess for signs and symptoms of HLH or MAS as described 
in this appendix.  
 Administer IV corti costeroids (e.g.,  methylprednisolone 
2 mg/kg/day or dexamethasone 10 mg every 6 hours).  
 Consider anti -cytokine therapy.  For patients who are refractory to 
anti-cytokine therapy, experimental treatments f may be 
considered at the discretion of the investig ator and in consultation 
with the Medical Monitor.  
 Hospi[INVESTIGATOR_70078].  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
205/Protocol BO40747 , Version 6 Table  7 Management Guidelines for Infusion -Related Reactions and 
Cytokine Release Syndrome  (cont.)   
ASTCT   American Society for Transplantation and Cellular Therapy; BiPAP   bi-level 
positive airway pressure; CAR   chimeric antigen receptor; CPAP   continuous positive 
airway pressure; CRS   cytokine -release syndrome; CTCAE   Common Terminology  
Criteria for Adverse Events; eCRF   electronic Case R eport Form; HLH   hemophagocytic 
lymphohistiocytosis; ICU   intensive care unit; IRR   infusion -related reaction  ; 
MAS   macrophage activation syndrome; NCCN   National Cancer Comprehensive 
Network; NCI   National Cancer Institute.  
Note:  These management guidelines have been adapted from the NCCN guidelines for 
the management of CAR T -cellrelated toxicities (Version 2.2019).  
a Grading system for management guidelines is based on ASTCT consensus grading for 
CRS.  NCI CTCAE v5.0 should be used when reporting severity of IRRs, CRS, or 
organ toxicities associated with CRS on the Adverse Event eCRF.  Organ toxicities 
associated with CRS should not influence overall CRS grading.  
b Fever is defined as temperature  38C not attributable to any other cause .  In patients 
who develop CRS and then receive antipyretic  medications , anti -cytokine, or 
corticosteroid therapy, fever is no longer required when subsequently determining 
event severity (grade).  In  this case, the grade is driven by [CONTACT_123601]/or hypoxia.  
c Symptomatic treatment may include oral or IV antihistamines, antipyretic  medications , 
analgesics, bronchodilators, and/or oxygen.  For bronchospasm, urticaria, or dyspnea, 
additional treatment may be administered as per instit utional practice.  
d Low flow is defined as oxygen delivered at  6 L/min, and high flow is defined as 
oxygen delivered at  6 L/min.  
e Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immun e-mediated event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented  by [CONTACT_093].  The Medical Monitor is 
available to advise as needed .  For subsequent infusions, administer oral premedication 
with antihistamines, antipyretic  medications , and/or analgesics, and monitor closely for 
IRRs and/or CRS.  Premedication with corticosteroids and extending the infusion time 
may also be considered after assessing  the benefit risk ratio.  
f Refer to Riegler et al. (2019).  
 
PANCREATIC EVENTS  
The differential diagnosis of acute abdominal pain should include pancreatitis.  
Appropriate workup should include an evaluation for ductal obstruction, as well as serum 
amylase and lipase tests.  Management guidelines for pancreatic events, including 
pancreatitis, are provided in  Table  8. 

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
206/Protocol BO40747 , Version 6 Table  8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis  
Event  Management  
Amylase and/or lipase 
elevatio n, Grade 2  Amylase and/or lipase  1.52.0   ULN: 
 Continue atezolizumab.  
 Monitor amylase and lipase weekly.  
 For prolonged elevation (e.g.,  3 weeks), consider treatment 
with 10 mg/day oral prednisone or equivalent.  
Asymptomatic with amylase and/or lipase  2.05.0   ULN: 
 Treat as a Grade 3 event.  
Amylase and/or lipase 
elevation, Grade 3 or 4   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to GI specialist.  
 Monitor amylase and lipase every other day.  
 If no improvement, consider treatment with 1 2 mg/kg/day 
oral prednisone or equivalent.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139015] the Medical Monitor. c 
 For recurrent events, p ermanently discontinue atezolizumab 
and contact [CONTACT_1689]. c 
GI   gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral prednisone or 
equivalent.  The acceptable length of the extended period of time must be based on t he 
investigator’s  benefitrisk assessment and in ali gnment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizu mab should be based on the investigator’s benefit risk assessment 
and documented by [CONTACT_093].  The Medical Monitor is available to advise as 
needed .  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
207/Protocol BO40747 , Version 6 Table  8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis  (cont.)  
Event  Management  
Immune -mediated 
pancreatitis, Grade 2 or 3   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to GI specialist.  
 Initiate treatment with 1 2 mg/kg/day IV methylprednisolone 
or equivalent and convert to 1 2 mg/kg/day oral  prednisone 
or equivalent upon improvement.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139016] the Medical Monitor. c 
 For recurrent events, p ermanently discontinue atezolizumab 
and contact [CONTACT_1689]. c 
Immune -mediated 
pancreatitis, Grade 4   Permanently discontinue atezolizumab and contact [CONTACT_76962]. c 
 Refer patient to GI specialist.  
 Initiate treatment with 1 2 mg/kg/day IV methylprednisolone 
or equivalent and convert to 1 2 mg/kg/day oral prednisone 
or equivalent upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive 
agent.  
 If event resolves to Grade 1 or better , taper corticosteroids 
over  1 month.  
GI   gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral prednisone or 
equivalent.  The acceptable length of the extended period of time must be based the 
investigator’s benefitrisk assessment and in alignm ent with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizum ab should be based on the investigator’s benefit risk assessment 
and documented by [CONTACT_093].  The Medical Monitor is available to advise as 
needed .  
 
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
208/Protocol BO40747 , Version [ADDRESS_139017] should evaluate persistent 
and/or severe rash or pruritus.  Although uncommon, cases of severe cutaneous 
adverse reactions such as Stevens -Johnson syndrome and toxic epi[INVESTIGATOR_123465].  A biopsy should be considered unless 
contraindicated.  Management guidelines for dermatolo gic events are provided 
in Table  9. 
Table  9 Management Guidelines for Derm atologic Events  
Event  Management  
Dermatologic 
event, Grade 1   Continue atezolizumab.  
 Consider treatment with topi[INVESTIGATOR_33423]/or other 
symptomatic therapy (e.g., antihistamines).  
Dermatologic 
event, Grade 2   Continue atezolizumab.  
 Consider patient referral to dermatologist  for evaluation and, 
if indicated, biopsy . 
 Initiate treatment with topi[INVESTIGATOR_33424].  
 Consider treatment with higher -potency topi[INVESTIGATOR_33425].  
 If unresponsive to topi[INVESTIGATOR_11930], consider oral 
prednisone 0.5  mg/kg/day.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day 
oral prednisone or equivalent .  The acceptable length of the extended period of time 
must be based on the investigator’s  benefitrisk assessment and in alignment with 
the protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to 
 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are  deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical 
Monitor is av ailable to advise as needed . 
 
  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
209/Protocol BO40747 , Version 6 Table  9 Management Guidelines for Dermatologic Events  (cont.)  
Event  Management  
Dermatologic 
event, Grade 3   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to dermatologist for evaluation and, if indicated, 
biopsy.  
 Initiate treatment with 10 mg/day oral prednisone or equivalent, 
increasing dose to 1 2 mg/kg/day if event does not improve 
within 4872 hours.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve t o Grade [ADDRESS_139018] the Medical Monitor. c 
Dermatologic 
event, Grade 4   Permanently discontinue atezolizumab and contact [CONTACT_76962]. c 
Stevens -Johnson 
syndrome or 
toxic epi[INVESTIGATOR_7387] 
(any grade)  Additional guidance for Stevens -Johnson syndrome or toxic 
epi[INVESTIGATOR_194]:  
 Withhold atezolizumab for suspected Stevens -Johnson 
syndrome or toxic epi[INVESTIGATOR_194].  
 Confirm diagnosis by [CONTACT_123602] a specialist 
(dermatologist, ophthalmologist, or urologist as relevant) for 
evaluation and, if indicated, biopsy.  
 Follow the applicable treatment and management guidelines 
above.  
 If Stevens -Johnson syndrome or toxic epi[INVESTIGATOR_123466], permane ntly discontinue atezolizumab.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must be based on the investigator’s  benefitrisk assessment and in alignment with 
the protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to 
 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical 
Monitor is available to advise as needed .   
NEUROLOGIC DISORDERS  
Patients may present with signs and symptoms of sensory and/or motor neuropathy.  
Diagnostic workup is essential for an accurate characterization to differentiate between 
alternative etiologies.  Management guidelines for neurologic disorders are provided in  
Table  10, with specific guideli nes for myelitis provided in  Table  11. 

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
210/Protocol BO40747 , Version 6 Table  10 Management Guidelines for  Neurologic Disorders  
Event  Management  
Immune -mediated 
neuropathy, 
Grade  1  Continue atezolizumab.  
 Investigate etiology.  
 Any cranial nerve disorder (including facial paresis) should be 
managed as per Grade 2 management guidelines below.  
Immune -mediated 
neuropathy, 
including facial 
paresis, Grade  2   Withhold atezolizumab for up to 12 weeks after event onset . a 
 Investigate etiology  and refer patient to neurologist . 
 Initiate treatment as per institutional guidelines.  
 For general immune -mediated neuropathy:  
– If event resolves to Grade 1 or better, resume 
atezolizumab. b 
– If event does not resolve to Grade [ADDRESS_139019]  the Medical Monitor. c 
 For facial paresis:  
– If event resolves full y, resume atezolizumab . b 
– If event does not resolve fully while withholding 
atezolizumab, permanently discontinue atezolizumab and 
contact [CONTACT_1689].  c 
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must 
be based on the investigator’s  benefitrisk assessment and in ali gnment with the 
protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to 
 10 mg/day oral  prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizu mab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor 
is available to advise as needed . 
 
  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
211/Protocol BO40747 , Version 6 Table  10 Management Guidelines for Neurologic Disorders  (cont.)  
Event  Management  
Immune -mediated 
neuropathy, 
including facial 
paresis, 
Grade  3 or 4  Permanently discontinue atezolizumab and contact [CONTACT_76962]. c  
 Refer patient to neurologist.  
 Initiate treatment as per institutional guidelines.  
Myasthenia gravis 
and Guillain -Barré 
syndrome 
(any grade)   Permanently discontinue atezolizumab and contact [CONTACT_76962].  
 Refer patient to neurologist.  
 Initiate treatment as per institutional guidelines.  
 Consider initiation of 1 2 mg/kg/day oral or IV prednisone or 
equivalent.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must  
be based on the investigator’s  benefitrisk assessment and in alignment with the 
protocol requirements for the duration of treatment and documented by [CONTACT_1275].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to 
 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor 
is available to advise as needed .  
 
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
212/Protocol BO40747 , Version 6 Table  11 Management Guidelines for Immune -Mediated Myelitis  
Event  Management  
Immune -mediated myelitis, 
Grade  1  Continue atezolizumab unless symptoms worsen or do not 
improve.  
 Investigate etiology and refer patient to a neurologist.  
Immune -mediated myelitis, 
Grade  2  Permanently discontinue atezolizumab and contact [CONTACT_76962].  
 Investigate etiology and refer patient to a neurologist.  
 Rule out infection.  
 Initiate treatment with corticosteroids equivalent to 
1-2 mg/kg/day oral prednisone.  
Immune -mediated myelitis, 
Grade  3 or 4   Permanently discontinue atezolizumab and contact [CONTACT_76962].  
 Refer patient to a neurologist.  
 Initiate treatment as per institutional guidelines.  
 
IMMUNE -MEDIATED  MENINGOENCEPHALITIS  
Immune -mediated meningoencephalitis should be suspected in any patient presenting 
with signs or symptoms suggestive of meningitis or encephalitis, including but not limited 
to headache, neck pain, confusion, seizure, motor or sensory d ysfunction, and altered or 
depressed level of consciousness.  Encephalopathy from metabolic or electrolyte 
imbalances needs to be distinguished from potential meningoencephalitis resulting from 
infection (bacterial, viral, or fungal) or progression of mali gnancy, or secondary to a 
paraneoplastic process.  
All patients being considered for meningoencephalitis should be urgently evaluated with 
a CT scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, or 
edema.  If deemed safe by [CONTACT_123603], a lumbar puncture should be 
performed and a neurologist should be consulted.  
Patients with signs and symptoms of meningoencephalitis, in the absence of an 
identified alternate etiology, should be treated according to the guidelines in  Table  12. 
  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
213/Protocol BO40747 , Version 6 Table  12 Management Guidelines for Immune -Mediated  
Meningoence phalitis  
Event  Management  
Immune -mediated 
meningoencephalitis, 
all grades   Permanently discontinue atezolizumab and contact [CONTACT_76962].  
 Refer patient to neurologist.  
 Initiate treatment with 1 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better , taper corticosteroids o ver 
 [ADDRESS_139020] adequate renal function .  Renal function, including serum 
creatinine, should be monitored throughout study treatment.  Patients with abnormal 
renal function should be evaluated and treated for other more common etiologies 
(including prerenal and postrenal causes, and concomitant medicat ions such as 
non-steroidal anti -inflammatory drugs).  Refer the patient to a renal specialist if clinically 
indicated.  A renal biopsy may be required to enable a definitive diagnosis and 
appropriate treatment.  
Patients with signs and symptoms of nephritis , in the absence of an identified alternate 
etiology, should be treated according to the guidelines in  Table  13. 
  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
214/Protocol BO40747 , Version 6 Table  13 Management Guidelines for Renal Events  
Event  Management  
Renal event, 
Grade  1  Continue atezolizumab.  
 Monitor kidney function, including creatinine  and urine protein , 
closely until values resolve to within normal limits or to baseline 
values.  
Renal event, 
Grade  2  Withhold atezolizumab for up to 12 weeks after event onset. a 
 Refer patient to renal specialist.  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/day oral prednisone.  
 If event  resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139021] the Medical Monitor. c 
Renal event, 
Grade  3 or 4   Permanently discontinue  atezolizumab and contact [CONTACT_76962]. c 
 Refer patient to renal specialist and consider renal biopsy.  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/day oral prednisone.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for cortico steroids (if initiated) to be reduced to the equivalent 
of  10 mg/day oral prednisone.  The acceptable length of the extended period of 
time must be based on the investigator’s  benefitrisk assessment and in alignment 
with the protocol requirements for the duration of treatment and documented by 
[CONTACT_093].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to the 
equivalent of  10 mg/day oral prednisone before atezo lizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated  event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigato r’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical 
Monitor is available to advise as needed .  
 
IMMUNE -MEDIATED  MYOSITIS  
Myositis or inflammatory myopathies are a group of disorders sharing the common 
feature of inflammatory muscle injury; dermatomyositis and polymyositis are among the 
most common disorders.  Initial diagnosis is based on clinical (muscle weakness, muscle 
pain, skin rash in dermatomyositis), biochemical (serum creatine kinase increase), and 
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
215/Protocol BO40747 , Version 6 imaging (electromyo graphy/MRI) features, and is confirmed with a muscle biopsy.   
Patients with possible myositis should be referred to a rheumatologist or neurologist.  
Patients with possible myositis should be monitored for signs of myocarditis.  
Patients with signs and symp toms of myositis, in the absence of an identified alternate 
etiology, should be treated according to the guidelines in  Table  14. 
Table  14 Management Guidelines for Immune -Mediated  Myositis  
Event  Management  
Immune -mediated  
myositis, Grade  1  Continue atezolizumab.  
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
Immune -mediated  
myositis, Grade  2  Withhold atezolizumab for up to [ADDRESS_139022] the Medical Monitor.  
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
 Consider treatment with corticosteroids equivalent to 
12 mg/kg/day IV methylprednisolone and convert to 
12 mg/kg/day oral prednisone or equivalent upon 
improvement.  
 If corticosteroids are initiated and event does not improve 
within 48  hours after initiating corticosteroids, consider adding 
an immunosuppressive agent.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139023] the Medical Monitor. c 
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent 
of  10 mg/day oral prednisone.  The acceptable length of the extended period of 
time must be based on the investigator’s  benefitrisk assessment  and in  alignment 
with the protocol requirements for the duration of treatment and documented by 
[CONTACT_093].  The Medical Monitor is available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to the 
equivalent of  10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated  event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical 
Monitor is available to advise as needed . 

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
216/Protocol BO40747 , Version 6 Table  14 Management Guidelines for Immune -Mediated Myositis  (cont.)  
Event  Management  
Immune -mediated  
myositis, Grade  3  Withhold atezolizumab for up to [ADDRESS_139024] the Medical Monitor.  
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
 Respi[INVESTIGATOR_70079].  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/day IV methylprednisolone, or higher -dose bolus if 
patient is severely compromised (e.g., cardiac or respi[INVESTIGATOR_037], dysphagia, or weakness that severely limits 
mobility); convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive 
agent.  
 If event resolves t o Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_139025] the Medical Monitor. c 
 For recurrent events, treat as a Grade [ADDRESS_139026] the Medical Monitor. c 
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent 
of  10 mg/day oral prednisone.  The acceptable length of the extended period of 
time must be based on the investigator’s  benefitrisk assessment  by [CONTACT_123604].  The Medical Monitor is available 
to advise as needed . 
b If corticosteroids have been initiated, they must be tapered ove r  1 month to the 
equivalent of  10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated  event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical 
Monitor is available to advise as needed . 
 
  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
217/Protocol BO40747 , Version 6 Table  14 Management Guidelines for Immune -Mediated Myositis (cont.)  
Event  Management  
Immune -mediated  
myositis, Grade 4   Permanently discontinue atezolizumab and contact [CONTACT_76962]. c 
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
 Respi[INVESTIGATOR_70079].  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/day IV methylprednisolone, or higher -dose bolus if 
patient is severely compromised (e.g., cardiac or respi[INVESTIGATOR_037], dysphagia, or weakness that severel y limits 
mobility); convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive 
agent.  
 If event resolves to Grade 1 or better, tap er corticosteroids 
over  1 month.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent 
of  10 mg/day oral prednisone.  The acceptable length of the extended period of 
time must be based on the investigator’s  benefitrisk assessment  by [CONTACT_123605].  The Medical Monitor is available 
to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to the 
equivalent of  10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of ate zolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune -mediated  event.  The decision to 
re-challenge p atients with atezolizumab should be based on the investigator’s 
benefitrisk assessment and documented by [CONTACT_093].  The Medical 
Monitor is available to advise as needed . 
 
HEMOPHAGOCYTIC LYMPH OHISTIOCYTOSIS AND M ACROPHAGE 
ACTIVATION SYNDROME  
Immune -mediated reactions may involve any organ system and may lead to 
hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome 
(MAS).  
Clinical and laboratory features of severe CRS overlap with HLH, and HLH should be 
considered when CRS presentation is atypi[INVESTIGATOR_123467].  
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
218/Protocol BO40747 , Version 6 Patients with suspected HLH sho uld be diagnosed according to published criteria by 
[CONTACT_70195] (2014).  A patient should be classified as having HLH if five of the 
following eight criteria are met:  
 Fever  38.5°C  
 Splenomegaly  
 Peripheral blood cytopenia consisting of at least tw o of the following:  
– Hemoglobin  90 g/L (9  g/dL)  
– Platelet count  100   109/L (100,000/ L) 
– ANC  1.0   109/L (1000/L) 
 Fasting triglycerides  2.992 mmol/L (265  mg/dL)  and/or  fibrinogen  1.5 g/L 
(150 mg/dL)  
 Hemophagocytosis in bone marrow, spleen, lymph node, or liver  
 Low or absent natural killer cell activity  
 Ferritin  500 mg/L (500  ng/mL)  
 Soluble IL -2 receptor (soluble CD25) elevated  [ADDRESS_139027] deviations above age -
adjusted laboratory -specific norms  
 
Patients with suspected MAS should be diagnosed ac cording to published criteria for 
systemic juvenile idiopathic arthritis by [CONTACT_70196]. (2016).  A febrile patient should be 
classified as having MAS if the following criteria are met:  
 Ferritin  684 mg/L (684  ng/mL)  
 At least two of the following:  
– Platelet count  181   109/L (181,000/ L) 
– AST  48 U/L 
– Triglycerides  1.761 mmol/L (156  mg/dL)  
– Fibrinogen  3.6 g/L (360  mg/dL)  
 
Patients with suspected HLH or MAS should be treated according to the guidelines 
in Table  15. 
  

Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
219/Protocol BO40747 , Version 6 Table  15 Management Guidelines for Suspected Hemophagocytic 
Lymphohistiocytosis or Macrophage Activation Syndrome  
Event  Management  
Suspected HLH 
or MAS   Permanently discontinue atezolizumab and contact [CONTACT_76962].  
 Consider patient referral to hematologist.  
 Initiate supportive care, including intensive care monitoring if 
indicated per institutional guidelines.  
 Consider initiation of IV corticosteroids , an immunosuppressive 
agent , and/or anti -cytokine therapy . 
 If event does not respond to treatment within [ADDRESS_139028] the 
Medical  Monitor and initiate treatment as appropriate according to 
published guidelines  (La Rosée 2015; Schram  and Berliner  2015; 
La Rosée  et al. 2019) . 
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
HLH   hemophagocytic lymphohistiocytosis; MAS   macrophage activation syndrome.  
 
REFERENCES  
Adashek ML, Feldman M. Cytokine release syndrome resulting from anti programmed 
death -1 antibody: raising awareness among community oncologist. J Oncol 
Practice 2019;15:502 4. 
La Rosée P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology 
Am Soc Hem atol Educ Protram 2015;1:190 6. 
La Rosée P, Horne A, Hines M, et al. Recommendations for the management of 
hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465 77. 
McClain KL, Eckstein O. Clinical features and diagnosis of hemophagocytic 
lymph ohistiocytosis. Up to Date [resource on the Internet]. 2014 [updated 
29 October 2018; cited: 17 May 2019]. Available from: 
https://www.uptodate.com/contents/clinical -features -and-diagnosis -of-
hemophagocytic -lymphohistiocytosis.  
Merad M, Martin JC. Patholog ical inflammation in patients with COVID -19: a key role for 
monocytes and macrophages. Nat Rev Immunol 2020;20:355 62. 
Ravelli A, Minoia F, Davi S, et al. 2016 classification criteria for macrophage activation 
syndrome complicating systemic juvenile idiopa thic arthritis: a European League 
Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology 
International Trials Organisation Collaborative Initiative. Ann Rheum Dis 
2016;75:481 9. 
Appendix 12: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated w ith Atezolizumab  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
220/Protocol BO40747 , Version 6 Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of 
cytokine release syndrome after chimeric antigen receptor T -cell therapy. Ther Clin 
Risk Manag 2019;15:323 35. 
Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient 
receiving PD -1-directed therapy. Pediat r Blood Cancer 2017;64:e26642.  
Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult 
patient. Blood 2015;125:2908 14. 
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
221/Protocol BO40747 , Version 6 Appendix  13  
Eastern Cooperative Oncology Group  
Scale of Performance Status  
Grade  Performance Status  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature (e.g., light house work, office work).  
2 Ambulatory and capable of all selfcare but unable to carry out any work 
activities.  Up and about  50% of waking hours.  
3 Capable of only limited selfcare, confined to bed or chair   50% of waking 
hours.  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair. 
 
REFERENCE S 
Oken MM, Creech RH, Tormey DC, et al:  Toxicity and response criteria of the eastern 
cooperative oncology group. Am J Clin Oncol 1982;5:649 55. 
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
222/Protocol BO40747 , Version 6 Appendix  14  
Guidelines for Management of Adverse Events Associated with 
Trastuzumab Emtansine  
Guidelines for managing specific adverse events are provided in the table below.  
For adverse events not listed in the table, the following guidance should be used:  for 
Grade  [ADDRESS_139029] medical 
intervention or for any Grade  4 non -hematologic adverse event, study treatment should 
be held until recovery to Grade   1.  A maximum dose delay of [ADDRESS_139030] 
administered dose of study drug will be allowed for recovery.  After appropriate recovery, 
trastuzumab emtansine may be resumed with one dose level reduction 
(e.g.,  trastuz umab emtansine reduced from 3.6  mg/kg to 3  mg/kg or from 3  mg/kg to 
2.4 mg/kg).  For patients who have an event while being treated with trastuzumab 
emtansine 2.4  mg/kg, trastuzumab emtansine will be discontinued.  The dose of 
trastuzumab emtansine, once r educed, may not be re -escalated.  
 
Appendix 14: Guidelines for Management of Adverse Events Associated with Trastuzumab Emtansine  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
223/Protocol BO40747 , Version 6 Table  1 Guidelines for Managing Specific Adverse Events  
 Event  Action to Be Taken  
Infusion reactions (caused by [CONTACT_123606])/Hypersensitivity (allergic reactions)  
Life threatening 
infusion -related reaction/  
Hypersensitivity (allergic 
reaction)  Stop infusion, study treatment permanently discontinued.  
Supportive care with oxygen, -agonists, antihistamines, antipyretics, or  corticosteroids may be used, 
as appropriate, at the investigator's discretion.  
Patients should be monitored until complete resolution of symptoms.  
Infusion -related or clinically 
significant hypotension  Stop infusion.  Administer supportive care with oxygen, -agonists, antihistamines, antipyretics, or 
corticosteroids, as appropriate, at the investigator’s discretion.  Monitor patients until complet e resolution of 
symptoms.  May re -treat at investigator’s discretion.  In  the event of a true hypersensitivity reaction (in  which 
severity of reaction increases with subsequent infusions), trastuzumab emtansine treatment must be 
permanently discontinued.  
Infusion -related symptoms 
(e.g.,  chills, fever)  Decrease infusion rate by 50% or interrupt infusion for patients who experience any other infusion -related 
symptoms (e.g.,  chills, fever).  
When symptoms have completely resolved, infusion may be restarted at  50% of prior rate and increased in 
50% increments every 30  minutes as tolerated.  Infusions may be restarted at the full rate at the next cycle, 
with appropriate monitoring.  
Supportive care with oxygen, -agonists, antihistamines, antipyretics, or corticosteroids may be used as 
appropriate at the investigator's discretion.  
Premedication with corticosteroids, antihistamines, and antipyretics may be used before subsequent infusions 
at the investigator’s discretion.  
Patients should be monitored unti l complete resolution of symptoms.  
Hematologic toxicity   
Grade   3 hematologic 
toxicity (other than 
thrombocytopenia)  Withhold study treatment until recovery to Grade   1.  Weekly CBC assessments should be 
performed until recovery, or as medically indicated.  
A maximum dose delay of [ADDRESS_139031] administered dose to Grade   1 or baseline will be allowed; 
otherwise, patients must be discontinued from study treatment.  
Appendix 14: Guidelines for Management of Adverse Events Associated with Trastuzumab Emtansine  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
224/Protocol BO40747 , Version 6 Table  1 Guidelines for Managing Specific Adverse Events (cont.)  
Event  Action to Be Taken  
Hematologic toxicity (cont.)   
Grade 2 or  3 
thrombocytopenia on day of 
scheduled treatment  Assess platelet counts weekly or as medically indicated until recovery.  Hold trastuzumab emtansine 
treatment until Grade   1.  Resume treatment without dose reduction.  If  a patient requires two delays due to 
thrombocytopenia, consider reducing dose by [CONTACT_12691].  
Grade 4 thrombocytopenia 
at any time  Assess platelet counts weekly or as medically indicated until recovery.  Hold  trastuzumab emtansine until 
Grade   1, then resume with one dose level reduction (i.e.,  from 3.6  mg/kg to 3  mg/kg or from 3  mg/kg to 
2.4 mg/kg) in subsequent cycles.  If  event occurs with 2.4  mg/kg dose, discontinue study treatment.  
Hepatotoxicity   
ALT For a Grade  2 or 3 ALT increase that occurs on the laboratory evaluation for cycle Day  1 or the planned day 
of dosing, hold trastuzumab emtansine until ALT recovers to Grade   1.  Resume with dose reduction by 
[CONTACT_123607]  2 or 3 elevations.  Grade  2 or 3 ALT elevations that are noted between cycles do not 
require dose delay or reduction unless ALT remains elevated (Grade   2) at the time of planned dosing.  
 
For Grade 4 ALT increase, discontinue trastuzumab emtansine.  Repeat laboratory evaluation (within 
24 hours) may be performed to exclude laboratory error prior to discontinuing study treatment.  
AST For Grade [ADDRESS_139032] recovers to  Grade   1.  Resume without dose reduction when recovered.  
 
For Grade [ADDRESS_139033] recovers to Grade   1.  Resume with dose reduction by [CONTACT_31806] l evel when 
recovered.  
 
For Grade [ADDRESS_139034] increase, discontinue trastuzumab emtansine.  Repeat laboratory evaluation (within 
24 hours) may be performed to exclude laboratory error prior to discontinuing study treatment.  
 
 
Appendix 14: Guidelines for Management of Adverse Events Associated with Trastuzumab Emtansine  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
225/Protocol BO40747 , Version 6 Table  1 Guidelines for Managing Speci fic Adverse Events (cont.)  
Event  Action to Be Taken  
Hepatotoxicity (cont.)   
TBILI  For TBILI   1.0   ULN to   2.0   ULN that occurs on the laboratory evaluation for cycle Day  1 or the day of 
planned dosing, hold trastuzumab emtansine until TBILI recovers  to  1.0   ULN (or direct bilirubin recovers 
to  1.0   ULN for patients with Gilbert’s syndrome).  For TBILI elevations   1.0   ULN to   2.0   ULN, 
resume when recovered with a one level dose reduction.  
 
For TBILI   2  ULN at any time (or direct bilirub in  2  ULN for Gilbert’s syndrome), discontinue 
trastuzumab emtansine and report the event as an serious ad verse eve nt (if applicable) or non -serious 
expedited adverse event  (if applicable).  
 
Assess AST, ALT, and TBILI weekly or as medically indicated until recovery.  Allow a maximum dose delay 
of [ADDRESS_139035].  If  there are signs of portal hypertension (e.g.,  ascites and/or varices) and a 
cirrhosis -like pattern is seen on CT scan of the liver, the possibility of NRH should be considered.  
Trastuz umab emtansine should be discontinued in the event of a diagnosis of NRH.  
Neurotoxicity   
Grade   3 peripheral 
neuropathy  Discontinue trastuzumab emtansine if event does not resolve to Grade   [ADDRESS_139036]  administered  dose.  
Cardiotoxicity   
LVSD  See Figure  3 for the algorithm for continuation and discontinuation of study treatment on the basis of 
asymptomatic LVEF assessment.  
Grade 3  or 4 LVSD or 
Grade  3 or 4 heart failure  Discontin ue study treatment.  
 

Appendix 14: Guidelines for Management of Adverse Events Associated with Trastuzumab Emtansine  
  
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
226/Protocol BO40747 , Version 6 Table  1 Guidelines for Managing Specific Adverse Events (cont.)  
Event  Action to Be Taken  
Cardiotoxicity (cont.)   
Grade 2 heart failure 
accompanied by [CONTACT_44990]   45% Discontinue study treatment.  
Interstitial lung disease   
Grade 3  or 4 pneumonitis  Discontinue study treatment regardless of attribution.  
Grade 1  or 2 pneumonitis  Discontinue study treatment if not radiotherapy -related.  For symptomatic (Grade  2) radiotherapy -related 
pneumonitis, discontinue if not resolving with standard t reatment (e.g.,  steroids).  Relationship to 
radiotherapy should be determined on the basis of timing and location of radiographic abnormalities 
relative to the radiation treatment.  
Upon diagnosis of drug -related ILD/pneumonitis, trastuzumab emtansine treatment has to be permanently 
discontinued.  
 Patients discontinued from trastuzumab emtansine for pneumonitis may not switch study treatment to 
trastuzumab and pertuzumab and have to discontinue all study treatment.  
Radiotherapy -related skin toxicity   
Grade  3 or 4 Do not administer study treatment until recovery to Grade   1. 
CBC   complete blood count; CT   computed tomography; ILD   interstitial lung disease; LVEF   left ventricular ejection fraction; LVSD   left 
ventricular systolic dysfunction; NR H  nodular regenerative hyperplasia; ULN   upper limit of normal.  
 
 
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
227/Protocol BO40747 , Version 6 Appendix  15  
Guidelines for Management of Adverse Events that are Potential 
Overlappi[INVESTIGATOR_123468] e vents are potential overlappi[INVESTIGATOR_123469]:  pulmonary and hepatic 
events.  If trastuzumab emtansine is held for toxicity, then atezolizumab/placebo must 
also be held.  If  trastuzuma b emtansine is discontinued for toxicity, 
atezolizumab/placebo must not be continued as single agent and must either be 
discontinued also or may be continued in combination with trastuzumab and pertuzumab 
to complete a total of 1  year of HER2 -targeted ther apy if the investigator considers the 
toxicity to be related to trastuzumab emtansine without compromising the continued use 
of trastuzumab.  If  treatment with atezolizumab/placebo had been discontinued prior to 
the discontinuation of trastuzumab emtansine  or if both treatments are discontinued 
concurrently, it is at the investigator’s discretion to switch treatment to trastuzumab and 
pertuzumab if the toxicity is not considered related to the trastuzumab component of 
trastuzumab emtansine.  
PULMONARY EVENTS  
Pulmonary events may present as new or worsening cough, chest pain, fever, dyspnea, 
fatigue, hypoxia, pneumonitis, and pulmonary infiltrates and have primarily been 
observed in patients with underlying non small cell lung cancer.  
Mild to moderate events o f pneumonitis have been reported with atezolizumab.  
All pulmonary events should be thoroughly evaluated for other commonly reported 
etiologies such as pneumonia/infection, lymphangitic carcinomatosis, pulmonary 
embolism, heart failure, chronic obstructive  pulmonary disease, or pulmonary 
hypertension:  
 Measurement of oxygen saturation (i.e., arterial blood gas)  
 High-resolution CT scan of the chest  
 Bronchoscopy with bronchoalveolar lavage and biopsy  
 Pulmonary function tests (diffusion capacity of the lung for  carbon monoxide)  
 Pulmonary function testing with a pulmonary embolism protocol  
 
Patients will be assessed for pulmonary signs and symptoms throughout the study.  
COVID -19 evaluation should be performed per institutional guidelines where relevant.  
See Table  1 for management  guidelines for pulmonary events and pneumonitis.  
  

Appendix 15:  Guidelines for Management of Adverse Events that are Potential Overlappi[INVESTIGATOR_123470] —F. Hoffmann -La [COMPANY_002] Ltd  
228/Protocol BO40747 , Version 6 Table  1 Management Guidelines for Interstitial Lung Disease and 
Pneumonitis  
Severity  Atezolizumab/Placebo  Trastuzumab Emtansine  
Grade 1 or 2 Grade 2:  withhold treatment and 
initiate corticosteroids  if 
radiotherapy -related.   If not 
radiotherapy -related, discontinue all 
study treatment . Discontinue  all study treatment if not 
radiotherapy -related.  For 
symptomatic (Grade  2) 
radiotherapy -related pneumonitis, 
discontinue if not resolving with 
standard treatment (e.g.,  steroids).  
Grade 3 or 4 Discontinue atezolizumab/placebo 
treatment.  Discontinue trastuzu mab emtansine 
treatment.  
Note:   Patients discontinued from trastuzumab emtansine for pneumonitis may not switch study 
treatment to trastuzumab and pertuzumab and have to discontinue all study treatment.  
 
HEPATIC EVENTS  
Eligible patients must have adequate liver function, as manifested by [CONTACT_33496].  Liver function will be monitored throughout 
study treatment.  
While in this study, patients who present with right upper  quadrant abdominal pain 
and/or unexplained nausea or vomiting should have liver function tests (LFTs) performed 
immediately and reviewed before administr ation of the next dose of study  drug.  
If outcome of LFTs is worsening, concurrent medications, viral hepatitis, and toxic or 
neoplasti c etiologies should be considered and addressed, as  appropriate.  Imaging of 
the liver, gall bladder, and biliary tree should be performed to rule out neoplastic or other 
causes for worsening outcome of LFTs.  Anti -nuclear antibody, perinuclear 
anti-neutro phil cytoplasmic antibody, anti -liver kidney microsomal antibodies, and 
antismooth muscle antibody tests should be performed if an autoimmune etiology 
is considered .  See Table  2 for management guidelines for increased transaminases 
(AST/ALT) and hepatic events.   See Table  3 for dose modifications of trastuzumab 
emtansine for hyperbilirubinemia.  Note:  No dose modification  for atezolizumab/placebo 
is indicated on the basis of hyperbilirubinemia alone.  
  

Appendix 15:  Guidelines for Management of Adverse Events that are Potential Overlappi[INVESTIGATOR_123470] —F. Hoffmann -La [COMPANY_002] Ltd  
229/Protocol BO40747 , Version 6 Table  2 Management Guidelines for Increased Trans aminases (AST/ALT) 
and Hepatic Events  
Severity  Atezolizumab/Placebo  Trastuzumab Emtansine  
ALT or AST 
increase that meets 
Hy's Law criteria:  
ALT or AST 
 3  ULN in 
combination with 
TBILI  2  ULN or 
clinical jaundice  Discontinue atezolizumab/placebo 
treatment.  Discontinue trastuzumab 
emtansine treatment.  
ALT/AST Grade  2 
( 3.05.0   ULN)  Withhold atezolizumab/placebo dose.  
If persists  57 days:  Consider 
starting 1 2 mg/kg/day prednisone or 
equivalent per day; when recover ed to 
Grade   1, taper steroids over 
 1 month.  
Resume therapy when systemic 
steroid dose is  10mg oral prednisone 
equivalent per day and when 
recovered to Grade   1 within 
12 weeks.  
Permanently discontinue 
atezolizumab/placebo and contact [CONTACT_123608]  1 within 12  weeks.  Withhold trastuzumab 
emtansine dose until 
recovery to Grade  1.  
Resume with dose reduction 
by [CONTACT_123609]  [ADDRESS_139037] el evation.  
ALT/AST Grade  3 
( 5.020.0   ULN)  Discontinue atezolizumab/placebo 
treatment.  
Consider patient referral to 
gastrointestinal specialist for 
evaluation and liver biopsy to 
establish etiology of hepatic injury if 
necessary.  
Start 60  mg prednisone or equivalent 
per day.  
If LFT results do not decrease within 
48 hours after initiation of systemic 
steroids, addition of an alternative 
immunosuppressive agent 
(e.g.,  mycophenolate or TNF - 
antagonist) may be considered.  
Taper steroids over  1 month, when  
symptoms improve to Grade  0 or 
Grade  1. Withhold trastuzumab 
emtansine dose until 
recovery to Grade  1.  
Resume with dose reduction 
by [CONTACT_123610].  
 
Appendix 15:  Guidelines for Management of Adverse Events that are Potential Overlappi[INVESTIGATOR_123470] —F. Hoffmann -La [COMPANY_002] Ltd  
230/Protocol BO40747 , Version 6 Table  2 Management Guidelines for Increased Transaminases (AST/ALT) 
and Hepatic Events (cont.)   
Severity  Atezolizumab/Placebo  Trastuzumab Emtansine  
ALT/AST Grade  4 
( 20.0   ULN)  Discontinue atezolizumab/placebo 
treatment.  
Consider patient referral to 
gastrointestinal specialist for 
evaluation  and liver biopsy to 
establish etiology of hepatic injury if 
necessary.  
Start 60  mg prednisone or equivalent 
per day.  
If LFT results do not decrease within 
48 hours after initiation of systemic 
steroids, addition of an alternative 
immunosuppressive agent 
(e.g.,  mycophenolate or TNF - 
antagonist) may be considered.  
Taper steroids over   1 month, when 
symptoms improve to Grade  0 or 
Grade  1. Discontinue trastuzumab 
emtansine treatment.  
Laboratory tests may be 
repeated (within 24  hours) to 
exclude laboratory error prior 
to discontinuing trastuzumab 
emtansine.  
NRH  
If there are signs of 
portal hypertension 
(e.g.,  ascites and/or 
varices) and/or a 
cirrhosis -like pattern 
is seen on a 
CT scan of the liver, 
the possibility of 
NRH should be 
considered.  Discontinue atezolizumab/placebo 
treatment.  For any clinical signs of liver 
dysfunction, discontinue 
trastuzumab emtansine and 
have the patient evaluated 
by a hepatologist.  If  there 
are signs of portal 
hypertension (e.g.,  ascites 
and/or varices) and a 
cirrhosis -like pattern is seen 
on CT scan of the liver, the 
possibility of NRH should be 
considered.  Trastuzumab 
emtansine should be 
discontinued in the event of 
a diagnosis of NRH.  
CT   computed tomography ; GI   gastrointestinal; LFT   liver function test; NRH   Nodular 
Regenerative Hyperplasia; TNF   tumor necrosis factor; ULN   upper limit of normal.  
 
Appendix 15:  Guidelines for Management of Adverse Events that are Potential Overlappi[INVESTIGATOR_123470] —F. Hoffmann -La [COMPANY_002] Ltd  
231/Protocol BO40747 , Version 6 Table  3 Trastuzumab Emtansine Dose Modification Guidelines for 
Hyperbilirubinemia  
Event  Action to be Taken  
TBILI  For TBILI   1.0   ULN to   2.0   ULN that occurs on the laboratory evaluation for 
cycle Day  1 or the day of planned dosing, hold trastuzumab emtansine until 
TBILI recovers to   1.0   ULN (or direct bilirubin recovers to   1.0   ULN for 
patients with Gilbert’s syndrome).  For TBILI elevati ons  1.0   ULN 
to  2.0   ULN, resume when recovered with a one level dose reduction.  
For TBILI   2  ULN at any time (or direct bilirubin   2  ULN for Gilbert’s 
syndrome), discontinue trastuzumab emtansine and report the event as an 
serious adverse event  (if applicable) or non -serious expedited adverse event  
(if applicable).  
Assess AST, ALT, and TBILI weekly or as medically indicated until recovery.  
Allow a maximum dose delay of [ADDRESS_139038]   upper limit of normal.  
 
Signature [CONTACT_123613] - BO40747 - TECENTRIQ - v6 - Global/Core - Published
System identifier: RIM-CLIN-469025
Approval Task
Company Signatory
23-Feb-2023 17:21:48 GMT[PHONE_006]
